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Abstract: The Genetics of Canine Atopic Dermatitis 
Shona Hiedi Wood 
Canine atopic dermatitis (cAD) is a common and severe pruritic, inflammatory skin 
disease that can be considered a naturally-occurring, spontaneous model of human Atopic 
Dermatitis (hAD). The genetics of cAD are poorly understood and therefore the aim of this 
project was to investigate the genetic factors involved in the pathogenesis of cAD and to 
identify specific gene associations with cAD within and between dog breeds. It was hoped 
that this study would further strengthen the evidence that dogs are a suitable model hAD. 
Using dogs as a model to study the genetic basis of AD is advantageous because dog 
breeds form genetically isolated populations exhibiting strong linkage disequilibrium (LD). 
In contrast to humans where LD across the genome is weak (10-100 kb), domestic dog breeds 
have strong LD which extends over long distances (0.8 -5 Mb). This is highly advantageous 
in genetic studies because fewer genetic markers and smaller sample sizes are needed to find 
disease associations in dogs. 
To study the genetic basis of cAD a dual approach of candidate gene association study 
and genome wide association study (GWAS) was used. This gave not only a novel unbiased 
approach but also used information from previous studies on which gene selection was based. 
Therefore increasing the likelihood that the causative genes involved in cAD pathogenesis 
could be identified.  
This thesis demonstrated altered mRNA expression in 54 genes out of 22,000 transcripts 
by mRNA microarray in cAD. Further to this qPCR was used to confirm the microarray 
results and quantify gene expression in potential cAD candidate genes. This approach 
identified 11 genes with altered expression in cAD. The qPCR results were further correlated 
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with the clinical outcomes: Canine Atopic Dermatitis and Severity Index (CADESI-03) and 
number of responses on intra-dermal allergen tests.  
Eleven novel SNPs and 1 novel microsatellite were identified by transgenomic WAVE 
analysis. The microsatellite was further typed in 659 dogs and but no association with cAD 
was found.  
A GWAS with 22,362 SNPs was performed. The significant results were validated by 
Sequenom along with the SNPs from the candidate gene study (literature selected genes) in 
659 dogs across 8 breeds. In total, 232 SNPs across 54 genes and 41 intergenic regions were 
genotyped on Sequenom. From this 45 putative associations were found in various breeds. A 
large number of these associations had relevant functions to AD and/or previous association 
with hAD.  
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Chapter 1 
Literature Review  
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1. Literature Review 
 
1.1 Introduction  
Canine atopic dermatitis (cAD) is a common and severe puritic, inflammatory skin 
disease that can be considered a naturally-occurring, spontaneous model of atopic 
dermatitis/eczema in humans (hAD).  In both dogs and humans AD can be differentiated into 
the more common allergen-mediated form of the disease (termed extrinsic AD in humans) 
and a less common non-allergen mediated form (termed intrinsic AD in humans and atopic-
like dermatitis [ALD] in dogs)
1;2
.  
There are many animal models which display clinical signs consistent with hAD but dogs 
are of particular interest as they share the same environment as humans, unlike the commonly 
used rodent models. The pathogenesis of the disease in both humans and dogs is strongly 
associated with immunological hyper-reactivity, although skin barrier function, microbial 
colonisation and infection also have a role
3;4
. The prevalence of hAD over the last three 
decades has increased two to three fold in industrialised countries
5
, it has been suggested that 
this could also be the case in cAD, however studies assessing cAD prevalence have been 
contradictory and biased
6
. 
1.2 Clinical descriptions 
CAD exhibits characteristic clinical features. The typical age of onset is 6 months to 3 
years
7
, though it is possible that signs will present in dogs less than 6 months and greater than 
7 years old
8;9
. Reports of sex bias are variable and contradictory
8;10
. Breed pre-dispositions 
have also been observed in cAD (detailed in section 1.6). Clinical signs of cAD can be both 
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seasonal and non-seasonal depending on which allergens are involved, but ALD is usually 
constant throughout the year
7
.  
Pruritus (itching) is a hallmark of cAD. This can occur in any one or all of these 
locations: around the face, ears, paws, flexor surfaces and/or the ventrum. Generalized 
pruritus is also common, although it has been noted that involvement of the dorsal lumbar 
skin and pinnal margins is characteristic of flea allergic dermatitis and Sarcoptes infestation 
respectively
11
.  
The primary lesions of cAD mainly consist of diffuse erythema of affected skin, although 
macular and papular erythema can be seen. Some dogs do not present with primary lesions at 
all and it has been suggested that primary lesions are only present when there is secondary 
infection
7
.  
Secondary lesions are also common at pruritic sites in cAD; these are non-specific and are 
thought to reflect chronic pruritus, inflammation and trauma. These include red-brown saliva 
staining, excoriations, self induced alopecia, hyper-pigmentation, scaling and lichenification.  
Atopic otitis externa and conjunctivitis are both common in cAD. Moreover atopic skin is 
readily colonized with staphylococci and Malassezia compared to healthy skin
12
, and 
therefore secondary skin and ear infections frequently complicate cAD. Clinical signs include 
surface overgrowth, superficial folliculitis, otitis,  pododermatitis, seborrhea and 
hyperhidrosis
7
. 
Management of cAD is difficult as the pathogenesis is complex and evolving
13
. Allergen 
specific immunotherapy (ASIT) is recommended to induce tolerance and prevent 
recurrence
14
. Other topical and systemic treatments include emollient shampoos, 
glucocorticoids
15
, antihistamines
16
, ciclosporin
17
 and essential fatty acids
18
. However, many 
6 
 
of these treatments can be time consuming, expensive, have adverse side effects and are not 
always effective in all patients
13
. 
1.3 Pathology 
Much of the pathology associated with allergic diseases such as AD is a consequence of 
long term chronic allergic inflammation
19;20
. Lesional skin samples from cAD often exhibit 
varying degrees of epidermal hyperplasia, orthokeratotic or parakeratotic hyperkeratosis, 
hypergranulosis, spongiosis, melanosis and leukocyte exocytosis
21
. The degree of epidermal 
spongosis, acanthosis and hyperkeratosis is related to the severity of the clinical signs
22
. A 
superficial to deep, peri-vascular to diffuse dermal infiltration of CD4+ and CD8+ T-cells, 
monocytes, eosinophils, neutrophils, mast cells and plasma cells, which correlates with 
clinical severity is often seen
22
. Epidermal Langerhans cells are common and tend to group as 
micro-aggregates in the epidermis. The epidermis exhibits increased numbers of IgE positive 
Langerhans cells. Dermal mast cell hyperplasia has also been observed, and, moreover, the 
dermal mast cells are also frequently IgE positive
22. γδ-T-cells, which are rare in humans, are 
seen in the epidermis and dermis in cAD. Whether they have any activity as effector or 
regulatory cells is unknown
23
. Eosinphils are also present in the dermis in cAD, and 
degranulated cells are also present and may be overlooked
22
. 
As in hAD, non-lesional skin in cAD is characterised by superficial peri-vascular 
infiltrates of lymphocytes, monocytes, dendritic cells and mast cells
23;24
, with mild epidermal 
spongiosis sometimes present
22;23
. 
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1.4 Atopic dermatitis in humans and dogs: A biphasic model? 
AD may be considered an unusual disease as it has immunological abnormalities that do 
not fit the models of other classical immunological diseases
25
. In AD increased levels of 
allergen specific IgE and epidermal eosinophils are often observed; this immunological 
profile would suggest that AD is driven by an allergic-type Th2 response. However, it is also 
reported that INF-γ levels are increased in AD suggesting a Th1 response26;27. This 
observation led to the theory of sequential activation or the biphasic model of AD 
pathogenesis
26
. Based on this model, it is suggested that AD is an abnormal, Th2 driven over-
reaction to allergens that proceeds into a chronic phase mediated by Th1 responses. It is 
thought that percutaneously absorbed allergens are taken up and processed by epidermal 
Langerhans cells
28
.  These cells then present the processed allergens via MHC class II 
molecules to naïve T-cells
29
.  There is evidence from both canine and human AD patients that 
this results in the activation of allergen specific T-helper2 (Th2)-like CD4+ T cells and the 
secretion of a Th2-type cytokine profile, which ultimately results in the production of 
allergen-specific IgE
30;31
.  Allergen specific IgE readily binds to the high affinity receptor, 
FCεRI, expressed on cutaneous Langerhans and mast cells32.  Binding of the allergen triggers 
mast cell degranulation and the release of inflammatory mediators such as leukotrienes, 
prostaglandins, proteases, various cytokines and chemokines, and histamine resulting in the 
classic acute inflammatory response seen in allergy. However, infiltrating eosinophils release 
IL-12, which leads to a Th1 mediated cell-mediated immune response and formation of 
chronic AD lesions
7;33
. This process is summarised in Figure 1.1. 
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Figure 1.1 Diagram of Th Cell and Cytokine Responses in Atopic Dermatitis Based on the Biphasic model 
Figure 1.1: The allergens are absorbed through the skin and taken up by Langerhans cells, and presented via MHC class II to naïve T cells these become Th2 cells. These Th2 cells 
release classic allergy cytokines. These cytokines cause keratinocyte activation, IgE production and eosinophil infiltration into the epidermis. Keratinocytes stimulate the release of 
more Th2 cells compounding the response. IgE binds to receptors on Langerhans and mast cells; this causes degranulation and an inflammatory response that further activates 
keratinocytes to stimulate the release of Th2. Subsequently TNF-alpha, IL-1 and IL-6 further compound the Th2 response. This represents the acute phase of AD with little or no 
lesions but a lot of inflammation and itching are seen. The eosinophils cause the release of IL-12 which leads to a Th1 response. Th1 stimulates INF-gamma release; this is thought to 
lead to chronic lesion formation. Concurrently TNF-alpha is still producing a Th2 response, which is further compounded by scratching and microbial colonisation with Staphylococci. 
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Intrinsic human AD and canine ALD are, however, not associated with allergen specific 
IgE. These conditions are nevertheless clinically  similar to extrinsic AD in humans and 
„classical‟ AD in dogs1;9;34-36. It is therefore likely that the pathogenesis is more complex than 
a simple Th2/Th1 switch, and that other factors contribute to the pathogenesis.  
1.5 Atopic Dermatitis as a complex disease 
In humans and dogs, over the last few years, it has become well established that AD is a 
complex disease with many factors contributing to the pathogenesis
37;38
. In the following 
sections I will discuss how skin barrier function, innate and adaptive immunity, microbial 
colonization and infection are all thought to contribute to the biphasic response and therefore 
the pathology of AD. 
Mechanical barrier: Epidermal dysfunction 
Allergic inflammation in AD is thought to be associated with sensitization to normally 
innocuous environmental allergens. Sensitization facilitates the Th2 response seen in Figure 
1.1.  Development of clinically significant sensitization can be affected by: individual 
susceptibility, allergen type/concentration, presence of endotoxin and/or chitin, and frequency 
and/or route of allergen challenge
39
. The route of allergen challenge is of interest in AD as 
the permeability of the epidermal barrier can be affected by genetic and environmental 
factors that increase allergen penetration and potential sensitization. Moreover, it has been 
demonstrated that allergen challenge by this route favours a Th2 response
37;40;41
.  
Consequently it has been proposed that AD is the result of faulty epidermal barrier protection 
42;43
 (see Figure 1.2), allowing either more allergens to pass the epidermal barrier and/or 
increasing sensitization to these allergens. A potential mechanism for the development of 
non-IgE associated disease (intrinsic AD/ALD) involving the skin barrier has also been put 
forward (Figure 1.2)
44
. 
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Figure 1.2  Disruption of the Skin Barrier and Different Routes of Allergen Presentation (adapted from Callard et al 44) 
                
Figure 1.2: (a) Healthy skin: The stratum corneum protects the 
epidermis and Langerhans cells from exposure to environmental chemicals 
and antigens. (b) Extrinsic AD: Following disruption of the stratum 
corneum, antigens enter the epidermis to be taken up by Langerhans cells 
and the Th2 response seen in the biphasic model (Figure 1.1) proceeds.    
(c) Intrinsic AD: Not only the stratum corneum but the epidermis is 
disrupted, antigens can be taken up by dermal DCs, which migrate to the 
draining lymph node and locate to the outer para-cortex just beneath the B 
cell follicles. In this case, T cells make IFNγ, typical of a Th1 response, 
circumventing the IgE response but still leading to AD symptoms. 
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Evidence to support the theory of epidermal barrier dysfunction in humans is extensive. 
An earlier study demonstrated that trans-epidermal water loss (TEWL) at lesional sites on 
human atopic patients was twice that at non-lesional sites and four times that of healthy 
skin
45
. In the same study, reduced ceramide levels were recorded, suggesting that the 
ceramide layer is essential for proper barrier function by limiting TEWL. However, it has 
been argued that the lack of ceramide is due to the high levels of bacteria that colonise atopic 
skin, especially in chronic AD. Bacterial ceramidases break the ceramides down, resulting in 
the characteristic low ceramide levels and dry skin seen in AD
46-48
. Interestingly, the enzyme 
sphingomyelin deacylase, which preferentially metabolises sphingomyelin to 
sphingosylphosphorylcholine instead of ceramide, is up-regulated in hAD patients
49
. The 
GCCCGC sphingomyelinase haplotype, furthermore, has been linked with hAD
50
, suggesting 
that a dysfunction in sphingomyelin deacylase and ceramide metabolism could be responsible 
for the lack of ceramide in hAD and be causative of some of the symptoms.  
Two independent loss of function variants in Filaggrin are associated with hAD (R501X 
and 2282del4)
51;52
, this is the strongest evidence to date for a defective skin barrier in AD 
pathogenesis. Filaggrin is an epidermal barrier protein that contributes to barrier formation by 
aggregating the keratin cytoskeleton causing the cells to compact into squames. It has also 
been shown that Filaggrin can be broken down at the stratum corneum to form a „natural 
moisturizing substance‟42;53, suggesting that Filaggrin is protective against the characteristic 
dry skin seen in AD. It has been estimated that Filaggrin mutations occur in as many as 50% 
of patients with AD
40
. This, however, leaves 50% of patients without Filaggrin as the 
causative mutation, emphasizing the complex nature of AD and the likelihood that there are 
multiple causative genes or environmental factors involved in patients with and without 
normal Filaggrin function.  
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Other proteins involved in the formation of the stratum corneum are located with 
Filaggrin on the epidermal differentiation complex (EDC), coded on chromosome 1q21 (in 
humans). Chromosome 1q21 has been implicated in hAD by linkage analysis
54
. This suggests 
that other genes involved in epidermal development could also be involved in the 
pathogenesis of AD.  
Allergens could also contribute to the breakdown of the skin barrier. Some allergens are 
proteases; for example house dust mite allergen Der p 1 is a cysteine protease that has been 
shown to directly reduce epithelial barrier function
55
 and hydrolyse the cell membrane 
proteins CD23, CD25 and CD40 which potentiates Th2 cell responses
56
. Moreover, 
exogenous proteases are a potential source of thymic stromal lymphopoietin precursor 
(TSLP), which can promote allergic inflammation
57
.  
It is clear that the skin barrier plays an important role in the development of hAD, 
however evidence for skin barrier dysfunction in cAD is limited
3
. Barrier function studies in 
dogs have focused on comparing the amount of lipids in plasma, sub-cutaneous fat and skin 
in atopic and healthy dogs. These studies yielded contrasting results from no difference in 
levels
58
 to significantly lower levels in cAD
59
, but these studies looked at the levels of lipids 
in different ways, at different sites and even at different lipids
60
. Furthermore treatment with 
essential fatty acid (EFA) supplementation was not associated with consistent changes in 
plasma or cutaneous EFAs, and showed no correlation with clinical outcome
61
. Nevertheless 
one study did record, via electron microscopy, that the epidermal lipid barrier was disrupted 
in canine atopic skin
62
.  More recent studies in a colony of atopic Beagles have detected 
decreased expression of Filaggrin and disturbed extrusion of lamellar bodies by keratinocytes 
in the epidermis
63
. While these animals do not represent the dog population as a whole, this 
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does suggests that cAD may display a similar lipid distribution and barrier dysfunction as 
seen in hAD.  
Innate immune response 
Once an allergen, irritant, toxin or micro-organism has penetrated the epidermis, it will be 
recognized by the innate immune response. Innate immunity comprises a series of highly 
conserved mechanisms thought to have evolved to provide rapid protection against 
pathogens. This frequently involves recognition of pathogens and other threats using pattern 
recognition receptors (PRRs)
64
. PRRs are trans-membrane and intra-cellular receptors, e.g. 
Toll-like receptors (TLR) and the NOD protein family
65
. PRRs identify pathogens via highly 
conserved molecular patterns such as bacterial cell wall components or peptidogylcan
64
. PRR 
activation leads to the production of chemokines, cytokines and recruitment of immune cells, 
as well as determining the extent of the adaptive immune response
56
.  
It is thought that deficiencies in PRR functionality may affect the maturation of the 
immune system and lead to high prevalence of atopic diseases and susceptibility of AD 
sufferers to secondary infection
65
. TLR-binding has been shown to favour the Th2 response
66
, 
and it is possible that the prolonged Th2 response seen in AD could be due to the innate 
immune system inappropriately responding to innocuous environmental antigens
67
. 
Keratinocytes express TLRs and also play a role in innate immune function in the 
skin
67;68
. In hAD, a weak TLR2 response has been observed, and as TLR2 is important in 
microbial recognition this could explain the increased colonization seen of AD patients
67
.  
Genetic changes in TLRs or other PRRs could therefore be important in the pathogenesis 
of AD. Functional changes in PRRs have been shown to affect their protective role in human 
atopic asthma
69
. A polymorphism in TLR2 has been associated with extreme cases of hAD 
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with re-current bacterial infections
70
, although this conclusion was not supported in another 
study
71
. TLR9 has been shown to have an association with a certain subset of hAD cases, but 
TLR6 and TLR4 have shown no association with hAD
72-74
. Nucleotide-binding 
oligomerization domain-containing protein 1 (NOD1), also known as, Caspase recruitment 
domain-containing protein 4 (CARD4) is essential in host defence against bacteria and has 
shown a polymorphism association with hAD
75
.  
β-definsins and cathelicidins, are effector molecules that form part of the innate immune 
response. They are antimicrobial peptides which are able to kill microbial pathogens either 
directly through their interactions with the microbial membrane
76 
or indirectly through 
immunomodulation
77;78
. Because AD patients (humans and dogs) show increased 
colonisation of Staphylococcus and other bacterial species it has been suggested that defects 
in β-defensin function may be responsible for the development and maintenance of chronic 
lesional skin in AD. Altered expression of β-defensins has been demonstrated in humans79;80 
and most recently in dogs
81
 suggesting a role for β-defensins in the pathogenesis of AD. 
Despite growing interest in this field, studies on PRRs and antimicrobial peptides are 
limited in cAD. However because of the shared pathology and immunological profile, and the 
fact that the innate immune system is highly conserved, it is thought that evidence from 
human studies do apply to cAD. 
Microbial colonization and infection 
As discussed earlier, secondary infection is important in the development and 
maintenance of chronic lesional AD. A variety of fungal, bacterial and viral infections 
complicate hAD
48
, although only Staphylococcus sp. and Malassezia pachydermatis are 
commonly associated with cAD
12
. These can contribute to the pathogenesis and clinical 
course of the disease in both humans and dogs
82
. 
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Ninety percent of hAD suffers are colonized with Staphylococcus aureus, compared to 
only ~30% of healthy humans
48
. It has been demonstrated in humans that Staphylococcus 
exotoxins can act as super antigens and produce an inflammatory response in the skin
83
. 
Superantigens are so-called because they elicit a widespread generalized activation of the 
immune system through cross linking surface MHCII molecules on antigen presenting cells 
with non-specific T-lymphocytes, rather than the specific binding seen with normal 
antigens
83
.  S. pseudintermedius is the main species of Staphylococci found in dogs and has 
been demonstrated to be present in greater numbers and have greater adherence to 
keratinocytes in AD compared to healthy dogs and those with other skin diseases
12;84
. No 
differences in binding ability, susceptibility to beta-defensins, or pulsed field gel 
electrophoresis (PFGE) types were seen between atopic and healthy dogs, indicating that 
colonization is associated with host factors
84
.   
Colonisation and infection with Malassezia sp. is also important in human and canine 
AD; in dogs approximately 50% of Malasszia dermatitis cases are concurrent with AD
82
. 
Numerous human studies have shown that Malassezia can act as an allergen in AD
85
, and that 
colonisation modulates cytokine production potentially playing a role in maintaining IgE 
mediated skin inflammation
86;87
. Specific treatment for Malassezia can help ameliorate AD in 
these patients. Several studies have also demonstrated the presence of Malassezia specific 
serum IgE, positive intra-dermal tests and passive transfer tests in atopic dogs
88-91
.  It 
therefore appears that Malassezia can act as an endogenous allergen in cAD, although the 
clinical significance of this and any response to specific treatment is unknown.     
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Adaptive immune response 
The adaptive immune system is often initiated by the innate responses discussed above. In 
AD the adaptive immune system responds as illustrated in Figure 1.1 Many genes associated 
with adaptive immunity have been investigated in AD, as it is likely that some of the changes 
seen in the adaptive allergic response are due to genetic differences.  
The Th2 cytokine cluster genes IL-3, IL-4, IL-5, IL-13, GMCSF (granulocyte-
macrophage colony stimulating factor) have been associated with hAD subtypes. 
Associations have also been demonstrated in RANTES (chemokine (C-C motif) ligand 5) and 
IL-4R (Interleukin-4 receptor)
38;92
, although these were in small populations and subsets of 
hAD. The similar immunological profile between human and canine AD suggests that similar 
genetic changes may also be important in dogs. 
Hygiene Hypothesis 
The inflammatory response seen in AD and other allergic diseases is similar to that seen 
in helmith infections
93
 or ectoparasite infestations
39
. Chronic infection with some parasites 
leads to a down-regulation of this inflammatory response to protect against inflammation 
generated tissue damage
93
. It is thought that in diseases such as AD this down-regulatory 
mechanism does not work effectively, either due to under development or being 
overwhelmed by the inflammatory response, therefore tolerance is not developed
93-95
. 
Interestingly it has been demonstrated in dogs that administration of helminths leads to an 
improvement of cAD symptoms – perhaps „kick starting‟ the down regulatory response and 
inducing tolerance
96
.  
Observations of a dysfunctional immune response and lack of tolerance to allergens have 
lead to the „hygiene hypothesis‟. This speculates that improved living standards, reduced 
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exposure to certain parasitic infections and micro-organisms in early life, affects the 
development of the immune system. Specifically maturation of cell-mediated (i.e. Th1) 
immune responses and T-regulatory cell mediated tolerance. In some individuals this could 
lead to an unregulated Th2 biased immune response and the development of abnormal 
allergic responses to environmental allergens to which healthy individuals are tolerant
93-95;97
. 
As described earlier, the rapid increase in AD in industrialised countries in recent years has 
been considered evidence for the hygiene hypothesis. The exact molecular mechanisms 
involved in the hygiene hypothesis are not fully understood, however the role of the 
environment is clear and research in humans is beginning to focus on gene-environment 
interactions in allergic inflammation. It has already been demonstrated that an individual‟s 
genotype can differ according to the microbial products they are allergic to
39
. These findings 
suggest that specific allergens may differ between individuals according to their genetic 
background, therefore personalised genetic/medical treatment for AD maybe be important in 
the future.   
Shared environmental factors may affect the occurrence of allergies in both pets and 
owners. A significant association was found between pet owners with hay fever and the rate 
of allergy in their dogs
98
. This further illustrates the usefulness of dogs as a model for allergic 
disease as they share the same environment as humans. There are, however weaknesses in the 
use of dogs as models for human disease. The presence of multiple breeds and selective 
breeding of dogs could mean that each breed could have a different genetic cause for the 
same disease. Secondly the clinical manifestation of disease can be variable in dogs, for 
example cAD can present has chronic otitis externa, whereas this is not the case in humans, 
however the use of dogs as models for human disease is of benefit when compared to rodent 
models.  
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1.6 Genetic component in canine AD 
Most research into cAD has so far been limited to reporting cytokine and chemokine 
profile changes
31
. Genetic research in cAD is sparse, although there is strong evidence for a 
genetic link from clinical observations of breed associations with cAD. Specific breeds are 
more likely to have cAD than others; West Highland white terriers and Boxers are especially 
susceptible, although many other breeds and crosses are affected
99-101
.  Sighthounds, in 
contrast, are rarely affected; suggesting genetic susceptibility to cAD is not evenly distributed 
among breeds
102
. However, these studies have rarely taken in account the numbers of these 
breeds in the whole population, resulting in a skew towards the more popular breeds
101
. 
Nevertheless, a recent publication from Hungary did take into account the „over-
representation‟ of certain breeds in the population and found that in most cases their results 
agreed with previous work
102
.  A study comparing multiple geographic regions and veterinary 
practices reported that breed predispositions to cAD was dependent on the geographic region 
and even the veterinary practice
103
, though this may highlight the popular breeds in those 
areas rather than a predisposition to cAD.  Further evidence for a genetic component in cAD 
comes from family associations; a study of British guide dogs showed a heritability of 
0.47
104
. Heritability is defined as the degree to which a phenotypic trait i.e. disease, is 
inherited rather than attributable to non-heritable factors i.e. the environment. Stronger 
evidence for heritability exists in hAD (heritability = 0.72-0.77 in monozygotic twins)
105;106
.  
Because of the similarities in the immunological profile of cAD to hAD it is thought there is 
a shared genetic/environmental cause. 
Unlike most murine AD models cAD does not appear to be caused by a single gene 
defect, and, like hAD, may be a polygenic disorder with complex inheritance and interactions 
with environmental influences. It is therefore a potential complex model for the human 
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condition. Using dogs as a model to study the genetic basis of AD is advantageous because 
dog breeds form genetically isolated populations exhibiting strong linkage disequilibrium 
(LD)
107
. LD occurs when not all the available allele combinations are present in the 
population, e.g. if loci A and B are represented by two alleles in the population (A and a; B 
and b) but only genotypes AABB and aabb are found in the population. This is due to the 
non-random association of alleles at two or more loci. The degree of LD describes how likely 
it is that these alleles are inherited together. The degree of LD in dogs is extensive, meaning 
that fewer genetic markers are required to find an association with disease in dogs and 
smaller sample sizes can be used to find these associations, compared to human genetic 
studies
107;108
.  
An association study or a linkage study can therefore be undertaken to investigate the 
genetics of cAD. When trying to characterise the genetics of cAD the heterogeneity of the 
breeds, the possibility of different disease expression and variable diagnosis, and the 
difficulty of making direct comparisons between breeds must all be considered
109
. 
1.7 Approaches to genetic study of complex diseases and findings in AD 
Linkage studies 
Two or more loci and their representative genes are said to be linked if they occur on the 
same chromosome. Contrary to the second of Mendal‟s laws of inheritance, eukaryotic genes 
which are linked will tend to be inherited together and are not randomly assorted. Cross-over 
and/or chromosome translocation can prevent linked loci from being inherited together, if 
cross-over and/or translocation do not take place this can lead to LD. If a loci is linked with a 
disease phenotype it will be in LD when disease affected and unaffected individuals in the 
same family are compared in a linkage study. Multiple families are usually analysed in order 
to find a common linked loci, which if found may suggest that the disease loci was inherited 
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from a common ancestor and could be disease causative in the general population. This 
approach is relatively unbiased but is limited to diseases where large relative risks are 
conferred by a limited number of genes. This is because for disease causing genes with a 
relative risk <2, large numbers are required to detect linkage. One study for example 
illustrated that 2500 families are required to detect a relative risk of 2
110
.  
In dogs, however, the situation is different, as they form genetically isolated populations 
which exhibit strong LD
107;108
, and 46% of  heritable dog diseases are breed specific
111
. 
Therefore, it can be said that certain breeds „are enriched for a small number of disease 
alleles, which are rare in the overall dog population‟108. The implications are that linkage 
analysis can be carried out using dramatically reduced numbers over an extended canine 
family, making this powerful approach viable for complex disease studies. 
Although no linkage studies in cAD have been reported, there have been a considerable 
number of linkage studies on hAD (Table 1.1). However human studies may fail to identify 
all or some genes which are relevant for cAD. Moreover, linkage studies only provide an area 
of linkage and not the specific gene or polymorphism associated with the disease. 
Nevertheless areas of linkage can serve as a starting point for candidate gene studies. 
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Table 1.1   Areas of Linkage Identified in Human AD  
Chromosome 
location 
Marker Phenotype Population & size Reference 
11q13 D11S97 Extrinsic AD 64 nuclear families 112 
13q12-14 D13S218 AD German AD = 192; German 
controls = 59; German parents of 
AD = 77; Sweden: 40 nuclear 
families 
113 
5q31-33 D5S436 – 
D5S643 
AD 
3q21 D3S3606 AD Germany: 199 sib pairs 114 
1q21 D1S498 AD  
UK:  AD = 153, Controls = 230 
(sib pairs) 
 
 
54 17q25 D17S784 AD 
20p D20S115 AD and 
asthma 
3q24-22 D18S851 AD Sweden: 109 nuclear families 115 
3q14 D3S1768 SCORAD* 
13q14 D3S2459 SCORAD* 
15q14-15 D1751290 SCORAD* 
17q21 D15S118 SCORAD* 
18q21 D13S325 Extrinsic AD 
3p26-24 D3S3594-
D3S3038 
Extrinsic AD Denmark: 100 nuclear families 116 
18q11-12 D18S877 Extrinsic AD Denmark: 100 nuclear families  
2p12 D2S1777 
 
Increased IgE  
 
Multiethnic European: 82 nuclear 
families 
 
 
117 16q21 D16S2620 
 
AD and 
asthma 
3q21.3 D3S3606 Extrinsic AD 
*SCORAD - SCORing Atopic Dermatitis Index, severity score for human AD 
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Candidate gene/association studies 
Association studies are usually the standard approach for investigating complex diseases. 
These are case-control comparisons that endeavour to identify polymorphisms (e.g. Single 
nucleotide polymorphisms) in candidate genes. The basis of this type of study being; if a 
polymorphisms frequency significantly differs between cases and controls it may be 
implicated in the disease pathogenesis. This type of study is more sensitive to small multiple 
gene effects
110
, but it is often biased and limited as it is largely restricted to small regions of  
genes that have already been annotated or previously linked with the disease. Again, the 
extensive LD exhibited by dog breeds allows for smaller sample sizes to be used to detect 
genetic risk factors and increase the statistical power. 
Currently no candidate gene studies have been undertaken for cAD. Genes identified by 
candidate gene studies in hAD are shown in Table 1.2.  
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Table 1.2 Genes Identified from Human AD Candidate Gene Studies  
Gene Name Gene 
symbol 
Chromosome 
Location 
Population & size Reference 
Filaggrin FLG 1q21 Irish n=52, Scottish n=279, 
Danish n=142 
52 
Cytotoxic T lymphocyte 
associated 4 
CTLA4 2q33 Australian: 112 nuclear 
families 
118 
Toll-like receptor 9 TLR9 3p21.3 British n=172 119 
Interferon regulatory factor 2 IRF2 4q35.1 Japanese: 48 nuclear 
families (n=180) 
120 
Granulocyte-macrophage 
colony-stimulating factor 
GM-CF 5q31.3 British n= 113 121 
Interleukin-13 IL-13 5q31-33 Japanese n=185 
German n=187 
122 
123 
Interleukin-4 IL-4 5q31-33 German n=187 
Japanese: 88 nuclear 
families 
123 
124 
Serine protease inhibitor kazal 
type 5 
SPINK5 5q31-33 British n=338 
Japanese: 41 nuclear 
families (n=177) 
Japanese n=124 
125 
126 
127 
Caspase recruitment domain-
containing  protein 4 
CARD4 
(NOD1) 
7p14-15 German: 189 nuclear 
families (n=454) 
75 
Β chain of the high affinity 
receptor for IgE 
FcεRIβ 11q12-13 British: 60 nuclear 
families (n=277) 
128 
Interleukin 18 IL-18 11q22 German n=225 129 
T cell immunoglobulin and 
mucin domain containing 
molecule 1 
TIM1 12q12-13 Korean n=112 130 
PHD finger protein 11 PHF11 13q14 Australian: 111 nuclear 
families 
131 
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Table 1.2 continued 
 
Mast cell chymase CMA1 14q11.2       Japanese n=100 
Japanese n=145 
Japanese n=169 
British 341 nuclear 
families 
German n=242 
       132 
133 
134 
135 
136 
IL-4 receptor alpha chain IL4R 16p12-p11     Japanese n=27 
Japanese n=101 
137 
138 
Caspase recruitment domain-
containing protein 15 
CARD15 
(NOD2) 
16q12 German n=330 139 
Regulated on activation 
normally T cell expressed and 
secreted 
RANTES 17q11.2 German n=268 140 
Eotaxin EOTAXIN 17q21.1-
21.2 
Japanese n=140 141 
TGF-β1 TGF-β1 19q13.1 British n=68 142 
Stratum corneum chymotryptic 
enzyme 
SCCE 19q13.3 British n=103 143 
Glutathione S-transferase,   
Theta 1 
GSTT1 22q11.2 Russian n=325 144 
BCL2-related protein A1 BCL2A1 15q24.3 Caucasian: AD=105, 
Controls=110 
145 
Late cornified envelope-like 
praline-rich 1 
LELP1 1q21 North India: 133 nuclear 
families & independent 
case-control cohort 
146 
interleukin 1 receptor-like 1 IL1RL1 2q12 Japanese: AD=452, 
Control=636 
147 
Sphingomyelinase SMPD2 11 Korean: 
AD(intrinsic)=251, 
AD(extrinsic)=284, 
Controls= 188 
50 
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Genome Wide Association Studies 
Ideally, an unbiased approach with extensive coverage should be used to investigate gene 
associations with disease. These criteria are fulfilled by genome-wide association studies 
(GWAS)
148
. These studies use known Single Nucleotide Polymorphisms (SNPs) spaced 
throughout the genome, and compare case and control frequencies of these SNPs. This 
identifies genes and SNPs that may be causative of the disease phenotype. The advantage of 
this approach is that it is unbiased as it looks at the whole genome. Nevertheless, it is still 
limited to known SNPs, and this approach can be expensive depending on the number of 
SNPs and samples used. To achieve whole genome coverage in human studies it is estimated 
that 200,000 to 500,000 SNPs are required
108
, dramatically increasing the cost of this 
approach. In dogs, however, the extensive LD exhibited by dog breeds
107
 means that only 
5,000 to 30,000 SNP markers need to be used, making genome wide association a viable 
option for canine research
108
.  
In GWAS and other studies measuring frequencies of SNPs, Hardy-Weinberg equilibrium 
(HWE) is an important consideration when interpreting the results. HWE states that allele 
frequencies in a population remain in equilibrium, from generation to generation, unless there 
is non-random mating, mutations, selection, limited population size, random genetic drift and 
gene flow.  In every population one or more of these effects is likely to be taking place, but 
nevertheless, HWE is used in human genetic studies as a quality check for genotyping data by 
comparing observed genotype frequencies to those expected within a population. The 
statistical tests used to measure genetic associations within a population are based on HWE 
which means SNPs must be within HWE to be associated with the disease. It is thought that 
dog breeds may deviate from HWE, because they are selectively bred (non-random mating). 
Nevertheless it has been shown that when dogs are grouped into pedigrees (breeds) and HWE 
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is measured they do conform to HWE more than if grouped as multiple breeds
149
, this is 
probably due to different breeding histories. This means that when interpreting SNP 
frequency data, HWE must be calculated in order to exclude SNPs which deviate from HWE 
and are therefore unreliable. By analyzing one breed at a time the likelihood that SNPs will 
conform to HWE is increased
149
.  
mRNA expression studies 
Microarrays can be used to identify disease associated genes by comparing specific gene 
expression (mRNA) profiles in affected and unaffected individuals. If significant 
dysregulation of a gene is observed in affected individuals it is possible that the gene is 
involved in the disease pathogenesis, and is therefore a good candidate for further study. 
Microarrays have the ability to examine a large number of genes, covering most tissue 
transcripts. One problem with this approach is that any observed dysregulation may be due to 
downstream inflammatory effects rather than aetiological cause. Furthermore, microarrays 
are prone to producing false positive results, although statistical corrections such as the 
Bonferroni correction
150
 or the Benjamini and Hochberg correction
151
 reduce the number of 
false positives. Microarray results should be validated by qPCR (preferably in larger sample 
sizes), as this technique is more sensitive and allows absolute quantification of the amount of 
transcript. As microarrays use RNA samples extracted from the diseased and control tissue, 
unlike the techniques described earlier, there are no known advantages to using dogs, apart 
from the benefits of confirming dysregulation of the same genes in a different organism. 
1.8 Hypothesis 
The working hypothesis for this project is that cAD is a complex disease with a 
significant genetic component, contributing to the pathogenesis. 
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1.9 Aims of the project 
The aims of this project were to: (1) Investigate the genetic factors involved in the 
pathogenesis of cAD, and (2) to identify specific gene associations with cAD within and 
between dog breeds. 
To do this a dual approach of candidate gene association study and GWAS was used. This 
was considered to give a novel unbiased approach and also use information from previous 
studies on which to base gene/SNP selection. This combined approach was taken in order to 
increase the likelihood that any genetic factors in cAD would be identified. Figure 1.3 shows 
the overall study design for this project. 
Figure 1.3  Study Design 
 
Figure 1.3: A dual approach of candidate gene and genome wide association study (GWAS) to select SNPs 
for a large-scale case-control comparison to test associations with cAD. The biased approach: Candidate genes 
were selected from the literature and by analysis of an mRNA microarray study. The unbiased approach: GWAS 
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2. General Materials & Methods 
2.1  Case and control selection 
Diagnosis 
Dogs with cAD were recruited from the dermatology clinic at the University of Liverpool 
Small Animal Teaching Hospital and through the WALTHAM® Centre for Pet Nutrition. 
Clinical diagnosis of cAD was based on compatible history and clinical signs, and exclusion 
of other causes of pruritus. Coat brushings, skin scrapings, Sarcoptes specific IgG serology 
and trial therapy were used to eliminate the possibility of an ectoparasite infestation. All 
atopic dogs underwent a six to eight week diet trial with either a home-cooked or commercial 
single, novel protein diet, or a commercial hydrolysed protein diet and water only, to 
eliminate the possibility of an adverse food reaction. Seborrhoea, staphylococcal pyoderma 
and Malassezia infections were managed appropriately. No anti-inflammatory medication 
was given for at least three weeks prior to examination. 
All dogs with a clinical diagnosis of AD, from the University of Liverpool Small Animal 
Teaching Hospital, had an intra-dermal allergen test (IDT) with 54 environmental allergens 
(Greer Laboratories Inc., Lenoir, NC, USA), performed and interpreted according to accepted 
criteria
152
. Clinical lesions were scored using the Canine Atopic Dermatitis and Severity 
Index (CADESI) -03. This is a validated assessment of clinical lesions (erythema, 
excoriation, lichenification and self-induced alopecia) at 62 anatomical sites from 0 (normal) 
to 5 (most severe) yielding a score of 0-1240
153
. 
Control dog DNA samples were obtained from the Veterinary Laboratories agency 
(VLA), Bath Championship Dog show and WALTHAM® Centre for Pet Nutrition. Control 
animals from the dog show and WALTHAM® Centre for Pet Nutrition did not have any 
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history or show any clinical signs compatible with cAD, Otis externa, immune regulated or 
skin diseases. The VLA samples represented a random population with no disease 
information. 
Various breeds were sampled and specific information on breed, sex and age is given in 
subsequent chapters. 
Sample collection 
Blood 
All blood samples were taken by a veterinarian from the jugular vein using a 1 inch 21 
gauge needle. Approximately 1-3 ml was taken and placed in an EDTA tube to prevent 
clotting. Blood was taken for diagnostic purposes, and only blood which was excess to 
clinical requirements was used for this study. The blood samples were stored at -40°C and 
used with informed consent from the owners of each dog. The study followed ethical 
guidelines as laid down by The University of Liverpool, The University of Manchester, and 
the Biology and Biotechnology Research Council.  
Skin 
Atopic skin samples were taken from dogs undergoing a diagnostic procedure as part of 
their treatment plan. Where necessary, the dogs were sedated with 10-20mg/kg medetomidine 
(Dormitor®; Pfizer Animal Health, Sandwich, UK) given IV. 0.5-1.0ml of 2% lignocaine 
without adrenalin was then infiltrated into the subcutis under the sites marked for biopsy.  
Non-lesional samples were taken from clinically unaffected skin on the flank.  Lesional 
samples were taken from areas of erythema and macular-papular dermatitis from the ventral 
body.  Grossly evident excoriation, staphylococcal pyoderma and Malassezia dermatitis were 
avoided.   
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Control samples were taken from healthy dogs that had been euthanized for reasons 
unconnected with the study, with no history and clinical signs of pruritus or conditions likely 
to alter immune function. There was a delay of approximately 30 minutes between euthanasia 
and sample collection. 
In both cases six millimetre diameter skin biopsies were taken and either snap frozen 
using liquid nitrogen or placed into RNAlater™ (Ambion Inc., Austin, TX, USA). 
RNAlater™ and snap frozen samples were stored at -80 C.  
The tissue samples were excess to clinical requirements, stored and used with informed 
consent from the owners of each dog. The study followed ethical guidelines as laid down by 
The University of Liverpool, The University of Manchester and the Biology and 
Biotechnology Research Council.  
Buccal Swabs 
Buccal swabs were taken from control dogs attending the Bath Championship Dog show. 
A foam applicator was rubbed on the inside of the dogs‟ cheeks and then applied to the 
Whatman Indicating FTA® cards. The FTA® cards were used because they allowed storage 
of the buccal samples at room temperature. 
The buccal swabs were stored and used with informed consent from the owners of each 
dog. 
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2.2 Sample processing 
DNA extraction from blood 
A previous experiment carried out by myself and others
154
 indicated that Qiagen Qiamp 
DNA blood midi kits (Crawley, UK) provide the best quality DNA for the blood samples 
used in this study. The DNA was extracted according to the manufacturer‟s instructions and 
assessed for quality using the Nanodrop® spectrophotometer ND-1000 (Thermo scientific, 
Delaware, USA). The DNA was then normalized to 20ng/µl or 50ng/ µl with distilled water 
or 10xTE using the Hamliton Microlab® Star (Bonaduz, Switzerland). The DNA was then 
stored at      -80°C or -20ºC until it was required.  
DNA extraction from buccal FTA® cards 
Two 6mm punches were taken from the FTA® cards (Whatman Inc., Florham Park, NJ) 
and the DNA was extracted using a variation on a previously optimised method
155
 . Figure 
2.1 shows this optimized method.  
 
 
 
 
 
 
 
33 
 
Figure 2.1 DNA extraction process from buccal FTA cards (Lema etal (2006)155) 
 
 
 
Figure 2.1 shows the method for DNA extraction from FTA cards. FTA-PR is FTA® Purification Reagent 
(Whatman Inc., Florham Park, NJ). A 6mm punch of the FTA card was placed into an eppendorf with 200µl 
FTA-PR and incubated in an ice bath for 30 minutes. The FTA-PR is discarded and a further 200µl was added, 
the sample was kept on ice for a further 15 minutes. This was discarded and 150µl of TE buffer (10ml 1M 
TRIS, 0.2ml 0.5M EDTA up to 1 litre with distilled water) were added and kept at room temperature for 5 
minutes. The punch was transferred into a clean eppendorf where 200µl of DNA elution solution (100ml 1M 
NaOH, 100ml 1M TRISHCL, 0.625ml 0.5M EDTA up to 1 litre with  distilled water) were added, the tube was 
inverted at room temperature for 5 minutes. The sample was then votexed 5 times for 2 seconds and left to stand 
at room temperature for 5 minutes. This was repeated 3 times. The punch was discarded leaving a DNA 
solution. 
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The protocol above was modified by doubling the volumes of FTA® Purification Reagent 
(Whatman Inc., Florham Park, NJ) and TE-1 buffer to allow for 2 punches being used instead 
of one. The volume of DNA elution solution (100ml 1M NaOH, 100ml 1M  Tris-HCL, 
0.625ml 0.5M EDTA, bring up to 1L) was unaltered; this was to maximize the concentration 
of DNA extracted. The DNA was stored at -20ºC until required. 
2.3 RNA extraction from skin, quality assessment & cDNA synthesis  
Total RNA was extracted from the skin biopsies using the dismembranator (Mikro-
Dismembrator, Sartorius Stedim Biotech, France). The powder was then placed in Trizol® 
(Sigma, Poole, UK) and extracted using a chloroform alcohol technique and a RNA 
extraction kit from Qiagen (Crawley, UK). The integrity and quality of the RNA was checked 
using the Agilent 2100 Bioanalyzer (Agilent Biotechnologies Inc., Santa Clara, CA, USA).    
cDNA synthesis was performed via reverse transcription using Superscript II reverse 
transcriptase (Invitrogen, Paisley, UK) according to the manufacturer‟s instructions 
(http://www.invitrogen.com). Initially 200μg (10μl) total RNA were pre-incubated with 
0.5μg (1μl) oligo-dT (Invitrogen) and 10mM (1μl) dNTP mix (Invitrogen) at 65°C for 5 
minutes. 4μl of 5x first strand buffer (containing 250 mM Tris-HCl (pH 8.3), 375 mM KC1, 
15 mM MgCl2), 2μl of 0.1M DTT and 40 units (1μl) of RNase inhibitor (Promega, 
Southampton, UK) were added to each sample and the samples incubated for 2 minutes at 
42°C, followed by the addition of 200 units (1μl) of Superscript II reverse transcriptase 
(Invitrogen) and incubation for 50 minutes. Reverse transcriptase activity was terminated by 
incubation at 70°C for 15 minutes. 
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2.4  Laboratory techniques  
The techniques described here are presented as an outline to the methodology; individual 
differences to the methods will be presented in subsequent chapters. 
Quality assessment of DNA 
The concentration and 230/240 and 260/280 ratios were measured using the Nanodrop® 
spectrophotometer ND-1000 (Thermo scientific, Delaware, USA). The 260-280nm ratio of 
samples needed to fall within 1.8 to 2 to be uncontaminated and be used in this study. 
Quality assessment of RNA 
The Bioanalyser 2100 (Agilent Biotechnologies Inc., Santa Clara, CA, USA) was used to 
assess the quality of the RNA using a RNA 6000 Nano Chip Kit (Agilent Biotechnologies). A 
RNA Integrity Number (RIN) is returned. In this study samples with a RIN score lower than 
6 were excluded. 
Normalisation, dilutions and sample sorting 
The Hamilton robot was used to normalize the DNA to either a concentration of 50ng/µl 
or 20ng/µl. All DNA was stored in the UK DNA Companion Animals archive at either -40ºC 
or -80ºC. The XL20 robot was used to cherry pick samples for the study using 2D barcodes 
on each sample tube. Finally the Cybio robot was used in some PCR protocols to dilute DNA 
or to add SAP solution to PCR products. 
RNA Microarray 
The canine microarray was designed and preformed by WALTHAM® Centre for Pet 
Nutrition; details of the assay are summarised in Chapter 3. 
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Q PCR assay design 
The qPCR assays were all performed in triplicate using a TaqMan™ ABI PRISM 7900 
SDS (Applied Biosystems, Foster City, CA, USA) in a 384-well plate format. A 10-μl 
reaction volume was used per well. This consisted of 5 μl Taqman 2X PCR master mix 
(Universal PCR Mastermix; Applied Biosystems), 0.1 μl each of 20 μM forward and reverse 
primers (MWG Biotech, Eurofins, Germany) 0.1 μl of 10 μM probe (Exiqon; Roche 
Diagnostics Ltd), 0.1 μl distilled water and 4.6 μl of sample cDNA or water for the negative 
controls. 
The amplification was performed according to the standard ABI 7900 protocol: 10 
minutes at 50°C followed by 40 cycles of 95°C for 1 minute and 60°C for 15 seconds, as 
recommended by the manufacturer (Applied Biosystems). The real-time data were analysed 
by Sequence Detection Systems software, version 2.2.1 (Applied Biosystems). The detection 
threshold was set manually at 0.05 for all assays. Standard curves were generated for each 
assay, to confirm the efficiency of the assay is between 93%-107% and the R
2
 value was       
> 0.98. 
Touchdown PCR 
Touchdown PCR was used as opposed to traditional PCR because it reduces non-specific 
priming and therefore the background „noise‟ caused by non-specific DNA fragments is 
reduced. It does this by gradually lowering the annealing temperature as the PCR cycles 
progress. Initially the annealing temperature is set 7°C above the temperature of melting 
(Tm) of the primers used, at each cycle the temperature is reduced by 0.5°C. The initial higher 
temperature increases specificity, and the subsequent lower temperatures permit more 
efficient amplification from the specific products formed during the initial cycles. 
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The touchdown PCRs were performed throughout to optimize primers and were on either 
a DNA engine Dyad™ peltier thermal cycler or a DNA engine Tetrad™ PTC-225 peltier 
thermal cycler (MJ research Inc., Waltham MA, USA) using these cycling conditions: 95ºC 
for 5minutes, followed by 95ºC for  30seconds, Ta+7ºC for 30 seconds (reduce by 0.5ºC per 
cycle) and 72ºC for 1minute for 13 cycles, and 95ºC for 20 seconds, Ta for 1 minute,  and 
72ºC for 1 minute for 19 cycles, and finally 72ºC for 5minutes.  
Gradient PCR 
Gradient PCR was used when touchdown PCR failed to optimise primers, this allowed a 
temperature range to be run across the primers establishing the correct temperature for 
amplification. Once this temperature was established touchdown PCRs were performed. 
Electrophoresis-gel quality check 
All PCR products were run on a 2% agarose gel with a 1kb ladder (Promega, 
Southampton, UK) to assess the concentration and size of the PCR product. 
Transgenomic WAVE 
Details of sample selection, primer design, cycling conditions and equilibration are in 
Chapter 6. Conditions were generated for each fragment using WAVEMAKER V4.1.44 
(Transgenomic, Huston, Texas, USA) software.  
Microsatellite genotyping 
The initial PCR assays were all performed on the Dyad™ peltier thermal cycler or a DNA 
engine Tetrad™ PTC-225 peltier thermal cycler (MJ research Inc., Waltham MA, USA) in a 
384-well plate format. A 10μl reaction volume was used per well: 0.04μl Hot start Taq 
(5U/µl Qiagen, Crawley, UK), 0.05μl each of 50pmol/µl forward (labelled) and reverse 
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primers (Metabion, Germany), 0.3µl MgCl2 (25mM, Qiagen, Crawley, UK), 0.5μl DNTPs 
(2mM), 1µl x10 buffer (Qiagen, Crawley, UK) 3.06µl distilled water and 5µl of DNA at 
5ng/µl. The cycling conditions were as follows: 95ºC for 5 minutes, then 94ºC for 20 
seconds, 55ºC for 30 seconds and 72ºC for 30 seconds for 10 cycles, 89ºC for 20 seconds, 
55ºC for 30 seconds and 72ºC for 30 seconds for 20 cycles and finally 72ºC for 10 minutes. 
ABI prism® Rox400 (Applied biosystems, Foster City, CA, USA) was used for accurate 
sizing. The ABI prism® 3100 genetic analyzer data collection software V1.1 (Applied 
biosystems, Foster City, CA, USA) was used to set up the run. The ABI prism® Genescan 
software V3.7 (Applied biosystems, Foster City, CA, USA) was then used to analyse the 
data.  ABI prism® Genotyper software V3.7 (Applied biosystems, Foster City, CA, USA) 
was used to group the results into genotypes/microsatellites. Full details are in Chapter 6. 
Illumina canine SNP20 GWAS array 
The Illumina canine SNP20 GWAS array was performed by the Barts and the London 
Genome Centre according to the manufacturers‟ instructions; assay details are in Chapter 7. 
Sequenom genotyping 
Sequences of genes to be genotyped were retrieved from Ensembl using the Biomart data 
mining tool
156
 and exported in FASTA format. A PERL script was used to convert the 
FASTA file into a suitable format for the Sequenom design tools. Using ProxSNP and 
Prextend
157
 quality control procedures were run on the sequences applied, rejecting 
unsuitable sequences for the Sequenom platform. The SNPs were then plexed together by the 
assay design software (MassARRAY) in a way that means the greatest chance of genotyping 
success and the largest number of SNP possible was included on each plex. 
39 
 
All primers and probes were supplied by Metabion (Germany); the probes were diluted 
using distilled water to 400µM and the primers to 100µM using the Hamilton Robot. The 
primers were then pooled together in plexes, each primer within the pool at a concentration of 
500nM done by the Hamilton robot. Probes were also pooled into plexes although the plex 
was split into low mass and high mass probes; low mass at a concentration of 7µM and high 
mass at 14µM, again performed on the Hamilton robot. The primers and probes were then 
ready for PCR, details of which are given in Chapters 8 & 9. 
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3. Candidate genes & Microarray Analysis of Gene Expression 
 
The mRNA microarray analysis has previously been published: Merryman-Simpson A.E., 
Wood S.H., Fretwell N., Jones P.G., McLaren W.M., McEwan N.A., Clements D.N., Carter 
S.D., Ollier W.E., Nuttall T.J. (2008), Gene (mRNA) expression in canine atopic dermatitis: 
microarray analysis. Veterinary Dermatology, 19(2):59-66. 
3.1 Introduction 
The literature review suggested that cAD has a heritable component with many complex 
interactions. It was hoped that by using a candidate gene approach and investigating gene 
expression and polymorphisms, the pathogenetic mechanisms contributing to disease 
aetiopathogenesis would be identified.  
In this chapter I will consider literature-based candidate gene selection and mRNA 
microarray analysis of gene expression. 
Candidate genes are usually selected for their identified function suggested in exsisting 
literature.  For example AD is often associated with keratinocyte hyper-proliferation; it is 
therefore logical to select a gene that is responsible for keratinocyte proliferation. Though 
previous association or linkage based studies also prove useful in gene selection. Literature 
searches are inevitably biased by personal opinion and current trends in research. 
Microarray analysis of gene expression (mRNA microarrays) allows comparison between 
disease-associated and control gene expression by measuring a selection of mRNA transcripts 
on a microarray chip. Microarray chips have multiple thousands of known RNA sequences 
attached, each representing an individual gene/protein. Figure 3.1 shows the preparation of an 
mRNA microarray chip.  
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Figure 3.1 mRNA Microarray preparation and analysis
 
Figure 3.1: RNA is extracted from control and diseased tissue samples. The RNA is then amplified using a 
PCR reaction. The control samples are mixed with red dye and the diseased with green dye. The control and 
disease samples are hybridized to the microarray and by measuring the intensity of dyes on the microarray it is 
possible to identify genes that are up-regulated, unchanged and down-regulated in each (i.e. if a transcript is up-
regulated in the disease state the intensity of the green dye will be greater than the red for that transcript and vice 
versa).  
This method allows for an unbiased approach in candidate gene selection as the 
transcripts used cover a large portion of the genome, including hypothetical proteins and 
genes of unknown function.  This broad sweep approach can potentially identify novel genes 
in the pathogenesis of cAD. Literature searches can be useful in narrowing down genes 
identified by microarray analysis by inferring function.  
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mRNA microarray analysis measures the levels of expression of mRNA transcripts for  
large numbers of genes and can justifiably be used in a relatively small number of case and 
control samples, keeping costs down whilst still providing a wealth of data. Statistical 
correction of mRNA microarray data is required as mRNA microarrays are prone to false 
positive results
158
. However, this correction can lead to crucial genes being omitted from the 
analysis. 
The purpose of this study was to identify potential candidate genes involved in cAD using 
literature searches and a canine mRNA microarray. To do this Ensembl
159;160
 and Pubmed
161
 
were used for the literature searches and an mRNA microarray designed by WALTHAM® 
Centre for Pet Nutrition and supplied by Agilent with 22,000 transcripts was utilized. Control 
skin from healthy dogs was compared to two disease skin samples (lesional and non-lesional) 
from each atopic dog. It was hoped the literature search and mRNA microarray would supply 
good candidate genes for further genetic study in cAD. 
3.2 Methods  
Case recruitment and sample collection 
 Diagnosis and sample collection/storage was performed as detailed in Chapter 2. This 
study compared 17 cAD cases with nine healthy controls. The cases included 12 pure breeds 
(Labrador retriever, German shepherd, Rhodesian ridgeback, West Highland white terrier, 
Staffordshire bull terrier, Scottish terrier, Jack Russell terrier, bulldog, Boxer, bull mastiff, 
Springer spaniel, Neapolitan mastiff) and five cross breeds. Seven were male (13 months – 8 
years 1 month) and 10 were female (7 months – 9 years 2 months). The healthy control dogs 
included seven pure breeds (Jack Russell, German shepherd, Staffordshire bull terrier, 
Labrador, Boxer and English bull terrier) and two cross breeds. All controls were male dogs 
(18 months - 8 years), All the animals were privately owned. 
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RNA extraction and quality assessment  
This was performed as detailed in Chapter 2. 
Agilent 22K oligonucleotide canine array  
The canine microarray experiments were designed and performed by WALTHAM® 
Centre for Pet Nutrition. All the data was analysed by me. 
The array was designed by definition of coding fragments from the 1.2x poodle genome 
sequence in collaboration with Celera (Celera diagnostics, Rockville, MD
162
). An in-house 
54,000 protein database and the NCBI reference sequence database
163
 were used to isolate 
matching islands for dog coding sequences using the Basic Local Alignment Search Tool 
(BLAST)
164
.  Non-redundant sequences matching the NCBI reference sequence database 
(cut-off of e-40) and the Protein database (cut-off of e-20) were submitted for oligonucleotide 
design to Agilent technologies (Agilent Technologies, Palo Alto, CA). Three 
oligonucleotides per sequence were designed and tested against mRNA derived from canine 
blood, testes and cell culture.  Based on maximum performance on the chip and uniqueness in 
the gene set, one of the three oligonucleotides was selected. 
Following the first round of in vitro transcription the amplified RNA underwent a second 
round of amplification and fluorescent labelling with Cyanine 5-CTP (PerkinElmer, Bucks, 
UK) or Cyanine 3-CTP (PerkinElmer, Bucks, UK) using the low RNA input fluorescent 
linear amplification kit protocol (Agilent Technologies, Palo Alto, CA).  The Cyanine 
labelled amplified RNA samples were subsequently purified using RNeasy® spin columns 
(Qiagen Ltd, West Sussex, UK) and were eluted in a volume of 60µl. 
Target solutions for the microarray chips were produced by combining 8 pmol of 
Cyanine-3 and Cyanine-5 labelled cRNA and 1x control targets in 1x fragmentation buffer as 
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described in the Agilent 60-mer oligo microarray processing protocol.  The hybridisation mix 
was loaded onto the 22K microarray which was incubated for 17 hours at 60
o
C with rotation 
at 4 rpm. 
The microarrays were initially washed in 6 x SSPE (0.75M NaCl, 50mM NaH2PO4, 5mM 
EDTA, pH 7.0) + 0.005% N-lauroylsarcosine followed by a 0.06 x SSPE+ 0.005% N-
lauroylsarcosine wash and finally a wash in acetonitrile Far UV (Fisher Scientific, Leic, UK). 
The microarrays were scanned at a resolution of 5µm in an Agilent G2565AA microarray 
scanner system (G2567AA Feature extraction software, version 7.1, Agilent Technologies, 
Palo Alto, CA.). The images were analysed using an Agilent Technologies software package.   
Statistical analysis of microarray data 
Data were imported into Genedata Expressionist Analyst (Genedata AG, Basel, 
Switzerland), and the Cy3 and Cy5 fluorescence intensities normalised using lowest weighted 
linear regression (LOWESS). Normalised data in tab delineated text format were uploaded 
into NIA array analysis
165
. This allowed a pair-wise comparison of gene signal intensity 
(expression) with fold difference of two or greater and statistical significance of P ≤ 0.05, as 
determined by single factor analysis of variance with multiple hypothesis correction by the 
false discovery rate (FDR). The fold change was calculated for each sample to represent a 
ratio of expression between disease and control samples.  This number was further corrected 
to provide the actual fold change in the sample as follows: ratio -1 if the sample was up-
regulated and by (-1/ratio) +1 for down-regulated samples.  This is stated as the true fold 
change.  
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Literature selected candidate genes 
PubMed
161
 and Ensembl
159;160
  databases containing research articles and gene sequence 
information, were employed to research genes and/or chromosomal regions with reported 
associations with cAD and/or hAD. These databases were also used to identify proteins with 
functions relevant to the disease pathogenesis. 
3.3 Results 
Microarray analysis 
Fifty four genes out of 22,000 were found to be significantly differentially expressed in 
cAD skin when compared to healthy control skin (p=<0.05).  Sixteen of the 54 genes showed 
an increase or decrease in expression in both lesional skin and non-lesional skin from dogs 
with AD when compared to skin from healthy controls (Table 3.1, Figure 3.2).  Twelve of the 
54 genes were only differentially expressed in lesional skin when compared to healthy 
controls (Table 3.2, Figure 3.3), and the remaining 26 were only differentially expressed in 
non-lesional skin (Table 3.3, Figure 3.4).  Only one gene, S100 calcium binding protein A8 
(S100A8), showed a significant increase in expression when comparing lesional to non-
lesional skin (Table 3.2).  The true fold change in expression between healthy, lesional and 
non-lesional skin and statistical significance are presented in Tables 3.1, 3.2 and 3.3, with the 
genes grouped according to function.  Figures are presented here to visually represent the 
patterns of expression (Figures 3.2, 3.3 and 3.4). 
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Table 3.1 Genes Differentially Expressed in Both Lesional and Non-lesional Atopic
   Skin Compared to Skin from Healthy Controls Grouped According to
   Function 
  Lesional skin Non-lesional skin 
 
Gene name Accession 
number 
True fold 
change 
P value 
corrected 
by (FDR)§ 
True fold 
change 
P value 
corrected 
by (FDR)§ 
Inflammation/Immunology      
LOC488898 (ARTS-1) XP_546015.1 -1.60 0.00 -3.4 0.00 
Cell cycle/apoptosis/repair/lesion formation     
LOC477298 (POSTN) XP_534490.1 4.52 0.00 2.85 0.00 
LOC478537 (down-
regulated in ovarian cancer 1 
isoform 2) 
XP_535715.2 2.53 0.04 3.07 0.01 
Translational control      
LOC474556 (eIF-5B) XP_531784.1 3.36 0.00 3.03 0.00 
Transport/regulation      
LOC480332 (kinectin 1) XP_537455.1 2.19 0.00 1.66 0.01 
LOC478312 (Myosin Va) XP_535487.1 2.05 0.02 1.98 0.02 
LOC475224 (A-kinase 
anchor protein 9 isoform 2) 
XP_532456.1 1.65 0.05 1.61 0.04 
Canis familiaris ret proto-
oncogene (RET) 
XP_543915.1 -2.31 0.03 -5.3 0.00 
Barrier formation      
Golgin subfamily a, 5 CAA54261.1 2.09 0.00 2.19 0.00 
Golgin subfamily a, 4 AAC51791.1 1.41 0.02 1.39 0.01 
Golgin subfamily a, 5 NP_002069.2 1.41 0.04 1.85 0.00 
Miscellaneous      
LOC475424 (EEA1) XP_532649.1 2.42 0.00 2.23 0.00 
LOC610752 (CG15747-PA) XP_868363.1 2.02 0.00 1.54 0.01 
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Table 3.1 continued 
 
C6orf142 (chromosome 6 
open reading frame 142) 
NP_612636.1 -2.28 0.00 -5.4 0.00 
LOC492014 (sushi-repeat-4) XP_549134.1 -2.50 0.00 -6.8 0.00 
Hypothetical protein 
LOC55086 
AAH70110.1 -2.70 0.03 -8.5 0.00 
 True fold change represents the actual change in expression. §FDR is the false discovery rate which was 
used to correct the P values, all of which are <0.05. The results show five significantly down-regulated genes 
and 11 significantly up-regulated genes. 
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Figure 3.2  True Fold Change of Gene Expression in Lesional and Non-lesional Skin Compared to Control Skin* 
                *The error bars represent standard error
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Table 3.2  Genes Differentially Expressed Only in Lesional Skin when Compared to
   Healthy Controls.  
Gene name Accession 
number 
True fold 
change 
P value corrected by 
(FDR)§ 
Inflammation/Immunology 
LOC490461 (S100A8)* * XP_547583.1 22.81 0.00 
LOC 485209 (INPPL1) NP_001558.2 7.49 0.00 
LOC483954 (SCCA-2) XP_541074.1 3.11 0.00 
LOC480749 (SAA3) XP_537868.1 3.07 0.01 
serum amyloid A protein [Canis 
familiaris]- no records 
AAA62765.1 2.91 0.00 
LOC403816 (TIMP1) BAA32393.1 2.72 0.04 
LOC751814 (SAA) AAA62762.1 2.67 0.01 
Cell cycle/apoptosis/repair/lesion formation 
LOC474674 (similar to RAD50 
homolog isoform 1) 
XP_531901.1 2.00 0.04 
LOC484662 (CIDE-3) XP_541777.1 -1.99 0.00 
Transport/regulation  
LOC480623 (Sperm-associated 
antigen 5 (Astrin)) 
XP_537743.1 1.56 0.05 
Barrier Formation  
LOC143662 (Mucin-15) AAH20912.2 1.29 0.05 
Miscellaneous  
LOC477037 (hypoxia induced gene 1) XP_534235.1 1.42 0.05 
 True fold change represents the actual change in expression. §FDR is the false discovery rate which was 
used to correct the P values, all of which are <0.05. The results show one significantly down-regulated gene and 
11 significantly up-regulated genes. ** Represents significant difference between lesional and non-lesional skin. 
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Figure 3.3  True Fold Change of Gene Expression in Lesional Skin Compared to Control Skin* 
 
                         *The error bars represent standard error
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Table 3.3 Genes Differentially Expressed Only in Non-lesional Skin when 
   Compared to Healthy Controls  
Gene name Accession number True fold 
change 
P value 
corrected by 
(FDR)§ 
Inflammation/immunology    
C10orf118 (CTCL (cutaneous T cell lymphoma) 
tumor antigen L14-2) 
AAM44457.1 2.16 0.03 
IL1RAPL1 (interleukin 1 receptor accessory 
protein-like 1) 
NP_001009038.1 -1.24 0.03 
Cell cycle/apoptosis/repair/lesion formation   
LOC482986 (SYND1) XP_540099.1 -1.13 0.04 
LOC489256 (Cadherin-14) XP_546374.1 -1.54 0.00 
LOC8451 (Cullin 4A) AAR13072.1 -1.60 0.03 
Transport/regulation    
LOC480045 (Nucleoprotein TPR ) XP_537167.1 2.21 0.05 
LOC479689 (potassium channel tetramerisation) XP_536820.2 -1.18 0.04 
LOC486205 (FERM, RhoGEF and pleckstrin 
domain protein 2) 
XP_543330.1 -1.26 0.01 
LOC487294 (ATP-binding cassette C12e) XP_544420.1 -1.58 0.01 
TJP3 (tight junction protein 3) NP_001003202.1 -1.63 0.00 
LOC486657 (phospholipase C, zeta 1) XP_543784.1 -1.65 0.05 
Barrier formation    
LOC483653 (Mucin-2) XP_540774.1 -1.47 0.03 
Transcription factor    
LOC481111 (STAT2) XP_538232.1 -1.21 0.02 
CGGBP1(CGG triplet repeat binding protein 1) AAD04161.1 -1.70 0.00 
LOC485022 (FUSE binding protein 2) XP_542140.1 -1.44 0.03 
FOXO4 (foxhead box) XP_549066.1 -1.66 0.03 
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Table 3.3 continued 
 
Miscellaneous    
LOC477332 (RING-H2 protein) XP_534526.1 2.49 0.03 
LOC480963 (ATRX1) XP_538084.1 1.83 0.01 
C1orf163 (hypothetical protein LOC65260) AAH15313.1 -1.47 0.02 
LOC 465184 (FBXL10) XP_520652.2 -1.50 0.01 
LOC2346 (FOLH1) AAC83972.1 -1.51 0.02 
LOC491989 (S6K-alpha 6) XP_549109.1 -3.71 0.00 
LOC476102 (mSin3A-associated protein 130 ) XP_533311.1 -1.66 0.02 
LOC489724 (PH domain leucine-rich repeat 
protein phosphatase-like) 
XP_546844.1 -1.72 0.02 
LOC488148 (similar to ecotropic viral 
integration site 1) 
XP_545272.1 -1.82 0.01 
LOC50525 (Spag6) NP_056588.1 -3.94 0.00 
 True fold change represents the actual change in expression. §FDR is the false discovery rate which was 
used to correct the P values, all of which are <0.05. The results show 22 significantly down-regulated and four 
significantly up-regulated genes. 
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Figure 3.4  True Fold Change of Gene Expression in Non-lesional Skin Compared to Control Skin
 
                        *The error bars represent standard error
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Literature & Microarray selected candidate genes 
The candidate genes selected for further study are summarised in Table 3.4. Candidate 
genes were chosen based on relevant function, any previous associations with hAD and/or 
significant changes in expression on the canine microarray. 
Table 3.4  Summary of Potential Candidate Genes in cAD, selected from Literature 
   Searches and mRNA Microarray   
Gene Name Evidence From: Supporting 
References 
Barrier Function 
GOLGA4 Canine microarray 45;166 
LOC483653 (homologue to MUC2) Canine microarray 167 
Filaggrin (FLG) Functionality, association, 
microarray and linkage. 
51;52;168;169 
SPINK5 Function and association 126;170 
SGPL1 Function and RT-PCR 45;49;171 
CSTA (cystatin A) Functionality and 
microarray 
45;172;173 
SPRR1B (cornifin) Function and microarray 169;174;175 
PKP2 (plakophillin) Function and microarray 176-180 
CARD4 Function and association 45;75 
Immunology/Inflammation 
TSLP Function 45;181;182 
INPPL1 (SHIP2) Canine microarray 183 
LOC480749 (homologue to serum 
amyloid SAA1) 
Canine microarray 184;185 
LOC483954 (homologue: SCCA2 
or SERPINB4) 
Canine microarray 186 
LOC490461 (homologue:S100A8) Canine microarray 187 
LOC488898 (homologue:ARTS-1) Canine microarray 188 
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Table 3.4 continued 
 
IL1RL1 Function and association 147;189 
CTLA4 Function and association 118 
DPP4 Function and microarray 178;190-193 
MS4A2 Linkage and function 43;45;112 
CMA1 Linkage and function 43;194 
Cell cycle/apoptosis/repair/lesion formation 
LOC477298 (homologue:POSTN) Canine microarray 195 
TIMP1 Canine microarray 196 
CUL4A Canine microarray 197 
LOC482986 (SYND1 – CD138 
antigen) 
Canine microarray 198 
SOCS3 (Suppressor of cytokine 
signalling 3) 
Linkage, microarray and 
function 
115;199;200 
CDH13 (cadherin 13) Function and microarray 178;201;202 
Calcium Transport 
LOC486657 (phospholipase C, zeta 
1) 
Canine microarray 203 
Transcription Factor/misc. 
LOC481111 (homologue: STAT2) Canine microarray 204 
PPARγ/α Function and microarray 178;205-209 
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3.4 Discussion 
This study set out to identify potential candidate genes involved in disease pathogenesis.  
The literature searches suggested 16 genes with either functions relevant to AD pathogenesis 
or reported associations to hAD. The canine mRNA microarray identified 54 genes that were 
dysregulated in cAD suggesting that a number of complex interactions lead to the atopic 
phenotype. A number of these genes have functions that potentially link them with cAD. 
Table 3.4 summarises the candidate genes selected for further study and the evidence upon 
which the selection was based, these included: function, human AD skin mRNA microarray 
studies, canine skin mRNA microarrays, qPCR, genetic linkage and association. The results 
of the microarray analysis are discussed below; the results of the literature search will be also 
be discussed in this section, under the sub-heading “literature selected candidates” (p.62). 
mRNA canine Microarray 
The greatest increase in gene expression observed in this study was by S100 calcium 
binding protein A8 (S100A8), which showed a 22.81 fold increase in lesional skin compared 
to control skin. The S100 gene family encode pro-inflammatory molecules released by 
phagocytes in inflammatory conditions
187
 and their levels have been shown to „track‟ the 
severity of inflammatory diseases
210
.  Release is stimulated by tumour necrosis factor (TNF)-
α, a cytokine expressed in both canine and human AD187. The RAGE/NF-κβ pathway is 
thought to maintain release of TNF-α and subsequent release of S100211 via a positive 
feedback loop.  Previous studies have shown that TNF-α expression is also correlated with 
the degree of inflammation in both canine and human AD
1;31
. S100A8 has also been linked to 
leukocyte recruitment, suggesting that it is a key gene in the inflammatory response
187
. In this 
study, S100A8 was not significantly over-expressed in non-lesional skin, suggesting that it 
has a purely inflammatory role in lesional skin. 
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Serum amyloid A (SAA) was over-expressed in lesional skin, and is produced in response 
to inflammation. SAA is an apolipoprotein that recruits immune cells to inflammatory sites 
and is regulated by interleukin (IL)-1, IL-6 and TNF-α184;185.  
 Squamous cell carcinoma antigen 2 (SCCA2) is another gene associated with 
inflammation and is induced in response to IL-4 and IL-13.  SCCA2 has been shown to 
disrupt the enzyme function of Dermatophagoides house dust mite allergens which are 
known triggers of allergic responses
186
, suggesting SCCA2 may be released as a protective 
measure. The dogs included in this study all had positive intra-dermal test reactions to 
Dermatophagoides farinae and D. pteronyssinus. SCCA2 expression, however, was only 
increased in lesional skin, indicating that expression will have little impact on early responses 
to dust mite allergen exposure. 
Several other genes differentially expressed only in lesional skin (Table 3.2, figure 3.3) 
were mainly inflammatory genes and, with the exception of cell death-inducing DFF45-like 
effector-3 (CIDE3), were over-expressed.  Genes expressed exclusively in non-lesional skin, 
in contrast, were generally under-expressed (Table 3.3, Figure 3.4) and represent a range of 
functions.  The majority of these down-regulated genes are involved in the transport of 
calcium, potassium and other ions.  Calcium transport is increased in inflammatory 
conditions and calcium is essential for the function of some pro-inflammatory molecules.  
The down-regulation of calcium transport may represent a lack of an anti-inflammatory 
stimulus in non-lesional skin. Differences in non-lesional skin compared to healthy control 
skin were unexpected; suggesting that non-lesional skin in cAD is not „normal‟ and could 
represent “pre-lesional” skin in AD. 
Increased levels of Signal transducer and activator of transcription 2 (STAT2), have been 
linked to allergic driven inflammation
212
 therefore, it would be expected that lesional skin 
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would show increased STAT2 expression when compared to control skin but no 
dysregulation of STAT2 was observed in lesional skin. However, STAT2 expression was 
decreased in non-lesional skin compared to control skin. Altered expression of STATs has 
also been linked with a number of inflammatory barrier-related diseases such as irritable 
bowel syndrome (IBS) and psoriasis
213;214
, and with human atopic diseases such as rhinitis 
and asthma
215;216
, suggesting that there may be a role for STATs in cAD. Furthermore, STAT 
is part of the JAK-STAT pathway
217
 which is the way interleukins transduce the signals that 
initiate cytokine specific gene transcription.  Whilst only STAT2 was included in this array, 
there are another six STAT genes within the family that perform a range of functions, some 
antagonistic to each other. It would therefore have been interesting to include all the STAT 
genes on this microarray. 
Forkhead box O4 (FOXO4), a transcription factor, was down-regulated in non-lesional 
skin.  Forkhead box P3 (FOXP3) is a related gene that is expressed on human T-regulatory 
cells
218
, whose expression leads to inhibition of the immune response
219
.  Defects in T-
regulatory cells are associated with immune pathologies; for example FOXP3 deficient mice 
develop allergic airway inflammation and exaggerated IgE responses
220
. If FOXO4 performs 
similar functions, initial down-regulation may lead to the poor T-regulatory cell function 
hypothesised in cAD
31
, resulting in increased levels of IgE, chronic inflammation and lesion 
formation. However, the function of FOXO4 has not yet been defined in any species. 
Not all human and canine AD cases present with increased IgE levels
1
 indicating that 
there is more to AD than allergic hypersensitivity.  It has been suggested that skin barrier 
formation may play a role in the development of human and canine AD
42;43
. A recent study 
suggested that differences in barrier function could be involved in both IgE and non-IgE 
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associated hAD (see Figure 1.2 for details)
44
.  Genes relating to skin barrier/epidermis 
formation could, therefore, be important in the pathogenesis of cAD. 
Strong genetic linkage to hAD has been previously reported within the epidermal 
differentiation complex (EDC) on chromosome 1q21
44;110;221
. The EDC comprises genes such 
as pro-Filaggrin, loricrin, involucrin, S100 and small proline rich proteins (SPRPs), which are 
essential for keratinocyte differentiation and epidermal barrier formation
221;222
. A large-scale 
microarray study of hAD
169
 found S100 to be up-regulated in lesional skin, as observed in 
this study, whilst Filaggrin and loricrin were down-regulated. We were not able to study 
Filaggrin and Lorcrin using the present canine array, as at the time of designing the array the 
importance of these genes was unknown. Moreover, designing primers for Filaggrin is 
difficult due to its repetitive sequence. With the exception of a few microsatellite markers I 
am currenlty unaware of any group that has successfully designed primers for canine 
Filaggrin.    
Ceramide is a lipid essential for barrier function and formation; it covalently binds to 
involucrin, envoplakin, elafin, SPRPs and loricrin to form a lipid layer and the cornified 
envelope
223
. Ceramide maintains the skin moisture levels by limiting trans-epidermal water 
loss (TEWL)
45
. In human atopic patients; atopic skin has significantly lower amounts of 
ceramide compared to healthy skin, and the TEWL in atopic patients is 2 fold greater in non-
lesional skin and 4 fold greater in lesional skin when compared to healthy skin
45
. It has also 
been demonstrated by chromatography that ceramide levels in non-lesional cAD skin 
decreased
224
. Ceramide was not on the canine array used but the ceramide transporter Golgi 
auto-antigen Golgi subfamily a4 (GOLGA4) gene was present
166
. The study results showed 
that GOLGA4 was up-regulated in lesional and non-lesional atopic skin suggesting that 
although GOLGA4 associated ceramide transport is enhanced, ceramide levels are still low in 
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atopic skin. The reported low ceramide levels may be associated with post-transcriptional 
defects or other functional abnormalities. Increased bacterial colonisation of atopic patients 
may explain the decreased levels of ceramide seen in atopic skin
46
. Bacterial ceramidases 
break down ceramide, giving the characteristically low ceramide levels and dry skin seen in 
atopic dermatitis
46
. This is consistent with the hypothesis that bacterial colonisation is linked 
to chronic AD
47;48
. It is possible that the increased expression of GOLGA4 is in response to 
low cutaneous ceramide levels. 
Both human and canine AD are characterised by spongiosis of the epidermis. This is most 
severe at lesional sites, though present at non-lesional sites
225
. Syndecan-1 (SYND1) is 
present in the keratinocyte membrane where it modulates cellular adhesion, regulating the 
cell architecture
226
. Down-regulation of SYND1 is associated with spongiosis
227
. In this 
study, SYND-1 was down-regulated in non-lesional skin but not in lesional skin. The reason 
for this is unclear although other inflammatory factors may influence expression. For 
example in IBS
198
 increased levels of  TNF-α cause down-regulation of SYND1, suggesting 
that if the levels of TNF-α were increased at non-lesional sites relative to lesional sites, this 
may have caused the down-regulation observed. As discussed in Chapter 1, AD shows a 
biphasic T cell response and is characterized by the presence of TNF-α in the early stages and 
IFN-γ in the latter stages. This suggests that non-lesional skin is perhaps “pre-lesional” skin 
(i.e. that is skin which is atopic but is yet to show clinical symptoms) and may have increased 
TNF-α levels which lead to the decrease SYND1 levels discussed above. This reasoning is 
however speculative, as TNF-α expression was not measured in this study. 
Chronic lesions in human and canine AD are characterised by fibrosis and lichenification.  
This is promoted by periostin (POSTN) and tissue inhibitor of metalloproteinase 1 
(TIMP1)
195;196
. These genes may therefore contribute to lesion formation in AD.  On the 
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canine microarray used, POSTN was over-expressed in both lesional (not statistically 
significant) and non-lesional skin (statistically significant).  TIMP1, in contrast, was only 
over-expressed in lesional skin.  In human studies, serum levels of TIMP1 were greater in 
atopic patients and levels correlated with the chronicity of lesions and degree of 
lichenification
196
. 
This study has identified genes expressed in atopic lesional and non-lesional canine skin 
compared to normal healthy canine skin.  The identification and inclusion of IgE responders 
and non-IgE responders as discrete groups (i.e. atopic dermatitis and atopic-like dermatitis) 
on the array may have further explained the pathogenic mechanisms of cAD. Given the 
previous implication in hAD of Filaggrin and involucrin, inclusion of these genes on the 
array would have been beneficial.  
Microarray experiments provide a rapid, wide ranging, unbiased assessment of many 
genes, allowing novel genes to be identified in the pathogenesis of cAD. However, it is 
relatively insensitive to small changes in expression which, when dealing with a complex 
disease such as cAD could result in important genes with small effects being missed. Given 
the incidence of false positive results when using microarray
158
, the Benjamini and Hochberg 
correction
151
 was used.  This gives a false discovery rate (FDR) and represents the probability 
the findings were due to chance.  In this study, all FDRs were between 0 and 0.05 indicating 
the findings in this study were robust. Nevertheless, the results will need to be confirmed 
using quantitative PCR (qPCR); a more sensitive, accurate and quantitative method. 
 Literature selected candidate genes 
Candidate genes selected from literature searches are presented in Table 3.4, which is 
divided into functionally relevant sections. These sections will be used to structure the 
discussion of the candidate genes.  
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Barrier formation  
The stratum corneum
221
 is formed from the basal layer and involves synthesis of keratins 
and cornified envelope proteins in the keratinocytes. The cornified envelope forms following 
interactions between involucrin, envoplakin, elafin, small proline rich proteins (SPRPs) and 
loricrin. Ceramide covalently bonds to these proteins to form a lipid layer
223
. Human genetic  
linkage studies demonstrate that chromosome 1q21, where these genes and Filaggrin are 
located, is linked with hAD
168
. 
Filaggrin is down-regulated in hAD in human microarrays
169
. Since the canine array was 
designed, multiple studies have reported the importance of Filaggrin in hAD.  Two loss of 
function variants were identified in filaggrin
52
 and other mutations and associations have 
been found
51;228-231
.  The variants R501X and 2282del4 were discovered in nine families. 
Linkage analysis confirmed that they are predisposing factors for AD, leading to the 
conclusion that AD is inherited as a „semi-dominant trait with high penetrance in 
homozygotes‟ and a „reduced penetrance in heterozygotes‟52. Filaggrin also contributes to 
barrier formation by causing the cells to compact into squames by aggregating to the keratin 
cytoskeleton. Filaggrin can be broken down at the stratum corneum to form a „natural 
moisturizing substance‟42;53.  A decrease in the amount of Filaggrin, as seen in hAD, could 
lead to dry skin and decreased barrier function. Because of the importance of Filaggrin in 
hAD it is an excellent candidate for cAD research. More recent studies have revealed that 
atopic canine skin features higher levels of trans-epidermal water loss, decreased ceramide 
levels
224
 and reduced expression of Filaggrin when compared with healthy canine skin
63
. 
However a decrease in Filaggrin expression has only been observed in an experimental 
colony of IgE sensitized Beagles. These Beagles are an experimental model for cAD but do 
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not represent the clinical disease in the dog population as a whole, therefore Filaggrin levels 
in clinical cases of AD across different breeds remains to be quantified. 
SPRR1B also represents a good candidate for further research, being a component of the 
cornified envelope, it is located in the same region as Filaggrin and is involved in epidermal 
formation via keratinocyte differentiation and peptide cross linking
174;175
. Furthermore, it has 
been shown to be up-regulated in a human microarray study
169
.  
PKP2 is a structural component of desmosomes
176
. Desmosomes are specialized cell 
junctions which are essential for adhesion and tensile strength of epithelia. There are many 
sub-components to desmosomes such as cadherins, desmogleins, desoplakins etc
177
. Because 
of their role in maintaining skin barrier strength it is possible that these could be involved in 
the pathogenesis of cAD. Furthermore, PKP2 has been shown to be down-regulated in 
microarray experiments
178
 in hAD. PKP2 expression has been implicated in beta catenin/T 
cell factor signalling activity
179
 and  T-cell survival
180
, further suggesting a possible role in 
cAD.  
SGPL1 is part of a complex pathway involved in lipid metabolism, and a key modulator 
of ceramide metabolism
232
, the importance of which in AD was discussed earlier. Its 
expression was shown to be increased in a human real-time PCR study
171
.  
Cystatin A produces a precursor of one of the proteins in the cornified envelope in 
keratinocytes, and it also plays a role in epidermal development and maintenance
233;234
. 
Cystatin A is also a cysteine protease inhibitor of house dust mite protease
235
, which has 
shown an association with hAD
236
. 
CARD4 (NOD1) has been associated, in a German human population, with AD
75
. It 
encodes cytosolic pathogen recognition receptors, with a preference toward recognition of 
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gram-negative bacteria, and because of this it has been suggested that CARD4 may represent 
a „novel barrier-based pathogenic mechanism underlying the development, maintenance, or 
both of AD‟43.  
SPINK5 functions in hair and skin morphology, proteolysis during epithelial formation 
and keratinocyte differentiation
170
. This suggests that altered SPINK5 expression will have 
implications for skin barrier function
237
. SPINK5 mutations are associated with the atopic 
phenotype in both British
125
 and Japanese
126;127
 human AD cohorts. It is also associated with 
Netherton syndrome in humans, where two of the symptoms are atopy and ichthyosis
125;238
. 
Immunology and inflammation  
Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine which has been 
implicated in allergic disease
181;182
. Immunohistochemistry in humans has shown that there is 
increased expression of TSLP by keratinocytes in atopic skin lesions in hAD
239
. Mouse 
studies have also suggested a role for TSLP in the pathogenesis of AD; over-expression of 
TSLP in the mouse model epidermis leads to the development of AD symptoms and cytokine 
profile
240;241. TSLP has been referred to as the „allergic master switch‟182 for allergic 
inflammation. Observations of TSLP-treated human blood dendritic cells, demonstrate an 
induction of an inflammatory Th2 cytokine pattern
239
. A recent study has demonstrated that 
TSLP also „converts human epidermal Langerhans cells into antigen-presenting cells that 
induce pro-allergic T cells‟242. Previous studies have noted that Langerhans cells serve as 
antigen-presenting cells in AD
243;244
, and expression of high-affinity IgE receptors allows for 
more efficient allergen capture, processing and presentation to T cells
245
. This effect of TSLP 
could render Langerhans cells capable of inducing or maintaining AD symptoms
242
. 
IL-1 receptor-like 1 (IL1RL1) is a protein coding gene for an IL receptor.  Studies of the 
gene in mice suggest that IL1RL1 can be induced by pro-inflammatory stimuli, and it is also 
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thought to be involved in helper T cell function
246
. IL1RL1 has many splice variants, and one 
of these, ST2L, has been linked to hAD because it is expressed in Th2 but not Th1 cells
189
.  A 
more recent study identified a SNP in the distal promoter of IL1RL1 gene that is significantly 
associated with human AD. Moreover, this SNP directly affects the expression level of 
ST2L
147
.  
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is in the immunoglobulin 
superfamily and encodes a protein which transmits an inhibitory signal to T cells. Altered 
expression of CTLA4 has been implicated in autoimmune disease. Although there is little to 
support a potential role for CTLA4 in AD, one study found an association with human 
(infant) AD and CTLA4 polymorphisms
118
. 
Membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high 
affinity I, receptor for; beta polypeptide; MS4A2) has been shown to be in an area of linkage 
with human AD. MS4A2 produces FcεRIβ which is important in IgE function43;112, as 
discussed in Chapter 1. FcεRIβ binds allergen specific IgE expressed on Langerhans and mast 
cells
32
. Binding of the allergen triggers mast cell degranulation and the release of 
inflammatory mediators which leads to the acute phase Th2 response seen in AD. Due to the 
implication of MS4A2 in the inflammatory Th2 response it is a potential candidate in the 
pathogenesis of AD.  
CMA1 produces the protein mast cell chymase 1, a chymotryptic serine proteinase which 
is expressed in mast cells and functions as a pro-inflammatory molecule. CMA1 is in a 
chromosomal region linked with hAD
43;194
 and  has shown associations with hAD and/or total 
serum IgE in three separate Japanese
132-134
, one British
135
 and one German population(s)
136
. 
Dipeptidyl-peptidase 4 (DPP4) is identical with the leukocyte surface antigen CD26 and 
belongs to the group of post-proline dipeptidyl aminopeptidases
191;247
.  DPP4 is expressed on 
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the surface of resting and activated T, B and NK cells
192
.  It has been implicated in the 
activation of regulatory T cells, T cell cycle arrest, inhibition synthesis and proliferation of T 
cells, and suppression of T-cell production of inflammatory cytokines
191
, making DPP4 an 
interesting candidate for AD. Down-regulation of DPP4 has been observed in AD on a 
human microarray
178
 and a human flow cytometery study
190
. It is suggested that reduced 
DPP4 expression could lead to less effective regulation of inflammation
192
, delayed wound 
healing
193
 and ultimately lesion formation in AD.   
Cell cycle/apoptosis/repair/lesion formation  
Cadherin-13 (CDH-13) is expressed in basal keratinocytes
248
 and may modulate cell–
matrix adhesion
202
. Down-regulation of CDH-13 protein was observed by 
immunohistochemistry in psoriasis vulgaris
249
.  It is thought to act as an endogenous negative 
regulator of keratinocyte proliferation and its inactivation may promote the keratinocyte 
hyper-proliferation in psoriasis vulgaris
201
.  It was found to be up-regulated in hAD using 
microarray experiments
178
. Because of its role in keratinocytes and increased detection on the 
microarray, CDH-13 represents a potential candidate gene for cAD. 
Suppressor of cytokine signalling 3 (SOCS3) is a cytokine-inducible negative regulator of 
cytokine signalling. It is induced by a number of cytokines, of which the most relevant to AD 
are IL-10 and IFNγ.  The chromosomal region of SOCS3 was associated with hAD in genetic  
linkage studies
54;115
. Furthermore, an expression study recorded significant increases in 
expression of SOCS3 mRNA and protein in hAD and identified haplotypes associated with 
human AD in a Swedish population
199
. It has been suggested that SOCS3 regulates 
keratinocyte proliferation and differentiation, implicating a role in skin repair and, 
potentially, AD
200
.  
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 Transcription Factor/miscellaneous  
Peroxisome proliferator-activated receptor gamma (PPARγ) is an anti-inflammatory 
molecule and may be important in the development of chronic inflammation. Down-
regulation of PPARγ was observed in a human microarray study of AD178. Reduced 
expression of PPARγ is associated with reduced lamellar body formation and lipid 
processing, and increased epidermal permeability. This could affect TEWL and barrier 
formation in AD
209
. However, another study using immunohistochemistry, western blotting 
and qPCR demonstrated that PPARγ is increased in lesional skin from AD patients250. The 
authors also demonstrated that IL-4, IL-13 and IFNγ, which are involved in the biphasic 
atopic immune response, directly regulate the expression of PPARγ250. Regulation of PPARγ 
therefore represents a potential novel therapeutic target AD
209
. 
Conclusion 
Using mRNA microarray a number of candidate genes with both barrier function and 
immunological activity have been identified. There are similarities between this studies 
finding and hAD studies, suggesting that cAD is a suitable model for hAD.  Using mRNA 
microarray and literature searches, 29 potential candidate genes were selected for further 
genetic research.  
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4. Quantitative Real Time PCR – Optimisation and Quality Control 
 
This work is presented in: Wood S.H., Clements D.N., McEwan N.A., Nuttall T., Carter 
S.D. (2008), Reference genes for canine skin when using quantitative real-time PCR. 
Veterinary Immunology and Immunopathology, 126 (3-4):392-5.  
4.1 Introduction 
Chapter 3 identified candidate genes for further research into cAD pathogenesis by using 
mRNA microarray analysis. This provided useful data relating to the expression of specific 
genes in diseased and control skin tissues in dogs. However, as discussed previously 
(Chapters 1 and 3) microarrays are prone to false positive results and require confirmation by 
a robust quantitative method of gene (mRNA) expression. Quantitative real time PCR 
(qPCR) is the current “gold standard” for RNA quantification in cells or tissues and is 
increasingly used in veterinary research to investigate various conditions. It therefore 
represents the best method to confirm the mRNA microarray results in Chapter 3.  
qPCR is essentially a polymerase chain reaction that is monitored in „real time‟, recording 
the  amount of PCR product generated over time instead of at one time-point, as with 
traditional quantification methods e.g. southern, northern blot, regular PCR. Fluorescent 
reporter molecules are used to monitor the amount of PCR product, the intensity is measured 
and a Ct value is produced. The Ct value represents the number of PCR cycles that elapse 
before a PCR product concentration threshold is reached. The sooner the threshold is reached 
the more PCR product present, allowing comparison of case and control samples.  
qPCR can be absolute or relative; absolute is the most accurate method as it uses a known 
concentration control to calculate the number of mRNA transcripts present in the samples, 
whereas relative quantification compares arbitrary Ct values.  
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There are many pitfalls when performing qPCR experiments therefore thorough 
optimisation and quality control is essential to obtain accurate and meaningful results. 
Therefore this chapter aims to consider and describe essential quality control experiments 
which will allow the accurate quantification of RNA to confirm the mRNA microarray results 
and quantify other candidate genes potentially involved in the pathogenesis of cAD. 
The comparison of qPCR data poses a number of problems because differences in tissue 
and mRNA storage/handling techniques
251
, mRNA quality
252;253
, method of reverse 
transcription
254
, concentration of the cDNA samples and presence of PCR inhibitors can all 
effect the data generated.  Minimisation of these differences is essential for accurate 
quantification of gene expression. By considering storage/handling techniques for the tissue 
samples and comparing subsequent mRNA quality it is possible to establish the best method 
for storage of tissue for RNA extraction.  
Assessing the quality of the RNA is traditionally done by comparing the 28S to 18S ratio, 
however this method has been shown to be inconsistent as it relies on human interpretation of 
gel pictures
253
. To improve RNA quality assessment the RNA Integrity Number (RIN) 
algorithm is used
255
. RIN provides a more robust universal measure of RNA quality therefore 
sample comparison is standardized enabling repeatability of experiments. RIN is calculated 
automatically by using the entire electrophoretic trace of the RNA sample (see Figure 4.1). 
By applying a RIN cut-off to samples used in subsequent studies it ensures reproducibility 
and that only high quality RNA is used. 
72 
 
Figure 4.1  Examples of Electrophoretic Traces Generated to Determine RNA Integrity
       Number (RIN) (adapted from Schroeder  et al (2006)
255
)  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: (a). Shows the areas of the electrophorectic trace that are assessed to calculate RIN, these are the 
5S region, fast region, 18s fragment, inter region, 28s fragment, precursor region and the post region. (b). Shows 
electrophoretic traces from RNA samples ranging in RIN from 2 to 10. 10 is the best quality. 
(a.) 
(b.) 
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Data transformation through “normalisation” is used to correct for these differences in 
handling and quality. Normalisation is achieved by quantifying the expression of a 
constitutively expressed gene, termed a reference gene, which is unaffected by the disease 
process or experimental condition being investigated. Normalisation equalises variability
256
, 
by relating the reference gene expression values to those of the gene of interest in samples 
analysed. Therefore, a reference gene must be stably expressed with consistent and repeatable 
levels of expression across all samples
257
. A reference gene that is not stably expressed could 
lead to errors in quantification. To improve the accuracy of results obtained from qPCR it is 
essential that suitable reference genes are identified and validated. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is often used as a universal reference gene for qPCR. It 
has, however, been demonstrated that this and other commonly used reference genes can 
have variable expression across tissue types and disease states
258;259
. Therefore the ideal 
reference gene(s) for use in a given experiment should be determined on an experiment to 
experiment basis, as it is unlikely there is a reference gene that is equally constitutively 
expressed in all tissues or cells in a given species.  
Standard curves are generated in a qPCR experiment, these are necessary for accurate 
quantification of gene expression using qPCR. They establish the limits of detection of the 
assay and give the efficiency of the assay which is essential for calculating the actual 
transcript number when using known concentration artificial oligonucleotides for 
quantification of gene expression
260
. Standard curves are generated before the main 
experiment and occasionally are generated using a different sample type to the sample type 
used in the final experiment, for example using RNA extracted from keratinocyte cultures 
instead of RNA extracted from tissue. The reasons for this are that culture represents a freely 
available resource of RNA whereas experimental tissue is limited. Therefore to preserve the 
experimental tissue, keratinocyte RNA is used for standard curve generation.  Because these 
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are effectively different sample types the effect on the generation of standard curves was 
investigated. 
The first aim of this study was to establish the best tissue storage technique by comparing 
RIN and yield of RNA extracted. The second aim was to compare expression of candidate 
reference genes in canine skin to identify those suitable for this qPCR experiment. Potential 
reference genes for canine skin were selected from a panel of commonly used reference 
genes
258
 and a previous microarray study that identified potential reference genes in canine 
tissue
257
. From this previous data IMP, CG14980, S7, HIRA, GAPDH, RPL13A and SDHA 
were identified as good candidates for reference genes in canine skin.  The stability of the 
reference genes was assessed by Bestkeeper
261
, GeNorm
258
 and Normfinder
262
 software 
packages. The final aim was to assess the effect of using different sample types e.g. cultured 
cells, clinical tissue and disease status tissues (lesional, non-lesional and control) on standard 
curve generation. It was considered that by performing these quality control steps the 
subsequent qPCR experiments would be accurate and robust. 
4.2 Method 
Diagnosis, sample collection, sample processing & dogs 
Diagnosis, sample collection, extraction and cDNA synthesis were preformed as set out in 
Chapter 2 (sections 2.1, 2.2 and 2.3). 
The RIN and yield comparison was performed on 57 skin samples stored by snap freezing 
and 22 stored in RNAlater™. The samples were a mix of lesional, non-lesional and control 
samples (see Appendix 1 for sample details). 
The following samples were used in the reference gene experiment. Lesional skin was 
obtained from 3 male and 4 female atopic dogs with a mean age of 4.8 years (range 2-9), 
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comprising Staffordshire bull terrier, Labrador, Scottish terrier, West Highland white terrier, 
Boxer (2) and Neapolitan mastiff.  Non-lesional skin was taken from seven atopic dogs, 4 
female and 3 male, with a mean age of 1.6 years (range 11 months to 3 years). The breeds 
were: crossbreed, Staffordshire bull terrier, Springer spaniel, Labrador and Boxer dogs (3). 
The control samples were from 4 females and 3 males that had an average age of 4.8 years 
(range 10 months to 10 years). The breeds were: crossbreed (4), Boxer, German shepherd dog 
and Siberian husky.  
For standard curve generation, ten-fold dilutions of cDNA derived from canine 
keratinocyte cultures (CELLnTEC, Bern, Switzerland), lesional skin, non-lesional skin and 
control skin were used. A pool of lesional, non-lesional and control cDNA skin samples were 
also used to generate standard curves.  
Primer & Assay design 
Transcript sequences and the assay design for the reference gene study were obtained 
from two previous studies
257;263
 and are reproduced in Table 4.1. See Chapter 2 (section 2.4) 
for cycling conditions and assay volumes. Transcript sequences obtained from Ensembl were 
cross checked with NCBI canine genome transcript sequences. The assays were designed in 
areas that showed 100% homology between the Ensembl and NCBI sequences. To design the 
primers the Roche universal probe library designer was used (https://www.roche-applied-
science.com/servlet/). Where possible, the primers were designed to cross an exon-exon 
boundary. If this was not possible, the primers were designed to be intron spanning to ensure 
that the primer hybridised on different exons. In these cases the intron was greater than 
1000bp to maintain specificity. This approach to primer design increases the chance that the 
primers are transcript specific and minimises genomic DNA contamination.  Finally, the 
specificity of the primers was checked using BLAST
164
. The primers used in the standard 
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curve generation were SCCA2 and Cystatin A. Table 4.1 lists the primers, probe numbers and 
amplicons for each gene.    
The samples for standard curves were diluted serially and the assays were performed as in 
the Chapter 2 (section 2.4). 
Table 4.1 Primers, probes and amplicons for qPCR 
Gene Forward 
Primer 
Reverse 
Primer 
Probe 
Number 
(Roche) 
Amplicon 
IMP cgctgcctcttt
caaacat 
tttggcctcatcttc
actgag 
62 cgctgcctctttcaaacatgtcagcccag
caggtgctgctgttggaattccactcagt
gaagatgaggccaaa 
CG14980 gcaggaaggg
attctccag 
gggtccagtaag
aaatcttccataa 
72 gcaggaagggattctccagtaagggcg
gagatgccaggaaatcttcaacattatgg
aagatttcttactggaccc 
S7 agtgcaggga
gaagaagcac 
cagcagctcgtgt
gacaact 
89 agtgcagggagaagaagcaccggcgg
atgctgatgccagagaagttgtcacacg
agctgctg 
HIRA aattcagaacat
gctgcaatttta 
tgattcatcatcca
taacctgttc 
39 aattcagaacatgctgcaattttatattcca
gaggtggagggtgtagaacaggttatgg
atgatgaatca 
GAPDH ctggggctcac
ttgaaagg 
caaacatggggg
catcag 
68 ctggggctcacttgaaaggcggggcca
agagggtcatcatctctgctccttctgctg
atgcccccatgtttg 
RPL13A ctgccccacaa
gaccaag 
gggatcccatcaa
acacct 
64 ctgccccacaagaccaagcgaggccag
gctgccctggaccgcctcaaggtgtttga
tgggatccc 
SDHA ggtggcacttct
acgacacc 
atgtagtggatgg
cgtcctg 
20 ggtggcacttctacgacaccgtgaaggg
ctccgactggctgggggaccaggacgc
catccactacat 
SCCA2 agaattctggct
ggacaagg 
tggtatttctagga
tcttggcttg 
65 agaattctggctggacaaggacacaagc
aaacctgtgcagatgatgagacaatcca
acgtttttaatttcacctcactggaggactt
gcaagccaagatcctagaaatacca 
Cystatin A ccaagaatttg
aagccgtaga 
ctattatcacctac
ccgcacct 
83 ccaagaatttgaagccgtagagtataaaa
ctcaagtggtggctggaataaattactac
attaaggtgcgggtaggtgataatag 
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Comparison of RIN in snap frozen & RNAlater stored tissues 
RIN and RNA yield was determined according to general methods in section 2.4. RIN 
and RNA yield was compared between tissues collected and stored in RNAlater and those 
snap frozen. 
Statistical analysis 
The Ct values for the reference genes were assessed for stability of expression across all 
samples using three different statistical algorithms; Bestkeeper
261
, GeNorm
258
 and 
Normfinder
262
.  Bestkeeper uses raw Ct value for analysis but Genorm and Normfinder use 
the average power of Ct. To calculate the power of Ct, the E value (efficiency of the assay) is 
required. This is calculated using the slope of the standard curve for each gene is used:  
           
  
           
                       
The consensus from these three programs was used to demonstrate the most stably 
expressed reference gene. 
Averages of the yield and RIN were taken and the Student t-test was used to assess the 
difference between tissue collection and storage (for full results see Appendix 1).  
The standard curves were assessed by the slope of the standard curve as established by 
the 7900 software and from this the percentage efficiency of the assay was calculated, as 
below: 
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4.3 Results 
Comparison of RIN 
Table 4.2 RIN and yield comparison 
 RNA 
concentration 
(ng/µl) 
% 
Variation 
(error) 
RNA Integrity 
Number (RIN) 
% 
Variation 
(error) 
RNAlater™ 
samples (n=22) 
732.5 17.7 8.1 1.9 
Snap frozen 
samples (n=57) 
268.6 19.1 6.8 3.3 
 
Table 4.2 shows the average RNA concentration and RIN. The percentage variation is 
used to represent the spread of values obtained. This is calculated using the standard error and 
the average value. Variation below 20% is usually acceptable in biological experiments. It is 
clear that the RIN has a lower percentage variation than the concentration; this is because 
RIN is independent of the sample concentration which is variable across samples. Using the 
Student T-test it was found that RNA concentration was significantly higher in RNAlater 
samples (p=0.0024) and that RIN was significantly higher in RNAlater samples (p=0.0005).  
Figure 4.2 shows the spread of RNA and RIN results for both RNA later and snap frozen 
samples. See Appendix 1 for full results. 
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Figure 4.2 RNA concentration and RNA integrity number results from Snap Frozen 
        and RNAlater preserved skin 
                 
                 
Figure 4.2: (a.) All RNA concentration values for snap frozen and RNAlater preserved skin. The mean is 
represented as is the standard deviation by error bars. (b.) All RNA integrity number values for snap frozen and 
RNAlater preserved skin. The mean is represented as is the standard deviation by error bars.  
 
(a.) 
(b.) 
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Reference gene selection 
Bestkeeper 
Bestkeeper (Table 4.3) determines a co-efficient of correlation, standard deviation and 
percentage covariance, with the user making a decision which is the best gene based on these 
three variables. GADPH had the best co-efficient of correlation, meaning that its expression 
correlated well with the other reference gene expression patterns. Nevertheless, the 
percentage co-variance and standard deviation were high, meaning that the stability of 
expression was low between the samples and replicates. SDHA and S7 had the lowest 
standard deviations but their correlation co-efficient was poor. Therefore, CG14980 and 
RPL13A offered the best stability with high co-efficient of correlation and low standard 
deviation and percentage co-variance.  
Table 4.3 Bestkeeper results 
Reference Gene 
Co-efficient of 
correlation 
Standard Deviation % Co-Variance 
CG-14980 0.992 2.008 7.20 
RPL13A 0.979 1.888 10.23 
GAPDH 0.99 2.756 12.12 
HIRA 0.956 2.291 9.13 
IMP 0.973 3.162 12.25 
SDHA 0.939 1.788 7.88 
S7 0.835 1.586 6.75 
The co-efficient of correlation, standard deviation and percentage covariance are all outputs from Bestkeeper 
that represent the stability of the reference genes. 
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Normfinder 
Normfinder (Table 4.4) returns an arbitrary stability value and standard error, based on 
the intra- and inter-group variations of each gene. It thereby selects the two best reference 
genes automatically. In this case CG14980 and RPL13A were chosen as they had the lowest 
stability value and standard error. 
Table 4.4 Normfinder Results 
Reference Gene Stability value Standard error 
CG-14980 0.288 0.109 
RPL13A 0.359 0.107 
HIRA 0.534 0.116 
SDHA 0.712 0.135 
GAPDH 0.741 0.139 
IMP 1.081 0.183 
S7 1.195 0.199 
Normfinder returns a stability value and standard error to represent the stability of the reference gene. 
GeNorm 
GeNorm (Figure 4.3) generates a graph to represent the data and calculates a stability 
value (M) via pair-wise comparisons. This method varies from the other two methods in that 
it assesses the stability of the best pair of reference genes and not individual stability. This 
means that the pair of genes with the most similar expression profile are selected, not 
necessarily the most stable gene
262
. GeNorm indicated that HIRA & RPL13A were the most 
stably expressed pair of reference genes, with a significant M value under 0.4
258
. CG14980 
was the third most stably expressed.  
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Figure 4.3 GeNorm results 
 
 
Figure 4.3 shows the output from Genorm, which plots the stability value (M) against the reference genes 
tested giving an order of stability.
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Standard curve generation 
Table 4.5 Standard curve efficiency results 
Sample Type SCCA2 efficiency (%) Cystatin A efficiency (%) 
Keratinocytes Not expressed 100.7 
Control Not expressed 103.6 
Lesional 96.1 98.7 
Non-lesional 84.2 95.2 
Pooled (lesion, non-lesional and 
control) 
93.9 100.2 
 
Table 4.5 shows that keratinocytes and healthy tissue did not express SCCA2. The 
efficiency of the standard curve must be within 93-107%
264;265
 for accurate quantification. 
The SCCA2 standard curve efficiency for non-lesional skin was 84% well below acceptable 
limits for accurate quantification. However lesional skin had an efficiency of 96% which 
meant that it did fall within acceptable limits for accurate quantification. When all the 
samples were pooled the efficiency was 94%, which was within the acceptable limits for 
accurate quantification.  
Cystatin A was expressed in all sample types and all fell within the efficiency parameters. 
However there was considerable variability with the efficiency ranging from 95% to 103%. 
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4.4 Discussion 
It has been demonstrated that RNAlater stored skin samples are better preserved than 
snap frozen tissues and therefore give higher concentrations and RIN values. This suggests 
that in future it would be best to collect skin for qPCR in RNAlater. 
Standard curve generation has shown variability in the percentage efficiency when using 
different sample types. Because the standard curve efficiency is required to calculate the 
transcript number of genes expressed it is essential that the value best represents the 
experimental conditions. In the case of SCCA2, keratinocytes and healthy skin did not 
express the gene, in this situation it would be best to use the pool of lesional, non-lesional and 
control skin samples because this best represents the experimental conditions and represents 
all sample types therefore establishing the most reliable standard curve available for this 
gene.  
Cystatin A was expressed in all sample types; however, the percentage efficiency was 
variable across the sample types. Using keratinocyte cultures was the most sample efficient 
method for generating standard curves; however, as demonstrated by this experiment the 
standard curve generated by the cultures was different to the experimental sample and in the 
case of SCCA2 no curve could be generated. Ideally, a separate standard curve would be 
generated for each experimental sample type; however, this is not only time consuming and 
wasteful of samples and reagents, but in some cases, as demonstrated by SCCA2, no standard 
curve which meets the efficiency parameters can be generated. Therefore a pool of all 
experimental samples is the most accurate and sample efficient way to generate standard 
curves for further qPCR experiments.  
  CG14980 and RPL13A were shown by Bestkeeper and Normfinder to be the most 
stably expressed reference genes. HIRA was ranked 3rd and 4th by these programs 
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respectively, but the paired result from GeNorm found that HIRA and RPL13A were the 
most stably expressed. This disparity in results was due to the different methods used. 
Normfinder uses a model based approach that assesses each gene on the intra- and inter-
group variations whereas GeNorm uses a pair-wise approach. It has been stated that the 
model based approach used by programs such as Normfinder is „more precise and robust 
measure of gene stability than pair-wise comparisons‟262. Also, in the case of pair-wise 
comparison, two genes with similar expression levels are selected, this poses a problem if 
candidate reference genes have different expression levels. A threshold is applied to GeNorm 
that avoids use of dissimilar reference genes; therefore, not only are the most stably 
expressed genes not selected, in some cases no genes will meet the stability threshold 
excluding potentially suitable reference genes. Because of the criticisms of the pair-wise 
approach and the consensus between Bestkeeper and Normfinder, it was determined that 
RPL13A and CG14980 were the most suitable reference genes from the panel of genes 
analysed for use with healthy and atopic canine skin. This study validates these reference 
genes for use in canine skin for future qPCR studies.  
The results also determined that GAPDH was not stably expressed in canine skin. It is 
therefore probable that reliance on this reference gene may have influenced the results of 
previous qPCR studies in canine skin. Clearly, it would be pertinent to determine how the use 
of CG14980 and RPL13A, compared to GADPH, alters the results obtained from real time 
experiments. 
There is a possibility that these results have wider application, as it has been suggested 
that reference genes are relatively species independent
266
. If this is the case then these 
reference genes may be suitable for skin research in other species including humans. 
However, it has been demonstrated that the feline and canine reference genes differ in 
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stability
267
, although this analysis was based on GeNorm pair-wise comparisons which as 
stated earlier may not always select the most stable reference genes.  
It is important to state that these reference genes are not necessarily optimal for use with 
other tissue types, even those derived from skin such as keratinocytes. Reference genes 
should be tested prior to qPCR studies and the most stable for the specific tissue type chosen. 
In addition, the use of one reference gene is discouraged as it has previously been 
demonstrated that the use of two to four reference genes improves accuracy of 
quantification
258;266;268
. 
In conclusion, it is best to collect and store skin samples in RNAlater (compared to snap 
frozen tissues); also the use of pooled samples for standard curve generation is recommended. 
And finally in cAD when performing qPCR on skin samples the use of CG14980 and 
RPL13A as reference genes is advised. 
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5. Quantitative Real Time PCR - Analysis of Gene Expression in Canine Atopic 
Dermatitis and Correlations with Clinical Severity Scores 
 
This work is presented in: Wood S.H., Clements D.N., Ollier W.E., Nuttall T., McEwan 
N.A., Carter S.D. (2009) Gene expression in canine atopic dermatitis and correlation with 
clinical severity scores. Journal of Dermatological Science, 55(1):27-33 
5.1 Introduction 
Chapter 4 detailed the quality control experiments undertaken to establish a robust 
methodology for quantification of RNA in canine skin samples. Using this methodology, this 
chapter will detail the qPCR experiments carried out to validate gene expression data from 
the microarray study (Chapter 3) and to investigate changes in gene expression in candidate 
genes identified from literature searches on the pathogenesis of canine and human AD 
(Chapter 3).  
Validation of the mRNA microarray results  is necessary because mRNA microarrays are 
prone to false positive results
158
. Moreover, mRNA microarrays are relatively insensitive to 
small changes in expression and, therefore, relevant genes could be missed.  
 Figure 5.1 shows the selection of genes for this study using Table 3.4. Twelve genes with 
relevant epidermal or immune functions ( Cystatin A
235;236
, CARD4
75
 P-selectin
269;270
, 
PKP2
176, PPARγ250;271, SGPL1171, TNF-α43;272, Cadherin-13178, CMA1132;136, DPP4190, 
SPINK5
126;127
, SAA-1
273
) were selected as potential candidate genes for cAD following a 
literature search. Eight further genes (ARTS-1, Cullin-4A, INPPL1, S100A8, POSTN, 
SCCA2, STAT2, TIMP-1) were selected using data from the canine mRNA expression 
microarray
274
 (Chapter 3) that indicated they were dysregulated in cAD.  
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Figure 5.1 Gene selection for q-PCR quantification 
 
Figure 5.1 From the 29 genes listed in Table 3.4, 20 were selected for quantification by qPCR, 12 of which 
were from literature searches and 8 were dysregulated on the cAD microarray. Nine genes were excluded 
because primers or assays within acceptable limits could not be designed. The excluded genes were: GOLGA4, 
MUC2, TSLP, SPRR1B, IL1RL1, CTLA4, SYND1, SOCS3 and Filaggrin. 
Optimisation and quality control of data are essential in qPCR experiments and therefore, 
CG14980 and RPL13A
275
 were chosen as reference genes and pooled samples were used to 
generate standard curves and give the results more accuracy and validity.  
It was hoped that quantifying gene expression in atopic skin would increase 
understanding of the complex gene interactions in this condition and identify causative genes 
involved in disease pathogenesis.  
Canine Atopic Dermatitis Severity Index (CADESI-03) scores were recorded for each 
atopic dog. This is a well validated assessment of clinical lesions (erythema, excoriation, 
lichenification and self-induced alopecia) at 62 anatomical sites from 0 (normal) to 5 (most 
severe) yielding a score of 0-1240 (similar to the human SCORAD index)
153
. This assessment 
provides a score summarising the severity of the clinical signs in the affected dogs. In 
addition, the number of positive reactions to an intra-dermal allergen test (IDT) using 54 
environmental allergens (Greer Laboratories Inc., Lenoir, NC, USA) (similar to prick tests in 
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human patients) were recorded, as a measure of allergen specific IgE. In contrast to humans, 
total IgE levels in dogs do not correlate with atopic status or clinical signs, and the specificity 
and sensitivity of IgE specific serology is variable
33;276
. 
The first aim of this study was to quantify the expression of the selected candidate genes 
in lesional atopic, non-lesional atopic and healthy canine skin. The second aim was to 
correlate gene expression in atopic skin with the two clinical measures: the CADESI-03 score 
and the number of positive reactions on IDT. This dual approach was designed to help 
identify gene changes that were relevant to the clinical cause and outcome of AD. 
Furthermore, it was hoped that these experiments would help to determine whether cAD and 
hAD share a similar genetic background and help identify novel target genes for further study 
of pathogenesis and intervention.  
5.2 Method 
Diagnosis, sample collection, sample processing & dogs 
Diagnosis, sample collection, extraction and cDNA synthesis was preformed as described 
in Chapter 2.  
Lesional Skin was obtained from 17 affected dogs (8 male and 9 female) with a mean age 
of 3.9 years (range 11 months to 9 years). The breeds were: Boxer (5), Staffordshire bull 
terrier (2), Labrador (2), crossbreed (2), Springer spaniel, Rhodesian ridgeback, Scottish 
terrier, bulldog, West Highland white terrier and Neapolitan mastiff.  
Fourteen of the non-lesional samples were taken from the same dogs as the lesional 
samples. Three samples were taken from different dogs and the non-lesional age range was 
11 months to 8 years with an average age of 3.4 years. Nine were male and 8 were female 
and the breeds were as follows: Boxer (5), crossbreed (3), Staffordshire bull terrier (2), 
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Springer spaniel, Labrador (2), Rhodesian ridgeback, bulldog, West Highland white terrier 
and Neapolitan mastiff.  
The control dogs had a mean age of 4.8 years (range 10 months to 10 years) and 
comprised 10 females and 7 males. The breeds were: crossbreed (14), Boxer, German 
shepherd dog, Siberian husky.  
Primer & Assay design 
PCR cycling conditions and assay volumes are described earlier in Chapter 2.4. 
Transcript sequences obtained from Ensembl
159;160
 were cross checked with NCBI canine 
genome transcript sequences. The assays were designed for sequence areas that showed 
100% homology between the Ensembl and NCBI sequences. To design the primers the Roche 
universal probe library designer was used
277
. Wherever possible, the primers were designed 
to cross an exon-exon boundary. If this was not possible, the primers were designed to be 
intron spanning to ensure that the primer hybridised on different exons. In these cases the 
intron was greater than 1000bp to maintain specificity. This approach to primer design 
increased the chance that the primers were transcript specific and minimised genomic DNA 
contamination.  Finally, the specificity of the primers was checked using BLAST
164
. Table 
5.1 lists the primers, probe numbers and amplicons for each gene (see Appendix 2 for R
2
, 
slope, percentage efficiency and E value for each assay. These values were used in the 
statistical analysis and were calculated in advance to ensure the assay was within acceptable 
limits of detection and the efficiency range of 97-103%).  
Synthesised oligos of the amplified region (supplied by Eurogentec) for each gene were 
used to calibrate and allow absolute quantification of transcript number in all samples as 
previously described
260
. A full explanation of data transformation is presented in this section 
under the heading “statistical analysis” (p.94).  
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Table 5.1 Primers, probes and amplicons for qPCR 
Gene Forward 
Primer 
Reverse 
Primer 
Probe 
Number 
(Roche) 
Amplicon 
SCCA2 agaattctggctgga
caagg 
tggtatttctagga
tcttggcttg 
65 agaattctggctggacaaggacacaagcaa
acctgtgcagatgatgagacaatccaacgttt
ttaatttcacctcactggaggacttgcaagcc
aagatcctagaaatacca 
Cystatin A ccaagaatttgaagc
cgtaga 
ctattatcacctac
ccgcacct 
83 ccaagaatttgaagccgtagagtataaaactc
aagtggtggctggaataaattactacattaag
gtgcgggtaggtgataatag 
Card 4 tcgtcctgcaccact
tcc 
tgatctggtttacg
ctgagtct 
85 tcgtcctgcaccacttccgcaagcggcttgc
cctcgacctggacaacaacaatctcaacgac
tacggcgtgagggagctgcagccctgcttca
gccgcctcaccgtcctcagactcagcgtaaa
ccagatca 
P-selectin ctgcaccaatctgca
aagc 
atgagggctgga
cactgaac 
17 ctgcaccaatctgcaaagcaggcatagtgtc
agctcctacttcaaaggttcagtgtccagccc
tcat 
PKP2 aagcatctttgggag
ctctg 
ggccattttccttct
ggac 
4 aagcatctttgggagctctgcagaatctcact
gcaggaagtggaccaatgccgacatcagta
gctcagacagttgtccagaaggaaaatggc
c 
PPARɣ caggaaagacaac
agacaaatca 
ggggtgatgtgttt
gaacttg 
7 caggaaagacaacagacaaatcaccatttgt
tatctatgacatgaattccttaatgatgggaga
agataaaatcaagttcaaacacatcacccc 
SGPL1 cgggttccactgaa
caaaat 
ggagatggctctc
ctcattg 
10 cgggttccactgaacaaaatgatggaggtgg
atgttcgggcaatgaggagagccatctcc 
TNF-α atggcctccaactaa
tcagc 
cttggggttcgag
aagatga 
61 atggcctccaactaatcagccctcttgcccag
acagtcaaatcatcttctcgaaccccaag 
Cadherin 13 gccctcttcctggca
atc 
tccagagttatca
gcaaagttcc 
59 gccctcttcctggcaatcgacagtggcaacc
ctcccgctaccggtaccggaactttgctgata
actctgga 
CMA1 aggcggaacttcgt
actgac 
cccagggtgacc
attatga 
4 aggcggaacttcgtactgacagctgctcact
gtgcaggaaggttcataatggtcaccctggg 
DPP4 agacgcaaagtact
atcaactgagat 
gctgctcctatgc
agggtat 
81 agacgcaaagtactatcaactgagatgttca
ggccctggtctgcccctctataccctgcatag
gagcagc 
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Table 5.1 continued 
POSTN gggaagaacgaatc
attacagg 
ttgcaacaatttctt
cagagtttc 
77 gggaagaacgaatcattacaggtcctgaaat
aaaatatactaggatttctactggtggtggag
aaacagaagaaactctgaagaaattgttgca
a 
SPINK5 gaaagaggaggac
aacttgagaa 
gaattcgtggcac
tgatcct 
2 gaaagaggaggacaacttgagaaacacag
gagaaaagagtaatgaaaaccaggatcagt
gccacgaattc 
SAA-1 ttgtgctccctggtcc
tg 
gagtaggctctcc
acatgtctct 
66 ttgtgctccctggtcctgggtgtcagcagcca
gagatggttgacattcctcaaggaagcgggt
caagggactagagacatgtggagagcctac
tc 
ARTS-1 cctcatctgtccacg
tctga 
tgaagtggaaaat
cagttcaagg 
66 tgaagtggaaaatcagttcaaggcctttctcat
caggctgctgagggacctcattgataa 
tcagacgtggacagatgagg 
INPPL1 tctcgaagctcttctt
gtactcc 
cgcaccaagttct
tcattgag 
39 cgcaccaagttcttcattgagttctactccacc
tgcctggaggagtacaagaagagcttc 
gaga 
Cullin4A ccttggagagttcca
tgtcc 
tctatgttgtcaaa
actaaagcatga 
11 tctatgttgtcaaaactaaagcatgaatgcgg
cgctgctttcaccagcaagctggaaggc 
atgttcaaggacatggaactctccaagg 
TIMP-1 gtggggcacaggta
cagg 
cccagagagact
caccagaga 
3 cccagagagactcaccagagaacccaccat
ggcaccctttgcgcccctggcctcctgcat 
cctgctgttgctgtggctgaccgcccccagc
agggcctgtacctgtgccccac 
S100A8 caatgagggagttta
tggcact 
aaacctggtggg
gcagat 
154 aaacctggtggggcagatccttgggcaccat
gctgacggaactggagagtgccataaact 
ccctcattg 
STAT2 tctccagctccaagg
actct 
aggctcattgtgg
tctctaacag 
36 aggctcattgtggtctctaacagacaggtgg
atgagctgcaacaaccgctggagcttaag 
ccggagccagaagcagagtccttggagctg
gaga 
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Statistical analysis 
Normalised transcript numbers obtained from calibration with synthesised oligos and 
reference genes were used for the statistical analysis to compensate for the differences in 
concentration of the samples and accurately quantify expression. To calculate normalized 
transcript numbers the following method was used: 
                                                                     
                            
 
The Ct difference between the synthesized oligo and experimental sample was calculated:  
                                                           
E power was derived from the E value of the assay (see Chapter 4 Section 4.2, statistical 
analysis for calculation of E value); using Ct difference a power calculation is performed: 
                            
The transcript number was calculated using the E power and calibrator template number: 
                                                      
To take into account the differences in RNA concentration the samples were normalized. 
The geometric means of the reference gene transcript numbers were used to do this, for each 
experimental sample in turn: 
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Normalised transcript number was used in all subsequent statistical calculations (see 
Appendix 2 for E values, percentage efficiency, slope and R
2
 values for each gene assayed). 
The data were considered to be not normally distributed and therefore non-parametric 
tests were employed. Wilcoxon ranked sign tests (systat 12) were used to compare matched 
lesional and non-lesional samples. Mann Whitney U tests were used to compare data from 
atopic and control samples. The level of statistical significance was set at p<0.05 
The correlation analysis was carried out using the Pearson R test (Excel) which gives a 
correlation coefficient and a p value (<0.05). 
Fold change was used to compare microarray and qPCR results: 
                                
                               
                 
The fold change was transformed to represent the true fold change this process is different 
if gene is up-regulated or down-regulated.  
Up-regulated gene correction to obtain true fold change: 
                     
Down-regulated gene correction to obtain true fold change: 
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5.3 Results 
Validation of microarray results  
In the majority of cases, the microarray data overestimated the fold change, apart from 
S100A8 where it was underestimated (Figure 5.1). INPPL1, S100A8 and ARTS-1 showed 
the same trend of expression in qPCR and microarray, whereas Cullin4A and POSTN 
displayed opposing trends. qPCR, but not microarray, revealed a fold change in SCCA2 (non-
lesional), S100 (non-lesional), INPPL1 (non-lesional), TIMP-1 (non-lesional), Cullin 4A 
(lesional) and STAT2 (lesional). Conversely, microarray, but not qPCR, revealed fold 
changes in TIMP-1 (lesional).  
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Figure 5.2  Comparison of microarray fold change to qPCR fold change 
ARTS-1 Cullin4A INNPL1 POSTN S100 SCCA2 STAT2 TIMP-1
QPCR Fold change: Lesional vs control -0.08 0.8 2.48 -1.09 34.47 1.12 -0.22 0.2
Microarray Fold Change: Lesional Vs control -1.6 0 7.49 4.52 22.81 3.11 0 2.72
QPCR Fold change: Non Lesional vs control -0.37 0.4 0.78 -0.87 0.85 3.56 -0.3 -0.18
Microarray Fold Change: Non Lesional Vs control -3.4 -1.6 0 2.85 0 0 -2.1 0
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Quantification of candidate genes  
Table 5.2 shows the fold change in gene-specific mRNA expression between lesional, 
non-lesional and control skin. Figure 5.2 demonstrates these changes in expression for all the 
statistically significant genes for each individual sampled. Statistically significant changes in 
fold change of gene expression were seen between lesional atopic and control skin for 
SPINK5, INPPL1, DPP4, SGPL1, PPARγ, S100A8, PKP2, POSTN and Cullin-4A. Non-
lesional skin also showed statistically significant changes in expression compared to control 
skin for DPP4, INPPL1, PPARγ and S100A8, though to a lesser extent than in lesional skin. 
Only PPARγ and S100 showed a statistically significant difference in expression in lesional 
and non-lesional skin. TNF-α was down-regulated in non-lesional skin compared to controls 
and lesional skin, although this was only statistically significant when compared to controls. 
There were large changes in expression of SAA-1 and SCCA2 in lesional and non-lesional 
skin respectively compared to control skin but these were not statistically significant due to 
the large variation between individual cases (e.g. percentage variation SCCA2 = 31-84%; 
SAA-1 = 19-46%).
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Table 5.2  Gene expression in lesional, non-lesional and control skin 
Gene Lesional 
vs. 
Control 
skin ≠  
P 
value 
Non-
lesional vs. 
Control 
skin ≠   
P 
value 
Non-
lesional vs. 
Lesional 
skin ≠ 
P 
value 
DPP4 -1.11* 0.002 -0.53* 0.03 -0.38 0.12 
INPPL1 2.48* 0.002 0.78* 0.01 0.95 0.21 
SPINK5 4.68* 0.004 0.22 0.07 3.66 0.10 
SGPL1 0.74* 0.004 0.94* 0.001 -0.12 0.11 
PPARγ -0.79* 0.01 -0.17 0.39 -0.53* 0.03 
S100A8 34.47* 0.02 0.85* 0.05 18.15* 0.02 
PKP2 0.38* 0.03 0.52* 0.001 -0.10 0.95 
POSTN -1.09* 0.03 -0.87 0.08 -0.12 0.45 
Cullin4A 0.80* 0.03 0.40 0.28 0.28 0.45 
Cadherin-
13 
-0.51 0.06 -0.25 0.12 -0.21 0.33 
TNF-α -0.71 0.12 -0.92* 0.04 0.12 0.16 
SAA-1 2.39 0.17 0.13 0.11 2.00 0.15 
P-selectin -0.22 0.18 -0.32 0.08 0.08 0.29 
TIMP-1 0.20 0.23 -0.18 0.83 0.42* 0.05 
SCCA2 1.12 0.27 3.56 0.44 -1.14 0.50 
STAT2 -0.22 0.32 -0.30 0.19 0.06 0.21 
Cystatin-A 0.07 0.33 0.37 0.43 -0.28 0.16 
CMA1 0.15 0.38 0.56 0.17 -0.36 0.29 
CARD4 -0.13 0.39 -0.04 0.27 -0.09 0.54 
ARTS-1 -0.08 0.49 -0.37 0.11 0.27 0.21 
The ≠ denotes that the figures given are true fold change. Genes highlighted in yellow show genes that have 
statistically altered gene expression, the * denotes which change is statistically significant (<0.05). 
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Figure 5.3  Scatter Plots of Individual Gene Expression for Control, Non-lesional and Lesional Skin in Atopic Dermatitis 
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Figure 5.2: All graphs show the expression level of a 
gene as normalised transcript number in controls, lesional, 
and Non-lesional samples. The average expression and the 
upper and lower CI are shown for each group. Each point 
represents an individual sample.   a. DPP4 expression,         
b. INPPL1 expression, c. SPINK5 expression, d. SGPL1 
expression, e. PPARγ expression, f. S100A8 expression,     
g. PKP2 expression, h. POSTN expression, i. Cullin4A 
expression, j. TNF-α expression, k. TIMP-1 expression 
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Correlation with IDT  
The majority of dogs included in this study had at least 5 positive reactions on the IDT. 
Figure 5.3a shows that CMA1 expression correlated with IDT data. CMA1 is a pro-
inflammatory molecule and increased expression would have been expected in AD; this, 
however, was not the case (Table 5.2). SAA-1, also a pro-inflammatory molecule, shows a 
correlation with IDT (Figure 5.3c). This too did not show a statistically significant change in 
expression in cAD samples (Table 5.2). S100A8 is a pro-inflammatory molecule that showed 
a strong correlation with IDT (Figure 5.3b). The range of IDT score limits the efficacy of the 
results. Nevertheless S100A8 expression was shown to be significantly increased in cAD 
(Table 5.2), further suggesting its involvement in the pathogenesis of AD. Finally, SPINK5 
expression showed a positive correlation with IDT (Figure 5.3d), although this was weaker 
than previous correlations with pro-inflammatory molecules. 
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Figure 5.4  Correlation between the total number of positive reactions on an IDT 
  with 54 environmental allergens and normalised transcript number in
  non-lesional atopic skin. 
 
 
 
 
 
 
 
Figure  5.3: The lines on the graph indicate the direction of the relationship and the 95% confidence 
intervals. (a). CMA1 normalised transcript number in non-lesional atopic skin (Pearson‟s R value 0.607; =0.01).         
(b). S100A8 normalised transcript number in non-lesional atopic skin (Pearson‟s R value 0.751; p=0.001).      
(c). SAA-1 normalised transcript number in non-lesional atopic skin (Pearson‟s R value 0.706; p=0.002).       
(d). SPINK-5 normalised transcript number in non-lesional atopic skin (Pearson‟s R value 0.53; p=0.021).   
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Correlation with CADESI 
Figure 5.5  Correlation between CADESI-03 and Normalised Transcript Number in
  non-lesional atopic skin.  
 
 
Figure 5.4: The lines on the graph indicate the direction of the relationship and the 95% confidence 
intervals. (a). SAA-1 Normalised Transcript Number in non-lesional atopic skin (Pearson‟s R value 0.505 ; 
p=0.039). (b). S100A8 Normalised Transcript Number in non-lesional atopic skin (Pearson‟s R value 0.54 ; 
p=0.031).  (c). PKP2 Normalised Transcript Number in lesional atopic skin (Pearson‟s R value 0.532; p=0.034).  
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SAA-1 showed a correlation with CADESI-03 (Figure 5.4a) as well as IDT, although the 
„r-value‟ was lower than with IDT (possibly because CADESI-03 assesses a number of 
variables whereas the IDT is positive or negative). S100A8 also showed a correlation with 
CADESI-03 (Figure 5.4b), again weaker than its correlation with IDT. PKP2 showed a 
correlation with CADESI-03 (Figure 5.4c). PKP2 expression is also increased in AD (Table 
5.2). 
5.4 Discussion 
Assessments of gene expression in health and disease have proven to be useful in 
studying the complex pathogenesis of many multi-factorial diseases. Relating such changes to 
measures of clinical progress/disease are less common but help to better understand the 
underlying disease mechanisms.  
Data from previous microarray studies and from the published literature (Chapter 3) were 
used to select candidate genes implicated in the pathogenesis of cAD.  The data showed that 
11 out of the 20 quantified genes demonstrated statistically significant altered mRNA 
expression between atopic and healthy skin. The functions of these genes vary, but include 
both immunological and skin barrier functions. Seven of the 11 genes have shown previous 
associations or altered expression in hAD. The remaining four genes were shown to be 
dysregulated in cAD on the canine microarray study in Chapter 3
274
. Three genes positively 
correlated with CADESI-03 scores and four with IDT results. The functions of these genes 
vary, but include both immunological and skin barrier functions. 
When comparing qPCR data with the microarray data, mixed results were generated; 
TIMP-1, POSTN and Cullin4A probably represent false positives on the microarray, because 
the qPCR results contradicted the microarray findings. ARTS-1, INPPL1 and S100A8, 
however, showed a similar trend in expression between qPCR and microarray, corroborating 
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evidence of changed expression of these genes in cAD. SCCA2 and STAT2 were not 
statistically significantly dysregulated in the qPCR experiment therefore no conclusions could 
be made with regards to their role in cAD. The detection of potential false positive findings 
demonstrated the importance of qPCR validation of microarray results.  
S100A8 levels correlated with CADESI-03, suggesting that S100A8 expression in dogs 
correlates with disease severity. Moreover, expression was markedly increased in lesional 
atopic skin compared to both non-lesional atopic (18.15 fold change) and healthy skin (34.5 
fold change). Expression in non-lesional atopic skin correlated with the number of positive 
reactions on an IDT, although the clinical relevance of this is unclear. S100A8 is a pro-
inflammatory molecule released by phagocytes in inflammatory conditions
187
 which „tracks‟ 
the severity of inflammatory diseases in humans
210
. S100A8 has also been linked to leukocyte 
recruitment, suggesting it is a key gene in the inflammatory response
187
. Due to the 
involvement of S100A8 in the immune response and its correlation with severity of 
symptoms these results suggest that S100A8 could be involved in the development of Th2 
mediated acute inflammation and Th1 mediated chronic inflammation in cAD as described in 
the biphasic response model
26
. The elevated expression of S100A8 in non-lesional skin could 
be due to infiltration of inflammatory cells from lesional sites, evidence of the early stages of 
lesion formation or possibly be an indication of cutaneous hyper-reactivity in non-lesional 
skin as well as lesional skin in dogs with cAD. 
INPPL1 mRNA expression was also up-regulated in both lesional (2.48 fold change) and 
non-lesional (0.78 fold change) atopic skin compared to healthy skin, suggesting that it may 
be a good candidate for further research. In humans, INPPL1 has roles in calcium transport, B 
cell activation, FcεRIβ mediated mast cell and Langerhans cell activation, regulation of IgE 
mediated IL-6 production
183
 and T cell development
278
. Dysregulation of INPPL1 could 
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therefore affect allergen specific IgE responses, allergen presentation and uptake, T-cell 
activation and inflammatory responses in AD. 
The DPP4 gene, which produces a protein identical to the T cell activation antigen CD26 
is expressed on the surface of resting and activated T cells, activated B cells, and activated 
NK cells
192
.  It has been implicated in: activation of regulatory T cells, T cell cycle arrest, 
inhibition synthesis and proliferation of T cells and suppression of inflammatory cytokines by 
T cells
191
.  In this study it was down-regulated in cAD tissues. This is similar to findings in 
human microarray
178
 and flow cytometery studies
190
. Reduced DPP4 expression could lead to 
less effective regulation of inflammation
192
, delayed wound healing
193
 and ultimately lesion 
formation in AD. 
PKP2 was slightly up-regulated in lesional and non-lesional skin, and expression 
correlated with CADESI-03. This was in contrast to the reduced expression reported in a 
human microarray, although this studied cultured fibroblasts and not whole skin
178
, as in this 
study. Increased PKP2 expression up-regulates beta catenin/T cell factor signalling 
activity
179
, enhancing T-cell survival
180
. Enhanced T cell survival and activity is thought to be 
a key factor in human and canine AD
31;279
.  
PPARγ expression was down-regulated in atopic lesional dog skin but not non-lesional 
skin. Similar findings were seen in a human microarray study of atopic skin
178
. Other 
members of the PPAR family (PPARβ/δ and PPARα) may represent potential pathogenic 
candidates as they too have been associated with inflammation and skin barrier function, and 
have been implicated in the pathogenesis of hAD
209.  PPARγ may be important in the 
development of chronic inflammation as it is an anti-inflammatory molecule. However, 
reduced expression of PPARγ is also associated with reduced lamellar body formation and 
lipid processing, and increased epidermal permeability. The epidermal barrier is of increasing 
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significance in AD research, particularly following the association of two independent loss of 
function Filaggrin variants (R501X and 2282del4) with hAD
52
. Filaggrin was considered for 
investigation but not included in this study due to a lack of reliable primers to quantify its 
expression in canine skin (data not shown).   
SPINK5 was up-regulated in lesional atopic skin compared to healthy skin (fold change 
4.68), and its expression correlated with the number of positive IDT reactions. SPINK5, 
which has been associated with hAD
126;127
, regulates hair and skin morphogenesis
170
, 
particularly proteolysis during epithelial formation and keratinocyte differentiation, 
suggesting altered SPINK5 expression will affect skin barrier function
237
. SPINK5 is also 
expressed in the thymus, where altered expression has been hypothesised to cause abnormal 
maturation of T-lymphocytes and Th2 polarisation
280
. SPINK5 protein, in contrast, is down-
regulated when associated with atopic symptoms in Netherton Syndrome in humans. This 
apparent contradiction in expression levels between humans and dogs may reflect differences 
in pathogenesis, SPINK5 activity in different disease states, and/or poor correlation between 
RNA and protein expression
281
. It is possible that errors in translation may lead to low protein 
expression despite enhanced mRNA levels. MicroRNAs, for example, have been observed to 
bind to the 3‟ region of mRNA and prevent translation of the message into protein282, without 
degrading mRNA which will still be detected by qPCR. It is, therefore possible that SPINK5 
mRNA in AD is up-regulated in an attempt to compensate for the low levels of protein but 
microRNAs may prevent the translation to protein causing a „feedback loop‟. The lower the 
protein level the higher the mRNA expression level, suggesting that low SPINK5 protein 
levels lead to skin barrier dysfunction and therefore more allergens can cross the skin barrier 
eliciting an inflammatory reaction. This is, however, a speculative argument until SPINK5 
protein levels in cAD are quantified and functional experiments on microRNAs in SPINK5 
can be conducted. 
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Expression of SGPL1 (Sphingosine-1-phosphate lyase 1) was increased in both lesional 
and non-lesional skin, as observed in a human qPCR study
171
. Sphingomyelin metabolism 
enzymes are highly conserved across species
283
, and are likely to have similar functions in 
dogs and humans. SGPL1 is involved in the skin barrier through regulation of sphingosine 1 
phosphate and enhanced catalytic cleavage
232
, influencing antimicrobial activity as well as 
keratinocyte proliferation and differentiation
284
.  
The pro-inflammatory gene CMA1 (Chymase Precursor- Mast cell protease I) is a 
chymotryptic serine proteinase that is expressed in mast cells and functions as a pro-
inflammatory molecule and is associated with hAD
43;135
. It was significantly correlated with 
the number of IDT reactions but was not significantly up-regulated in lesional and non-
lesional skin.  SAA-1 (Serum amyloid A-1 protein Precursor), which is an apolipoprotein that 
recruits immune cells to inflammatory sites and is regulated by interleukin (IL)-1, IL-6 and 
TNF-α184;185 and therefore is associated with acute inflammation185, has shown a significant 
correlation with both the number of IDT reactions and CADESI-03. However, it was not 
statistically significantly dysregulated in cAD.  Finally, P-selectin which has been shown to 
prime leukocyte integrin activation during inflammation
270
, did not show a statistically 
significant change in expression, contradicting a canine immunohistochemistry study which 
reported an increased expression of P-selectin protein
269
. This may be explained by the fact 
that P-selectin protein is preferentially bound to eosinophils in AD
285
 and eosinophils 
infiltrate the epidermis in AD
22
 giving the impression of increased P-selectin protein 
expression. 
Genes correlated with CADESI-03 scores were pro-inflammatory except PKP2, although 
PKP2 has been shown to have T-cell related functions through implication with the beta 
catenin/T cell factor signalling activity
179
 and  T-cell survival
180
. The correlations with 
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CADESI-03 suggest an association between specific gene activity and disease severity. The 
strength of the correlations could have been affected by the use of different clinicians in 
CADESI-03 assessments, although this has been shown to have high inter- and intra-observer 
reliability
153
.   
Genes correlated with the IDT results were also mainly inflammatory related, with the 
exception of SPINK5, although this also has T-cell related activity. The number of positive 
reactions to IDT was used as a measure of allergen specific IgE because, unlike humans, total 
IgE levels do not correlate with atopic status or clinical signs, and the specificity and 
sensitivity of IgE specific serology is variable in dogs
33;276
. In this study the majority of dogs 
showed positive reactions to the same 5 allergens, these were: Dermatophagoides farinae, D. 
pteronyssinus, Acarus siro, Tyrophagus putresceantiae, Lepidoglyphus destructor. These are 
all house dust mites or storage mites, it has been observed that there is extensive cross-
reactivity among house dust and storage mites which may lead to false positive results on an 
IDT
286
.  
There was no correlation between CADESI-03 and number of positive reactions on IDT 
(data not shown; r=0.29 p=0.26), suggesting that IDTs are a measure of individual 
susceptibility and exposure to allergens but not AD severity.  This supports previous evidence 
that allergic sensitisation is not the only cause of AD; if it were there should be a linear 
relationship between the number of allergens sensitized too and the severity of disease. The 
IDT does only assess the reactions to 54 allergens therefore it could be argued that the dog 
may be allergic to allergens not included on the IDT panel. Even though an animal is 
sensitized to allergen it does not necessarily mean it comes into contact with those allergens, 
therefore the symptoms may be mild due to the lack of environmental exposure. Thus, the 
clinical significance of the associations with the number of positive IDT reactions is unclear 
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and further investigation of the clinical relevance of IDT reactions to disease severity may be 
needed. 
Human AD studies have shown that some patients with negative skin prick tests have 
positive specific IgE, and, when given the allergen orally, flare ups were seen at lesional 
sites
287
. This supports the hypothesis that there is a gut borne and/or dietary component in 
AD, which is also seen in some canine cases
288
. The atopy patch testing (APT) “may detect 
relevant sensitisation in the absence of specific IgE”289. Comparisons between APT and skin 
prick test (SPT) demonstrated this; atopic patients showed two patterns of allergic response, 
one IgE mediated (positive SPT) and one cell mediated (positive APT)
290
. The lack of 
correlation between CADESI-03 and IDT reactions suggest that non-IgE mediated 
mechanisms are involved in cAD pathogenesis. Further studies analysing gene expression, 
CADESI-03, and APT and IDT reactions would help clarify this issue.   
A weakness of this study was the inclusion of multiple dog breeds and the variable time 
scale of the lesions at presentation. This was dictated by the nature of obtaining samples from 
clinical cases.  It is possible, however, that different breeds may have different genetic traits 
that result in clinical AD, and therefore it would be valuable to study expression and 
polymorphisms of the genes identified in this study with larger single breed cohorts. It would 
also be useful to repeat this work on samples taken at defined time points following allergen 
exposure in experimental canine models of AD. The results may have been influenced by the 
differing home environments for each dog. The effect of the environment, including diet, is 
recognised in both canine and  human AD
288;291
, though not assessed or controlled for in this 
study (apart from exclusion of food allergy by a 6 week food trial performed as part of the 
diagnosis).  
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In conclusion, this study identified 11 genes that were significantly dysregulated in cAD. 
They are either associated or dysregulated in hAD, or regulate immune reactions and skin 
barrier function. It is therefore likely that dogs with naturally occurring AD are models for 
the human condition.  Moreover, this gene expression study supports the selection of the 
identified genes for a large-scale SNP study which will help to elucidate their roles in the 
pathogenesis of AD.  
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6. SNP Discovery Using Denaturing High-performance Liquid Chromatography and 
Investigation of a Novel Microsatellite in CMA1 
 
6.1 Introduction 
Altered expression of candidate genes has been demonstrated in cAD in Chapters 3 and 5, 
and a number of literature based candidates from Chapter 3 have also been implicated in the 
pathogenesis of cAD. As this was a candidate gene study with the ultimate aim of identifying 
disease susceptibility alleles for cAD, the next step was to identify SNPs within the candidate 
genes for further study. Once identified these SNPs could be included in a large-scale case-
control comparison study which would genotype the SNPs and compare frequencies between 
cases and controls. If a SNP is present in a significantly higher frequency in one group it may 
be associated with that disease phenotype (see Chapter 1, Figure 1.3). 
SNP identification can be done electronically “in silico” by searching databases, such as 
the Broad Institute or Ensembl, which provide data on SNPs identified by other scientists. 
However, as yet these canine databases are not well populated and there are a large number 
SNPs yet to be identified in the canine genome. As such, it was necessary to expand the 
number of SNPs to investigate in this study by first performing a SNP discovery programme 
for genes of potential interest in cAD. There are many technologies available for the 
identification of novel SNPs, the most reliable method is nucleotide sequencing
292
. However, 
this is an expensive approach and is „not compatible with cost-effective large-scale 
population-based genetic screening‟293.  
Although DNA sequencing has become more affordable, the cost of re-sequencing for 
large-scale SNP discovery studies remains high. This means that pre-screening is often used 
in SNP discovery studies; this allows SNPs to be rapidly and cheaply identified in a large 
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population in multiple genes. From this, individuals with potentially new SNPs are selected 
for sequencing to confirm the location and base pair sequence of the SNP. Pre-screening is 
the most cost-effective and efficient approach to SNP discovery. There are many methods to 
pre-screen, and a summary is presented in Table 6.1 (adapted from Suh & Vijg (2005)
293
): 
Table 6.1 SNP Discovery Methods 
Pre-screening Method Accuracy Supporting references 
Sequencing High 
294
 
SSCP Low 
295;296
 
CFLP Medium 
297
 
CSGE Low 
298;299
 
DHPLC Medium 
300;301
 
DDGE High 
302;303
 
TDGS High 
304;305
 
 
Table 6.1: Assuming, no human error, sequencing as the gold standard set at 100%, High =100%, Medium 
=90-100%, Low = 60-90%.  SSCP - Single Strand Conformation Polymorphism, CFLP - Cleavage Fragment 
Length Polymorphisms, CSGE - Conformation-Sensitive Gel Electrophoresis, DHPLC - Denaturing high-
performance liquid chromatography, DDGE - Denaturing gradient gel electrophoresis, TDGS - Two 
dimensional gene scanning 
Single Strand Conformation Polymorphism (SSCP) measures electrophoretic mobility 
and is based on the rationale that electrophoretic mobility is altered if there is a mutation 
present. This is due to conformational changes in the DNA molecule, caused by the mutation. 
Not all mutations, however, lead to changes in the secondary structure and although this is a 
simple method, multiple electrophoretic conditions need to be used, making it time 
consuming. Moreover, its sensitivity is between 60-95% and this becomes more unreliable 
with fragments greater than 250bp
306
, making screening of a whole gene unrealistic. 
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Cleavage Fragment Length Polymorphisms (CFLP) use endonuclease enzymes to cleave 
the DNA molecule; if there are mutations present the pattern and sizes of the resulting 
fragments (when run on a gel) are different. CFLP is rapid and allows for analysis of large 
fragments
307
. However, reproducibility can be an issue as this technique is sensitive to the 
experimental conditions used.  
Conformation-Sensitive Gel Electrophoresis (CSGE) detects SNPs by analysing DNA 
secondary structure; this technique forms hetero and homo duplexes by heat denaturation and 
reannealing with wild type and mutant DNA
308
 (see Figure 6.1 for full explanation of 
heteroduplex formation). These homoduplexes and heteroduplexes show differences in 
electrophoretic mobility. However, it is only sensitive enough when combined with other 
methods such as SSCP
293
. 
Figure 6.1 Formation of Homoduplexes and Heteroduplexes 
 
 
Figure 6.1: The formation of hetero and homoduplexes using wild type and mutant DNA by heating and 
cooling to reanneal the DNA. Heteroduplexes are formed when the reannealed DNA is mismatched - 
represented by a „bump‟ in the DNA strands in the diagram. Homoduplexes are formed when the DNA 
reanneals correctly and no mismatch occurs. Thus, the „bump‟ or change in the secondary DNA structure allows 
identification of heteroduplexes and therefore mutations for sequencing. 
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Denaturing gradient gel electrophoresis (DGGE)
309
 and temperature gradient gel 
electrophoresis (TGGE)
310
 are both based on the changes of the secondary structure of DNA 
fragments under denaturing conditions and the fact that fragments with polymorphisms 
behave differently to those without, resulting in changes in the electrophoretic mobility. 
DGGE uses an increased concentration of denaturant and TGGE uses increasing temperature 
to achieve this. The use of GC rich clamps in DGGE has improved sensitivity to 100%
311
.  
Two dimensional gene scanning (TDGS) is based on DGGE and allows analysis of an 
entire gene for all possible sequence variants in one gel under one set of conditions
312;313
. 2D 
electrophoresis can be combined with multi-colour fluorescent detection
314
, fragments can be 
analysed in parallel and multiplex PCR can be utilised with up to 26 fragments in one 
reaction, making TDGS a cost-effective alternative to nucleotide sequencing and with an 
equal accuracy
305
. 
Denaturing high-performance liquid chromatography (DHPLC)
315;316
 uses ion pair 
reverse phase liquid chromatography to detect heteroduplexes, which are formed as shown in 
Figure 6.1. DHPLC uses partially denaturing conditions and an acetonitrile gradient to 
denature the DNA fragments being analysed. If a mutation is present the DNA fragment 
forms a heteroduplex and is more easily denatured – this means that the retention time in the 
column is reduced compared to homoduplexes. Therefore mutations can be identified in 
specific individuals. This approach is advantageous because it is relatively hands free 
compared to the previously described gel based techniques. It allows fragments between 200 
– 700bp to be analysed and is also relatively rapid. However, only one sample can be 
processed at a time making high throughput processing slow. In Table 6.1, DHPLC is 
described as medium accuracy; this is because of the difficulty of optimising the temperatures 
for heteroduplex detection. In DHPLC, multiple runs at different temperatures are required to 
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ensure that the whole fragment is denatured and all the possible heteroduplexes are identified. 
If the method includes all the temperatures required for full denaturing of the entire fragment, 
then the accuracy of DHPLC is 100%. However, if one temperature is missed the accuracy 
drops to 90%.  
TDGS is considered the best technique for studying large fragments and multiple genes. 
However, in this study the transgenomic WAVE system (which uses DHPLC) was used for 
the detection of SNPs. This is because only eight genes were analysed, making DHPLC the 
most cost effective and time efficient approach for this number of genes. The genes (CMA1, 
SGPL1, DPP4, SPRR1B, S100A8, IL1RL1, MS4A2 and P-selectin) are all candidates for 
cAD (See Chapter 3) and were selected for SNP discovery because there is little or no SNP 
information available within these genes in the Broad institute and Ensembl databases. After 
pre-screening with WAVE, sequencing was performed to characterise the identified SNPs.   
It was hoped that by identifying SNPs in these genes they would be included on a large 
case-control comparison of SNP genotypes which may help define the genetic basis of cAD. 
In the course of this SNP discovery study a novel microsatellite was identified by subsequent 
sequencing of mutations indicated by WAVE. This was not included in a large-scale SNP 
genotyping study and was investigated for an association with cAD separately; the results of 
this microsatellite association study are presented in this chapter.  
Microsatellites or variable number tandem repeats (VNTRs) are polymorphic loci which 
consist of repeating units of 1-6 base pairs in length. Microsatellites are can be used for 
identity matching and paternity identification. They have also been implicated in disease 
pathogenesis through both loss-of-function and gain-of function mechanisms. For example 
almost 20 unstable repeats (microsatellites) have been associated with different neurological 
disorders
317. The most well known of these is Huntington‟s disease, although there are 
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several others, including fragile X syndrome (FRAXA)
318
, and X-linked spinal and bulbar 
muscle atrophy (Kennedy‟s disease) which also have microsatellite associations with disease 
pathology
319
. Moreover, disease risk can be associated with microsatellites; for example, 
breast cancer risk in North Indians is associated with microsatellites in the vitamin D 
receptor
320
.  
The novel microsatellite was identified in CMA1 which produces the protein mast cell 
chymase 1. CMA1 is a chymotryptic serine protease which is expressed in mast cells and 
functions as a pro-inflammatory molecule. It has also been shown to be in an area of linkage 
with hAD
43;194
 and has shown associations with hAD and/or total serum IgE
132-136
.  
Therefore, it was an excellent candidate for cAD susceptibility and the discovery of a novel 
microsatellite offered an opportunity to investigate a potential association with different kind 
of mutation (other than SNPs) in a large number of cases and controls. 
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6.2 Methods 
WAVE analysis 
Sample selection 
Blood samples from 11 Boxers and 11 West Highland White Terriers (WHWTs), excess 
to diagnostic requirements and supplied by the Veterinary Laboratory agency (VLA) were 
selected for this experiment. The samples represented a random population of dogs with no 
disease phenotype information. Because this was a SNP discovery exercise, the use of a 
diverse random population was recommended to obtain rare SNPs. The blood was collected, 
extracted and processed as set out in Chapter 2. The DNA was normalized to 2ng/µl with TE 
for this experiment. 
Primer design  
Primers were designed using the genomic sequences of candidate genes; the focus was on 
promoter regions and exons as these are coding regions and are more likely to contain SNPs 
that can affect disease pathology. 
Primers were designed using primer3 plus software
321
; highly repetitive areas were 
avoided and the primers were designed around areas between 200 – 700bp. To reduce self 
complementary and primer dimer reactions, the maximum self complementary was reduced 
to 4, the maximum self 3 primed was set to 2, and the maximum poly x was set at 4. 
Temperatures for primer design were set to a minimum 57°C, optimum of 60°C and 
maximum of 63°C. A GC clamp was added to the primer design parameters to increase 
stability of binding.  
The primers were ordered from Metabion (Germany), 0.02mmol scale and standard 
purification (see Table 6.2 for the primer sequences). 
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Table 6.2 Primers for WAVE 
Gene Location Forward Reverse Product 
size 
CMA1 Promoter cagattcccccagtcacaag taacaggcagagtgtcgtttc 375 
 Exon 5 ttgaaggagaaggccaacc tggtcaaaagccatgtagtgtc 203 
 Exon 6 ctcttctgtgtgctggggtag gggtctgagggatgtagtgg 250 
SGPL1 Exon 2 cattgaagaagtgagtgaagaacag cccattaaactcgcctgaag 206 
 Exon 5 gtgctctcacctgtgtgcttc gccgaaccagtcctccac 294 
 Exon 14 accgccagtaacgacctc tcagggtcacagagtatccag 197 
DPP4 promoter acaaacaaacagcaacccaag ttccacaccccacactcac 493 
 Promoter gtgtggaaggctgaggtaatg cttgaacttggagggtggtg 278 
 Exon 7 caagcactcctcatttgatgc tgaccttcggattcatctcc 287 
 Exon 21 caagcactcctcatttgatgc tgaccttcggattcatctcc 287 
SPRR1B Promoter cacttctcccccaacacaag cctcaccagccctcttacac 414 
 Promoter ccctttcagcaacaccactc gaccatgtggcatacctgtg 434 
 Exon 1 agaagcaaccctgcatcc gtcactgttgagggacatgg 214 
 Exon 3 caacaggtgaaacagacttgc aggtcatggctaaggaccac 300 
S100A8 Exon 1 - 2 cccatgtgtttcgtgttgc tattattcggcagggacagc 500 
 Promoter gggattagcagcagcaagag tccagacctcccttagctttc 480 
IL1RL1 Exon 10 cacagcaacaagaaatctgacc cggaaatctggtgcattagc 461 
 Promoter tgccaaatgaagtgttgagg ccaaactgaaaggcagaagg 459 
 Promoter ttggtgagtcttggggacac aggttgatggtgcctcctg 573 
MS4A2 Promoter aagatggcacgggtttaatg tgattttgacgatggcagag 419 
 Exon 5-6 acacacagggctattgaacg gcttcagcttgtcattcagg 700 
P-SELECTIN Exon 5 aagggctcatgctattgctc ggccactgtcatctgtactcac 296 
 Exon 11 gactctgttatgctccgtttattg gcctgttcctttcccattac 289 
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Touchdown PCR, WAVE PCR & WAVE assay design 
After Touchdown PCR (see Chapter 2 section 2.4; reagent volumes used per well (µl): 
Taq 0.25, dNTP 0.5, Primer F 0.25, Primer R 0.25, X10 2.5, dH20 16.25) the product was run 
on a DNA engine Dyad™ peltier thermal cycler or a DNA engine Tetrad™ PTC-225 peltier 
thermal cycler for a short denaturing program to form heteroduplexes for analysis (see Figure 
6.1). The denaturing program was as follows: 95ºC 5 minutes, then reduce temp by 1.5 ºC per 
minute until 25 ºC was reached. 
The melting temperatures and percentage of buffers were selected by the WAVEMAKER 
V4.1.44 (Transgenomic, Huston, Texas, USA) software by uploading sequences and 
generating methods. Occasionally more than one temperature was required to analyse the full 
sequence (see Appendix 3 for full details on temperatures and fragments uploaded). The 
temperatures and percentage buffers could be altered manually to optimize the resolution of 
the chromatographs. 
The WAVE was equilibrated before use with 50% buffer A (Transgenomic 
Bioconsumables, Huston, Texas, USA) and 50% buffer B (Transgenomic Bioconsumables, 
Huston, Texas, USA) for 15 minutes at a flow rate of 1.5/min to„clean‟ the column before 
use. Low range mutation standard (Transgenomic Bioconsumables, Huston, Texas, USA) 
was used to check the efficacy of the column before, during and after the run. 5µl of sample 
was run through the WAVE at the predefined temperature generating a chromatograph. 
Before each temperature/method change, blanks were run to ensure the column was at the 
correct temperature and equilibrated therefore reducing false positive results. Between plates 
a 75% acetonitrile (Transgenomic Bioconsumables, Huston, Texas, USA) wash was 
performed to ensure no product was left on the column before starting the next plate. 
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Chromatograph analysis 
The chromatographs from the WAVE were analysed for double or unusual peaks and 
then chosen for sequencing.  
Sequencing 
The samples were prepared for sequencing by taking 2µl of PCR product and adding 7µl 
of distilled water and 1µl Exo-SAPIT® (USB, USA). A SAP purification program was run 
on the Dyad™ peltier thermal cycler or a DNA engine Tetrad™ PTC-225 peltier thermal 
cycler (MJ research Inc., Waltham MA, USA). The conditions were as follows: 37ºC for 1 
hour followed by 85ºC for 15 minutes. 
Following this 2µl of cleaned PCR product were aliquotted into a 96 well plate, to this 
8µl of forward OR reverse primers at 0.4mM were added to each well (the primers used were 
not specific sequencing primers, the original PCR primers were re-used). 
Sequencing was performed by the DNA sequencing facility in the Faculty of Life 
Sciences at the University of Manchester, using the Applied Biosystems 3730 DNA Analyzer 
(Applied biosystems, Foster City, CA, USA). 
Microsatellite analysis 
Sample selection 
Disease diagnosis, sample collection and processing of DNA samples from dogs with and 
without cAD were performed detailed in Chapter 2. In total, 659 DNA samples were included 
on the microsatellite array. Eight breeds were included in this study; Table 6.3 shows the 
numbers of each breed and disease status. 
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Table 6.3 Samples included in Microsatellite  genotyping 
Breed Cases Controls Total 
Boxer 11 24 35 
GSD 19 38 57 
Labrador 64 129 193 
G. Retriever 40 66 106 
Shiba Inu 23 33 56 
Shih Tzu 47 62 109 
Pit Bull 20 17 37 
WHWT 18 48 66 
Totals 242 417 659 
 
Primer design 
The microsatellite was discovered in the promoter region of CMA1 (see WAVE results 
section, Figure 6.3 for details). The primers were designed as described in the WAVE 
analysis primer design section above. The primers were supplied by Metabion (Germany), at 
0.02mmol scale with standard purification. The forward primers 5‟ end was labelled with 
fluorescent probe FAM for identification of the microsatellite size:  
Forward: CTGGGAGAAAGCTCCATGTC 
Reverse: GGCAGAGTGTCGTTTCTCTTG 
Assay design 
The initial PCR reaction to amplify the microsatellite was performed as set out in Chapter 
2.  After the initial PCR, 1µl of PCR product was aliquotted into a 384 well plate and a mix 
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(4.8µl/0.2µl) of de-ionised Formamide (Sigma-Aldrich Inc.) and ABI prism® Rox400 
(Applied Biosystems, Foster City, CA, USA) was added into each well giving a reaction 
volume of 6µl. The ABI prism® 3100 genetic analyzer data collection software V1.1 
(Applied biosystems, Foster City, CA, USA) was used to set up the run; the following 
variables were selected - dye set D, default POP4 run module which uses ABI prism®  3100 
POP4™ polymer (Applied Biosystems, Foster City, CA, USA) and GS400HD analysis 
module as per the manufacturer‟s instructions. The ABI prism® Genescan software V3.7 
(Applied biosystems, Foster City, CA, USA) was then used to analyse the data according to 
the ROX size standard used, the files were saved from this and used in the ABI prism® 
Genotyper software V3.7 (Applied biosystems, Foster City, CA, USA). Genotyper allows 
accurate sizing between plates and wells, using macros to group the results into 
genotypes/microsatellites which are dependent on the length of the microsatellite. 
Statistical analysis 
Gene frequencies and phenotype frequencies were estimated by direct counting. The 
percentage distribution of the genotype in cases and controls was calculated in order to 
identify any differences. The significance of the distribution of genotype between cases and 
controls was tested using 2x2 contigency tables; the chi –squared (χ2) test with Yates‟ 
correction was used to produce p values. The statistical tests were only performed on 
genotypes which were present in more than 5 dogs to ensure statistical robustness. These 
analyses were performed on the whole data set (all breeds as one panel) and within individual 
breeds to test the association of microsatellite genotype with cAD. Further to this analysis, 
the association between breed and microsatellite genotype was also tested using χ2 analysis. 
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6.3  Results 
WAVE Results  
To analyse the results from WAVE, chromatographs were generated to display the 
retention time on the WAVE column. As described in the introduction, a change in retention 
time suggests a SNP is present. Heteroduplexes (mutations) come off the column first as they 
are more easily denatured; this means they have a lower retention time than homoduplexes. 
Therefore, when looking at WAVE chromatographs it is possible to either get a single peak 
after the size standard (Figure 6.2), which means there are no SNPs, only homoduplexes, or a 
double peak after the size standard indicating a heteroduplex, suggesting a SNP is present 
(Figure 6.2). Figure 6.2 demonstrates the differences in chromatographs when homo and 
heteroduplexes are present. 
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Figure 6.2  Retention Time Graphs (Chromatographs) from WAVE 
 
Figure 6.2: Two examples of chromatographs generated by the WAVE. The first chromatograph displays a 
negative SNP result showing a single peak indicating that only homoduplexes are present. The second graph 
shows two peaks indicating that both homo and heteroduplexes are present indicating a SNP may be present in 
this individual. 
 
Figure 6.3 shows the chromatograph results for this study, but only when a SNP was 
identified. Potential SNPs were identified in MS4A2 exons 5 and 6 (Figure 6.3a), S100A8 
promoter regions (Figure 6.3b & c), SPRR1B promoter region (Figure 6.3d), CMA1 
promoter region (Figure 6.3e), SPRR1B exon 3(Figure 6.3f &g), and SGPL1 exon 2 (Figure 
6.3h).  
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Figure 6.3  Chromatograph examples of individual dogs with SNPs   
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Figure 6.3 cont. 
 
Figure 6.3: (a) MS4A2 exon 5 and 6 shows a shift in the position of the peaks (change in retention time); this suggests that there is a SNP present. (b) S100A8 promoter 
region showed three distinct peaks, suggesting multiple SNPs were present.  (c) S100A8 promoter region shows two peaks suggesting that different SNPs are present in this 
individual compared to b (d) SPRR1B promoter region (e) CMA1 promoter region has a flattening of the top of the peak suggesting the presence of two peaks and therefore a 
SNP (f) SPRR1B exon 3 shows a large peak with a shoulder which could be a distinct peak or a PCR artifact; there is also a small peak to the right which could indicate the 
presence of a SNP.  (g) SPRR1B exon 3 shows two peaks in a different position to (f), suggesting that there are different SNPs present in this individual. (h) SGPL1 exon 2 
shows two small peaks suggesting a SNP is present. 
f. g. h
. 
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Sequencing 
The individuals identified by WAVE as having SNPs present were selected for 
sequencing to characterize the SNPs. For all sequences from each individual see Appendix 4. 
A summary of the SNPs found in this study is shown in Table 6.4. For the position of each 
SNP in the gene see Appendix 5. 
In all, 11 novel SNPs and 1 novel microsatellite were found by WAVE in the 8 genes 
under analysis. Three existing database (Ensembl) SNPs were confirmed by WAVE. 
Table 6.4  Numbers of SNPs identified by WAVE 
Gene Region Novel  SNPs Ensembl SNPs 
CMA1 Promoter 1*  
MS4A2 Exon 5 & 6 3 2 
S100A8 Promoter 3 1 
SGPL1 Exon 2 1  
SPRR1B Exon 3 2  
SPRR1B Promoter 2  
* Denotes a microsatellite instead of a SNP 
Microsatellite results 
The microsatellite identified by WAVE and sequencing was genotyped in 659 dogs (64 
excluded from the analysis due to low genotyping success) across 8 breeds. The 
microsatellite analysis identified 28 different genotypes, 26 of which were found in the atopic 
dogs and 24 in the healthy controls. For the most part the numbers of individuals with each of 
these 28 genotypes was low. The exception to this was A06/A06, which was by far the most 
common microsatellite genotype with over half the cases and controls typed having this 
131 
 
genotype. For a full list of allele frequencies see Appendix 6. This also shows the relative 
sizes of each allele. The results below are divided into case-control comparison across all 8 
breeds and an individual case-control comparison in each breed. 
Case-Control Comparison across All Breeds 
Microsatellite genotypes which were found in less than 5 dogs (in either cases or controls) 
were excluded from χ2 analysis; this is because there was not enough data to produce an 
accurate analysis. On this basis, 20 genotypes were excluded from analysis, with the 
remaining 8 genotypes displayed in Table 6.5 (this shows the p value results from the χ2 test 
and the percentage distribution of alleles in the case-control comparison across all 8 breeds). 
None of the tested alleles shows a significant difference in prevalence between cases and 
controls.  
Table 6.5 Case-Control Analysis in All Breeds: Chi Squared Test Results for       
       Microsatellite Genotypes found in CMA1 
Allele 1 Allele 2 Number of Cases % Cases Number of Controls % Controls p value 
A10 A10 8 3.6 25 6.7 0.15 
A06 A07 6 2.7 19 5.1 0.22 
A04 A06 10 4.5 9 2.4 0.26 
A06 A13 9 4.0 20 5.4 0.58 
A01 A06 5 2.2 6 1.6 0.82 
A10 A13 5 2.2 6 1.6 0.82 
A06 A10 26 11.6 41 11.1 0.94 
A06 A06 125 55.8 209 56.3 0.97 
 
Case-Control Comparison: Individual Breeds 
Each of the eight breeds under study were analysed separately for any significant 
association between the microsatellite genotype and cAD. As in the previous analysis, 
microsatellite genotypes which were found in less than 5 dogs (in either cases or controls) 
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were excluded from χ2 analysis, meaning that in most cases only the A06/A06 genotype 
could be analysed. Only one breed, Shiba Inu, showed a significant association between the 
microsatellite genotype A06/A06 and cAD. 
Table 6.6 shows the p value results from the χ2 test and the percentage distribution for 
each genotype in the case-control comparison in each individual breed.  
Table 6.6  Case-Control Analysis in Individual Breeds: Chi Squared Test Results for
       Microsatellite Genotypes found in CMA1 
Breed Allele 1 Allele 2 Number of 
Cases 
% 
cases 
Number of 
Controls 
% 
controls 
p value 
Shiba Inu A06 A06 12 54.5 5 15.6 0.006* 
Shih Tzu A06 A06 7 15.2 19 31.1 0.09 
WHWT A06 A06 14 93.3 36 97.3 0.50 
Boxer A06 A06 7 63.6 6 42.9 0.53 
German shepherd 
dog 
A06 A06 9 52.9 16 42.1 0.65 
Pit Bull terrier A06 A06 13 68.4 9 56.3 0.70 
golden retriever A06 A06 21 58.3 34 63.0 0.83 
Shih Tzu A06 A10 12 26.1 14 23.0 0.88 
Shih Tzu A10 A10 5 10.9 7 11.5 0.92 
Labrador A06 A06 42 72.4 84 70.6 0.94 
Shih Tzu A06 A13 7 15.2 9 14.8 0.95 
* Denotes statistically significant 
Further to the case-control analysis, a comparison across breeds was conducted to see 
whether the variation in microsatellite genotype was attributable to breed. Again, 
microsatellite genotypes which were found in less than 5 dogs (in any breed) were excluded 
from χ2 analysis, leaving only 2 microsatellite genotypes that could be tested. Table 6.7 
shows the percentage distribution for each genotype in the breed comparison and the p values 
from the χ2 test. It can be clearly seen that in the two microsatellite genotypes tested there 
was a significant difference between the breeds, suggesting that the microsatellite is 
associated with breed rather than disease status.
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Table 6.7  Breed Comparison of Microsatellite Genotype: Chi Squared Results 
Allele 1 Allele 2 %Lab %Gret %GSD %Box %WHWT %Pit %Shi %Tzu χ2 P value 
A06 A06 71.2 61.1 45.5 52.0 96.2 62.9 31.5 24.3 2.09 x 10
-8
 
A06 A10 4.5 5.6 18.2 32.0 0.0 11.4 11.1 24.3 6.32 x 10
-8
 
 
Lab = Labrador, Gret=Golden retriever, GSD= German shepherd dog, Box= Boxer, WHWT= West Highland 
white terrier, Pit= Pit Bull terrier, Shi = Shiba Inu, Tzu = Shih Tzu 
 
6.4 Discussion 
Eleven novel SNPs and 1 novel microsatellite have been identified in 5 genes by WAVE 
analysis. These SNPs, however, require further confirmation by screening in a large 
population to allow the minor allele frequency (MAF) and Hardy-Weinberg equilibrium 
(HWE) to be estimated. Until this is done, the frequency of these SNPs in the population is 
unknown. They can be still used in a case-control study, but if one or more are found to be 
significant further characterization will be necessary to submit the SNP to dbSNP databases. 
The SNP discovery experiment could have been improved by including more dogs of 
different breeds to identify more SNPs across a larger population. It may have been beneficial 
to use a technique such as TDGS which only requires one experimental condition to identify 
all SNPs, whereas WAVE requires multiple temperatures and buffer concentrations. This 
suggests that it is possible that some SNPs were missed. 
WAVE analysis can be of use in SNP identification, as it can screen a given number of 
dogs/breeds in the population to identify novel SNPs in these breeds. WAVE, however, 
cannot identify whether these SNPs are causative of the disease. These SNPs will therefore 
134 
 
be included on a large-scale case/control comparison of SNP genotypes to investigate 
potential associations with cAD. 
The microsatellite analysis showed that when all the breeds were analysed together, cAD 
had no significant association with the microsatellite discovered by WAVE. However, in the 
individual breed analysis the Shiba Inu did show a significant association between the 
A06/A06 genotype and cAD (odds ratio = 6.48, data not shown). Breed association analysis, 
nevertheless, appeared to indicate that it was more strongly associated with breed than 
disease status. There were a number of rare microsatellite alleles that had to be excluded from 
the analysis as they were found in less than 5 dogs. It may be interesting to follow up disease 
and breed association in more dogs.  
The apparent association of the microsatellite in the Shiba Inu is interesting and is worth 
further investigation. Only 17 Shiba Inu's were A06/A06, and to validate the potential 
association with Shiba Inu microsatellite genotype and cAD more dogs of this breed would 
have to be typed. However, it is likely that the association seen is due to the low numbers of 
Shiba Inu and the microsatellite genotype is associated with breed rather than disease status. 
In conclusion, the novel microsatellite identified in CMA1 has shown a potential 
association with cAD in the Shiba Inu and a strong association with breed. SNPs were 
identified by WAVE in five candidate genes and will be included on a large-scale case-
control comparison to test for an association with cAD. 
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Chapter 7 
Genome Wide Association Study - 
Identifying Canine Atopic Dermatitis 
Susceptibility Genes 
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7.  Genome Wide Association Study - Identifying Canine Atopic Dermatitis 
Susceptibility Genes 
 
This work is presented in: Wood, S.H., Ke, X., Nuttall, T., McEwan, N., Ollier, W.E., 
Carter, S.D., (2009) Genome Wide Association Analysis of Canine Atopic Dermatitis and 
Identification of Disease Related SNPs, Immunogenetics, 61(11-12):765-72 
7.1 Introduction 
In Chapters 3 to 6, candidate genes and SNPs for further investigation of the genetic basis 
of cAD were identified. For the most part, however, the genes were selected because of 
literature based evidence of their potential involvement in AD. This chapter introduces a new 
and unbiased method for the identification of novel SNPs associated with a disease 
phenotype. This method is referred to as genome wide association study (GWAS) and 
enables the simultaneous study of thousands of SNPs in individual dogs.  
In humans, GWAS has been shown to be an effective approach in identifying gene 
polymorphisms associated with disease phenotypes. GWAS approaches use simultaneous 
high density SNP genotyping with the aim of providing coverage across the complete 
genome. This hypothesis-free approach allows many novel disease susceptibility loci to be 
identified in a single experiment. Given the chance of false positive discovery through 
multiple testing, findings should be replicated by other molecular approaches.  
The Welcome Trust Case-Control Consortium (WTCCC) is a good example of the 
usefulness of GWAS. This has recently met with success in identifying novel SNPs in bipolar 
disorder, coronary heart disease, Rheumatoid arthritis, and type 1 and 2 diabetes in 
humans
322
. Moreover, GWAS was recently used to investigate hAD in approximately 1000 
cases and 1000 controls, and an association was found with an intergenic SNP on 
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chromosome 11. Validation by another technique in approximately 3000 cases and 4000 
controls was required to confirm the association
323
. This demonstrates the need for validation 
on large numbers of cases and controls (usually mulitple thousand) to achieve sufficient 
statistical power to detect small genetic risk factors (≤1.5) in human studies. In the recent 
hAD study, the chance of identifying a risk factor of 1.5 was 84%. This dropped to 12% 
when identifying a risk factor of 1.2
323
. The most recent SNP arrays used in human studies 
are of greater density (up to 1.6x10
6
 SNPs), which is needed to detect association effects, as 
LD across the genome is weak in humans (10-100 kb
324;325
). 
 Domestic dog breeds are of recent origin and represent highly inbred genetically 
isolated populations. Consequently, LD extends over long distances (0.8 -5 Mb
107;326
). This is 
advantageous in GWAS as fewer genetic markers and smaller sample sizes are required to 
find disease associations in dogs
107;108
. For example, to achieve complete coverage of the dog 
genome, only 5,000 to 30,000 SNP markers are required
324
, compared to an estimated 
200,000 to 500,000 SNP markers in humans
108
, making GWAS in dogs both cheaper and 
easier to conduct
107;108
.   
Previous genome wide genetic studies in canines have mainly been done using 
microsatellites and have mapped mutations causing lens luxation
327
, putative Quantitative 
Trait Loci (QTLs) in osteoarthritis
328
, dilated cardiomyopathy (DCM)
329
 and cone-rod 
dystrophy
330
. One study used a panel of 1500 SNPs in a family of Boxers to identify the loci 
responsible for white spotting
331
, although not truly a genome wide study as the coverage was 
not complete enough. The only true genome wide SNP based study in dogs used an Illumina 
custom made array (26,625 SNPs) to identify two monogenetic traits (white spotting
332
 and 
hair ridges in ridgeback dogs
333
), but used only 10 cases and 10 controls
324
.   
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High density SNP arrays for GWAS in dogs are now available and are beginning to be 
used to analyse both single gene and complex canine diseases. As a tool for genetic studies, 
these systems represent a huge leap forward in our ability to understand complex diseases 
with a genetic component. Until their development, it had been necessary to select individual 
candidate genes for analysis and to sequence the potential SNPs. As each SNP array contains 
thousands of SNPs, the chances of discovery are much greater than previously possible.  
This is the first study to investigate the genetics of cAD using GWAS. The study used the 
Illumina canine SNP20 chip with 22,362 SNPs assembled from the CanFam2.0 genome 
release from the Broad Institute based on Boxer and poodle sequences.  In the production of 
this array highly polymorphic loci were chosen from a diverse population of dog breeds. This 
means that there is likely to be segregation amongst breeds, making the assay suitable for 
within-breed association studies, and therefore a single breed, the golden retriever, was used.  
An issue when analysing GWAS data is that allele differences between cases and controls 
may be unrelated to the disease phenotype, resulting in false positive associations. 
Inappropriate statistical correction and genotyping errors can lead to false positive 
associations. These are taken into account relatively easily by calculating the minor allele 
frequency (MAF) and Hardy-Weinberg equilibrium (HWE), and applying cut-offs to the 
data. The Benjamini and Hochberg False Discovery Rate
151
 correction is also used to limit 
false positives arising from inappropriate statistical correction.   
The most important factor in false positive discovery is the presence of unrecognised 
populations structure
334
 within the samples used for study.  Population structure in this type 
of study is defined as the presence of a systematic difference in allele frequencies between 
subpopulations within a study population. The stratification is caused by non-random mating 
between groups, which in most cases is due to physical separation (e.g., populations of 
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African and European descent), leading to genetic drift of allele frequencies in each group. 
Population structure can be a problem for case-control based association studies as 
associations found may be due to the underlying structure of the population and not a disease 
associated locus. In addition, the real disease causing locus may not be found if less prevalent 
in the population of cases chosen for study. There are a number of ways to control for the 
effects of population structure which compensate for any population bias. The two most 
common methods are genomic control correction, which is a non-parametric method for 
controlling the inflation of test statistics
335
, and structured association methods
336
, which use 
genetic information to estimate and control for population structure. A structured association 
method, Identity-By-State (IBS) clustering, was used in this study. Following the IBS 
clustering, a meta-analysis was performed taking into account the populations identified by 
IBS and allowing all data to be compared without population structure effects.  
This is the first canine study to employ these human-based population structure 
adjustment approaches, and therefore the “unadjusted” results are also presented for 
comparison (See Figure 7.1 for the methodology).  
Until now the genetics and immunopathogenesis of cAD has been largely limited to 
cytokine profiling and gene expression studies
31;274;337
.  It was hoped that the results of this 
study would help identify novel loci in cAD, which could be validated at a later stage in 
large-scale case-control comparison studies. These data may identify possible novel 
pathogenic pathways and potential routes for therapeutic intervention. This form of analysis 
should narrow down the search for cAD susceptibility genes. 
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7.2 Methods 
Sample selection for whole genome scan 
Forty eight golden retrievers were selected for GWAS. 25 dogs with AD (14 female, 11 
male, age range: 2 to 13 years,) and 23 controls (9 female, 14 male, age range: 1-14 years) 
were included. Samples were collected by the WALTHAM® Centre for Pet Nutrition from 
Japanese and US veterinary clinics. The diagnoses of cAD and control selection were 
performed as stated in Chapter 2.1. Blood samples were taken as described in Chapter 2.2 and 
processed according to Chapter 2.3. The DNA was normalised to 50ng/µl.  
GWAS Array 
The SNP array analysis of the 48 golden retriever samples was performed using the 
Illumina canine SNP20 array (San Diego, California), by the Barts and the London Genome 
Centre according to the manufacturer‟s instructions using Illumina‟s software to call the data.  
GWAS data were analysed using the freely available whole genome association analysis 
toolset; PLINK
338
.  Only SNPs which conformed to Hardy-Weinberg expectations, exhibited 
90% genotyping success and had a minor allele frequency ≥0.01 were included in subsequent 
analysis. Two hundred and twenty-nine SNPs were excluded on this basis.  
Figure 7.1 shows the methodology for this study and explains the separate analysis of 
“population structure adjusted” and “unadjusted” results. 
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Figure 7.1 Study Methodology and Analysis 
 
Figure 7.1: The GWAS data was first subject to quality control procedures described in the main text. Hardy-Weinberg Equilibrium (HWE)  and minor allele frequency 
(MAF) cut offs were applied to the data. Two analyses were performed: 1. Fisher exact test and Benjimini and Hochberg correction (“unadjusted” for population structure), 
and, 2. IBS clustering and meta-analysis (“Adjusted” for population structure). Both analyses generated a whole genome association plot of significance and the top 40 
associated SNPs from each analysis are presented.
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As shown in Figure. 7.1, comparisions between cases and controls without accounting for 
population structure, using the Fisher exact test were performed and the Benjamini and 
Hochberg correction/False Discovery Rate was applied
151
. Significance values from this were 
used to generate a whole genome association plot of significance (also known as a Manhattan 
plot) using the statistical package R
339
 (the R script was written by Matthew Settles of 
Washington State of University). This displays the results for each chromosome as a log of 
the p value.  Further to this a Q-Q plot was generated to show the difference between 
observed and expected results.  
To account for the effects of population structure the GWAS results were re-analysed. 
Population structure was defined using IBS clustering methods on the GWAS data, allowing 
differences in genotype across the array to be calculated and individuals grouped according to 
these differences (see Figure.7.1). Further to this Multi-Dimensional Scaling (MDS) was used 
to visually represent the population clusters. Using the clusters defined by IBS, a meta-
analysis (Cochran-Mantel-Haenszel test for 2x2xK stratified tables) was used to compare all 
results in the cases and controls, independent of population structure. A whole genome 
association plot of significance was generated for these population structure adjusted results. 
Using a HWE cut off of 0.05 and a 95% confidence interval the top 40 SNPs from both 
analyses were identified.  
Haplotype analysis 
PLINK was used to perform haplotype analysis on the GWAS data. Haplotype 
association tests were performed using a sliding window specification. Originally a sliding 
window of 3 SNPs was specified, but after this analysis the sliding window was dropped to 2 
SNPs. These data were subject to the same quality control procedures specified above. The p 
values from the haplotype analysis were compared to those of the single SNP associations. If 
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the p value is lower in the haplotype analysis compared to the single SNP analysis it indicates 
that the haplotype is significant. Using Ensembl
159;160
 chromosome view the haplotype 
positions were represented visually. 
 
7.3  Results 
Figure 7.2 shows the “unadjusted” results from the Fisher exact test as a whole genome 
association plot of significance for individual SNPs. This shows the log of the p value, and 
results above the cut off of 3 are considered relevant and significant. The 40 most significant 
SNPs from the Fisher exact test are listed in Table 7.1 (all of which are above the cut off of 3 
on the genome association plot). 
Figure 7.3 shows the Q-Q plot, which displays the difference between the observed and 
expected results. The large difference between the results suggests that there are wide 
differences in population structure. The genomic control inflation factor quantifies this 
difference and can be used to adjust the “population structure unadjusted” p values, to 
attempt to account for population structure. However, it is considered that IBS clustering and 
MDS plots do this with greater accuracy (see Figure 7.4). 
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Figure 7.2 Population Structure Unadjusted: Whole genome association plot of significance for Canine Atopic Dermatitis  
Figure 7.2: A plot showing significance of association of all SNPs in the GWAS using Fisher‟s exact test (“unadjusted” for population structure) with atopic and healthy 
control phenotypes. SNPs are plotted on the x-axis according to their position on each chromosome against association with atopic dermatitis on the y-axis (shown as -log10 
P value). 
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Figure 7.3  Q-Q plot of the observed and expected results from the GWAS 
 
 
 
 
 
 
 
 
Figure 7.3: A plot showing the difference between the observed and expected results from the GWAS. 
SNPs are plotted on the x-axis according to the expected –Log10 p value (Red squares) against the observed –
Log10 p value (blue circles) on the y-axis. The Genomic control inflation factor is calculated from this plot to 
represent the difference between observed and expected results. Genomic control inflation factor = 1.41 
 
Figure 7.4  MDS plot of IBS Clusters: Defining Population Structure 
 
 
 
 
 
 
 
 
 
Figure 7.4: A plot showing cases (green triangles) and controls (black crosses) from GWAS clustered by 
IBS clustering according to the whole genome differences between individuals. Two components are plotted, 
component one is plotted on the x-axis against component two on the y-axis.  
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Figure 7.4 represents the population structure of the dogs included on the Illumina canine 
SNP20. It can be seen that there are two distinct groups and a third more spaced group 
containing some outliers. The plot also shows that there is no stratification between the cases 
and controls, suggesting that the three observed population subgroups are not due to 
differences between cases and controls. It was expected that these subpopulations would 
represent the two geographical groups included in this study (i.e. USA and Japan). The 
groups do not, however, cluster according to geographical origin (see Appendix 7). 
Suggesting that population structure seen here is independent of disease status and 
geographical location (point of origin); probably reflecting the inbreeding/non-random 
mating seen in dog breeds. The IBS clusters were used in the meta-analysis of GWAS data to 
account for population structure. The result this analysis is presented in Figure 7.5. 
Figure 7.5 shows the whole genome plot of significance for the “population structure 
adjusted” results. It can be seen that the significance values are lower than the previous whole 
genome plot (Figure 7.2), which showed the “unadjusted” results.  
Table 7.1 shows the top 40 associated SNPs with cAD from the “population structure 
unadjusted” and “adjusted” analysis.  
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Figure 7.5  Population structure adjusted: Whole genome association plot of significance for Canine Atopic Dermatitis  
     
Figure 7.5: A plot showing significance of association of all SNPs from the IBS clustering and meta-analysis (“adjusted” for population structure), with atopic and 
healthy control phenotypes. SNPs are plotted on the x-axis according to their position on each chromosome against association with atopic dermatitis on the y-axis 
(shown as -log10 P value).
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Table 7.1  Top 40 Associated SNPs from the Population Structure Unadjusted GWAS Results and the Top 40 Associated SNPs from
  the Population Structure Adjusted GWAS Results 
Population Structure: Unadjusted Population Structure: Adjusted 
SNP Chromosome Odds Ratio P value SNP Chromosome Odds Ratio P value 
rs22859255 2 4.4 0.0048 rs21994080 1 0.1 0.0015 
rs23545080 3 5.4 0.0019 rs22738169 2 0.2 0.0009 
rs23567144 3 0.2 0.0018 rs22808564 2 6.3 0.0027 
rs23602938 3 3.8 0.0047 rs24092655 4 0.0 0.0013 
rs24872415 3 9.5 1.27x10
-06
 rs24131580 4 45.3 0.001 
rs24194054 5 4.8 0.0011 rs24275059 6 40.7 0.0019 
rs24267550 5 0.2 0.0042    rs24332727 * 6 0.1 0.0028 
rs24318716 6 0.3 0.0076 rs24354997 6 40.7 0.0019 
rs24327271 6 0.2 0.0008 rs24462950 7 44.5 0.0011 
rs24332727 * 6 0.2 0.0012 rs24556501 9 0.1 0.0006 
rs24408651 7 0.2 0.0008    rs24732893 * 12 0.2 0.0028 
rs24482628 8 4.1 0.0025 rs22524918 17 NA 0.0027 
rs22020166 10 3.8 0.0022 rs22576724 17 0.2 0.0031 
rs22114085 10 5.1 0.0008 rs22720467 19 19.8 0.0014 
rs22155657 11 5.9 0.0063   rs22864357 * 20 5.6 0.0017 
rs22181912 12 0.3 0.0028 rs22991453 21 0.1 0.003 
rs22184220 12 4.3 0.0009 rs23029421 22 0.1 0.0017 
rs22185491 12 3.4 0.0045   rs23066224 * 22 16.8 0.0012 
rs22212359 12 7.2 0.0016 rs23117702 23 0.1 0.0004 
rs22212677 12 5.3 0.0049 rs23224877 25 19.5 0.0024 
rs24732893 * 12 0.2 0.0007 rs23313105 26 10.5 0.0003 
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Table 7.1 continued 
 
 
rs22328353 14 5.8 0.0025 rs23316823 26 0.0 0.0013 
rs22523565 16 3.3 0.0067 rs23444049 29 6.3 0.0016 
rs8649732 19 0.2 0.0044 rs9132002 29 0.0 0.0029 
rs22864357 * 20 4.1 0.0025 rs23622647 30 0.0 0.0008 
rs22913552 20 4.6 0.0005 rs23684720 31 5.6 0.0028 
rs22915894 20 0.2 0.0017 rs23708599 31 0.2 0.0022 
rs8806978 20 3.8 0.0021 rs23767031 32 9.8 0.0012 
rs9081246 20 0.2 0.0017 rs23768387 * 32 0.1 0.0019 
rs22959786 21 5.9 0.0009 rs23769251 32 0.1 0.0018 
rs22989468 21 0.2 0.0057 rs23769439 32 0.1 0.0024 
rs23026134 22 5.4 0.0019 rs23770102 32 0.0 0.0017 
rs23066224 * 22 7.2 0.0016 BICF2G630250121 33 0.0 0.0022 
rs23122280 23 5.4 0.0019 rs23803267 34 0.0 0.0016 
rs23428471 28 3.6 0.0036 rs23856926 34 0.2 0.0029 
rs23478400 28 3.6 0.0036 rs23865825 34 0.1 0.0027 
rs23472497 29 0.2 0.0009 rs23870923 34 0.2 0.0011 
rs23690306 31 5.3 0.0003 rs23932942 35 6.3 0.0009 
rs23768387 * 32 0.2 0.0031 rs23968934 36 NA 0.003 
rs23828846 33 0.2 0.0007 rs23974741 36 NA 0.0007 
* Denotes the SNPs identified on population structure adjusted analysis as well as population structure unadjusted analysis 
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Table 7.2 shows the haplotypes significantly associated with cAD (the individual SNP 
associations are indicated with an *). A haplotype is significant when the p value for the 
haplotype is higher than the p value for the individual SNP. Table 7.2 only shows those 
haplotypes significantly associated with cAD. Figure 7.6 presents results graphically, by 
indicating the positions of the haplotypes and highlighting which genes are in close 
proximity. Figure 7.6 (a) shows the haplotypes within the gene RAB3C; (b) shows 4 
haplotypes in this area which encompasses 9 different genes on chromosome 6; (c) shows 
two haplotypes in chromosome 6 which encompass SDK1, ACTB_CANFA and FBXL18; 
(d) shows 4 overlapping haplotypes most of which fall within RAB7A_CANFA; (e) shows 7 
haplotypes on chromosome 20, the majority of which fall within SUCLG2 and LR1G1; and 
(f) shows 2 haplotypes in intergenic regions on chromosome 20 near 12 genes. 
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Table 7.2  All Haplotypes significantly associated with Canine Atopic Dermatitis 
Chr Haplotype P value of haplotype SNP P value individual SNP SNP P value individual SNP SNP P value individual SNP 
2 12 0.0004 rs22859255* 0.0048 rs22784610 0.4131 n/a n/a 
6 21 0.0032 rs24327392 1 rs24327060 0.008 n/a n/a 
6 12 0.0044 rs24327060 0.008 rs24259668 0.5711 n/a n/a 
6 22 0.0026 rs24301782 0.0225 rs24354816 0.4683 n/a n/a 
6 22 0.0005 rs24344762 0.4949 rs24332727* 0.0012 n/a n/a 
6 221 0.0002 rs24315819 1 rs24327231 1 rs24327271* 0.0008 
6 212 0.0002 rs24327231 1 rs24327271* 0.0008 rs24348619 0.4866 
20 111 0.0007 rs22915894* 0.0017 rs8806978* 0.0021 rs22929054 0.405 
20 122 0.001 rs9081246* 0.0017 rs22915887 0.1115 rs22915894* 0.0017 
20 222 0.001 rs22915887 0.1115 rs22915894* 0.0017 rs8806978* 0.0021 
20 221 0.001 rs22915894* 0.0017 rs8806978* 0.0021 rs22929054 0.405 
20 21 0.0029 RS8891640 0.0893 rs22892223 0.0093 n/a n/a 
20 11 0.0001 rs22845779 0.2683 rs22913552* 0.0005 n/a n/a 
20 22 0.0007 rs22880046 0.0385 rs22864357* 0.0025 n/a n/a 
20 11 0.0011 rs22883166 0.2626 rs22930928 0.0121 n/a n/a 
20 11 0.0013 rs22930928 0.0121 rs22926113 1 n/a n/a 
20 21 0.0025 rs22913940 1 rs22912434 0.0503 n/a n/a 
20 22 0.004 rs22914527 0.4812 rs22918497 0.0154 n/a n/a 
20 21 0.0047 rs22912434 0.0503 rs22883166 0.2626 n/a n/a 
20 11 0.0049 rs22892983 0.3114 rs22883015 0.0154 n/a n/a 
20 21 0.0099 rs8625504 0.0639 rs22883400 0.35 n/a n/a 
* Denotes that the SNP was significant in the single SNP association analysis 
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Figure 7.6  Ensembl Chromosome View: A Representation of Haplotype Analysis 
 
 
 
 
 
 
 
 
 
 
 
(a). 
(b). 
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Figure 7.6 continued 
 
 
 
 
 
 
 
 
 
 
(c). 
(d). 
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Figure 7.6 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(e). 
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Figure 7.6 continued 
 
 
 
 
 
 
 
Figure 7.6: Using Ensembl chromosome view, the position of SNPs have been plotted (purple lines), and, 
using the information in Table 7.2, the significant haplotypes have been indicated in order to give a visual 
representation of the haplotype data.  (a) Chromosome 2, 48061748 to 49061747;  (b) Chromosome 6, 8226831 
to 9226830 base pairs;  (c) Chromosome 6, 15340731 to 16340 730 base pairs;  (d) Chromosome 20, 5301142 
to 6301141 base pairs; (e) Chromosome 20, 25859421 to 290000000 base pairs; (f) Chromosome 20, 
290000000 to 33818500 base pairs. 
(f). 
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7.4  Discussion 
The results of the GWAS were analysed with and without population structure 
adjustment. In comparing the top 40 associated SNPs from these two approaches only five 
SNPs were identified by both tests (marked with* in Table 7.1).  
The importance of accounting for population structure in GWAS has been discussed in 
the context of human
334;340;341
, but not in canine studies as this is the first commercially 
available chip for canine GWAS. Applying the same principles as used in human studies, 
however, should have accurately defined and accounted for the population structure.  
Confounding results due to differences in population structure can mask actual results; 
especially in complex traits where the effect of each allele is smaller
340
. This may explain 
higher levels of significance in the “population structure unadjusted” results and only 5 SNPs 
being identified in both the population structure “adjusted” and “unadjusted” analyses. 
The genomic control (GC) inflation factor (calculated by q-q plot, Figure 7.3) can be used 
to adjust for population structure. Although, it has been shown that GC inflation factor does 
not accurately correct for population structure
340;341
. This is because GC inflation factors are 
global and do not account for differences that are specific to each SNP
342;343
. It has been 
stated that the “potential for stratification based on differences in population structure in case 
and control groups is different for each SNP”334, therefore a blanket correction like GC 
inflation factor is not viable and was not used in this study.  
Principle component analysis (PCA) has been shown to account for population structure 
effectively
334;340;341;343
. However, it has been noted that high LD SNPs affect the population 
structure findings because they group according to local LD patterns instead of global 
genome wide population structure. The accuracy of PCA is therefore improved if high LD 
SNPs are excluded from the analysis
341;344
. In dogs, however, there is insufficient LD 
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information available to exclude high LD SNPs. As a result this study did not use PCA, and 
relied on IBS clustering and MDS, which are good alternatives to accurately defining the 
population structure
334;340
. The issue of high LD SNPs remains. 
Population structure results (Figure7.4) and the Q-Q plot (Figure 7.3) shows differences 
within the golden retriever breed. It was expected that these differences would be due to 
different points of origin as these samples were obtained from veterinary practices in Japan 
and the US. The population structure, however, did not group according to point of origin and 
it seems there is a discreet population structure present. Unknown familial relationships 
between cases and controls can result in them appearing to have their own population 
structure
334
. This has implications for population structure in dogs because they are inbred, 
especially amongst pedigrees that have a limited number of or particularly popular sires
345
. 
No familial relationship information for the golden retrievers used on the array was available, 
therefore it is possible that the results grouped according to a unknown familial relationship.  
The use of family based cases and controls excludes false positives due to population 
structure, and this principle has been effectively applied to human GWAS
346;347
. This could 
be a viable approach for future canine GWAS studies because of the population structure 
issues. However, first degree relatives are required for analysis and, as discussed in Chapter 
1, obtaining enough samples for family studies is difficult.  
The “population structure adjusted” results may be more accurate because there are such 
large differences within the breed they need to be accounted for. However, the methods used 
rely on a dense set of trait independent and unlinked SNPs
340
, and, given the lack of LD 
information on dogs, it is impossible to say whether this has been accounted for. It cannot be 
concluded that the “population structure adjusted” results are the more accurate results and 
therefore both sets of results need to be considered. 
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Three of the 5 SNPs found (on both “population structure adjusted” and “unadjusted” 
analyses, and the majority of the SNPs identified on either analysis) were present in 
intergenic regions. Further fine mapping and re-sequencing will be required if they are found 
to be significant in the subsequent validation study. Only a few of the potentially associated 
SNPs were found in or around genes. 
SDK1 and LRIG1 SNPs were identified by both analyses. SDK1 is cell adhesion protein 
containing immunoglobulin-like and fibronectin domains. It is considered to only operate in 
axonal terminals and therefore SDK1 has no apparent direct functional link to cAD. LRIG1, 
on the other hand, acts as a negative regulator of signalling through enhancement of receptor 
ubiquitination (the process of protein inactivation by addition ubiquitin, to allow transport of 
the protein to the proteasome for degradation) and accelerated intracellular degradation, 
suggesting a possible function in cAD. Interestingly haplotype analysis demonstrated that 
both SDK1 (Figure 7.6c) and LRIG1 (Figure 7.6f) have more significant p values when 
analysed with certain intergenic SNPs (see Table 7.2), suggesting a haplotypic effect. 
In the “population structure unadjusted” results SNPs within RAB3C, SORCS2, PROM1, 
FXYD8, KHDRBS2, TFEB, COL19A1, RAB7A, RARB, MAPK8, SEMA5B and 
ENSCAFG00000004115 were identified (Figure 7.2, Table 7.1).  
RAB3C has a potentially relevant function to the pathogenesis of AD as it codes for a 
protein transporter found on lipid anchors
348
. The importance of lipids and the skin barrier 
has been demonstrated multiple times in both human and canine AD
3;4;45;349;350
.  The 
associated SNPs (rs22859255, rs22784610) show a more significant p value when analysed 
together, suggesting that they form a haplotype which is significantly associated with cAD 
(see Table 7.2, Figure 7.6a). 
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COL19A1 is a collagen gene with roles in the formation and maintenance of the 
extracellular matrix
351
, changes to which may affect the pathogenesis of AD. TFEB 
recognizes E-box sequences in the heavy-chain immunoglobulin enhancer
352
; this could have 
implications for AD due to the potential effects on the recognition of allergens.   
RAB7A produces a protein which is a cellular component of the melanosome, containing 
melanin for skin pigmentation. The association with cutaneous metabolism suggests that 
RAB7A could be involved in cAD although the precise pathogenesis is unclear. Multiple 
significant haplotypes with RAB7A intronic and downstream SNPs have been demonstrated 
(see Table 7.2, Figure 7.6d), suggesting that further fine mapping of the region could be 
beneficial.  
MAPK8 (JNK1) is involved in the JNK signalling pathway
353
 which activates in response 
to environmental stress and pro-inflammatory cytokines
354
. In T-cells, JNK1 and JNK2 are 
required for polarized differentiation of T-helper cells into Th1 cells. These functions are 
therefore potentially relevant to the immunology of AD. 
The IBS cluster/meta-analysis (“population structure adjusted”) results found SEZ6L, 
RAB11-FIP4, precursor C5orf46, Solute carrier family 35 member F3, PREX2, F-box only 
protein 41 ENSCAFG00000004544 (novel gene), ENSCAFG00000007979 (novel gene) and 
ENSCAFG00000015477 (novel gene) to have an association with cAD. However, none of 
these genes show immediately obvious functions which may be involved with the 
pathogenesis of cAD (Figure 7.5 and Table 7.2). 
The haplotype analysis showed increased significance in two intergenic SNPs 
(rs24327271 [Figure 7.6b] and rs22913552 [Figure 7.6f]) when analysed with other nearby 
intergenic SNPs, suggesting that further haplotype analysis and fine mapping of these regions 
is required. There were also other haplotype associations found with SNPs that were not 
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significant on the single SNP analysis. For example, SNPs in SUCLG2 (Succinyl-CoA ligase 
[GDP-forming] subunit beta, mitochondrial) which is involved in carbohydrate metabolism
355
 
and FAM19A4, a brain specific protein of unknown function
356
 formed separate significant 
haplotypes (Figure 7.6d). Moreover SNPs within Williams-Beuren syndrome chromosomal 
region 16 protein (WBSCR16), ENSCAFG00000011514 (an orthologue of Williams-Beuren 
syndrome chromosomal region 6 protein [WBSCR6]), FSCN1 and STAG3OS also formed 
significant haplotypes with intergenic SNPs (Figure 7.6b). 
 WBSCR6 produces a protein which is necessary for induction of immunoglobulin heavy-
chain transcription
357
 and FSCN1 organizes filamentous actin into bundles and associates 
with beta catenin
358
. These two functions could be linked with AD pathogenesis, although 
further fine mapping and analyses of these areas is required before conclusions can be drawn.  
Haplotype analysis provides a useful way to gain more information from GWAS data. 
Because of the high LD in dogs, it is difficult to know whether the haplotypes identified are 
causal or simply in linkage with other causative alleles. Until a canine HAPMAP equivalent 
is available it will be difficult to further differentiate or investigate this fully.  
In conclusion, using GWAS identified novel candidate SNPs in cAD for a large-scale 
case-control comparison/validation study. However, the numbers of dogs were low, 
increasing the risk of detecting false positive associations. This was statistically corrected for, 
although this does not eliminate false positives all together. It would have been better to use a 
large number of cases and controls to enhance the statistical power and confidence in the 
results.  The issue of population structure indicates that in future studies sample selection for 
GWAS should use ancestry informative markers to initially define population structure 
before selecting grouped individuals for inclusion on GWAS
334
. Although this would reduce 
the already small sample sizes available. Finally, it is important to note that while the canine 
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SNP20 array is defined as having good coverage across the genome, the success of the study 
depends on whether the array includes the causative allele. In this array there are large gaps 
in coding regions, and Filaggrin, for example, which appears to be of great importance in 
hAD
228;230;231;359;360
, is not covered by the Illumina canine SNP20.  
These results therefore need to be validated and should be considered a first sweep or 
novel SNP identification method. By performing further genotyping validation it is hoped 
that true associations with the disease phenotype will be found. 
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 GWAS Validation Study   
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8.  GWAS Validation Study 
 
This work is presented in: Wood, S.H., Ke, X., Nuttall, T., McEwan, N., Ollier, W.E., 
Carter, S.D., (2009) Genome Wide Association Analysis of Canine Atopic Dermatitis and 
Identification of Disease Related SNPs, Immunogenetics, 61(11-12):765-72 
8.1 Introduction 
In Chapter 7, SNPs associated with cAD were identified by GWAS. Validation of these 
results is necessary to have confidence in the associations found, as a small number of dogs 
were included on the GWAS array, which could lead to false positive associations. To 
validate the GWAS results, the associated SNPs were genotyped by another method. 
Sequenom is a high throughput genotyping system that uses multiplex PCR followed by a 
single base primer extension reaction. Subsequent analysis by MALDI-TOF spectrophometry 
ensures accurate identification of the alleles present. As Sequenom is a multiplex system, it is 
relatively inexpensive and only requires small quantities of DNA sample. 
In Chapter 7 the GWAS data were analysed in two ways: Firstly using the Fisher‟s exact 
test, which does not take into account population structure present in the dogs studied and 
could be prone to false positive associations
341
, and secondly, a meta-analysis, which using 
IBS clustering and MDS, defines and accounts for population structure
334
. When comparing 
the results from these two methods only five SNPs were identified in both analyses as 
potentially associated with cAD.  
 The disparity between the two analyses was not unexpected, as the results observed can 
be masked by differences in population structure, especially in complex traits where the 
effect of each allele is small
340
.  As the results were different and IBS clustering/MDS has not 
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been used to identify population structure in dogs before, the decision was taken to validate 
the top 40 results from the analysis using the Fisher‟s exact test (“population structure 
unadjusted”) and the top 40 SNPs from IBS and MDS analysis (“population structure 
adjusted”). The five SNPs identified by both analyses were used as quality control markers of 
inter-assay variation.  
By validating results from both “population structure adjusted” and “unadjusted” analyses 
it was hoped that we would be able to identify whether IBS clustering was adequately 
identifying population structure. Theoretically, if IBS/MDS was identifying true associations 
and Fisher‟s exact test was detecting false positives due to population structure, the IBS/MDS 
“population structure adjusted” analysis should show more positive associations when 
genotyped by Sequenom, than the “population structure unadjusted” analysis. The validation 
and comparison of these two analyses could have implications in future canine GWAS study 
design and analysis. Moreover, if positive associations were found after validation it would 
indicate that the use of small sample size GWAS in canines for novel SNP identification is of 
scientific merit. 
The study design is presented in Figure 8.1, which outlines the selection of SNPs from the 
GWAS and the subsequent analyses that were performed on the Sequenom validation results 
in this chapter.  
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Figure 8.1  GWAS Validation Study Design 
 
 
Figure 8.1: GWAS array was performed in Chapter 7 and the results were analysed in two ways; 
“population structure adjusted” and “population structure unadjusted”. The top 40 from both these analyses were 
typed on the Sequenom to validate the results. The analysis was three fold; meta-analysis on all breeds, 
individual breed meta-analysis and individual breeds split by geographic region association tests. 
 
The validation of the GWAS data was carried out in 659 dogs across 8 breeds, including 
the golden retriever as used in the GWAS (Chapter 7). The inclusion of multiple breeds 
complicates the analysis of the Sequenom data. Firstly, differences in breed and geographical 
region need to be taken into account, requiring meta-analysis of all 8 breeds clustered by 
breed and geographical region. Secondly, there is no evidence that cAD will be caused by the 
same genetic variations in different breeds therefore an individual breed analysis was 
required. This was done in two ways: meta-analysis on individual breeds clustered by 
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geographic region, e.g. all golden retrievers; and allelic association, genotypic model and 
logistic association tests performed on individual breeds from specific geographical regions, 
e.g. three separate analyses on British, US and Japanese golden retrievers. Analysing the data 
in this way allowed population structure caused by geographical region and inter-breed 
differences to be accounted for. 
The aim of this study was to validate results obtained from a GWAS in a larger sample 
set using the Sequenom SNP genotyping platform. Validation of the GWAS results that show 
SNP associations with cAD will help validate the use of small sample size GWAS as a novel 
SNP discovery method for potentially causative SNPs in cAD.  
 
8.2 Methods 
Atopic dogs and healthy controls – breed, sex and age matching 
Disease diagnosis, sample collection and processing of samples from dogs with and 
without cAD were performed as detailed in Chapter 2. Five hundred and four dog DNA 
samples were breed, age and sex matched. One hundred and fifty five samples were only 
breed matched. In total, 659 DNA samples were included on the Sequenom array, 41 of 
which were previously included on the GWAS array. Eight breeds were included in this 
study. Table 8.1 summerises the breakdown of breed, geographical region and disease status. 
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Table 8.1 Samples included in Sequenom genotyping 
  CASE CONTROL   
Breed  UK USA JAPAN Total UK USA JAPAN Total Grand 
Total 
Boxer 11 - - 11 24 - - 24 35 
GSD 10 9 - 19 23 15 - 38 57 
Labrador 23 33 8 64 75 43 11 129 193 
G. Retriever 4 23 13 40 28 21 17 66 106 
Shiba Inu - - 23 23 - - 33 33 56 
Shih Tzu 2 6 39 47 12 2 48 62 109 
Pit Bull - 20 - 20 - 17 - 17 37 
WHWT 14 4 - 18 34 14 - 48 66 
Totals       242       417 659 
 
Primer and probe design 
Table 8.2 summerises the SNPs selected from the GWAS in Chapter 7. Full primer and 
probe sequences for these SNPs are listed in Appendix 8. Primers and probes could not be 
adequately designed for BICF2G630250121, and 5 SNPs were identified in both analyses, 
bringing the total number of SNPs genotyped to 74.  
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Table 8.2  Top 40 SNPs identified on GWAS from Population Structure Unadjusted Analysis and Population Structure Adjusted   
       Analysis 
Population Structure: Unadjusted Population Structure: Adjusted 
SNP Chromosome Odds Ratio        P value            SNP Chromosome Odds Ratio       P value 
rs22859255 2 4.4 0.0048 rs21994080 1 0.1 0.0015 
rs23545080 3 5.4 0.0019 rs22738169 2 0.2 0.0009 
rs23567144 3 0.2 0.0018 rs22808564 2 6.3 0.0027 
rs23602938 3 3.8 0.0047 rs24092655 4 0.0 0.0013 
rs24872415 3 9.5 1.27x10
-06
 rs24131580 4 45.3 0.001 
rs24194054 5 4.8 0.0011 rs24275059 6 40.7 0.0019 
rs24267550 5 0.2 0.0042 rs24332727 * 6 0.1 0.0028 
rs24318716 6 0.3 0.0076 rs24354997 6 40.7 0.0019 
rs24327271 6 0.2 0.0008 rs24462950 7 44.5 0.0011 
rs24332727 * 6 0.2 0.0012 rs24556501 9 0.1 0.0006 
rs24408651 7 0.2 0.0008 rs24732893 * 12 0.2 0.0028 
rs24482628 8 4.1 0.0025 rs22524918 17 NA 0.0027 
rs22020166 10 3.8 0.0022 rs22576724 17 0.2 0.0031 
rs22114085 10 5.1 0.0008 rs22720467 19 19.8 0.0014 
rs22155657 11 5.9 0.0063 rs22864357 * 20 5.6 0.0017 
rs22181912 12 0.3 0.0028 rs22991453 21 0.1 0.003 
rs22184220 12 4.3 0.0009 rs23029421 22 0.1 0.0017 
rs22185491 12 3.4 0.0045 rs23066224 * 22 16.8 0.0012 
rs22212359 12 7.2 0.0016 rs23117702 23 0.1 0.0004 
rs22212677 12 5.3 0.0049 rs23224877 25 19.5 0.0024 
rs24732893 * 12 0.2 0.0007 rs23313105 26 10.5 0.0003 
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Table 8.2 continued 
 
 
rs22328353 14 5.8 0.0025 rs23316823 26 0.0 0.0013 
rs22523565 16 3.3 0.0067 rs23444049 29 6.3 0.0016 
rs8649732 19 0.2 0.0044 rs9132002 29 0.0 0.0029 
rs22864357 * 20 4.1 0.0025 rs23622647 30 0.0 0.0008 
rs22913552 20 4.6 0.0005 rs23684720 31 5.6 0.0028 
rs22915894 20 0.2 0.0017 rs23708599 31 0.2 0.0022 
rs8806978 20 3.8 0.0021 rs23767031 32 9.8 0.0012 
rs9081246 20 0.2 0.0017 rs23768387 * 32 0.1 0.0019 
rs22959786 21 5.9 0.0009 rs23769251 32 0.1 0.0018 
rs22989468 21 0.2 0.0057 rs23769439 32 0.1 0.0024 
rs23026134 22 5.4 0.0019 rs23770102 32 0.0 0.0017 
rs23066224 * 22 7.2 0.0016 BICF2G630250121 33 0.0 0.0022 
rs23122280 23 5.4 0.0019 rs23803267 34 0.0 0.0016 
rs23428471 28 3.6 0.0036 rs23856926 34 0.2 0.0029 
rs23478400 28 3.6 0.0036 rs23865825 34 0.1 0.0027 
rs23472497 29 0.2 0.0009 rs23870923 34 0.2 0.0011 
rs23690306 31 5.3 0.0003 rs23932942 35 6.3 0.0009 
rs23768387 * 32 0.2 0.0031 rs23968934 36 NA 0.003 
rs23828846 33 0.2 0.0007 rs23974741 36 NA 0.0007 
* Denotes the SNPs identified on population structure adjusted analysis as well as population structure unadjusted analysis 
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Quality control, plex dilutions and plate setup 
See Chapter 2 for details of quality control, plexing and plate setup for the Sequenom. 
PCR and SAP treatment 
The PCR assays were all performed in a 384-well plate format. A 5μl reaction volume 
was used per well. This consisted of 0.1μl Hot start Taq (5U/µl, Qiagen, Crawley, UK), 0.5μl 
each of 500 nM forward and reverse primers (Metabion, Germany), 0.325µl MgCl2 (25mM, 
Qiagen, Crawley, UK), 0.1μl DNTPs (25mM), 0.625µl x10 buffer (Qiagen, Crawley, UK) 
0.35µl distilled water and 2.5µl of DNA at 10ng/µl. The amplification was performed as 
follows: 94ºC for 15 minutes, then 94ºC for 20 seconds, 56ºC for 30 seconds and 72ºC for 1 
minute (35 cycles), and finally 72ºC for 3 minutes. 
Shrimp Alkaline Phosphatase (SAP) clean was performed by adding 1.53µl distilled 
water, 0.17µl 10x SAP buffer (Sequenom, San Diego, CA, USA) and 0.3µl SAP enzyme 
(1U/µl) to each well, to make a total reaction volume of 7µl. This was incubated at 37ºC for 
40 minutes and 85ºC for 5 minutes. 
iPLEX reaction and Resin clean 
The iPLEX reactions were all performed in a 384-well plate format. To the SAP cleaned 
plate, 0.619μl distilled water, 0.2µl x10 iPLEX buffer (Sequenom, San Diego, CA, USA), 
0.2µl iPLEX termination mix (Sequenom, San Diego, CA, USA), 0.041µl iPLEX enzyme 
(Sequenom, San Diego, CA, USA) and 0.94µl probe mix (7µM and 14µM, Sequenom, San 
Diego, CA, USA) were added to make a total reaction volume of 9µl. The cycling conditions 
were as follows: 94ºC for 30 seconds, then 94ºC for 5 seconds, 52ºC for 5 seconds and 80ºC 
for 5 seconds (40 cycles), and finally 72ºC for 3 minutes. 
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A resin clean was performed by adding 16µl of distilled water per well and the 
appropriate amount of resin (Clean resin, Sequenom, San Diego, CA, USA) per well (3mg if 
the plex was lower than 5 and 6mg if the plex was above 6).  The plate was inverted for 10 
minutes allowing the resin to settle each time. The plate was then centrifuged at 4000rpm for 
15 minutes. 
Spotting and running arrays 
The sample plates and arrays (Spectro chip®, Sequenom, San Diego, CA, USA) were 
spotted using Massarray™ Nanodispenser. Sequenom Samsung 3pt calibrant (Sequenom, 
San Diego, CA, USA) was also spotted to allow the MALDI-TOF spectrophotometer 
(Sequenom, San Diego, CA, USA) to take a control reading. Spots were read by the MALDI-
TOF spectrophotometer (Sequenom, San Diego, CA, USA).  
Data collection, calling and analysis 
The Spectro-aquire and mass array typer software packages (Sequenom, San Diego, CA, 
USA) interpreted these data and automatically called the genotypes from the spectra. These 
data were reviewed using Typer analyser V3.4.0.18 (Sequenom, San Diego, CA, USA) and 
the data were exported into Excel format for statistical analysis. 
Statistical analysis 
PLINK
338
 was used for all the downstream analysis. All data were subject to quality 
control procedures; only SNPs which conformed to Hardy-Weinberg expectations, exhibited 
90% genotyping success and had a minor allele frequency ≥ 0.01were included in subsequent 
analysis. On this basis eleven of the 74 SNPs tested were excluded (rs23567144, rs22020166, 
rs22155657, rs9081246, rs22959786, rs23122280, rs21994080, rs23444049, rs23803267, 
rs23856926 and rs23029421).  A variety of association tests were undertaken (see Figure 8.1 
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for overview). Using PLINK, each breed was analysed separately according to geographic 
region, and allelic association, logistic association and genotypic model tests were performed. 
Meta-analysis (Cochran-Mantel-Haenszel test for 2x2xK stratified tables) was used in two 
ways. Firstly to analyse all 8 breeds together taking into account breed and geographic region 
(defined by user from supplied phenotype information). Secondly, meta-analysis was used on 
individual breeds where samples were obtained from different geographic regions, e.g. 
golden retrievers were obtained from USA, UK and Japan. It is considered that this approach 
eliminates false positives due to population substructure
334
. P values were corrected for 
multiple testing by using the number of independent loci (38 in this study). 
8.3 Results 
The 41 samples included in both the GWAS discovery study (Chapter 7) and Sequenom 
arrays showed an average concordance of 99% in all genotyped SNPs. Of the 5 SNPs 
identified in both analyses, 3 were genotyped on each Sequenom array to act as an inter-array 
control revealing 100% concordance between the arrays. 
Sequenom SNP data from all breeds were combined and analysed using meta-analysis to 
account for the differences between breeds and geographic region. Table 8.3 shows the 
corrected p value significant SNPs from the meta-analysis for all 8 breeds, and compares the 
results to the GWAS (Chapter 7) and a combined meta-analysis of the GWAS data and the 
Sequenom data. A complete summary of the results from the meta-analysis are presented in 
Appendix 9. A conditional regression on the meta-analysis data from Table 8.3 is presented 
in Table 8.4.  
Table 8.5 shows the results from the individual breed analysis as a matrix of corrected p 
values obtained from the allelic association tests and individual breed meta-analysis. Where 
indicated, the associations were significant on the logistic and genotypic association tests. 
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The complete results from all of the statistical tests undertaken on individual breeds are 
presented in Appendices 10 and 11.  
Seventy four SNPs were typed on the Sequenom platform, 11 of which were excluded 
due to low genotyping success. Out of the 63 remaining SNPs, 30 had statistically significant 
corrected p values (summarised in Table 8.5). The meta-analysis on all 8 breeds showed 
strong association with cAD in 2 SNPs (Table 8.3).  
Table 8.3  Comparison of the Validation Study Meta-Analysis, GWAS Analysis and a
       Combined Analysis of Validation and GWAS Data 
SNP GWAS Discovery Study Validation Study - Meta 
analysis 
Combined Validation study 
& GWAS meta-analysis 
rs number 
 
Odds Ratio Corrected P 
value 
Odds ratio Corrected P 
value 
Odds Ratio Corrected P 
value 
RS22114085 
 
5.1 0.00084 2.0 0.00014 2.0 4.8x10
-05
 
RS23472497 
 
0.2 0.00086 0.6 0.0015 0.6 0.0011 
 
Table 8.4  Conditional Regression of Significant Meta-analysis SNPs 
 ADD RS22114085 
RS23472497 0.00056 0.00399 
RS22114085 0.00399 0.00056 
 
Table 8.4 shows the results of a conditional regression on the two SNPs identified by 
meta-analysis as statistically significant in cAD. The p values were significant in this test 
indicating that the two SNPs are independent of each other. 
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Table 8.5  Individual Breed Analysis: Matrix of Corrected P value Significant SNPs   
  Boxer GSD Labrador Golden retriever Shiba Inu Shih Tzu Pit Bull WHWT 
Rs number UK All UK USA All USA UK All USA UK Japan Japan USA All UK USA 
RS22114085 - - - - - - 2.0x10
-4
** - - - - - - - - - 
RS22184220 - - - 0.034 - - - - - - - - - - - - 
RS22523565 - - - - - - - - 0.022 - - - - - - - 
RS22859255 - - - - - - - 0.001 - - - - - - - - 
RS22915894 - - - - - - 0.002** - - 1.6x10
-6
* - - - 0.033 - 0.006* 
RS23026134 - - - - - 0.009* - - - 0.018* - - - - - - 
rs23472497 - - - - - - - 0.032 - - - - - - - - 
RS23545080 - - - - - - - 0.045 - 1.0x10
-6
* - - - - - - 
RS23602938 - - - - - - - 0.018 - - - - - - - - 
RS23690306 - - - - - - - - - 0.024* - - - - - - 
RS24194054 - - - - - - - - - - - - - - 0.032* - 
RS24327271 - - - - - - - 0.01 0.014 - - - - - - - 
RS24408651 - - - - - - - 0.019 - - - - - - - - 
RS24482628 - - - - - - - - - - - - - 0.023 0.006* - 
RS24872415 - - 0.009 - - - - - - - - - - - - - 
RS8806978 - - - - - - 0.006* - - 2.3x10
-6
* - - - 0.033 - 0.006* 
RS22720467 - - 0.001 - - - 0.032 - - - - - - - - - 
RS23224877 - - - - - - - - - - - - - - 0.029 - 
RS23316823 - - - - - - - - 0.007* - - - - - - - 
RS23708599 - - - - - - - - 0.013 - - - - - - - 
RS23767031 - - - - - - - - - - 8.0x10
-4
** - - - - - 
RS23769251 - - 0.006 - - - - - - - - - - - - - 
RS23770102 - - - - - - - - 0.027 - - - - - - - 
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Table 8.5 continued 
 
RS23968934 - - - - - - - - - 4.0x10
-4
 - - - - - - 
RS24092655 - - - - - - - - - - 0.004 - - - - - 
RS24275059 - - 0.047 - - - 0.035 - - - - - - - - - 
RS24354997 - - 0.047 - - - - - - - - - - - - - 
RS9132002 - - - - - - 0.002* - - - - - - - - - 
RS22864357 - - - - - - - - - 2.0x10
-4
* - - - - - - 
RS24332727 - - - - - - - - - 0.007 - - - - - - 
* denotes that this association is significant on trend analysis using the genotypic model. ** denotes that this association is significant on trend analysis using the 
genotypic model and logistic association using the additive model. For the results of all statistical tests undertaken on individual breeds, which include p values, upper and 
lower confidence intervals, and odds ratios (see appendices 10 and 11). 
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8.4 Discussion 
Meta-analysis of the eight breeds under study found two independent associations, which, 
represent a cAD susceptible SNP (RS22114085) and a cAD protective SNP (RS23472497). 
These two SNPs are both intergenic within chromosomes 10 and 29 respectively.  Both of 
these SNPs were selected from the “population structure unadjusted” GWAS analysis. The 
breeds were also analysed separately for associations, revealing that rs22114085 was 
significantly cAD-associated in UK Labradors (see Table 8.5). All golden retrievers showed a 
significant cAD association with rs23472497, but individual breed associations for these two 
SNPs were not seen in the other breeds. This could have been because the small sample 
sizesanalysed affected statistical power. These results suggest that the associated SNPs, 
rs22114085 and rs23472497, may represent novel loci suitable for further re-sequencing and 
fine mapping in cAD research.  
An individual breed analyses was also undertaken, as it was unknown whether cAD has a 
common genetic cause in all breeds. The results of this analysis are presented in Table 8.5. 
Thirty SNPs were associated with cAD in various breeds; the majority of the associations 
found were in intergenic SNPs (SNPs not within genes). Only the associations with SNPs 
within genes will be discussed here as the role of SNPs in intergenic regions is unknown.  
In all golden retrievers, two intronic SNPs, rs23602938 (PROM1) and rs22859255 
(RAB3C), were found to be significantly associated with cAD. RAB3C has a potentially 
relevant function contributing to the pathogenesis of cAD as it codes for a protein transporter 
found on lipid anchors
348
, and the importance of lipids and the skin barrier has been 
previously demonstrated in both human and canine AD
3;4;44;349;350
. Moreover, using the 
GWAS data I demonstrated that the cAD-associated SNP forms a significant haplotype with 
another intronic SNP from RAB3C (rs22859255 and rs22784610, p value=0.000386, see 
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Chapter 7). This, coupled with the validation of this SNP by Sequenom, indicates that the 
association is of potential importance in cAD. However, rs22784610 was not genotyped in 
this validation study because it was not individually significant on the GWAS. 
In Labradors meta-analysis revealed no significant associations, but when the analysis 
was split into geographic regions, UK Labradors showed associations between cAD and an 
intronic SNP within RAB7A, rs22915894, and rs8806978, which is downstream of RAB7A. 
These associations were also seen in WHWTs. RAB7A, produces a protein which is a 
cellular component of the melanosome, containing melanin for skin pigmentation. As cAD is 
a dermatological disease, the function of RAB7A could be relevant to the pathogenesis.  
Identification of an association with these two intronic SNPs may also suggest that there is a 
haplotypic effect; in Chapter 7 a significant haplotype between these two SNPs was 
demonstrated (p=0.0007) from the GWAS data. The same analysis cannot be performed on 
this data, however, because the data are not genome wide or of sufficient density. Further 
investigation by fine mapping/re-sequencing is therefore required to confirm this haplotype. 
These SNPs were also significant before multiple testing corrections in all breeds on the 
validation study meta-analysis (see Appendix 7). This could suggest that SNPs in linkage in 
this region could be causative or have a haplotypic effect in other breeds.  
RS24872415, an intronic SNP within SORCS2, which was the most significant SNP on 
the “population structure unadjusted” GWAS analysis (p=1.27x10-6, odds ratio 9.55), was 
only associated with cAD in UK GSDs in the validation study and the level of significance 
was lower than that seen in the GWAS. This suggests that the result could have been a false 
positive potentially caused by unrecognised population structure.  
The majority of the associations found following validation of SNPs selected from the 
“population structure adjusted” GWAS analysis were intergenic and the p values were more 
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modest than found with the “population structure unadjusted” GWAS selected SNPs. 
However, it has been stated that false positive associations due to population structure can 
mask actual results
340
.  This may be the case when comparing validation of SNPs selected 
from “population structure unadjusted” and “adjusted” analyses.  
In Shiba Inu‟s a strong association was found with RS23767031. This SNP is upstream of 
U4 (ENSCAFG00000021950), a small nuclear RNA (snRNA) involved in RNA splicing.  In 
addition, RS24092655, an intronic SNP within Solute carrier family 35 member F3 
(SLC35F3), was also associated with cAD. SLC35F3 is thought to be a putative solute 
transporter
361
. It is therefore possible that it affects Ca
2+
 transport and that it could have 
implications for keratinocyte differentiation and presence of Filaggrin in keratinocytes
362
. 
A weak association was found with two intronic SNPs: RS24275059 and RS24354997. 
These are located within ENSCAFG00000015477, an orthologue of human Radial spoke 
head 10 homolog B (RSPH10B), the function of which is unknown. This association was 
found in UK GSDs and UK Labradors (rs24275059 only). 
From the GWAS, there were 5 SNPs identified by both “population structure unadjusted” 
and “adjusted” analyses. Two of these SNPs showed an association in this study: 
RS22864357, a synonymous coding SNP within Leucine-rich repeats and immunoglobulin-
like domains of protein 1 Precursor (LRIG1 [ENSCAFG00000006680]); and RS24332727 
within intronic SDK1 (ENSCAFG00000016192) Protein sidekick-1 Precursor. LRIG1 acts as 
a negative feedback regulator of receptor tyrosine kinase signalling
363
. SDK1 produces a cell 
adhesion protein which functions in neuronal development
364
. BDNF has been implicated in 
AD via the itch scratch response
365
 and it is possible that a neuronal component is involved in 
cAD. However, these associations were only seen in UK golden retrievers, and the small 
numbers within this group make a false positive result a possibility. 
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The strongest associations in this study were found with SNPs selected from the GWAS 
“population structure unadjusted” results. This raises questions regarding the suitability of 
IBS clustering and MDS as a method for defining population structure in dogs. One reason 
why the “population structure adjusted” analysis may not have identified SNPs which have 
been validated from the “population structure unadjusted” analysis is that the validated SNPs 
may be in LD with other SNPs. This would mask their effect in the “population structure 
adjusted” analysis. This may have happened, as high LD SNPs need to be removed from the 
analyses to allow population structure to be accurately defined (discussed in Chapter 7). This 
is difficult in dogs because of the lack of LD information. Furthermore the majority of SNPs 
in the dog genome appear to be in high LD. This throws into question the use of „human‟ 
population structure adjustment methods for analysis of dog data.  
It can also be argued that the meta-analysis clusters used to analyse the Sequenom data 
may not have been accurate, leading to false positives in the Sequenom validation analysis. 
The clusters were defined by the user based on the breed and place of origin supplied by the 
veterinary practice, which could lead to mistakes. Moreover, as seen in Figure 7.3, Japanese 
and American populations of golden retrievers do not cluster according to origin. This 
undermines the use of non-marker informed clusters and suggests that false positives due to 
population structure could be present in the Sequenom meta-analysis results. Ideally the 
meta-analysis should be repeated with IBS clusters defined from a set of population 
informative genetic markers run on the entire sample set. This would provide confidence that 
the population structure effects had been accounted for.  
SNPs selected from “population structure unadjusted” and “adjusted” analyses have 
proven useful in identifying SNPs for further research. The validation of some of the GWAS 
results does indicate that the use of GWAS as a novel SNP discovery tool is valid in dogs. 
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For future studies it is recommended that sample selection for GWAS is based on the use of 
ancestry informative markers to initially define population structure and then select grouped 
individuals for inclusion on GWAS
334
. Furthermore, using ancestry informative markers on 
all individuals selected for the large-scale validation study would improve the analysis and 
confidence in the results.   
It may have been beneficial to use the same breed for the validation study to ensure a 
more direct comparison. The cAD phenotype is clinically heterogeneous
7
, which may have 
caused problems in the across breed comparisons. It is possible that cAD is caused by 
different loci in different breeds, and in support of this, many of the associations found were 
only in one breed. However, the fact that the SNP is associated in one breed but not another 
does not necessarily mean the SNP isn‟t a risk factor for cAD, as the SNP may have different 
levels of penetrance in different breeds
366
. There are examples of this in human GWAS where 
discovery of important SNPs initially made in non-European populations was then 
demonstrated to be present in European populations at a different penetrance
367-369
. In support 
of the decision to include multiple breeds for the validation study, it has been stated that 
although effects of certain variations may be different in each population it can still be 
beneficial to analyse multiple populations to increase statistical power
366
. Demonstrating the 
same association in different populations is also advantageous to further study design and 
increases confidence in the results
326
. 
The majority of associations found were SNPs in intergenic regions, and, although these 
were not discussed in detail, they do represent important areas for further fine mapping and 
re-sequencing. The reason why so many of the associations were within intergenic regions is 
unknown but it is possible that SNPs could be in linkage disequillibrium with other structural 
variations, e.g. microsatellites, Variable Number Tandem Repeats (VNTRs), retro-element 
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insertions, deletions and duplications. It is also important to note that GWAS is limited to 
identifying common SNPs with small effects; it cannot identify rare SNPs with large effects, 
un-typed SNPs and parent of origin effects, which could be important in cAD.  
In conclusion, this is the first GWAS on cAD that has been subsequently validated in a 
larger cohort. In total, 30 SNPs were shown to be associated with cAD, 2 of which were 
associated in all 8 breeds tested.  However, methods for analysis of GWAS results in the dog 
still require some development to ensure population structure is adequately controlled for and 
to increase the likelihood of identifying lower penetrance alleles.  
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9.  Candidate Gene Case-Control SNP Association Study 
 
9.1 Introduction 
In the previous chapter, SNPs selected by GWAS were validated for an association with 
cAD. In this chapter, SNPs selected from literature searches and following canine microarray 
(Chapter 3), some of which have been investigated at the expression level by qPCR (Chapter 
5), and other SNPs identified by WAVE SNP discovery (Chapter 6) will be assessed for any 
cAD association using the same panel of dog cases and controls and Sequenom genotyping 
methodology as in Chapter 8.  
This approach is referred to as a candidate gene study (see Chapter 1 for details) and is 
commonly used to study complex diseases. The basis of this type of study is the same as 
GWAS, in that if a polymorphism is identified at a higher (or lower) frequency in cases than 
in controls it may be associated with the disease. The main differences between the 
approaches are the methods used for SNP selection. GWAS is an unbiased whole genome 
approach but a candidate gene study is biased as SNPs are selected based on previous 
evidence of association or relevant function to the disease pathogenesis. Therefore, this type 
of study is limited to small regions of genes that have already been annotated or previously 
linked with the disease. It is, nevertheless, relevant to use this approach, as previously 
discussed the GWAS array used to investigate cAD has gaps in coding regions potentially 
missing important genes, e.g. Filaggrin, which may be involved in the disease pathology. 
Ninety seven SNPs from 25 genes (Table 9.1), all of which have shown previous 
evidence of functionality or changed expression in cAD have been included in this study. A 
further 18 SNPs from 10 genes selected from the GWAS data were also included (see Table 
9.1). These genes were not covered in the GWAS array but SNPs in intergenic regions 
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surrounding the genes were (see Figure 9.1). When these intergenic SNPs showed high odds 
ratios or increased significance in p value, the gene they flanked was included in this study 
(assuming the gene was not covered by the array). This is similar to the principle of tagging 
SNPs, although no LD information is available for the canine genome and without this the 
validity of this method is questionable. See Figure 9.1 for further explanation. Figure 9.2 
shows the selection of candidate genes for the genotyping study relative to the rest of this 
thesis. Table 9.1 lists all genes included in this study and the evidence for inclusion. It was 
hoped that by including genes with relevant functions to AD or previous linkage/association, 
an association with cAD would be found. 
Figure 9.1  Significant hits in intergenic areas surrounding genes 
 
 
Figure 9.1: The purple area represents the coverage of the Illumina array, the red area is a protein coding 
gene. It can be seen that the gene is not covered by the array. The arrows represent intergenic SNPs which show 
high odd ratios or increased significance. In this case it can be seen that these flank the gene, suggesting that the 
gene could be of importance. 
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Figure 9.2 Gene selection for Candidate gene case control study 
 
 
 
Figure 9.2: Candidate gene selection for this study was based on the original 29 candidate genes listed in 
Table 3.4, 22 were selected and 7 excluded due to primer design issues. The excluded genes were: GOLGA4, 
MUC2, IL1RL1, CTLA4, Cystatin A, SOCS3 and phospholipase C, zeta 1. Extra literature searches were 
undertaken and 2 more candidate genes included; IL-4 and TLR2. 10 genes were inferred from GWAS and 
included as per Figure 9.1. 
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Table 9.1  Genes selected for Sequenom study and supporting evidence for inclusion 
Gene Chromosome Evidence 
Interleukin 4 11 Human and canine Literature 
ARTS-1 3 Canine microarray 
Cadherin 13 5 Canine microarray 
POSTN 25 Canine microarray 
SYND1 17 Canine microarray 
INPPL1 21 Canine microarray and qPCR 
SAA-1 21 Canine microarray and qPCR 
SCCA2 1 Canine microarray and qPCR 
PKP2 27 Canine qPCR 
PPAR GAMMA 20 Canine qPCR 
P-selectin 7 Canine qPCR and literature 
TNF ALPHA 12 Human and canine literature 
CARD 4 14 Human Literature 
CMA1 8 Human Literature 
Filaggrin 17 Human Literature 
MS4A2 21 Human Literature 
PPAR ALPHA 10 Human Literature 
SPRR1B 17 Human literature 
TLR2 15 Human literature 
TSLP receptor X Human literature 
STAT2 10 Human literature and canine microarray 
DPP4 36 Human Literature and canine qPCR 
SPINK5 2 Human Literature and canine qPCR 
S100A8 7 Human literature, canine microarray and 
canine qPCR 
CUX1 6 Based on region identified by GWAS 
DOCK2 4 Based on region identified by GWAS 
GATA-3 2 Based on region identified by GWAS 
GTF2I 6 Based on region identified by GWAS 
IRAK1BP1 12 Based on region identified by GWAS 
NEK7 7 Based on region identified by GWAS 
PDGFD 5 Based on region identified by GWAS 
SORCS2 3 Based on region identified by GWAS 
TFEB 12 Based on region identified by GWAS 
COL19A1      12 
 
 
Based on region identified by GWAS 
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9.2 Methods 
Atopic dogs and healthy controls – breed, sex and age matching 
The same samples were used as in Chapter 8 (see section 8.2) 
Primer and probe design 
See Appendix 12 for full primer and probe sequences for the SNPs listed in Table 9.2. 
Table 9.2 lists the SNPs included in the Sequenom genotyping assay. 
Table 9.2  SNPs included in the Sequenom genotyping assay. 
RS number Chr Base Pair Gene Location 
rs21902676 1 16469324 SCCA2 Upstream 
rs21941198 1 16475961 SCCA2 Non synonymous coding 
rs21902632 1 16476102 SCCA2 Non synonymous coding 
rs9013510 1 16476441 SCCA2 Downstream 
rs21902631 1 16476541 SCCA2 Downstream 
rs9013509 1 16476584 SCCA2 Downstream 
rs22821176 2 30911977 GATA-3 Downstream 
rs22750909 2 30930868 GATA-3 Upstream 
rs22871624 2 45133450 SPINK5 Upstream 
rs22871627 2 45133465 SPINK5 Upstream 
rs22871630 2 45133611 SPINK5 Upstream 
rs22871646 2 45133786 SPINK5 Upstream 
rs22819627 2 45159024 SPINK5 Non synonymous coding 
rs22872666 2 45162084 SPINK5 Synonymous coding 
rs22818977 2 45167469 SPINK5 Synonymous coding 
rs22874976 2 45176838 SPINK5 Splice site, intronic 
rs22839343 2 45201929 SPINK5 Synonymous coding 
rs22807086 2 45212191 SPINK5 Downstream 
rs23593765 3 15767342 ARTS-1 Synonymous coding 
rs9196801 3 15767484 ARTS-1 Frame shift - coding 
rs24872954 3 15782443 ARTS-1 Synonymous coding 
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Table 9.2 continued 
 
rs9190946 3 15784064 ARTS-1 Synonymous coding 
rs8857124 3 62477640 SORCS2 Synonymous coding 
rs9241373 3 62483849 SORCS2 Frame-shift coding, splice site 
rs23586992 3 62483869 SORCS2 Synonymous coding 
rs24150067 4 45333435 DOCK2 Synonymous coding 
rs24202381 5 31088631 PDGFD Synonymous coding 
rs24264853 5 71503539 Cadherin-13 Downstream 
rs8988459 6 8748612 GTF2I Synonymous coding 
rs9255897 6 10862928 CUX1 Synonymous coding 
rs24328835 6 10890690 CUX1 Synonymous coding 
rs8667691 6 10898270 CUX1 Synonymous coding 
rs24319791 6 10917564 CUX1 Synonymous coding 
rs24404799 7 7553657 NEK7 Non synonymous coding 
rs24404800 7 7553658 NEK7 Non synonymous coding 
rs24380950 7 7570280 NEK7 Synonymous coding 
rs24435410 7 31958066 P-Selectin Non synonymous coding 
rs24438947 7 46517606 S100A8 Upstream 
s100a8_p 7 46517638 S100A8 Promoter region 
s100a8_p2 7 46517792 S100A8 Promoter region 
s100a8_p3 7 46517859 S100A8 Promoter region 
rs8867188 8 7447456 CMA1 Upstream 
rs22655272 9 5852692 SOCS3 Upstream 
rs22655274 9 5852893 SOCS3 Upstream 
rs22655276 9 5853219 SOCS3 Upstream 
rs22655278 9 5853780 SOCS3 Upstream 
rs22615134 9 5860501 SOCS3 Downstream 
rs22000453 10 3625056 STAT2 Downstream 
rs22000474 10 3625180 STAT2 Downstream 
rs22029672 10 3631328 STAT2 Non synonymous coding, splice site 
rs22009467 10 23005117 PPAR-α Splice site, intronic 
rs22146864 11 23976639 IL-4 Upstream 
rs9095590 12 4078693 TNF-α Synonymous coding 
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Table 9.2 continued 
 
rs22217971 12 13373163 TFEB Synonymous coding 
rs22263793 12 35504037 COL19A1 Synonymous coding 
rs8860216 12 42878364 IRAK1BP1 Downstream 
rs22374481 14 46159795 CARD4 Upstream 
rs22374487 14 46159824 CARD4 Upstream 
rs22410121 15 54484550 TLR2 Non synonymous coding 
rs22349093 15 54485784 TLR2 Synonymous coding 
rs22349092 15 54486859 TLR2 Downstream 
rs22605727 17 18202904 SYND1 Downstream 
rs22529256 17 64273415 Filaggrin Synonymous coding 
rs22542234 17 64296141 Filaggrin Non synonymous coding 
rs8555036 17 64296436 Filaggrin Synonymous coding 
rs22542260 17 64296760 Filaggrin Synonymous coding 
rs22542262 17 64296821 Filaggrin Non synonymous coding 
rs22542263 17 64296837 Filaggrin Splice site, intronic 
rs22588226 17 64297000 Filaggrin Non synonymous coding 
rs22588227 17 64297022 Filaggrin Non synonymous coding 
rs22588228 17 64297028 Filaggrin Non synonymous coding 
rs8555045 17 64298442 Filaggrin Non synonymous coding 
rs8555046 17 64298495 Filaggrin Non synonymous coding 
rs8555044 17 64298566 Filaggrin Synonymous coding 
rs22511502 17 64298621 Filaggrin Non synonymous coding 
rs22511526 17 64298647 Filaggrin Non synonymous coding 
rs22509070 17 64298685 Filaggrin Non synonymous coding 
rs22511501 17 64300264 Filaggrin Synonymous coding 
rs22509072 17 64300322 Filaggrin Non synonymous coding 
rs22509074 17 64300703 Filaggrin Non synonymous coding 
rs22511518 17 64301581 Filaggrin Synonymous coding 
rs22542266 17 64301700 Filaggrin Non synonymous coding 
rs22511504 17 64301968 Filaggrin Synonymous coding 
rs22509090 17 64301986 Filaggrin Synonymous coding 
rs22509067 17 64302067 Filaggrin Non synonymous coding 
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Table 9.2 continued 
 
rs22565034 17 64303134 Filaggrin Non synonymous coding 
rs22599138 17 64303187 Filaggrin Non synonymous coding 
SPRR1B_e3_1 17 64883377 SPRR1B Exon 3 
rs8944179 20 9156340 PPARγ Synonymous coding 
rs22931896 20 9213048 PPARγ Upstream 
rs22931897 20 9213053 PPARγ Upstream 
rs22935368 21 28904622 INPPL1 Downstream 
rs9070190 21 28910870 INPPL1 Synonymous coding 
rs9150577 21 28912392 INPPL1 Synonymous coding 
rs22976618 21 28912506 INPPL1 Synonymous coding 
rs8488679 21 43871640 SAA-1 Upstream 
rs22908459 21 43872759 SAA-1 Synonymous coding 
rs22910701 21 43875650 SAA-1 Synonymous coding 
rs22908463 21 43891974 SAA-1 Synonymous coding 
rs22986026 21 53629181 MS4A2 Upstream 
rs8877519 21 53631150 MS4A2 Splice site, synonymous coding 
rs8877521 21 53631234 MS4A2 Synonymous coding 
rs22986033 21 53631825 MS4A2 Non synonymous coding 
MS4A2_E5 21 53634435 MS4A2 Exon 5 
rs22986082 21 53634938 MS4A2 Synonymous coding 
rs9019919 21 53636716 MS4A2 Downstream 
rs23274229 25 6184255 POSTN Synonymous coding 
rs23360288 27 19048662 PKP2 Synonymous coding 
rs23907319 36 10444284 DPP4 Synonymous coding 
rs24630571 X 745241 TSLP 
receptor 
Synonymous coding 
rs24630609 X 745403 TSLP 
receptor 
Synonymous coding 
rs24613434 X 750979 TSLP 
receptor 
Synonymous coding 
rs24613432 X 751050 TSLP 
receptor 
Splice site, intronic 
rs24639522 X 755348 TSLP 
receptor 
Synonymous coding 
rs24657063 X 755447 TSLP 
receptor 
Synonymous coding 
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Sequenom genotyping 
97 SNPs had probe and primer sequences successfully designed for Sequenom-based 
genotyping. These SNPs were genotyped in each dog using the Sequenom platform.  
See Chapter 2 for details of quality control, plexing and plate setup for the Sequenom. 
The methods used for Sequenom genotyping were the same as in Chapter 8. See Chapter 8 
methods (section 8.2) for details of PCR, SAP treatment, iPLEX reaction, resin clean, 
spotting and running of the arrays. The data collection, calling and analysis were also 
performed as detailed in Chapter 8 (section 8.2). 
Statistical analysis 
The whole-genome association analysis toolset PLINK was used to analyse the data. 
All data were subject to quality control procedures; only SNPs which conformed to HWE, 
exhibited ≥90% genotyping success and had a minor allele frequency≥0.01 were included in 
subsequent analysis. 
As in Chapter 8, Figure 8.1 three types of analysis were conducted. Asssociation tests 
were undertaken on all breeds separately, including basic association, allelic association, 
logistic regression and the genotypic model statistical test. Meta-analysis was also undertaken 
on all breeds and individual breeds grouped according to geographic region. This considers 
the data as a whole taking into account variables between them such as breed and geographic 
region (defined by user from supplied phenotype information), eliminating false positives due 
to population substructure. P values were corrected for multiple hypotheses testing by 
multiplying p values by the number of independent loci (48 in this study).  
 
192 
 
9.3 Results 
Table 9.3 shows the SNPs found to be cAD associated in all eight dog breeds tested using 
meta-analysis. In each sample, the corrected p value represents the level of significance after 
correction for multiple testing, which is based on the number of independent loci in the 
analysis (48 in this study). Only one SNP was significant after correction, this was 
rs24613432 which is intronic within TSLP receptor.  
Table 9.4 shows the results from the individual breed analysis as a matrix of corrected p 
values obtained from the allelic association tests. Where indicated, the cAD associations were 
significant on the logistic and genotypic association tests (See Appendix 13 for a more 
complete summary of the results). The results from the individual breed meta-analysis are not 
shown in the main text as there were no significant results after multiple testing correction 
(see Appendix 14 for a summary of the results). 15 SNPs were associated with cAD, although 
these associations were in a variety of dog breeds. 
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Table 9.3  Meta-analysis of All Breeds Clustered by Breed and Geographic region  
SNP CHR BP Gene Location Odds 
ratio 
P value Corrected 
p value 
RS24613432 X 751050 TSLP receptor Splice Site, Intronic 0.38 8.0 x10
-4
 0.037 
RS23907319 36 10444284 DPP4 Synonymous Coding 1.54 0.004 0.20 
SPRR1B_e3_1 17 64883377 SPRR1B Exon 3 0.64 0.011 0.51 
RS22819627 2 45159024 SPINK5 Non Synonymous Coding- 
Amino Acid Change D/E 
1.40 0.014 0.67 
RS21902632 1 16476102 SCCA2 Non Synonymous Coding – 
Amino Acid Change R/S 
0.70 0.017 0.84 
RS8860216 12 42878364 IRAK1BP1 Downstream 1.66 0.023 1.08 
RS22565034 17 64303134 Filaggrin Non synonymous Coding – 
Amino Acid Change E/K 
0.36 0.026 1.23 
RS22818977 2 45167469 SPINK5 Synonymous coding 0.75 0.031 1.48 
RS9150577 21 28912392 INPPL1 Synonymous coding 0.76 0.033 1.56 
RS9190946 3 15784064 ARTS-1 Synonymous coding 1.33 0.043 2.08 
RS8877521 21 53631234 MS4A2 Synonymous coding 1.28 0.044 2.10 
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Table 9.4  Individual Breed Analysis: Matrix of Corrected P value Significant SNPs in cAD   
    Boxer GSD Labrador Golden retriever Shiba Inu Shih Tzu Pit Bull WHWT 
Rs number Gene region UK All UK USA All USA UK All USA UK Japan Japan USA All UK USA 
RS22009467 PPAR-alpha - - - - - - - - - - - - - - - 0.031 
RS22542260 Filaggrin - - - - - - - - - 0.007* - - - - - - 
RS22542263 Filaggrin - - - - - - - - - 0.014* - - - - - - 
RS22588227 Filaggrin - - - - - - 0.009**  - - - - - - - - 
RS22807086 SPINK5 - - - 0.014 - - - - - - - - - - - - 
RS22871630 SPINK5 - - - - - - - - 0.021ª 0.030* - - - - - - 
RS22986026 MS4A2 - - - - - - - - - - 8.7 x 10-4* - - - - - 
RS23274229 POSTN - - - - - - - - - - - - - - - 0.001 
RS23907319 DPP4 - - - - - - 5.2 x10-4**  - - - - - - - - 
RS24319791 CUX1 - - - - - - - - - - - - 0.044 - - - 
RS24328835 CUX1 - - - - - - - - - - 0.012 - - - - - 
RS24613432 TSLP receptor - - - - - - - - - - - - 0.005* - - - 
RS24613434 TSLP receptor - - - - - - - - - 0.020 - - - - - - 
RS9070190 INPPL1 - - - - - - - - - - 4.6 x10-5** - - - - - 
RS9150577 INPPL1 - - - - - - - - - - 1.9 x10-4** - - - - - 
* denotes that this association is significant on trend analysis using the genotypic model. ** denotes that this association is significant on trend analysis using the 
genotypic model and logistic association using the additive model. ª denotes that this association did not make the HWE cut off of 0.05 
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9.4 Discussion 
As these data include multiple breeds, the analysis needs to be carefully selected. Meta-
analysis allowed all of the data to be clustered according to breed and point of origin 
information and then analysed independently of these variables. Hence, meta-analysis was 
the preferred method for analysis of this type of data, giving greater statistical confidence due 
to the larger number of cases and controls. It was, however, useful to analyse these data breed 
by breed as there was no assurance that the same disease phenotype in different breeds had 
the same genetic cause. Moreover, in complex diseases, such as AD, different levels of 
penetrance can be observed in different SNPs and breeds.  
Data derived from this study clearly showed some SNP associations with cAD. It was 
also clear, from a visual check of the data sets, that these SNP associations were different 
from breed to breed. In fact, only one SNP was associated with cAD in all 8 breeds. However 
up to 4 SNPs were found to be cAD associated in some breeds when studied individually. 
The results from the meta-analysis on all eight breeds revealed only one SNP 
(rs24613432) to be significantly associated with cAD after correction for multiple testing. 
This SNP is within Thymic stromal lymphopoietin (TSLP) receptor gene. The same SNP was 
also significantly associated in the Pit Bull terrier when using allelic association testing and 
the genotypic model (Table 9.4). RS24613434 is another SNP within TSLP receptor that was 
found to be significant in UK and European golden retrievers (Table 9.4).  
TSLP receptor forms a functional complex with TSLP and IL-7 receptor which can 
stimulate cell proliferation through STAT3 and STAT5 activation
370
. It can also activate 
JAK2 and is expressed by dendritic cells and activated monocytes
371
. Its involvement in the 
JAK-STAT pathway
217
, which is used by interleukins to transduce the signals that initiate 
cytokine specific gene transcription, is of interest in the immunological response of AD.  
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Furthermore, the functional complex with TSLP links its function closely with that of TSLP, 
which has been called the „master switch‟ for allergic inflammation182. Evidence for this is 
based on observations of TSLP-treated human blood dentritic cells which induce an 
inflammatory Th2 cytokine pattern
239
. Increased expression of TSLP by keratinocytes in 
atopic skin lesions in hAD has been observed by immunohistochemistry
239
. It has also been 
demonstrated that TSLP “converts human epidermal Langerhans cells into antigen-presenting 
cells that induce pro-allergic T cells”242. This is of interest because previous studies have 
noted that Langerhans cells serve as antigen-presenting cells in AD
243;244
, by expressing high-
affinity IgE receptors that allows for more efficient allergen capture, processing and 
presentation to T cells
245
. This effect of TSLP could render LCs capable of inducing or 
maintaining atopic dermatitis symptoms
242
.  
TSLP, however, is yet to be characterised in the canine genome, consequently it could not 
be included here, although the TSLP receptor was included. Because of TSLP‟s potential 
relevant function to the pathogenesis of AD it is likely that TSLP receptor may also have a 
role. As these results demonstrate a cAD association with TSLP receptor, they indicate that it 
is a good candidate for further fine mapping and re-sequencing studies.  
The remaining single breed analysis presented in Table 9.4 found 15 SNPs in nine genes 
to be significantly associated with cAD in a variety of breeds. CUX1 was one of these genes, 
with associations being found in the Pit Bull terrier and the Shiba Inu. These associations 
were found in different SNPs, rs24319791 and rs24328835 respectively. Both of these are 
synonymous coding suggesting that a non-synonymous SNP that was not included in the 
Sequenom assay could be the actual causative SNP. It is interesting to note that CUX1 was 
not selected for Sequenom analysis based on its function or previous association with hAD, 
but was inferred from the GWAS conducted in Chapter 7. Suggesting that inference from 
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GWAS as described in the introduction may be a useful way to compensate for the gaps 
present on the canine Illumina SNP20 chip (discussed in Chapter 7). Of further note is the 
interaction of CUX1 with GOLGA5
372
, a mRNA transcript that was found to be dysregulated 
on the canine microarray performed in Chapter 3.  
Two SNPs in SPINK5 were found to be associated with cAD: rs22807086 in USA GSDs, 
and rs22871630 in UK and USA golden retrievers although the association with USA golden 
retrievers did not met the HWE cut-off.  In the meta-analysis two SPINK5 SNPs (rs22819627 
and rs22818977) showed an association with all eight breeds, but this was not significant 
after multiple testing corrections. This is noteworthy because these multiple weak 
associations with SPINK5 suggest a link with this gene and the disease. It is possible that the 
causative SNP was not included in this study or different SNPs within this gene lead to the 
same phenotype in different breeds. Further analysis by fine mapping and re-sequencing will 
be required to better characterise the SNPs in this gene and locate the causative mutation. 
SPINK5 is a good candidate for further research because of these associations and also 
because it functions in hair and skin morphology, proteolysis during epithelial formation and 
keratinocyte differentiation
170
. Moreover, as discussed in Chapter 3, SPINK5 mutations have 
been shown to be associated with hAD
125-127
 and in Chapter 5 differential gene expression of 
SPINK5 in cAD was demonstrated. 
Peroxisome proliferator-activated receptor alpha (PPARα, rs22009467) was associated 
with cAD in the WHWT. Members of the PPAR family (PPARβ/δ, PPARα, PPARγ) have 
been associated with inflammation and skin barrier function in humans, and have been 
implicated in the pathogenesis of hAD
209
. PPARs represent interesting candidates because 
treatment with them has improved atopic symptoms in human patients
209
. However, the 
numbers of WHWT tested were low, meaning that this may be a false positive result. 
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In hAD, two Filaggrin loss of function variants (R501X and 2282del4) were identified to 
be major risk factors for the development of AD
51;52;228
. Filaggrin contributes to barrier 
formation by causing the cells to compact into squames by aggregating to the keratin 
cytoskeleton. It can also be broken down at the stratum corneum to form a “natural 
moisturizing substance”42;53. In this study, the UK golden retrievers showed an association 
with Filaggrin SNPs (rs22542260 and rs22542263), although the numbers of dogs were low, 
suggesting that these results may be false positives. Nevertheless, the UK Labradors showed 
an association with rs22588227, which is a non-synonymous SNP in Filaggrin, and therefore, 
may lead to a loss of function. In addition, rs22565034, another non-synonymous SNP, 
showed an association on the meta-analysis, although this was not significant after correcting 
for multiple testing. The weak association on meta-analysis could be due to differing SNPs 
within the gene leading to the same phenotype in different breeds. Also, the associations 
found here could represent SNPs in linkage disequillibrium with another causative SNP not 
included on the array. There were many non-synonymous SNPs in Filaggrin that were not 
included on this array, due to assay design issues, that could be contributing to the disease 
phenotype.  
Dipeptidyl-peptidase 4 (DPP4) (rs23907319) was found to have a strong association 
(confirmed by logistic association and genotypic model tests) with cAD in UK Labradors. 
The same SNP was identified on meta-analysis as potentially cAD associated, although it was 
not significant after correction for multiple testing. DPP4 has been implicated in: activation 
of regulatory T cells, T cell cycle arrest, inhibition synthesis and proliferation of T cells, 
suppression of inflammatory cytokines by T cells
191;192
 and wound healing
193
.  In Chapter 5, 
mRNA expression of DPP4 was down-regulated in cAD and this, coupled with the 
association evidence here, suggests that it is a good candidate for further re-sequencing and 
fine mapping research.  
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MS4A2 produces FcεRIβ, which is important in IgE function43;112. As discussed in 
Chapter 1, FcεRIβ binds allergen specific IgE expressed on Langerhans and mast cells32, 
leading to the inflammatory responses seen in allergic inflammation. One MS4A2 SNP, 
rs22986026, was associated with cAD in the Shiba Inu (rs8877521 was also associated on the 
meta-analysis, but after correction for multiple testing it was not significant). The functions 
described and associations seen in this experiment do indicate that this gene is of interest in 
understanding the pathogenesis of cAD.    
Two SNPs in INPPL1 (rs9070190 and rs9150577) were strongly associated (confirmed 
by logistic association and genotypic modelling) with cAD in the Shiba Inu. Another SNP, 
rs9150577, was associated in meta-analysis but was not significant after correction. INPPL1 
was up-regulated in cAD in the qPCR experiment described in Chapter 5. The encoded 
protein also plays a role in the regulation of epidermal growth factor and controls the shift of 
lipid balance by increased tyrosine phosphorylation
373
. Moreover, the SRC2 domain present 
on INPPL1 has been implicated in T cell development
278
. This evidence of T cell and lipid 
involvement, along with potential disease associations, strengthens the evidence for a 
pathogenetic role for this gene in cAD.  
An association between USA WHWTs and POSTN (rs23274229) was seen, although the 
case numbers were small, therefore this could represent a false positive result. 
Finally, SNPs in SPRR1B, SCCA2 and IRAK1BP1 were found to be associated on meta-
analysis but not after correction. The fact that these genes did not stand up to multiple testing 
and were not implicated on any of the other association tests suggests they may be false 
positives. 
There are issues to consider with this study. Firstly as there were eight different breeds 
from variable locations, the numbers for single breed analysis were small, especially for a 
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complex disease such as cAD. It is possible that associations may have been missed due to a 
lack of statistical power. Repeating this experiment with larger numbers and better defined 
breeds from one area (e.g. the UK) could strengthen the results. Moreover, cAD is a clinically 
heterogeneous condition that may have several different genetic determinants impacting upon 
the clinical outcome. Different breeds and different individuals within a breed may also have 
different genetic determinants leading to the same clinical phenotype. This is possible 
because SNPs in linkage disequilibrium with each other can be variable in different breeds. 
For example, multiple associations were seen within Filaggrin and SPINK5 in different 
breeds indicating that a shared causative SNP may have not been genotyped. Further fine 
mapping and re-sequencing of these areas may identify a causative mutation common to all 
breeds that was not included in this study. In addition, multiple associations within the same 
gene may indicate a haplotypic effect. Haplotype analysis, however, could not be performed 
on these results because the data was not genome wide or of sufficient density. If the genes 
indicated here were to be fine mapped this would allow for haplotype analysis of that area. 
Furthermore, LD analysis could not be undertaken because dogs do not have a HAPMAP 
equivalent. Nevertheless, this study does illustrate some potential associations with good 
candidate genes which warrant further research by fine mapping and re-sequencing. 
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Chapter 10  
General Discussion 
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10. General Discussion 
 
This thesis set out to investigate the genetics of cAD and to assess whether cAD was a 
suitable model for the human disease. In order to achieve this, a candidate gene approach was 
used. Selection of candidate genes was based on a canine mRNA microarray, qPCR and 
literature searches. SNPs were selected from these candidate genes to be included in a large-
scale case-control comparison. Further to this a GWAS was undertaken which identified 
potential associations with novel SNPs, and these associations were validated in a large-scale 
case-control comparison study. Using a variety of approaches to select SNPs for study helped 
to reduce bias and include novel candidates. In order to test the associations of cAD with 
these SNPs the genotyping platform Sequenom was used. In total 659 dogs across 8 breeds 
were genotyped in 232 SNPs across 54 genes and 41 intergenic regions. From this 45 putative 
associations were found in various breeds (summarised in Table 10.1). 
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Table 10.1  Summary of the Associations Found by Sequenom 
RS Number Gene/Region Breed associated Study 
RS9150577 INPPL1 Shiba Inu Candidate Gene Study- Canine microarray (chapter 3) 
RS9070190 INPPL1 Shiba Inu Candidate Gene Study- Canine microarray (chapter 3) 
RS23274229 POSTN USA WHWT Candidate Gene Study- Canine microarray (chapter 3) 
RS24319791 CUX1 Pit Bull Candidate Gene Study- Inferred from GWAS 
RS24328835 CUX1 Shiba Inu Candidate Gene Study- Inferred from GWAS 
RS24613432 TSLP receptor All Breeds Candidate Gene Study- Literature 
RS24613434 TSLP receptor UK golden retriever Candidate Gene Study- Literature 
RS22542260 Filaggrin UK Golden retriever Candidate Gene Study- Literature 
RS22542263 Filaggrin UK Golden retriever Candidate Gene Study- Literature 
RS22588227 Filaggrin UK Labrador Candidate Gene Study- Literature 
RS22986026 MS4A2 Shiba Inu Candidate Gene Study- Literature 
RS22009467 PPAR-alpha USA WHWT Candidate Gene Study- Literature 
RS23907319 DPP4 UK Labrador Candidate Gene Study- Literature and canine qPCR (chapter 5) 
RS22807086 SPINK5 USA GSD Candidate Gene Study- Literature, canine qPCR (chapter 5) 
RS22871630 SPINK5 USA & UK golden retriever Candidate Gene Study- Literature, canine qPCR (chapter 5) 
RS22864357 LRIG1 UK golden retriever GWAS Validation Study 
RS23602938 PROM1 All golden retrievers GWAS Validation Study 
RS22859255 Rab-3C All golden retriever GWAS Validation Study 
RS22915894 Rab-7a UK Labradors & UK golden retriever GWAS Validation Study 
RS24332727 SDK1 UK golden retriever GWAS Validation Study 
RS24092655 SLC35F3 Shiba Inu GWAS Validation Study 
RS24872415 SORCS2 UK GSD GWAS Validation Study 
RS24275059 ENSCAFG00000015477 UK GSD & UK Labrador GWAS Validation Study 
RS24354997 ENSCAFG00000015477 UK GSD GWAS Validation Study 
RS23224877 Upstream - ENSCAFG00000007979 UK WHWT GWAS Validation Study 
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   Table 10.1 continued 
 
    
RS23767031 Upstream - U4 Shiba Inu GWAS Validation Study 
RS22523565 Downstream - KIAA1549 USA golden retriever GWAS Validation Study 
RS8806978 Downstream - RAB7a UK Labrador, All WHWT & UK golden retriever GWAS Validation Study 
RS22114085 Intergenic - Chromosome 10 All Breeds GWAS Validation Study 
RS22184220 Intergenic - Chromosome 12 USA GSD GWAS Validation Study 
RS22720467 Intergenic - Chromosome 19 UK GSD & UK Labrador GWAS Validation Study 
RS23026134 Intergenic - Chromosome 22 USA Labradors & UK golden retriever GWAS Validation Study 
RS23316823 Intergenic - Chromosome 26 USA golden retriever GWAS Validation Study 
RS23472497 Intergenic - Chromosome 29 All Breeds GWAS Validation Study 
RS9132002 Intergenic - Chromosome 29 UK Labrador GWAS Validation Study 
RS23545080 Intergenic - Chromosome 3 All golden retrievers GWAS Validation Study 
RS23690306 Intergenic - Chromosome 31 UK golden retriever GWAS Validation Study 
RS23708599 Intergenic - Chromosome 31 USA golden retriever GWAS Validation Study 
RS23769251 Intergenic - Chromosome 32 UK GSD GWAS Validation Study 
RS23770102 Intergenic - Chromosome 32 USA golden retriever GWAS Validation Study 
RS23968934 Intergenic - Chromosome 36 UK golden retriever GWAS Validation Study 
RS24194054 Intergenic - Chromosome 5 UK WHWT GWAS Validation Study 
RS24327271 Intergenic - Chromosome 6 All golden retrievers GWAS Validation Study 
RS24408651 Intergenic - Chromosome 7 All golden retrievers GWAS Validation Study 
RS24482628 Intergenic - Chromosome 8 All WHWT GWAS Validation Study 
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Interesting candidate genes were found to be associated with cAD by Sequenom 
genotyping. SPINK5 and TSLP receptor in particular were associated with cAD in certain 
breeds indicating similarities to the human condition, and opening cAD research to further 
functional study. The GWAS that was undertaken was the first study of cAD using a genome 
wide SNP array. Novel areas were identified by GWAS and confirmed by Sequenom – two 
SNPs in intergenic regions showed independent and strong associations with all breeds. 
However an association with intergenic regions does raise some questions as to how these 
could be affecting the disease phenotype. It is possible that other variations, not SNPs, could 
be effecting the association, for example copy number variations, imprinting/methylation, 
long range genetic regulation via promoter regions and other structural variations, e.g. 
microsatellites, Variable Number Tandem Repeats (VNTRs), retro-element insertions, 
deletions and duplications. This is possible because the SNP could be in linkage 
disequilibrium with the variation leading to increased association with that SNP on GWAS 
despite it not being the disease causative allele. There are many different types of variation 
that can contribute to disease pathogenesis, for example increased copy number of β defensin 
is associated with psoriasis
374
. Only one other type of mutation, a microsatellite in one gene, 
was investigated in this study, as it was outside the scope of this thesis to further investigate 
other sources of mutation/variation. 
These results will lead to further work in fine mapping and re-sequencing of these areas 
to identify the causative SNPs or the SNPs in linkage disequilibrium with this region. 
This study has been reasonably successful in identifying candidate genes and SNP 
associations in cAD, however there are a number of criticisms that can be made regarding 
gene selection and assay design. For example in the candidate gene section for this study a lot 
of the candidate genes were chosen because of dysregulation on canine mRNA microarray 
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(which was later confirmed using qPCR), but the coverage of the microarray was poor, 
especially in regions covering Filaggrin. It may have been beneficial to re-analyse the 
microarray data using Gene Set Analysis (GSA), which treats expression data as a group and 
measures subtle co-ordinated changes in the gene group
375
. This means that all changes in 
expression are relevant and no cut-offs are applied to the data (cut-off is usually less than 2 
fold change), shifting the emphasis to the small cumulative and potentially co-ordinated 
changes that may be more representative of what is seen in complex diseases. Network 
theory
376
 supports this approach stating that biological systems function as a fine network 
with certain genes functioning as hubs which connect to multiple genes
377
. Therefore a small 
change in one part of the network may lead to subtle changes across the whole network. GSA 
tools, however, are limited to humans and the major model species because there is more 
genomic and gene interaction information available. If a GSA tool is created for dogs it is 
possible that new information could be gained from the microarray data. 
If an mRNA expression study was undertaken now, recent developments in technology 
would have to be taken into account. RNA-seq is a relatively new process that allows for 
quantitative measurement and accurate sequencing of RNA essentially combining microarray 
with qPCR
158
. Therefore it would be a more time efficient, unbiased and accurate method 
than microarray and qPCR confirmation. Furthermore, by combining the analysis of the 
microarray data and the GWAS data using GSEA-SNP analysis, SNP information can be 
combined with expression data leading to a pathway driven analysis
378
. This approach is 
more geared to understanding the biological process as a whole and identifying the pathways 
interacting in disease pathology. It was not possible to do this analysis as the statistical power 
would not have been sufficient due to the limited amount of samples used in GWAS and lack 
of coverage on the canine microarray. Nevertheless this is an interesting approach to analysis 
of this data type and could prove useful in the future. 
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The GWAS array was not optimal because of the assay design; there were a limited 
amount of SNPs and large gaps on the array, meaning that areas such as Filaggrin were not 
included. Affymetrix has recently produced a larger canine SNP array with better coverage, 
which may be beneficial in future studies. The statistical analysis of GWAS studies is still 
developing, even in humans. For example the WTCCC study has been re-analysed in 
multiple ways giving new information each time
379-382
. It is also important to note that 
GWAS is limited to identifying common SNPs with small effects, and it cannot identify rare 
SNPs with large effects, un-typed SNPs, parent of origin effects and, as discussed above, 
other variations (with the execption of CNVs). 
The GWAS data provides Copy Number Variants (CNV) information; CNV‟s are defined 
as stretches of DNA larger than 1 kb that display differences in copy number in the 
population
383
. As they are variable in the population their association with disease has been 
investigated.  Effects of the copy number of individual CNVs have been associated with 
diseases through dosage effects of a single gene, a neighbouring set of genes as in Williams-
Beuren syndrome and infantile spasms or through allele combinations in the case of some 
complex diseases
384
. CNV analysis can be done on the GWAS data presented in this thesis, 
but dogs do not have a whole genome CNV catalogue making this process difficult
385
. This 
may be something to consider for the future because CNVs are increasingly being studied and 
linked with complex diseases
384
. 
HAPMAP provides human researchers with a rich data set of linkage and SNP 
information which is invaluable in interpreting results or calculating frequencies of tagging 
SNPs. The major limitation with analysis of GWAS data in dogs is the fact that no HAPMAP 
equivalent exists. A recent study (Ke etal "Assessment of the 
functionality of genome-wide canine SNP arrays and implications for canine 
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disease association studies," manuscript in prep) noted that because of the lack of a 
HAPMAP the canine GWAS arrays were designed based on the Boxer assembly and SNPs 
were selected by physical distance. This means that LD coverage and SNP tagging capability 
varies greatly from breed to breed. This suggests that the selection of golden retrievers for the 
GWAS may have been ill advised due to reduced LD and SNP tagging. Also only 48 samples 
were included due to budget constraints. It would be better in future studies to use a larger 
number when studying complex diseases to allow low penetrance SNPs to be identified.  
Other criticisms of this study include the number of SNPs typed and the case-control 
selection. SNPs/genes shown to be of great importance in hAD, for example 
Filaggrin
52;228;230;231;359;360
, were not included on the microarray, qPCR or covered in the 
GWAS. A small number of Filaggrin SNPs were included on the Sequenom, but the majority 
of SNPs available for Filaggrin could not be included, due to the highly repetitive sequence 
of Filaggrin which limits assay design
386
 for Sequenom, microarray and qPCR. The Filaggrin 
SNPs that were included on the Sequenom were mainly synonymous SNPs, again because of 
assay design limitations, rather than the more crucial non synonymous SNPs. However weak 
associations were found in the Filaggrin SNPs included, and therefore further research by fine 
mapping and re-sequencing is recommended. 
Case and control selection for the genotyping was breed, sex, age and country of origin 
matched for the most part. But grouping by country of origin may have been flawed as the 
population structure results in Chapter 7 (Wood etal “Genome Wide SNP Arrays Reveal 
Underlying Population Substructure in domestic Dog Breeds”, manuscript in prep) indicates 
that there are discreet levels of population structure even within a breed from the same point 
of origin. In human Malaria research similar issues of population stratification effect the 
result outcome - the populations used are stratified despite the fact they had all been sampled 
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from similar regions. The stratification was based on the dialect of each village meaning each 
village and dialect was representing a separate population that was affecting the results
387-389
. 
This demonstrates that population structure can have a significant effect on the study 
outcome and highlights the importance of defining population structure accurately. Therefore 
it would have been better to use ancestry informative markers to group and select dogs for 
genotyping. This would have made the results more accurate and improve the statistical 
power. However, it could have also reduced the number of useable samples to  low levels and 
would have exceeded time and financial restraints.  
The major limiting factor in this research was the availability of case and control samples. 
Samples could only be collected if they were excess to diagnostic requirements, therefore the 
control group often had a disease state. This could have led to segregation in the control 
group due to other disease states. Efforts to avoid this were made, and samples were 
generally taken from „healthy‟ dogs with no history of immunological or skin disease 
(although the samples taken from the VLA had no phenotype information available). 
Collection of cAD samples was also difficult because confirming the diagnosis takes time 
and the heterogeneity of the clinical presentation may have affected the results. 
Future research in cAD should focus around fine mapping and re-sequencing of the areas 
identified by GWAS and Sequenom. Using a small sample set of severe cases of cAD and 
fine mapping them may allow rare variants not identified by GWAS to be found. Moreover, 
there is an opportunity for functional work on some of the regions.  
Another potential area for investigation is epigenetics; methylation studies could be 
undertaken in SPINK5, for example, perhaps identifying maternal inheritance as suggested 
by human research
170
.  A mouse epigenetic study indicated that distal regulatory elements can 
direct transcription of INF-γ390. As INF-γ is important in the pathogenesis of AD 
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investigating this epigenetic regulation would of interest in cAD. Studies using RNA 
interference (RNAi) in keratinocyte cultures could also allow the role of particular genes to 
be identified, although this requires a robust and validated in vitro model for cAD. Protein 
profiling would also be of use in cAD research, either through immunohistochemistry or 
proteomic approaches. 
The findings presented in this thesis are broadly similar to the human condition, 
indicating that cAD is a good model for hAD. Further work is required to confirm, 
nevertheless dogs could provide an excellent tool for revealing gene-environment interactions 
in AD because of their shared environment with humans.  
This work has the potential to inform further studies into the pathogenesis of cAD. By 
understanding the pathology of the disease it is possible that better treatments for cAD can be 
developed. Furthemore by illustrating similarities between cAD and hAD treatments used for 
humans could be considered for dogs, for example improvement in hAD symptoms have 
been seen when using PPARs
209
 (one of the candidates in this study), this could benefit cAD. 
Therefore in the longterm the work presented in this thesis may provide an important starting 
point for improved treatment and management of cAD. 
In conclusion, several genetic associations have been found in cAD, demonstrating that it 
is a complex disease with a significant genetic component. This validates the hypothesis of 
the study. Nevertheless, more research is required to identify other associated genes and to 
further confirm and identify the roles these genes have in the pathogenesis of cAD. 
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Appendix 1  RNA concentration and RIN values obtained by Bioanalyser 
 
Sample Name Type Storage RNA 
Concentration 
RNA Integrity 
Number (RIN): 
206080L Lesional snap frozen 524.4 9.3 
206462nl Non-lesional snap frozen 213.8 5.8 
206556L Lesional snap frozen 536.7 4.9 
206821L Lesional snap frozen 468.6 5.5 
206821nl Non-lesional snap frozen 216.8 6.2 
207616L Lesional snap frozen 248.9 5.2 
207616NL Non-lesional snap frozen 63.3 7.2 
207632L Lesional snap frozen 80.7 4.9 
207632NL Non-lesional snap frozen 105.7 6.6 
207676L Lesional snap frozen 205.2 5.1 
207676NL Non-lesional snap frozen 64.3 5.9 
207935L Lesional snap frozen 1020.1 5.0 
207935nl Non-lesional snap frozen 446.4 4.6 
208462L Lesional snap frozen 503.4 6.0 
208511L Lesional snap frozen 329.9 5.7 
208511nl Non-lesional snap frozen 140.4 6.4 
208628L Lesional snap frozen 436.5 5.9 
208628nl Non-lesional snap frozen 99.7 6.3 
208781L Lesional snap frozen 798.3 5.4 
208781nl Non-lesional snap frozen 303.8 5.9 
208829L Lesional snap frozen 729.6 4.8 
208829nl Non-lesional snap frozen 228.3 5.2 
A10L Lesional snap frozen 259.5 8.3 
A10NL Non-lesional snap frozen 29.0 7.9 
A11L Lesional snap frozen 265.3 8.2 
A12L Lesional snap frozen 25.8 9.4 
A12NL Non-lesional snap frozen 25.8 9.5 
A13L Lesional snap frozen 240.0 7.7 
A13NL Non-lesional snap frozen 119.0 8.1 
A14NL Non-lesional snap frozen 119.1 8.4 
A16L Lesional snap frozen 168.1 8.0 
A16NL Non-lesional snap frozen 79.6 9.0 
A17L Lesional snap frozen 224.1 8.3 
A18L Lesional snap frozen 119.1 7.3 
A18NL Non-lesional snap frozen 37.4 7.3 
A1L Lesional snap frozen 45.6 8.9 
A1NL Non-lesional snap frozen 2252.7 8.2 
A2L Lesional snap frozen 85.5 6.1 
A2NL Non-lesional snap frozen 91.5 8.0 
A3L Lesional snap frozen 1614.6 7.2 
A3NL Non-lesional snap frozen 87.5 7.9 
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Appendix 1 continued 
 
A4L Lesional snap frozen 73.2 8.3 
A4NL Lesional snap frozen 42.1 8.4 
A6L Lesional snap frozen 36.8 8.1 
A6NL Non-lesional snap frozen 94.3 7.9 
A7NL Non-lesional snap frozen 74.3 8.1 
A8L Lesional snap frozen 192.7 8.2 
N10 Control snap frozen 58.1 2.4 
N11 Control snap frozen 107.2 7.5 
N13 Control snap frozen 55.2 2.4 
N14 Control snap frozen 35.4 2.5 
N15 Control snap frozen 18.6 9.0 
N3 Control snap frozen 25.4 6.1 
N4 Control snap frozen 254.4 7.6 
N5 Control snap frozen 83.0 7.5 
unknL Lesional snap frozen 353.4 6.4 
unknNL Non-lesional snap frozen 152.9 6.4 
206140nl Non-lesional rnalater 267.5 9.0 
210817nl Non-lesional rnalater 266.9 8.7 
210488nl Non-lesional rnalater 1088.1 8.5 
cbNL Non-lesional rnalater 21.5 8.5 
206140L Lesional rnalater 46.0 8.4 
210817L Lesional rnalater 452.5 7.3 
210488L Lesional rnalater 69.1 7.3 
210534L Lesional rnalater 708.4 6.6 
210479L Lesional rnalater 54.1 6.1 
Control 2 Control rnalater 59.2 9.0 
Control 4 Control rnalater 649.3 8.9 
MARVIN Control rnalater 653.6 8.7 
Control 6 Control rnalater 1234.7 8.5 
Control 8 Control rnalater 1332.7 8.4 
Control 5 Control rnalater 1105.0 8.3 
Control 3 Control rnalater 707.2 8.3 
CLYDE Control rnalater 1224.5 8.2 
Control 7 Control rnalater 1155.5 8.1 
edin 1 Control rnalater 1846.1 8.0 
Control 1 Control rnalater 87.0 8.0 
HELEN Control rnalater 2136.3 7.7 
Control 9 Control rnalater 949.6 7.6 
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Appendix 2  Slope, R2, percentage efficiency and E values for each qPCR assay 
 
Gene Slope R
2
 % efficiency E value 
SCCA2 -3.477 0.99 94 1.88 
Cystatin A -3.316 0.99 100 2 
Card 4 -3.445 0.99 95 1.9 
P-selectin -3.441 0.99 95 1.91 
PKP2 -3.415 0.99 96 1.93 
PPARɣ -3.195 0.98 106 2.11 
SGPL1 -3.247 0.99 103 2.06 
TNF α -3.268 0.98 102 2.05 
Cadherin 13 -3.211 0.99 105 2.10 
CMA1 -3.440 0.99 95 1.91 
DPP4 -3.505 0.99 93 1.86 
POSTN -3.505 0.99 93 1.86 
SAA-1 -3.469 0.99 94 1.88 
SPINK5 -3.366 0.99 98 1.96 
ARTS-1 -3.329 0.99 100 1.99 
INPPL1 -3.388 0.98 97 1.95 
S100A8 -3.471 0.99 94 1.88 
Cullin4A -3.494 0.99 93 1.87 
STAT2 -3.434 0.99 96 1.91 
TIMP1 -3.317 0.99 100 2 
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Appendix 3 WAVE methods: Fragments and Temperatures 
 
 
CMA1 Promoter region 
 
CAGATTCCCCCAGTCACAAGCTCAAGCTAAGACCAAGGGCATGGTAGGATGATTTAGGGAAGGTA
TGTTTTCCCTGTGATTCCTTATCTCTGAATTAAATGGCTTCTGAATCTCCAAAAGAGTGGCGCCTGG
GTGGCTCAGTCAGTTAAGCATCTGCCTTTGACTCAGGTCATGATCCTGGGGTTCTGGGAGAAAGCT
CCATGTCAGGCTCCTTGTCAGCATGGAATCTGCTTCTCCCTCTTCCTCTGCAGCTCCTCGTGATTGT
TTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTGTCAAATAAATAAATAAAATATAA
TAAATCTTCAAGAGAAACGACACTCTGCCTGTT 
 
Temps: 50, 57.5, 60.5 
Fwd: CAGATTCCCCCAGTCACAAG 
Rev: TAACAGGCAGAGTGTCGTTTC 
Product size: 375bp 
 
 
CMA1 5th exon 
 
TTGAAGGAGAAGGCCAACCTGACCCTGGCCGTGGGGACCCTCCCCCTCTCACCCCAGTTCAACTTC
GTCCCACCTGGGAGAATGTGCCGGGTGGCTGGCTGGGGAAAAAGACAAGTCAATGGATCAGGCTC
TGACACTCTGCAAGAGGTGAAGCTGAGGCTCATGGACCCCCAGGCCTGTAGACACTACATGGCTTT
TGACCA 
 
Temps: 62.3, 64.2 
Fwd: TTGAAGGAGAAGGCCAACC 
Rev: TGGTCAAAAGCCATGTAGTGTC 
Product size: 203bp 
 
 
CMA1 6th exon 
 
CTCTTCTGTGTGCTGGGGTAGCCCAGGGAATTGTGTCCTATGGGCAGAATGATGCAAAGCCCCCTG
CTGTCTTCACCCGAATCTCCCACTACCGGCCCTGGATCAATAAGGTTCTGAAGCAGAATAAAGCCT
GAATGGAGCCTGGGCAAGCCTGAGGGGAAATCTGGAACCAGACCTGAGCAGGCTCTCTGCCACTT
ACTCTGGAGCTGCCTCTAGTCTCTACTGAGGCCCCACTACATCCCTCAGACCC 
 
Temps: 61.4 
Fwd: CTCTTCTGTGTGCTGGGGTAG 
Rev: GGGTCTGAGGGATGTAGTGG 
Product size: 250bp 
 
 
SGPL1 2nd exon 
 
CATTGAAGAAGTGAGTGAAGAACAGACTACCATCAGATGAACTTGTTTTGTACTGGACACTGTGG
GGGCTTGAAATGATGACTAAGGTCTGATCAGTGTTCAAGGACTCAACCACGTAGTGCGGAAGATA
AAAACAGATGAGTAGGCTGACTGGTGATAGGCTCTGTGTGGTGGCACAAGGAGATACTTCAGGCG
AGTTTAATGGG 
 
Temps: 59.8 
Fwd: CATTGAAGAAGTGAGTGAAGAACAG 
246 
 
Rev: CCCATTAAACTCGCCTGAAG 
Product size: 206bp 
 
 
SGPL1 6th exon 
 
GTGCTCTCACCTGTGTGCTTCTCCCCCTCAGTATGGCTACGCCCCCAAAGGCTCTTCCGTGCTGTTA
TACAGTGACAAGAAGTACAGGAGCCATCAGTTCTTCGTGGCGACTGACTGGCAGGGCGGCATCTA
CGCTTCCCCGACCATCGCGGGCTCACGGCCCGGAGGCATTAGCGCGGCCTGTTGGGCTGCCTTGAT
GCACTTCGGTGAGAGCGGCTATGTTGAAGCCACCAAACAGATCATCAAAACTACTCGCTTCCTCAA
GTCAGAGTATGTGTGGAGGACTGGTTCGGC 
 
Temps: 59.2, 61.2, 65.7 
Fwd: GTGCTCTCACCTGTGTGCTTC 
Rev: GCCGAACCAGTCCTCCAC 
Product size: 294bp 
 
 
SGPL1 14th exon  
 
ACCGCCAGTAACGACCTCTCACTGGATTTGTAGGGTGCGATCTATGGCATGGCCCAGACGACAGTT
GACAGGAACCTGGTCGCAGAATTGTCCTCGGTCTTCTTGGACAGCCTCTTCAGCACGGACACTGTG
ACTCCAAGCAGCCAGATGAATGGTTCTCCGAAACCCCGCTGAGCCTGGATACTCTGTGACCCTGA 
 
Temps: 62.4 
Fwd: ACCGCCAGTAACGACCTC 
Rev: TCAGGGTCACAGAGTATCCAG 
Product size: 197bp 
 
 
DPP4 Promoter region (p1) 
 
ACAAACAAACAGCAACCCAAGGCCCTTTCTTCAATGAATACGTGGCCTAGCTGAGTACACCACAC
TGGTAGGCATGGAAAGATAGTCATTAACACAAGTTATTAATTACAAAAGCCAAATGAGTAGTGTG
AGGGCAGAAGTCAAAGGAGGCAGTATTGAAGTCTCCATGAGAGAGGAGGGAATTGGCAGGTGGA
GGACTGTGACAGCCCGGGAAGCAGTTGGAGATGCTGCAGGGAAGAGGCTGAGGAAGAGAGGCAA
AGACAGAAAAGACAAAATTGGATGCAGGTGGTAGTAAAAGAGAGGGAGACATCAAAAATGATTT
TCAGACTTTGAATTTGGATCTCCAGTAACAGAATCTAAAACCACACAAATTCCATAGGGAACATTA
TTTTGGAAGGAATTATTTTAGACAAGGTAAGCCTAGGGTTAGCATGGGACAAATCAACTAAAAAG
GCCCAACACAGCACCAGAAATGTGAGTGTGGGGTGTGGAA 
 
Temps: 56,61 
Fwd: ACAAACAAACAGCAACCCAAG 
Rev: TTCCACACCCCACACTCAC 
Product size: 493bp 
 
 
DPP4 promoter region (p2) 
 
GTGTGGAAGGCTGAGGTAATGAGTATAGGTTTTGTCATGTATTCAAATGGAAAATATGCCTGAAGC
CCAGGAAGTCATATTCTCTAGAGTCCTCTAGAAGGAGAAATGGAGGCAGAGAAGGGCAAAGAAG
CTGATGCTCTGGGCATTTCTACCTTAGAGGTTAATAGAGAAAAATAAAGTCAAAGGAGGATGGAA
AATTAAGGGTCAGAGGTCAGGAGAAGTGAGGTGCCCTAGAATCCAAAGGAGAGTTTCATAAATCA
CCACCCTCCAAGTTCAAG 
247 
 
 
Temps 57.5 
Fwd: GTGTGGAAGGCTGAGGTAATG 
Rev: CTTGAACTTGGAGGGTGGTG 
Product size: 278bp 
 
 
DPP4 6
th
 exon 
 
CAAGCACTCCTCATTTGATGCAGAAAAACCACAAAGGCTAACAATTTGGGATTTTTCACAGATATG
CAGGCCCATGTAGTCAAAAAGCAGACGCTGTCTTCAGACTCAACTGGGCTACTTACCTTGCAAGCA
CAGAAAACATTATCGTAGCTAGCTTTGATGGCAGAGGAAGTGGTTACCAAGGAGATAAGATCATG
CACGCCGTCAACAGAAGACTGGGAACATTTGAAGTTCAAGATCAAATTGACGCAGCCAGGTGAGT
GACTAGGAGATGAATCCGAAGGTCA 
 
Temp: 59.5 
Fwd: CAAGCACTCCTCATTTGATGC 
Rev: TGACCTTCGGATTCATCTCC 
Product size: 287bp 
 
 
DPP4 21st exon  
 
CAAGCACTCCTCATTTGATGCAGAAAAACCACAAAGGCTAACAATTTGGGATTTTTCACAGATATG
CAGGCCCATGTAGTCAAAAAGCAGACGCTGTCTTCAGACTCAACTGGGCTACTTACCTTGCAAGCA
CAGAAAACATTATCGTAGCTAGCTTTGATGGCAGAGGAAGTGGTTACCAAGGAGATAAGATCATG
CACGCCGTCAACAGAAGACTGGGAACATTTGAAGTTCAAGATCAAATTGACGCAGCCAGGTGAGT
GACTAGGAGATGAATCCGAAGGTCA 
 
Temps: 59.5 
Fwd: CAAGCACTCCTCATTTGATGC 
Rev: TGACCTTCGGATTCATCTCC 
Product size: 287bp 
 
 
SPRR1B Promoter region (p1) 
 
CACTTCTCCCCCAACACAAGCCCAAAGCCTGGGTCTAAGGCAGAGGGTGGCACTGGGGATTAGGC
ATCAGTGACATCATTTGTCACACAGCCAGTGCCAAAAAATATCAAGTGGGTGGTTTTCATCACAAA
AGCTGATCCAACTGGTAATTGAGGGGAATAGGGTGAATCATGTTTGACAAGTAAGGAATGAAAAC
AGAGGGGGCCTGGGGTGATTCTGTTTCCTTGAGGCAGGGCTCATGCATCCTATAAAAAGCTAGCTG
GCCACTGACTTTACATCAGATCAGAGCAACCAGGCACCCCTTTCTCTGTGTACCAGGTAAGTCTCT
GATTGGAATCAATTTGAAATTCATGTTTATTTTTTTTATTATTGGAAACTGGACAAAGGCAAACCTG
TGTAAGAGGGCTGGTGAGG 
 
Temps: 58.5 
Fwd: CACTTCTCCCCCAACACAAG 
Rev: CCTCACCAGCCCTCTTACAC 
Product size: 414bp 
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SPRR1B Promoter region (p2) 
 
CCCTTTCAGCAACACCACTCTTTTCTCTGTGTATGACACCTATAAAAATGTTGATTCATGAGATGGA
CCTCTGTTGTGCATTTGTTATATCTCAGGCACCATGCTAGTCACTTTGGGTAGATCAGACCATTATG
GAACTTACTCAGCAAGCTCACAGCCTAGCAGGGAAGATAATGCATGCTTATACATAGGTGAAATA
CAAAGCAGATACTGACTGGTATGGGAACAGAGGGACAGAGAAGGGCCATGGCAGTTTGGGGGAG
CTATGCTCAGGATCTCCTGGTACAAGATATGAGCTATAATGGAGGCATATCTGGACAAGCAAAAT
GGGAAGGAGAGCATTTCAGAGCAGATTGCATAAGCAAAGGCAGAATGAGGTCACAGGAGCTGAG
ACTCACAGAGGCATATTTAAGTCACAGGTATGCCACATGGTC 
 
Temps: 57.9 
Fwd: CCCTTTCAGCAACACCACTC 
Rev: GACCATGTGGCATACCTGTG 
Product size: 434bp 
 
 
SPRR1B Exon 1 
 
AGAAGCAACCCTGCATCCCTCCCCCCCAGCCTCAGCAGCAGGTGAAACAGCCATGCCAGCCTCCA
CCCCAGGAGCCATGTGCCCCCAAAACCAAGGAGCCATGCCACCCCAAGGTTCCAGAGCCTTGCCA
CACCAAGATTCCAGAGCCCTGCCACACCAAGGTTCCAGAGCCCTGCCAGCCCAAGGTTCCAGAGC
CATGTCCCTCAACAGTGAC 
 
Temps: 63.8 
Fwd: AGAAGCAACCCTGCATCC 
Rev: GTCACTGTTGAGGGACATGG 
Product size: 214bp 
 
 
SPRR1B 3rd exon  
 
CAACAGGTGAAACAGACTTGCCAGCCTCTACCTCAGGAGCCATTTGTTCCCATAACCAAGAATCCA
TGTGACACCAAGTTACCGCAACCTGGGAACACCAAACTTCCTGAACCAAACTACCCTAAATATCCT
GAGCCAGGCCATCCCATAATTCCTGAATCAGGCCACATCAAGGTCCCCGAGCCAGCCTACTCTGAG
GTCCTTCAGCCTGGCTACACCAAGGTACCAGAACCAAGTCCCTCAACCATTATTCCAGGCCAGAAG
ACCAAGCAGAAATGATGTGGTCCTTAGCCATGACCT 
 
Temps: 59.8, 61.8 
Fwd: CAACAGGTGAAACAGACTTGC 
Rev: AGGTCATGGCTAAGGACCAC 
Product size: 300bp 
 
 
S100A8 1st & 2nd exons 
 
CCCATGTGTTTCGTGTTGCAGGTGGGGCAGATCCTTGGGCACCATGCTGACGGAACTGGAGAGTGC
CATAAACTCCCTCATTGAGGTTTACCACAAGTACTCCCTGGTGAAGGGGAATTACCACGCCCTCTA
CAGAGATGACTTGAAGAAATTGTTAGAGACAGAGTGTCCTCAGTACATGAAGGTGAGGAGGGGCT
GGGTGTGGCAGGGGTCTCTGTCTGGCCAATGAAGCCCTGGGTCCCTGGTCCCCTACGCCACCCTAT
GCAGACAGCCATGGCTCAGCTCTTGCCAAGGTCTTTACGCACTGGCTTCTTTCTCCTCCATCTTGAC
AGAAAAAGGATGCAGACACCTGGTTCCAAGAGTTGGATGTCAATAGCGATGGTGCAATTAACTTC
GAGGAGTTCCTCATATTGGTGATAAAGGTGGGCGTGGCCTCCCACAAAGACATCCACAAGGAGTA
GCAGAGCCCTGGGCCCCGGGGCTGTCCCTGCCGAATAATA 
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Temps: 59.5, 61 
Fwd: CCCATGTGTTTCGTGTTGC 
Rev: TATTATTCGGCAGGGACAGC 
Product size: 500bp 
 
 
S100A8 Promoter region (p2) 
 
GGGATTAGCAGCAGCAAGAGAGGAGGACTTGAGAGTGGGCATCCAGGCTGGCTGAGCCAAATGA
TGCCAGTGGCCCAGCAAAGGAGTCCTCACCATGGCCTCTTCCTGATTTATCCTGCTGGGCACTACT
GCCTAGCAAATACCTTCCTCTTTCCATTTTTCCTACTTCCCCACCTCCCATCAAAATTTTTCATTCCG
TGCAGTGATTGCCCCATTCACCTGGTTGAGAAACCAGAGGCTGTGGCAACCTGGGGAGGGAGGGG
CTATCTCTGCATGGCCTAGGGCCCTGGCAGCTGGCCACAGCCTGGCTGCTATAAAGGGGAGCTGCC
ACTGAGCCCTGCATATCCTCTGTCAACTCTGTTTCGGGAAACCTGGTAAGTAAGACTGCCTCAGTC
TGCTCCATGCTTTGGGGCTGCCCCCCCACCCCGGGAGGGCCAGAGGTGGAGCAGAGAGGGGAGAG
AAAGCTAAGGGAGGTCTGGA 
 
Temps: 60, 62 
Fwd: GGGATTAGCAGCAGCAAGAG 
Rev: TCCAGACCTCCCTTAGCTTTC 
Product size: 480bp 
 
 
IL1RL1 10th exon  
 
CACAGCAACAAGAAATCTGACCCGTGTCCTTTATTCCTAGATGCAGCCACCGCAGTGGAAACCAA
CATACGAAAGAGTAGGCGCCACATTTTTATCCTGACTCCTGAGATCACACACAGCAGGGAGTTTGC
CTACGAGCAGGAGATCGCCCTGCACAGTGCCCTCATCCAGAACGACGCCAAGGTGATTCTTATAG
AATTGGAGGCTCTGAGCAAGCCAGGTGGACTACAGTTTGGGGAGCTTCAAGATTCCCTCAAGCAC
CTTGTGGAAGTGCAAGGTACCATCAAGTGGAGGGAAGACCATGTGGCCAACAAACAGTCGCTGAA
TTCCAAATTCTGGAAGCATGTGAGGTACCACATGCCTGTGCCCAACAGACTGCCAGGGAAGACAT
CCAGTTTGGCTTCCCTGAGTGCCCAGGGGCAGTAGTGCTTGCTTTGATGTGCTAATGCACCAGATT
TCCG 
 
Temps: 60.4 
Fwd: CACAGCAACAAGAAATCTGACC 
Rev: CGGAAATCTGGTGCATTAGC 
Product size: 461bp 
 
 
IL1RL1 Promoter region (p1) 
 
TGCCAAATGAAGTGTTGAGGGATATCTGGAAAGGCCAACCCAAAGCGCCAGGATTTCAGTATCAT
TGAGAACCCGATGAGTAATAATATTAGGACAATAAACAGCCAGTGTTATTTAGTTTGAGAAACTG
ATGCTAAAATAAGAGGAGGTAGTTTAATTATTTCCTCTTAAGGCATTACTCAGTGTTGTCCTTATGT
TTAAATATTTATGTACCAAGGTCAAGAATTCTTGGTACATGATGCACCAGGATTTTTGAACAGTCA
TAAATCGTGGCTAAAAATCTAACTTCAGTGTGGGTGGAGTGATGAATTTCAGGACGTCTTTGAGTG
TCTCCTCTTCAAAATATAAGAGAGAGGCCATACACCTGAGGAGTCTTCAGGGCAAGAGACTCGGG
AGCTGGAAACTATTCCTTGCTCAGTCACAGACTTGGATTTTATTCCCTTCTGCCTTTCAGTTTGG 
 
Temps: 55, 56.8 and 59 
Fwd: TGCCAAATGAAGTGTTGAGG 
Rev: CCAAACTGAAAGGCAGAAGG 
Product size: 459bp 
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IL1RL1 Promoter region (p2) 
 
TTGGTGAGTCTTGGGGACACGCTGAGGCAGGGACACATTTTGTGTAGTGTCTAGGGCAATCACTTG
ATTAACACTTTACCAATCACTTTCCTATATTTTTAGTTGCTTTGTGATGACTATTTGTATATGTGTCT
GCATGTGGGTCACACATGTGTGCAGGCAAGTCCCCAGCCTATGTGCATATCTGTGGATTTATGTTA
GCATTTATAACATTGTATTTTCTAGGGTCTGTTGAAATATAGTTTTAATTTGTTTCAAAAATGACAA
CTACTTTTCTTTCCTCCTAATTCAGCTTCTTCCAGTCCATTCTCATGATACTATGAAATAGTACAACT
ATTGCAAGGCCTCTGTTGTCCAAAGGTTCAGTAGGAATAAATGCAATGTTTCATATCTGAAACCCT
GCTGTTATACATATTTCTACCTAATGAATACCTGTTGATTGATGAATTCTCCTAGGGGGTATTGGAC
AAGTAAAAATCATGGCAATTTTGCTTGTGATTCTGTGTGATTTATGTTTCAGTGGAGACACTAAAA
CTCTTTCTAACTGTAAATCTCAGGAGGCACCATCAACCT 
 
Temps: 55 and 56.5 
Fwd: TTGGTGAGTCTTGGGGACAC 
Rev: AGGTTGATGGTGCCTCCTG 
Product size: 573bp 
 
 
MS4A2 Promoter region  
 
AAGATGGCACGGGTTTAATGCATTGCTGTCAGAAAGGTGCACTCATATGTCTTCTGGTGTCCTCTT
GCTGTACGTAGCCTAGCTTCCCGGAGAAGGAGGAGAAGTTTCATCACATCCCAGGGAGGTAATAC
ATGTGCAATTTACAGTGTCTTACAGTGTAGGGAAGAGCCACTCAAGGTTATGTCTAAATTCAACTG
AAACAAAAGGACCCGGAATCTGTGAATCTCACCTGTGGATTCATTTCACCACGTATTCCAATTCTT
GTAAGTTATTCATGCTATTAACATGAACATGTCCGTTAAGCTCTGACCCTATTCAGATGCCCTGCTC
CATCCAGGGCGGCCTAGATCTACTCACAGGATCATCAGGCTCTTGTCCCTTGGTGCTTCGTGGCCA
CAGCTCTGCCATCGTCAAAATCA 
 
Temps: 58 and 61 
Fwd: AAGATGGCACGGGTTTAATG 
Rev: TGATTTTGACGATGGCAGAG 
Product size: 419bp 
 
 
MS4A2 5th & 6th exon 
 
ACACACAGGGCTATTGAACGCACTGGCAGGTGGGGGCTCAGGCCTGCCTGCTGTCCTTCACCATCA
GGCGTGGGGCAGCCTGGGAGCCAACACTGTCAGCAGCATAGCTGCGGGAATAGGAATCTTTATCC
TGACGGTCAACCTGCAGAGGAGCTCGGCTTACATCCACAACTGCCAGCAAGCTCCCAGAGACGAC
TTCTGCTTTGTGGCTTGTTTTTCCACAGTACGTATTTCTTGTGAGGGGGCTAAGGTCTGGGTCCTAC
TCTAAGTACAAGCCCTCTCCTTTCCCACGAACGTCGTCCTTTGCTGTAACCTCTATCACATAGTGTA
GTGTTCGGGGGGTTCATGGACAAAGATGCTGGCTGCCGCTCCCTCCCCAGCTGGGTTCTGTGAGGC
TGGAGTCACCCGCCTTGACCTCCCTTTTTGTGGCTTTCCCACGTATGTGTCACTTCATTGGGAGTGA
TCACATCGGGGTGATGAAATCAGGGGCTTCTGTTAGGAACACACCTTTGGGGCACCTGCCTTGTGA
CTCTACTTGTCTTGTTGGTTACTGTTCAACAGGAAATTGTGGCTATGATCCTGTTTCTCACTATTCTG
GGGTTTTGCAGTGCTGTGTCACTGACGATCTATGGAGTTGGAGAATTAGTCCAAGGGAACAAGGT
AAGTAGAGGCCTGATAATCCTGAATGACAAGCTGAAGC 
 
Temp: 58, 60, 62 
Fwd: ACACACAGGGCTATTGAACG 
Rev: GCTTCAGCTTGTCATTCAGG 
Product size: 700bp 
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P-selectin 5th exon 
 
AAGGGCTCATGCTATTGCTCTGTGGCTGTTTGTAGCTACCCAGTGTCCACCCCTAAAGACTCCTGA
GCAAGGAAGCATGAACTGTCTTCACTCTGTCGAAGCATTCCAGTATCAATCCAGCTGCCACTTTAG
TTGTGAAGAGGGATTTGCATTAGTTGGGCCAGAGGTGGTACAGTGCACGGCCTCAGGGATGTGGA
CGGCTGCAGCCCCAGTGTGTGAAGGTGAGTTTCCAGCAGCTGAGGGTGTGTAATGTTCACTGCACC
CAGTTCTTGCTGTGAGTACAGATGACAGTGGCC 
 
Temps: 60, 63.8 
Fwd: AAGGGCTCATGCTATTGCTC 
Rev: GGCCACTGTCATCTGTACTCAC 
Product size: 296bp 
 
 
P-selectin 11th exon 
 
GACTCTGTTATGCTCCGTTTATTGGGAGCTCTCTAAATGGAATCATGTTTTCACAGCAGGCATAGTG
TCAGCTCCTACTTCAAAGGTTCAGTGTCCAGCCCTCATCACTCCAGAGCAAGGAACAGTGTCCTGT
AGGCACCATCTGGGAACCTTTGGTCTGAATACCACTTGCTACTTTGGATGCAAAGCTGGATTCATA
CTCATGGGAGACAGTGCTCTCAGATGCAGACCTTCAGGAAAATGGACAGCAGGAACGCCAACATG
CCAAGGTAATGGGAAAGGAACAGGC 
 
Temp: 60 
Fwd: GACTCTGTTATGCTCCGTTTATTG 
Rev: GCCTGTTCCTTTCCCATTAC 
Product size: 289bp 
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Appendix 4 Sequences from Jalview 
 
CMA1 promoter region 
 
MS4A2 Exon 5-6 
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MS4A2 Exon 5-6 
 
MS4A2 Exon 5-6 
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S100A8 promoter
 
S100A8 promoter 
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S100A8 promoter 
 
S100A8 promoter 
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SGPL1 Exon 2 
 
SPRR Exon 3 
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SPRR1B promoter 
 
SPRR promoter 
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Appendix 5 Sequences of SNPs found by WAVE 
 
Microsatellites are highlighted in blue. Novel SNPs found on wave are yellow. SNPs already on electronic databases such as ensembl are 
green. Peach and bold represent exons. Pink represents SNPs which were found on WAVE but were already available on electronic databases 
such as ensembl.  
 
>CMA1 Promoter region ENSCAFG00000012443 (1500bp upstream) 
CAGATTCCCCCAGTCACAAGCTCAAGCTAAGACCAAGGGCATGGTAGGATGATTTAGGGAAGGTATGTTTTCCCTGTGATTCCTTATCTCTGAATTAAATGGCT
TCTGAATCTCCAAAAGAGTGGCGCCTGGGTGGCTCAGTCAGTTAAGCATCTGCCTTTGACTCAGGTCATGATCCTGGGGTTCTGGGAGAAAGCTCCATGTCAG
GCTCCTTGTCAGCATGGAATCTGCTTCTCCCTCTTCCTCTGCAGCTCCTCGTGATTGTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTGTCWAAT
AAATAAATAAAATATAATAAATCTTCAAGAGAAACGACACTCTGCCTGTT 
 
>MS4A2 Exon 5-6 
ACACACAGGGCTATTGAACGCACTGGCAGGTGGGGGCTCAGGCCTGCRTGCTGTCCTTCACCATCAGGCRTGGGGCAGCCTGGGAGCCAACACTGTCAGCAG
CATAGCTGCGGGAATAGGAATCTTTATCCTGACGGTCAACCTGCAGAGGAGCTCGGCTTACATCCACAACTGCCAGCAAGCTCCCAGAGACGACTTCTGCTT
TGTGGCTTGTTTTTCCACAGTACGTATTTCTTGTGAGGGGGCTAAGGTCTGGGTCCTACTCTAAGTACAAGCCCTCTCCTTTCCCACGAACGTCGTCCTTTGCTGT
RACCTCTATCACATAGTGTAGTGTTCGGGGGRTTCATGGACAAAGATGCTGGCTGCCGCTCCCTCCCCAGCTGGGTTCTGTGAGGCTGGAGTCACCCGCCTTGA
CCTCCCTTTTTGTGGCTTTCCCACGTATGTGTCACTTCATTGGGAGTGATCACATCGGGGTGATGAAATCAGGGGCTTCTGTTAGGAACACACCTTTGGGGCACC
TGCCTTGTGACTCTACTTGTCTTGTTGGTTACTGTTCAACAGGAAATTGTGGCRATGATCCTGTTTCTCACTATTCTGGGGTTTTGCAGTGCTGTGTCACTGACG
ATCTATGGAGTTGGAGAATTAGTCCAAGGGAACAAGGTAAGTAGAGGCCTGATAATCCTGAATGACAAGCTGAAGC 
>S100A8 promoter region 
GGGATTAGCAGCAGCAAGAGAGGAGGACTTGAGAGTGGGCATCCAGGCTGGCTGAGCCAAATGATGCCAGTGGCCCAGCAAAGGAGTCCTCACCATGGCCT
CTTCCTGATTTATCCTGCTGGGCACTACTGCCTAGCAAATACCTTCCTCTTTCCATTTTTCCTACTTCCCCACCTCCCATCAAAATTTTTCATTCYGTGCAGTGATTG
CCCCATTCACCTGGTTGARAAACCAGAGGCTGTGGCAACCTGGGGAGGGAGGGGCTATCTCTGCATGGCCTAGGGCCCTGGCAGCTGGCCACAGCCTGGCTG
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CTATAAAGGGGAGCTGCCACTGAGCCCTGCATATCCTCTGTCAACTCTGTTTCGGGAAACCTGGTAAGTAARACTGCCTCAGTCTGCTCCATGCTTTGGGGCTG
CCCCCCCACCCCGGGAGGGCCAGAGGTGGAGCARAGAGGGGAGAGAAAGCTAAGGGAGGTCTGGA 
>SGPL1 Exon 2 
CATTGAAGAAGTGAGTGAAGAACAGACTACCATCAGATGAACTTGTTTTGTACTGGACACTGTGGGGGCTTGAAATGATGACTAAGGTCTGATCAGTGTTCAA
GGACTCAACCACGTAGYGCGGAAGATAAAAACAGATGAGTAGGCTGACTGGTGATAGGCTCTGTGTGGTGGCACAAGGAGATACTTCAGGCGAGTTTAATGG
GAGAGATGA 
>SPRR1B exon 3 
CAACAGGTGAAACAGACTTGCCAGCCTCTACCTCAGGAGCCATTTGTTCCCATAACCAAGAATCCATGYGACACCAAGTTACCGCAACCYGGGAACACCAAAC
TTCCTGAACCAAACTACCCTAAATATCCTGAGCCAGGCCATCCCATAATTCCTGAATCAGGCCACATCAAGGTCCCCGAGCCAGCCTACTCTGAGGTCCTTCA
GCCTGGCTACACCAAGGTACCAGAACCAAGTCCCTCAACCATTATTCCAGGCCAGAAGACCAAGCAGAAATGATGTGGTCCTTAGCCATGACCT 
>SPRR1B promoter region 
CCCTTTCAGCAACACCACTCTTTTCTCTGTGTATGACACCTATAAAAATGTTGATTCATGAGATGGACCTCTGTTGTGCATTTGTTATATCTCAGGCACCATGCTA
GTCACTTTGGGTAGATCAGACCATTATGGAACTTACTCAGCAAGCTCACAGCCTARCAGGGAAGATAATGCATGCTTATACATAGGTGAAATACAAAGCAGAT
ACTGACTGGTATGGGAACAGAGGGACAGAGAAGGGCCATGGCAGTTTGGGGGAGCTATGCTCAGGATCTCCTGGTACAAGATATGAGCTATAATGGAGGCA
TATCTGGACAAGCAAAATGGGAAGGAGAGCATTTCAGAGCARATTGCATAAGCAAAGGCAGAATGAGGTCACAGGAGCTGAGACTCACAGAGGCATATTTAA
GTCACAGGTATGCCACATGGTC
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Appendix 6 Allele size and frequency for microsatellite analysis 
 
Allele Frequency Number Size 
A01 0.01 16 150 
A03 0.00 4 154 
A04 0.02 27 156 
A05 0.00 2 158 
A06 0.71 842 160 
A07 0.03 36 162 
A08 0.01 7 164 
A09 0.00 3 166 
A10 0.12 143 168.5 
A11 0.01 12 170.5 
A12 0.03 35 172.5 
A13 0.05 61 175 
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Appendix 7 MDS plot of population structure – grouped according to country of  
   origin 
 
 
USA golden retrievers are represented by green triangles and Japan Golden retrivers are represented by 
black crosses, the figure represents the intra-breed variation within golden retrievers from USA and Japan, as 
defined by IBS clustering using genome wide data. 
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Appendix 8 Primer and probe sequences for GWAS validation analysis 1   
  (population structure unadjusted) and 2 (population structure adjusted) 
 
SNP Reverse Primer Forward Primer Probe Sequence Analysis 
rs21994080 ACG TTG GAT GAA GAA 
GGG AGA TCC ACT GGG 
ACG TTG GAT GAC ATT 
GTC TAA TGT TAC TG 
GGG GAG ACA TGT 
CTG CTT AT 
2 
rs22524918 ACG TTG GAT GTG CTC 
TCT CTT CCC GTT CAG 
ACG TTG GAT GAG GCT 
TCT GTT GGA AAG CAG 
CCC GTT CAG TTC 
CAA TT 
2 
rs22576724 ACG TTG GAT GTG TCT 
ACA GAT GAC TCC CAC 
ACG TTG GAT GAA AGG 
TGA AGC TGA GTC TGG 
CTC CCA CTC ATG 
CTC TTT CAA CA 
2 
rs22720467 ACG TTG GAT GAG CAA 
GGC AGG GAT TGT GTC 
ACG TTG GAT GAA TGA 
ATC AGG CAG TCG CTC 
TGT GTC TGC AGG 
CTC TGG CAG CTC 
G 
2 
rs22738169 ACG TTG GAT GGT GTG 
CCA TAT GAG TAG CAG 
ACG TTG GAT GCT CCT 
AGT TAA AAG CAA ATC C 
AAG CTG TGA CTT 
ATC CTC CAT 
2 
rs22808564 ACG TTG GAT GCT GGA 
TGC CCT TCC AGT TAA 
ACG TTG GAT GTC ACA 
AGC CCA GGA AAA TTG 
GTT AAA AAC TTA 
TCA ACA ATT CAA 
TT 
2 
rs22864357 ACG TTG GAT GAC TGA 
GCG ACA CCA CTT CAC 
ACG TTG GAT GAG ATC 
TCG CAC GTG TAC TGG 
CCG GCA ACC AGC 
TGC TTA TCG TTC 
AGA A 
2 
rs22991453 ACG TTG GAT GGT CCC 
AGA CTA TGA ACT TGC 
ACG TTG GAT GGT TGC 
TAT TCA CCT CCT CAG 
TCC CAG ACT ATG 
AAC TTG CAT GAT 
GTT T 
2 
rs23029421 ACG TTG GAT GGC ATA 
ATA GAA CTG TGA AGC 
ACG TTG GAT GGT ATA 
TAT AAT TCT GAA AAA TG 
AAC ATA GTA AAA 
TAA CAC GTG ATT 
AA 
2 
rs23117702 ACG TTG GAT GCG GTC 
TGG TCG TTT ATG ATG 
ACG TTG GAT GGT AAA 
TAC ACC AGA AGC CCG 
TGC TGC CCC CTT 
CAC C 
2 
rs23224877 ACG TTG GAT GAG AAG 
CTC AAA AGT CAG CCC 
ACG TTG GAT GGG AGG 
AAG TAA TAG TCG GTG 
CGT AGG CCT GTT 
TTC TCC C 
2 
rs23313105 ACG TTG GAT GGC ACC 
ACC TCA TTG TTT CTC 
ACG TTG GAT GAG CAG 
GTG CTC AGC AAA TAC 
TCC TGC ATG CCC 
CTT 
2 
rs23316823 ACG TTG GAT GAC ATA 
GTG CCT TTG GGA CCG 
ACG TTG GAT GTC AGA 
AAC CCA AAG CAG GAG 
TGT GAA CCC CGT 
GAA 
2 
rs23444049 ACG TTG GAT GGT AAA 
ATA GCA AAT CAG TAC 
ACG TTG GAT GTT GCA 
CTA CTG TTA TTA CC 
AGC AAA TCA GTA 
CCA AAA A 
2 
rs23622647 ACG TTG GAT GAC ATT 
CAT GGA AAT GTG GC 
ACG TTG GAT GGC TCT 
CTC TCT TTC TCT CTC 
ATG GAA ATG TGG 
CAT TCT GTC C 
2 
rs23684720 ACG TTG GAT GGG TGA 
GTG ACT TGC CAT TTG 
ACG TTG GAT GGT GTG 
ATA GCC TGC CTT ATG 
GTG ACT TGC CAT 
TTG AAG TTT GCT 
2 
rs23708599 ACG TTG GAT GCA TGG 
GAT ACC CCC TAT GTG 
ACG TTG GAT GCT ACT 
CCC CTC TAA CCT GAC 
ACC CCC TAT GTG 
TTC AGA 
2 
rs23767031 ACG TTG GAT GCC AAG 
TAG GGT GGA TTT CTG 
ACG TTG GAT GCA GGA 
AAG CTA ATG GAA CTC 
AGG GTG GAT TTC 
TGG TCC TTT G 
2 
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Appendix 8 continued 
rs23769251 ACG TTG GAT GCA ATC 
AAT ACT GCT TCA GGC 
ACG TTG GAT GAG AGG 
CAA TGA CAT ATT GGC 
CAT TTC TTC TAC 
CAT TCA GT 
2 
rs23769439 ACG TTG GAT GAC TGA 
CAA GGT GAT CAG AGC 
ACG TTG GAT GTG CTT 
ACC TAT CAG CCA GTC 
GGT GAT CAG AGC 
TAA AAT GA 
2 
rs23770102 ACG TTG GAT GTA TCT 
ATG CTT CAG CCT GAC 
ACG TTG GAT GGG CAG 
TGA CGC TTG TAT ATG 
AGC CTG ACA GCA 
GAT GCT AAA 
2 
rs23803267 ACG TTG GAT GTC CAG 
TGT TAA AGA ACA GAG 
ACG TTG GAT GAG TTG 
GAA AGA GTT CAG TGG 
AGT GTT AAA GAA 
CAG AGA AGT TAT 
A 
2 
rs23856926 ACG TTG GAT GCT TTA 
TAA AAC AGA GAT GTG 
G 
ACG TTG GAT GAG GAG 
ACA TTG GTT TTT CCC 
ACA GAG ATG TGG 
AGA AAA 
2 
rs23865825 ACG TTG GAT GGA ATC 
TGT TGG CAA CTT GGC 
ACG TTG GAT GAT GGT 
ACG CTA CCT GGA AAG 
AAC TTG GCA GGC 
AGG GAG ATG 
2 
rs23870923 ACG TTG GAT GGA AAT 
CTA GGG AGA GGA AGC 
ACG TTG GAT GTG GAG 
AGA CTC TGA TGT CAC 
GAA ACA CAT GAA 
TCC ATA TCA 
2 
rs23932942 ACG TTG GAT GGT CAC 
CCA TAT TCT GAC TCC 
ACG TTG GAT GTC CAG 
ATT CTT CAC CCT GAG 
GTC TTG GCT TCT 
CTG TGA 
2 
rs23968934 ACG TTG GAT GCT TCT 
ACA GTC AGC CCT TGC 
ACG TTG GAT GTT GCG 
TCG TGA GCT TTG AGG 
CCT TGC ACC TAC 
CTT CGT GGT GTG 
GAG A 
2 
rs23974741 ACG TTG GAT GCA CAG 
TGT GTA AAC TGA GGG 
ACG TTG GAT GTA TTT 
GAG AGT TGG TGG CCC 
GCT ACC GTA ATT 
TTT ATC ACC AT 
2 
rs24092655 ACG TTG GAT GAG TAG 
GAG ACT CCT GGG AC 
ACG TTG GAT GTG GCC 
ATG AAG ATG CAT GTG 
TCC TGG GAC CCC 
TCT TC 
2 
rs24131580 ACG TTG GAT GCC AAT 
CTC AGA AGG ACT GTG 
ACG TTG GAT GGG GAT 
CAT TTT CAG GTG AGG 
GGA CTG TGC ACA 
TAC AT 
2 
rs24275059 ACG TTG GAT GCC AAA 
GCA TTC TTT TCC CAG 
ACG TTG GAT GTC GGT 
AGA ACC ACT GAC TTG 
CTT TTG GCC TTT 
GTA GAT G 
2 
rs24332727 ACG TTG GAT GTG TGG 
AGA GAT GGA TGG AAC 
ACG TTG GAT GAT CCT 
TGA GCA ACA GCC TTC 
GGT GAG GCT GTG 
TGT CC 
2 
rs24354997 ACG TTG GAT GTT GAC 
TAC TGC ACA CTG CTC 
ACG TTG GAT GGT ATG 
TTA GAG AAG GAA GGG 
TCC TCT GTG GAA 
ACA GT 
2 
rs24462950 ACG TTG GAT GCT CAT 
GGC CTA TAT AAG CTC 
ACG TTG GAT GAG ACT 
CAA CTA CGA GCT ATG 
ATC AAC AGA GAG 
CCC T 
2 
rs24556501 ACG TTG GAT GCG TAG 
TTC ATA CAT GTT TGG 
ACG TTG GAT GAG CTG 
GGA GTA GAT ATG GTA 
CAT GTT TGG ACT 
AAA GAA ATG AA 
2 
rs24732893 ACG TTG GAT GTT TCT 
TTG ATT CTC TGG CGG 
ACG TTG GAT GTT GGT 
ACC AGA TCC AGC TAC 
GCG AAG ATC CCC 
CAA 
2 
rs9132002 ACG TTG GAT GAA AGT 
TCC TGG CAA CCA AGC 
ACG TTG GAT GAA AAC 
CAA AGC CCC TTT GCG 
CTG GCA AGC TCC 
CAG 
2 
rs22020166 ACGTTGGATGGTCTTTC
CTTCTTAACCTGC 
ACGTTGGATGGGGAATCA
AGAAAGGCTTTAC 
TATTAACCTGCATA
CAAAATTGTTGCT 
1 
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Appendix 8 continued 
rs22114085 ACGTTGGATGAAGCTCC
ACGATGAACAGTC 
ACGTTGGATGGACTGTACA
CGACCTTTACC 
CAGCAGCACTTCC
AGAATGTACC 
1 
rs22155657 ACGTTGGATGATGTTGA
AGATTGAATGAC 
ACGTTGGATGTATCTAAAC
CACCAGTTTC 
TGTATATAAAGATT
TCTCCTCAA 
1 
rs22181912 ACGTTGGATGTTCTGCA
AGGATGGGCATTC 
ACGTTGGATGTCCAGTTTT
TCTATGTCCTG 
AGAACATGTCCTTG
TGG 
1 
rs22184220 ACGTTGGATGAGACCAT
AGCCAGCTTGCAC 
ACGTTGGATGTGGCACAAT
CCCTTTGATGG 
GAGTTAAAGGTAT
CTTCCATAGG 
1 
rs22185491 ACGTTGGATGGGGAAT
ACAGCGGTCTTGA 
ACGTTGGATGTTGTTCTCC
TTCATCCTGGG 
GGAATACAGCGGT
CTTGACGGGTTG 
1 
rs22212359 ACGTTGGATGAATCCCT
CTTTTCCCCTCTG 
ACGTTGGATGGCACAAGA
TGGAAGATGGAG 
CCCCTCTGAAATTC
CCTTT 
1 
rs22212677 ACGTTGGATGTAACTTC
TGCTCAGAAATG 
ACGTTGGATGTGTGGTTTT
GTATTCAAGGG 
AATTGAGAATAAT
CAGTGAAATAG 
1 
rs22328353 ACGTTGGATGACCTGCT
ACCAGCATTAAAG 
ACGTTGGATGTTGCTTTCC
TTCTCCCTTAG 
GCTACCAGCATTA
AAGCTTTAAC 
1 
rs22523565 ACGTTGGATGAGACTG
GATCTCTTGCTGTG 
ACGTTGGATGGAAAAGGA
GCTGTGAGGATG 
CTTCACAAACTCTT
GCC 
1 
rs22859255 ACGTTGGATGGCATCTC
AAATATTTCTGGG 
ACGTTGGATGTCAGAGAA
AGCCAAAAGCCG 
TCTGGGTAAGAGG
AACA 
1 
rs22864357 ACGTTGGATGAGATCTC
GCACGTGTACTGG 
ACGTTGGATGACTGAGCG
ACACCACTTCAC 
CGTCCTCCACTACC
AC 
1 
rs22913552 ACGTTGGATGTGAAAC
AAGATCACAAAGCC 
ACGTTGGATGTGCAGCACT
GTGTGTGTTC 
CCAAAGCCAAACT
GAACAATAATC 
1 
rs22915894 ACGTTGGATGGCACTAT
CGTGTTGTCTAC 
ACGTTGGATGCTGAGAATG
GCTTCACAGAG 
TGTCTACAGAACC
AGATTTTGCAGAA
GG 
1 
rs22959786 ACGTTGGATGGGATGC
AGACCGTCTGGATT 
ACGTTGGATGGTCAGCAG
ACAACACTTAAC 
CCGTCTGGATTTCC
TTA 
1 
rs22989468 ACGTTGGATGAGGGAG
TCACCTGCAAACTG 
ACGTTGGATGATGCTCACC
TTGCGGAACTC 
GCAAATGCAGTTGT
GATGCAGTCGTG 
1 
rs23026134 ACGTTGGATGAGATCCT
GGTTTGGAAGGAG 
ACGTTGGATGCTTGGTGAG
ATCTCCTATGG 
GGAGCATTGAGTG
AGTCTAT 
1 
rs23066224 ACGTTGGATGGGGCTAT
TAGTGACCCAATG 
ACGTTGGATGTCTGCAGTC
AGATCAACTGT 
CAGAAGTAGGATC
ATCTGCTC 
1 
rs23122280 ACGTTGGATGGATTTCA
CTCAGCCCCATAG 
ACGTTGGATGAAACAGAT
GTCTCTAGTTGG 
AGCCCCATAGAGC
TTTCTTTAAAT 
1 
rs23428471 ACGTTGGATGCCACATG
CTGATTACAAGCC 
ACGTTGGATGGACCACTTT
TGTCTAGTAAG 
CTATTGGAGTTGTA
TTTATCGACAAAC 
1 
rs23472497 ACGTTGGATGGGCCAG
AGGATGGGAAATTC 
ACGTTGGATGATCTCTGTC
AGTGCACTAGG 
ACCTGTCAAGGTC
ATGTC 
1 
rs23478400 ACGTTGGATGTCTGCCT
AGAATCTTGTCAC 
ACGTTGGATGTTGCCCCCA
GACATTTTTTG 
GTACTTACATATGC
ATTTCCCA 
1 
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rs23545080 ACGTTGGATGCTTCTAA
CCTGAGTGAAGGC 
ACGTTGGATGTGTGTTTCT
GGAGTCCTACC 
TGTGTTTGTGGGGT
TA 
1 
rs23567144 ACGTTGGATGGATGAG
CCCACACACAGAG 
ACGTTGGATGTATCCCTGA
AGCATCTGGGC 
CCCACACACAGAG
GCTGCTGGAATA 
1 
rs23602938 ACGTTGGATGAGAGGG
TCCTGTTGATACAC 
ACGTTGGATGGCCAGTAA
GCTAGAAGTTCG 
CCCATACTCCTCAG
GC 
1 
rs23690306 ACGTTGGATGTACTTCA
CCTGCAAGCTTGG 
ACGTTGGATGGGTAGTTGA
GGTAGATGAGG 
AATAAGCCAATCC
TCCTG 
1 
rs23768387 ACGTTGGATGTCTCACT
TCTCAGTCAGTGC 
ACGTTGGATGGAAGAAAG
AGATGAGGAGAG 
TCACTTCTCAGTCA
GTGCTGTCTCATA 
1 
rs23828846 ACGTTGGATGACTGCAG
ACTTCCTATCTGG 
ACGTTGGATGAGGTCAATC
AGACAGTGGTG 
TCTGCCCCTCGACA
A 
1 
rs24194054 ACGTTGGATGCAAACA
GATTGCTCCGTGTG 
ACGTTGGATGGGTACAGA
GACCAAGGAAAG 
GTTGATGGAGAAC
AGCATGT 
1 
rs24267550 ACGTTGGATGTCAATTT
GAGCCCGGACTTG 
ACGTTGGATGTCAAGAATG
GACCCTCTGAC 
CGGGTAGATTCTCA
TAGTC 
1 
rs24318716 ACGTTGGATGGTTGAAC
AGGACACCTCATC 
ACGTTGGATGACTGTTGGA
GGAGGCAGGAG 
GAATCGGGCCCAT
TTGTTTCTA 
1 
rs24327271 ACGTTGGATGAGAACTC
ACTCTCTGTGGAC 
ACGTTGGATGTGCCAAGA
ACAAGCCCAAAC 
TCTGTGGACTAACT
GAAA 
1 
rs24332727 ACGTTGGATGTGTGGAG
AGATGGATGGAAC 
ACGTTGGATGATCCTTGAG
CAACAGCCTTC 
GTGAGGCTGTGTGT
CC 
1 
rs24408651 ACGTTGGATGTCCTCTA
CCAAATCTATGTG 
ACGTTGGATGGCCAACAGT
ATGCTGGTTAG 
CAAATCTATGTGAA
TAGCCCT 
1 
rs24482628 ACGTTGGATGCAGGAT
GCAGATTTTTCCAG 
ACGTTGGATGACTGGTGAT
TCTATGGAGG 
TTCCAGTTTTCCCA
TAGCCTG 
1 
rs24732893 ACGTTGGATGTTTCTTT
GATTCTCTGGCGG 
ACGTTGGATGTTGGTACCA
GATCCAGCTAC 
GGCCGGCGAAGAT
CCCCCAA 
1 
rs24872415 ACGTTGGATGTTGGCAA
GCCTGACAAATGG 
ACGTTGGATGTGTTGAGGA
GACTTCACCTG 
ACCCAAGTGCCCA
AACAA 
1 
rs8649732 ACGTTGGATGGCTATTC
AACTTTGGTGGCG 
ACGTTGGATGTGGTTGTTG
TCACTAGTTGG 
CCTCACAAATCGG
CTTAACTCT 
1 
rs8806978 ACGTTGGATGGATGTGA
CAAGCCTTTCTGC 
ACGTTGGATGAGTCCGTGC
TTTATCAAGCC 
AGAGGCACCACAT
GTGCCCAGTTA 
1 
rs9081246 ACGTTGGATGGACCCA
AAGATATTCTGACC 
ACGTTGGATGCCGCCCATG
TCTCATGAATA 
AAAGATATTCTGAC
CTAAAATACTATG 
1 
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Appendix 9 GWAS Validation Study: Meta-analysis (p <0.05) 
 
Chromosome SNP A1 A2 Base 
Pairs 
CHISQ P corrected 
p value 
(x38) 
OR L95 U95 
10 rs22114085 T C 14087517 21.4 3.7 x 10
-6
 0.0001 2.0 1.5 2.7 
29 rs23472497 A G 34162404 16.9 3.9 x 10
-5
 0.0015 0.6 0.5 0.8 
32 rs23769439 G A 10826789 8.2 0.0042 0.1598 0.7 0.5 0.9 
30 rs23622647 T C 37858940 7.7 0.0054 0.2070 0.6 0.4 0.9 
9 rs24556501 C T 44666435 7.5 0.0062 0.2360 0.7 0.5 0.9 
6 rs24332727 A G 16258930 7.1 0.0076 0.2875 1.4 1.1 1.8 
3 rs23545080 C A 69975205 7.1 0.0078 0.2963 1.5 1.1 2.0 
16 rs22523565 T C 12801246 6.9 0.0084 0.3208 1.4 1.1 1.8 
12 rs22181912 C T 35696615 6.7 0.0095 0.3596 1.4 1.1 1.8 
31 rs23684720 T G 35018207 6.6 0.0102 0.3880 1.4 1.1 1.8 
20 rs22915894 T C 5771454 6.4 0.0117 0.4438 1.4 1.1 1.7 
12 rs22184220 A G 13111985 6.1 0.0136 0.5179 1.4 1.1 1.7 
32 rs23769251 T C 10876880 5.7 0.0165 0.6281 0.7 0.5 0.9 
20 rs8806978 T C 5779740 5.0 0.0257 0.9774 1.3 1.0 1.7 
6 rs24327271 A C 8499991 5.0 0.0259 0.9857 0.7 0.6 1.0 
32 rs23768387 C T 30365964 4.8 0.0290 1.1012 0.7 0.5 1.0 
3 rs23602938 C G 67125807 4.5 0.0330 1.2544 1.3 1.0 1.8 
32 rs23767031 G T 11760674 3.9 0.0485 1.8445 1.4 1.0 2.0 
 
  
267 
 
Appendix 10 GWAS Validation Study: Individual Breed Meta-analysis (p<0.05) 
 
Breed SNP Chr A1 A2 BP CHISQ P value Corrected 
P value 
(x48) 
ORX L95 U95 
All golden 
retrievers 
RS22859255 2 T C 48522803 18.1 2.1 x 10
-5
 0.0008 5.2 2.4 11.4 
All golden 
retrievers 
RS24327271 6 A C 8499991 13.3 0.0003 0.0101 0.2 0.1 0.5 
All golden 
retrievers 
RS23602938 3 C G 67125807 12.2 0.0005 0.0180 3.9 1.8 8.7 
All golden 
retrievers 
RS24408651 7 G A 7829497 12.1 0.0005 0.0195 0.3 0.1 0.6 
All golden 
retrievers 
RS23472497 29 A G 34162404 11.1 0.0009 0.0329 0.3 0.2 0.6 
All golden 
retrievers 
RS23545080 3 C A 69975205 10.5 0.0012 0.0452 3.7 1.6 8.4 
All golden 
retrievers 
RS23622647 30 T C 37858940 10.3 0.0013 0.0507 0.1 0.0 0.5 
All golden 
retrievers 
RS24482628 8 C A 27285603 9.8 0.0017 0.0652 3.0 1.5 6.0 
All golden 
retrievers 
RS22212677 12 A G 29078487 8.9 0.0028 0.1074 3.3 1.5 7.5 
All golden 
retrievers 
RS22523565 16 T C 12801246 8.3 0.0039 0.1498 2.7 1.4 5.3 
All golden 
retrievers 
RS23708599 31 A G 30830928 7.9 0.0048 0.1834 0.4 0.2 0.8 
All golden 
retrievers 
RS23313105 26 C T 23047328 7.0 0.0080 0.3050 2.7 1.3 5.6 
All golden 
retrievers 
RS23690306 31 C G 25600053 7.0 0.0082 0.3131 2.6 1.3 5.1 
All golden 
retrievers 
RS22915894 20 C T 5771454 6.1 0.0134 0.5092 0.4 0.2 0.8 
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All golden 
retrievers 
RS23932942 35 G A 15274395 5.5 0.0187 0.7095 2.3 1.2 4.4 
All golden 
retrievers 
RS23478400 28 C G 3406416 5.3 0.0212 0.8045 2.2 1.1 4.3 
All golden 
retrievers 
RS8806978 20 C T 5779740 5.0 0.0253 0.9599 0.5 0.2 0.9 
All golden 
retrievers 
RS22212359 12 C G 43043338 4.6 0.0320 1.2145 2.5 1.1 6.1 
All golden 
retrievers 
RS23428471 28 G A 3366214 4.5 0.0333 1.2639 2.1 1.1 4.1 
All golden 
retrievers 
RS22184220 12 G A 13111985 4.0 0.0447 1.6971 2.0 1.0 3.8 
All golden 
retrievers 
RS23767031 32 G T 11760674 4.0 0.0452 1.7168 2.5 1.0 6.0 
All golden 
retrievers 
RS24131580 4 A G 20849589 4.0 0.0455 1.7305 2.7 1.0 7.5 
All Gsd RS22184220 12 A G 13111985 7.7 0.0054 0.2054 5.3 1.7 16.7 
All Gsd RS24318716 6 C T 4224712 6.2 0.0127 0.4834 0.1 0.0 0.8 
All Gsd RS23472497 29 G A 34162404 5.8 0.0159 0.6046 3.2 1.2 8.6 
All Gsd RS23026134 22 T C 55676006 5.4 0.0201 0.7634 3.7 1.2 11.7 
All Gsd RS23313105 26 C T 23047328 4.3 0.0375 1.4242 3.0 1.0 8.9 
All Gsd RS22720467 19 C T 32273778 3.8 0.0508 1.9285 0.0 NA NA 
All Labs RS24354997 6 T G 14408543 7.2 0.0071 0.2712 2.4 1.3 4.5 
All Labs RS23708599 31 A G 30830928 6.7 0.0097 0.3692 2.0 1.2 3.4 
All Labs RS23026134 22 T C 55676006 5.0 0.0259 0.9853 0.5 0.2 1.0 
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All Labs RS24275059 6 C A 14365278 3.9 0.0478 1.8156 1.8 1.0 3.2 
All Whwt RS24482628 8 A C 27285603 11.7 0.0006 0.0232 8.1 2.2 29.7 
All Whwt RS22915894 20 C T 5771454 11.1 0.0009 0.0337 5.4 1.8 15.7 
All Whwt RS8806978 20 C T 5779740 11.1 0.0009 0.0337 5.4 1.8 15.7 
All Whwt RS23224877 25 A G 29485983 8.1 0.0045 0.1722 6.3 1.4 27.4 
All Whwt RS24194054 5 T C 56199928 7.7 0.0056 0.2132 4.3 1.4 13.3 
All Whwt RS23769439 32 G A 10826789 4.4 0.0368 1.3995 3.1 1.1 9.2 
All Whwt RS23769251 32 T C 10876880 3.9 0.0487 1.8502 2.9 1.0 8.4 
All Whwt RS23684720 31 T G 35018207 3.8 0.0508 1.9304 3.5 0.9 12.8 
All Whwt RS22738169 2 T C 45023367 3.8 0.0509 1.9338 2.7 1.0 7.4 
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Appendix 11 GWAS Validation Study: Individual breed analysis (p <0.05) 
 
Breed Statistical test SNP CHR BP A1 F_A F_U A2 CHISQ ORX P Corrected p 
value (x38) 
L95 U95 
Boxer Allelic RS22913552 20 33818500 G 0.2 0.5 T 7.4 0.2 0.0065 0.2471 0.0 0.6 
Boxer Allelic RS23968934 36 32710839 C 0.6 0.3 T 6.0 4.5 0.0145 0.5510 1.3 15.5 
Boxer Allelic RS23478400 28 3406416 C 0.4 0.1 G 4.2 4.5 0.0411 1.5618 1.0 20.3 
Japan golden 
retriever 
Allelic RS22576724 17 52668444 C 0.1 0.5 T 8.8 0.1 0.0031 0.1172 0.0 0.6 
Japan golden 
retriever 
Allelic RS23545080 3 69975205 C 0.5 0.1 A 8.5 6.3 0.0035 0.1337 1.7 23.7 
Japan golden 
retriever 
Allelic RS22181912 12 35696615 T 0.2 0.6 C 8.3 0.2 0.0040 0.1523 0.1 0.6 
Japan golden 
retriever 
Allelic RS24408651 7 7829497 G 0.2 0.6 A 8.3 0.2 0.0040 0.1523 0.1 0.6 
Japan golden 
retriever 
Allelic RS24872415 3 62441438 A 0.6 0.3 G 7.5 4.6 0.0061 0.2307 1.5 14.3 
Japan golden 
retriever 
Allelic RS22859255 2 48522803 T 0.5 0.2 C 6.9 4.7 0.0087 0.3312 1.4 15.4 
Japan golden 
retriever 
Allelic RS22808564 2 55063211 T 0.4 0.1 C 6.9 5.4 0.0088 0.3331 1.4 20.1 
Japan golden 
retriever 
Allelic RS22913552 20 33818500 G 0.7 0.3 T 6.7 4.2 0.0099 0.3751 1.4 12.7 
Japan golden 
retriever 
Allelic RS23066224 22 39938082 T 0.2 0.0 C 6.7 NA 0.0099 0.3753 NA NA 
Japan golden 
retriever 
Allelic RS24732893 12 40204012 G 0.0 0.3 A 5.9 0.1 0.0152 0.5765 0.0 0.9 
Japan golden 
retriever 
Allelic RS8649732 19 45495526 A 0.2 0.5 G 5.8 0.2 0.0165 0.6259 0.1 0.8 
Japan golden 
retriever 
Allelic RS23602938 3 67125807 C 0.5 0.2 G 5.7 3.8 0.0168 0.6384 1.2 11.9 
Japan golden 
retriever 
Allelic RS22212677 12 29078487 A 0.3 0.1 G 5.5 5.2 0.0190 0.7228 1.2 22.2 
Japan golden 
retriever 
Allelic RS24332727 6 16258930 G 0.3 0.6 A 5.5 0.3 0.0193 0.7345 0.1 0.8 
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Japan golden 
retriever 
Allelic RS23117702 23 39572738 T 0.1 0.4 C 4.7 0.2 0.0308 1.1700 0.1 0.9 
Japan golden 
retriever 
Allelic RS24131580 4 20849589 A 0.3 0.1 G 4.3 5.3 0.0376 1.4277 1.0 29.2 
Japan golden 
retriever 
Allelic RS23968934 36 32710839 T 0.5 0.2 C 4.2 3.3 0.0407 1.5458 1.0 10.4 
Japan golden 
retriever 
Allelic RS22212359 12 43043338 C 0.3 0.1 G 4.1 4.3 0.0434 1.6484 1.0 18.6 
Japan golden 
retriever 
Allelic RS23974741 36 26538495 A 0.4 0.1 T 4.0 3.5 0.0457 1.7374 1.0 12.3 
Japan Labrador Allelic RS22808564 2 55063211 T 0.0 0.5 C 9.9 0.0 0.0017 0.0638 0.0 NA 
Japan Labrador Allelic RS23767031 32 11760674 G 0.3 0.0 T 7.9 NA 0.0049 0.1861 NA NA 
Japan Labrador Allelic RS24354997 6 14408543 T 0.4 0.1 G 4.5 6.0 0.0339 1.2893 1.0 35.3 
Japan Labrador Allelic RS24327271 6 8499991 A 0.4 0.1 C 4.3 4.9 0.0374 1.4212 1.0 23.6 
Pit Bull Allelic RS22212677 12 29078487 A 0.1 0.4 G 6.9 0.2 0.0088 0.3348 0.1 0.7 
Pit Bull Allelic RS23769251 32 10876880 T 0.2 0.5 C 6.5 0.3 0.0106 0.4039 0.1 0.7 
Pit Bull Allelic RS22524918 17 8695250 C 0.2 0.0 T 6.0 9.6 0.0143 0.5445 1.1 80.7 
Pit Bull Allelic RS24354997 6 14408543 T 0.2 0.4 G 5.4 0.3 0.0199 0.7573 0.1 0.8 
Pit Bull Allelic RS23865825 34 17995250 T 0.3 0.5 C 5.3 0.3 0.0217 0.8246 0.1 0.9 
Pit Bull Allelic RS24732893 12 40204012 A 0.6 0.3 G 5.1 3.2 0.0238 0.9052 1.2 9.0 
Pit Bull Allelic RS23545080 3 69975205 C 0.1 0.3 A 4.7 0.3 0.0308 1.1712 0.1 0.9 
Pit Bull Allelic RS23313105 26 23047328 C 0.5 0.3 T 4.6 3.0 0.0323 1.2274 1.1 8.3 
Pit Bull Allelic RS23769439 32 10826789 G 0.3 0.5 A 4.2 0.4 0.0411 1.5603 0.1 1.0 
Shiba Inu Allelic RS23767031 32 11760674 G 0.3 0.0 T 18.1 26.4 0.0000 0.0008 3.3 211.2 
Shiba Inu geno/trend RS23767031 32  - - - - - - 0.0000 0.0009 - - 
Shiba Inu Allelic RS24092655 4 8627345 T 0.4 0.1 C 15.3 7.4 0.0001 0.0035 2.5 22.2 
Shiba Inu logistic/ADD RS23767031 32  - - - - - - 0.0013 0.0508 4.0 297.5 
Shiba Inu Allelic RS24332727 6 16258930 G 0.3 0.6 A 7.9 0.3 0.0049 0.1847 0.1 0.7 
Shiba Inu Allelic RS24267550 5 18815805 A 0.2 0.0 G 7.7 5.8 0.0057 0.2153 1.5 22.5 
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Shiba Inu Allelic RS23622647 30 37858940 T 0.1 0.0 C 7.6 NA 0.0058 0.2187 NA NA 
Shiba Inu Allelic RS23313105 26 23047328 C 0.3 0.5 T 7.6 0.3 0.0058 0.2193 0.1 0.7 
Shiba Inu Allelic RS24275059 6 14365278 C 0.3 0.1 A 7.4 4.4 0.0064 0.2417 1.4 13.7 
Shiba Inu Allelic RS23968934 36 32710839 T 0.5 0.3 C 7.4 3.0 0.0066 0.2491 1.3 6.8 
Shiba Inu Allelic RS24872415 3 62441438 G 0.5 0.3 A 7.4 3.0 0.0066 0.2491 1.3 6.8 
Shiba Inu Allelic RS23870923 34 5326438 C 0.4 0.1 T 7.3 3.5 0.0069 0.2636 1.4 8.9 
Shiba Inu Allelic RS24354997 6 14408543 T 0.3 0.1 G 7.1 4.3 0.0079 0.3010 1.4 13.2 
Shiba Inu Allelic RS23865825 34 17995250 T 0.3 0.1 C 6.0 3.4 0.0144 0.5487 1.2 9.4 
Shiba Inu Allelic RS23974741 36 26538495 A 0.2 0.4 T 5.4 0.3 0.0206 0.7839 0.1 0.9 
Shiba Inu Allelic RS22212359 12 43043338 C 0.2 0.1 G 5.3 3.7 0.0208 0.7912 1.2 11.7 
Shiba Inu Allelic RS22991453 21 18223929 G 0.0 0.2 A 5.1 0.1 0.0242 0.9188 0.0 1.0 
Shiba Inu Allelic RS22524918 17 8695250 C 0.1 0.0 T 4.8 8.1 0.0289 1.0982 0.9 71.7 
Shiba Inu Allelic RS23828846 33 29024878 T 0.5 0.3 C 4.7 2.4 0.0296 1.1244 1.1 5.4 
Shiba Inu Allelic RS23066224 22 39938082 T 0.2 0.1 C 4.7 4.2 0.0308 1.1708 1.1 17.0 
Shiba Inu Allelic RS22931896 20 9213048 A 0.3 0.1 G 4.5 3.1 0.0342 1.2977 1.1 9.2 
Shiba Inu Allelic RS22576724 17 52668444 C 0.3 0.2 T 4.1 2.5 0.0435 1.6530 1.0 6.1 
Shih Tzu Allelic RS24092655 4 8627345 T 0.0 0.1 C 8.6 0.1 0.0034 0.1288 0.0 0.7 
Shih Tzu Allelic RS23865825 34 17995250 T 0.1 0.2 C 7.0 0.3 0.0080 0.3034 0.1 0.7 
Shih Tzu Allelic RS23708599 31 30830928 A 0.5 0.3 G 5.9 2.0 0.0155 0.5871 1.1 3.5 
Shih Tzu Allelic RS23026134 22 55676006 T 0.1 0.3 C 5.2 0.4 0.0224 0.8523 0.2 0.9 
Shih Tzu Allelic RS22808564 2 55063211 T 0.2 0.4 C 5.1 0.5 0.0241 0.9173 0.3 0.9 
Shih Tzu Allelic RS23472497 29 34162404 A 0.3 0.4 G 4.3 0.5 0.0385 1.4630 0.3 1.0 
UK golden 
retriever 
Allelic RS23545080 3 69975205 C 0.6 0.1 A 31.0 29.3 0.0000 0.0000 5.8 148.2 
UK golden 
retriever 
Allelic RS22915894 20 5771454 T 1.0 0.2 C 30.0 NA 0.0000 0.0000 NA NA 
UK golden 
retriever 
Allelic RS8806978 20 5779740 T 1.0 0.2 C 29.3 NA 0.0000 0.0000 NA NA 
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UK golden 
retriever 
geno/trend RS23545080 3  - - - - - - 0.0000 0.0000 - - 
UK golden 
retriever 
geno/trend RS22915894 20  - - - - - - 0.0000 0.0000 - - 
UK golden 
retriever 
geno/trend RS8806978 20  - - - - - - 0.0000 0.0000 - - 
UK golden 
retriever 
Allelic RS23968934 36 32710839 T 1.0 0.3 C 19.4 NA 0.0000 0.0004 NA NA 
UK golden 
retriever 
geno/trend RS22864357 20 28025372 - - - - - - 0.0000 0.0016 - - 
UK golden 
retriever 
Allelic RS24332727 6 16258930 A 1.0 0.3 G 14.0 NA 0.0002 0.0068 NA NA 
UK golden 
retriever 
Allelic RS23026134 22 55676006 T 0.5 0.1 C 12.2 9.8 0.0005 0.0180 2.2 44.4 
UK golden 
retriever 
Allelic RS23690306 31 25600053 C 0.8 0.2 G 11.7 11.2 0.0006 0.0238 2.1 58.7 
UK golden 
retriever 
geno/trend RS23690306 31  - - - - - - 0.0007 0.0263 - - 
UK golden 
retriever 
geno/trend RS23026134 22  - - - - - - 0.0008 0.0311 - - 
UK golden 
retriever 
Allelic RS23472497 29 34162404 G 0.9 0.4 A 8.7 12.8 0.0033 0.1241 1.5 107.1 
UK golden 
retriever 
Allelic RS24872415 3 62441438 A 0.9 0.4 G 8.3 12.4 0.0039 0.1473 1.5 103.6 
UK golden 
retriever 
Allelic RS24092655 4 8627345 T 0.8 0.3 C 8.0 7.8 0.0048 0.1811 1.5 40.6 
UK golden 
retriever 
Allelic RS24194054 5 56199928 C 0.6 0.2 T 7.4 6.4 0.0066 0.2522 1.4 28.3 
UK golden 
retriever 
Allelic RS22913552 20 33818500 G 0.8 0.3 T 7.1 7.2 0.0077 0.2922 1.4 37.2 
UK golden 
retriever 
Allelic RS22212677 12 29078487 A 0.3 0.0 G 6.9 8.2 0.0088 0.3346 1.3 51.3 
UK golden 
retriever 
Allelic RS23602938 3 67125807 C 0.6 0.2 G 6.6 5.8 0.0105 0.3971 1.3 25.8 
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UK golden 
retriever 
Allelic RS23974741 36 26538495 A 0.0 0.4 T 5.8 0.0 0.0160 0.6091 0.0 NA 
UK golden 
retriever 
Allelic RS24275059 6 14365278 C 0.0 0.4 A 5.6 0.0 0.0177 0.6718 0.0 NA 
UK golden 
retriever 
Allelic RS22720467 19 32273778 T 0.9 0.5 C 5.4 8.4 0.0206 0.7843 1.0 70.4 
UK golden 
retriever 
Allelic RS24408651 7 7829497 A 0.8 0.4 G 4.6 5.2 0.0313 1.1875 1.0 26.7 
UK golden 
retriever 
Allelic RS24131580 4 20849589 A 0.0 0.4 G 4.5 0.0 0.0333 1.2662 0.0 NA 
UK golden 
retriever 
Allelic RS23708599 31 30830928 A 0.1 0.5 G 4.4 0.1 0.0356 1.3509 0.0 1.2 
UK GSD Allelic RS22720467 19 32273778 C 0.4 0.0 T 17.6 NA 0.0000 0.0011 NA NA 
UK GSD Allelic RS23769251 32 10876880 T 0.3 0.0 C 14.4 NA 0.0002 0.0057 NA NA 
UK GSD Allelic RS24872415 3 62441438 G 0.4 0.0 A 13.4 15.6 0.0002 0.0094 2.8 87.7 
UK GSD Allelic RS24275059 6 14365278 C 0.3 0.0 A 10.4 18.6 0.0013 0.0476 2.0 176.4 
UK GSD Allelic RS24354997 6 14408543 T 0.3 0.0 G 10.4 18.6 0.0013 0.0476 2.0 176.4 
UK GSD Allelic RS23316823 26 18288615 A 0.2 0.0 G 8.3 NA 0.0040 0.1503 NA NA 
UK GSD Allelic RS24092655 4 8627345 T 0.2 0.0 C 8.3 NA 0.0040 0.1503 NA NA 
UK GSD Allelic RS23224877 25 29485983 A 0.3 0.0 G 7.5 13.7 0.0061 0.2312 1.4 134.1 
UK GSD Allelic RS24732893 12 40204012 A 0.3 0.1 G 7.2 8.6 0.0073 0.2770 1.5 50.8 
UK GSD Allelic RS24556501 9 44666435 T 0.4 0.1 C 7.2 5.8 0.0075 0.2832 1.5 22.4 
UK GSD Allelic RS23472497 29 34162404 G 0.7 0.3 A 5.9 4.4 0.0149 0.5670 1.3 15.2 
UK GSD Allelic RS23690306 31 25600053 G 0.7 0.4 C 5.1 4.0 0.0238 0.9025 1.2 13.6 
UK GSD Allelic RS24408651 7 7829497 A 0.4 0.1 G 4.9 4.4 0.0263 0.9979 1.1 17.6 
UK GSD Allelic RS22184220 12 13111985 A 0.3 0.1 G 4.1 4.9 0.0434 1.6481 0.9 25.7 
UK Labrador Allelic RS22915894 20 5771454 T 0.5 0.2 C 16.8 4.4 0.0000 0.0016 2.1 9.2 
UK Labrador Allelic RS9132002 29 22197558 G 0.2 0.0 A 16.4 23.2 0.0001 0.0020 2.8 194.0 
UK Labrador geno/trend RS22114085 10 14087517 - - - - - - 0.0001 0.0052 - - 
UK Labrador Allelic RS8806978 20 5779740 T 0.5 0.2 C 14.2 3.9 0.0002 0.0064 1.9 8.1 
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UK Labrador geno/trend RS22915894 20  - - - - - - 0.0003 0.0104 - - 
UK Labrador logistic/ADD RS22114085 10 14087517 - - - - - - 0.0005 0.0208 1.8 7.7 
UK Labrador logistic/ADD RS22915894 20  - - - - - - 0.0008 0.0296 1.7 7.0 
UK Labrador geno/trend RS8806978 20  - - - - - - 0.0008 0.0323 - - 
UK Labrador Allelic RS22114085 10 14087517 T 0.6 0.2 C 20.9 6.1 4.8 x 10-6 0.0002 2.7 14.1 
UK Labrador Allelic RS22720467 19 32273778 C 0.3 0.5 T 11.1 0.3 0.0009 0.0329 0.1 0.6 
UK Labrador geno/trend RS9132002 29  - - - - - - 0.0009 0.0333 - - 
UK Labrador Allelic RS24275059 6 14365278 C 0.2 0.4 A 10.9 0.2 0.0009 0.0360 0.1 0.6 
UK Labrador Allelic RS24327271 6 8499991 A 0.2 0.5 C 9.4 0.3 0.0021 0.0814 0.1 0.7 
UK Labrador Allelic RS23545080 3 69975205 C 0.2 0.1 A 8.3 4.3 0.0040 0.1534 1.5 12.3 
UK Labrador Allelic RS24872415 3 62441438 A 0.6 0.4 G 7.1 2.5 0.0078 0.2953 1.3 5.0 
UK Labrador Allelic RS22212677 12 29078487 A 0.2 0.0 G 6.7 4.4 0.0094 0.3577 1.3 14.7 
UK Labrador Allelic RS23684720 31 35018207 T 0.3 0.2 G 5.7 2.5 0.0174 0.6616 1.2 5.4 
UK Labrador Allelic RS22913552 20 33818500 G 0.5 0.3 T 4.8 2.2 0.0291 1.1066 1.1 4.4 
UK Labrador Allelic RS24194054 5 56199928 C 0.4 0.2 T 4.7 2.2 0.0293 1.1145 1.1 4.7 
UK Labrador Allelic RS24131580 4 20849589 A 0.2 0.4 G 4.7 0.4 0.0306 1.1628 0.2 0.9 
UK Labrador Allelic RS24556501 9 44666435 C 0.3 0.5 T 4.1 0.5 0.0423 1.6089 0.2 1.0 
UK Labrador Allelic RS23767031 32 11760674 G 0.1 0.3 T 4.0 0.4 0.0452 1.7157 0.2 1.0 
UK Labrador Allelic RS23472497 29 34162404 G 0.5 0.4 A 4.0 2.0 0.0456 1.7309 1.0 3.9 
UK WHWT Allelic RS24482628 8 27285603 A 0.5 0.1 C 14.4 11.0 0.0002 0.0057 2.8 43.7 
UK WHWT geno/trend RS24482628 8  - - - - - - 0.0003 0.0107 - - 
UK WHWT Allelic RS23224877 25 29485983 A 0.2 0.0 G 11.4 NA 0.0008 0.0286 NA NA 
UK WHWT Allelic RS24194054 5 56199928 T 0.7 0.3 C 11.2 7.0 0.0008 0.0316 2.1 23.5 
UK WHWT geno/trend RS24194054 5  - - - - - - 0.0011 0.0427 - - 
UK WHWT Allelic RS23708599 31 30830928 G 0.4 0.1 A 7.1 5.5 0.0076 0.2874 1.5 20.6 
UK WHWT Allelic RS23066224 22 39938082 T 0.1 0.0 C 5.5 NA 0.0190 0.7228 NA NA 
UK WHWT Allelic RS24872415 3 62441438 G 0.1 0.0 A 5.5 NA 0.0190 0.7228 NA NA 
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UK WHWT Allelic RS22523565 16 12801246 T 0.2 0.0 C 4.9 9.4 0.0270 1.0264 0.9 97.3 
UK WHWT Allelic RS24092655 4 8627345 T 0.2 0.0 C 4.9 9.4 0.0270 1.0264 0.9 97.3 
UK WHWT Allelic RS23684720 31 35018207 T 0.3 0.1 G 4.2 4.2 0.0404 1.5337 1.0 18.1 
USA golden 
retriever 
Allelic RS23316823 26 18288615 A 0.0 0.4 G 13.9 0.0 0.0002 0.0075 0.0 0.4 
USA golden 
retriever 
Allelic RS23708599 31 30830928 A 0.3 0.7 G 12.8 0.2 0.0003 0.0129 0.1 0.5 
USA golden 
retriever 
Allelic RS24327271 6 8499991 A 0.1 0.5 C 12.6 0.1 0.0004 0.0145 0.0 0.4 
USA golden 
retriever 
Allelic RS22523565 16 12801246 T 0.6 0.2 C 11.9 5.4 0.0006 0.0219 2.0 14.7 
USA golden 
retriever 
Allelic RS23770102 32 11802242 C 0.0 0.3 G 11.4 0.0 0.0007 0.0275 0.0 NA 
USA golden 
retriever 
geno/trend RS23708599 31  - - - - - - 0.0011 0.0405 - - 
USA golden 
retriever 
Allelic RS22859255 2 48522803 T 0.5 0.1 C 10.3 5.7 0.0013 0.0502 1.9 17.6 
USA golden 
retriever 
Allelic RS23472497 29 34162404 A 0.3 0.6 G 10.0 0.2 0.0015 0.0587 0.1 0.6 
USA golden 
retriever 
Allelic RS23684720 31 35018207 T 0.6 0.3 G 10.0 4.5 0.0015 0.0587 1.7 11.7 
USA golden 
retriever 
Allelic RS23622647 30 37858940 T 0.1 0.3 C 7.4 0.1 0.0064 0.2424 0.0 0.7 
USA golden 
retriever 
Allelic RS23313105 26 23047328 C 0.4 0.2 T 7.4 4.2 0.0066 0.2501 1.4 12.2 
USA golden 
retriever 
Allelic RS24482628 8 27285603 C 0.6 0.3 A 7.4 3.6 0.0066 0.2526 1.4 9.1 
USA golden 
retriever 
Allelic RS23602938 3 67125807 C 0.4 0.1 G 7.2 4.8 0.0074 0.2820 1.4 16.4 
USA golden 
retriever 
Allelic RS24408651 7 7829497 A 0.6 0.3 G 6.2 3.2 0.0125 0.4742 1.3 8.2 
USA golden 
retriever 
Allelic RS8649732 19 45495526 A 0.1 0.4 G 6.1 0.2 0.0133 0.5035 0.1 0.8 
USA golden Allelic RS24318716 6 4224712 C 0.2 0.5 T 5.6 0.3 0.0179 0.6802 0.1 0.8 
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USA golden 
retriever 
Allelic RS23690306 31 25600053 C 0.5 0.3 G 5.1 2.9 0.0244 0.9264 1.1 7.6 
USA golden 
retriever 
Allelic RS22915894 20 5771454 T 0.6 0.4 C 5.0 2.8 0.0252 0.9561 1.1 6.9 
USA golden 
retriever 
Allelic RS23026134 22 55676006 T 0.4 0.2 C 4.9 3.1 0.0262 0.9956 1.1 8.8 
USA golden 
retriever 
Allelic RS23932942 35 15274395 G 0.6 0.3 A 4.1 2.5 0.0425 1.6158 1.0 6.3 
USA golden 
retriever 
Allelic RS9132002 29 22197558 G 0.2 0.0 A 3.9 6.9 0.0479 1.8198 0.8 60.1 
USA GSD Allelic RS22184220 12 13111985 A 0.8 0.3 G 11.0 9.5 0.0009 0.0341 2.3 38.9 
USA GSD Allelic RS23684720 31 35018207 T 0.5 0.1 G 7.9 7.7 0.0049 0.1845 1.7 35.0 
USA GSD Allelic RS22859255 2 48522803 T 0.4 0.1 C 6.4 7.6 0.0117 0.4431 1.4 42.9 
USA GSD Allelic RS24318716 6 4224712 C 0.1 0.4 T 5.4 0.1 0.0203 0.7703 0.0 0.9 
USA GSD Allelic RS24872415 3 62441438 G 0.2 0.5 A 5.1 0.2 0.0238 0.9055 0.0 0.9 
USA GSD Allelic RS22913552 20 33818500 G 0.7 0.3 T 4.4 3.8 0.0364 1.3821 1.1 13.5 
USA GSD Allelic RS23690306 31 25600053 C 0.6 0.3 G 4.1 3.8 0.0436 1.6568 1.0 13.9 
USA GSD Allelic RS22720467 19 32273778 C 0.0 0.2 T 3.9 0.0 0.0481 1.8289 0.0 NA 
USA Labrador Allelic RS23026134 22 55676006 T 0.0 0.3 C 13.4 0.1 0.0003 0.0098 0.0 0.4 
USA Labrador geno/trend RS23026134 22  - - - - - - 0.0007 0.0253 - - 
USA Labrador Allelic RS24354997 6 14408543 T 0.3 0.1 G 6.7 3.3 0.0096 0.3653 1.3 8.3 
USA Labrador Allelic RS24275059 6 14365278 C 0.3 0.2 A 6.0 2.7 0.0146 0.5563 1.2 6.1 
USA Labrador Allelic RS22738169 2 45023367 T 0.6 0.4 C 5.9 2.3 0.0148 0.5632 1.2 4.5 
USA Labrador Allelic RS23313105 26 23047328 C 0.4 0.2 T 5.1 2.4 0.0236 0.8960 1.1 5.0 
USA Labrador Allelic RS23968934 36 32710839 T 0.3 0.5 C 4.9 0.5 0.0275 1.0446 0.2 0.9 
USA Labrador Allelic RS22913552 20 33818500 G 0.4 0.6 T 4.3 0.5 0.0381 1.4467 0.3 1.0 
USA Labrador Allelic RS23708599 31 30830928 A 0.5 0.4 G 4.1 2.0 0.0431 1.6370 1.0 3.9 
USA Labrador Allelic RS9132002 29 22197558 G 0.0 0.0 A 4.0 NA 0.0468 1.7765 NA NA 
USA Labrador Allelic RS23545080 3 69975205 C 0.1 0.2 A 3.9 0.4 0.0469 1.7826 0.1 1.0 
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USA WHWT Allelic RS22915894 20 5771454 C 1.0 0.2 T 14.3 NA 0.0002 0.0060 NA NA 
USA WHWT Allelic RS8806978 20 5779740 C 1.0 0.2 T 14.3 NA 0.0002 0.0060 NA NA 
USA WHWT geno/trend RS22915894 20  - - - - - - 0.0012 0.0443 - - 
USA WHWT geno/trend RS8806978 20  - - - - - - 0.0012 0.0443 - - 
USA WHWT Allelic RS23932942 35 15274395 A 0.9 0.3 G 7.3 15.0 0.0069 0.2608 1.5 146.5 
USA WHWT Allelic RS24556501 9 44666435 C 0.5 0.1 T 6.1 10.0 0.0132 0.5031 1.3 74.5 
USA WHWT Allelic RS24408651 7 7829497 A 0.0 0.5 G 5.5 0.0 0.0195 0.7418 0.0 NA 
USA WHWT Allelic RS23828846 33 29024878 T 0.1 0.6 C 5.1 0.1 0.0237 0.9006 0.0 0.9 
USA WHWT Allelic RS24482628 8 27285603 C 0.1 0.5 A 4.2 0.1 0.0399 1.5151 0.0 1.1 
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Appendix 12 Candidate genes: Sequenom Primers and Probes 
 
SNP  Reverse Primer Forward Primer Amplicon 
Length 
Probe Sequence 
rs8488679 ACGTTGGATGTGGCTG
CTGGAAGCTTATTG 
ACGTTGGATGACTGAG
GGATGCAAAGCCTG 
110 CTCCCTCCCGCTCCC 
rs23828846 ACGTTGGATGACTGCA
GACTTCCTATCTGG 
ACGTTGGATGAGGTCA
ATCAGACAGTGGTG 
115 TCTGCCCCTCGACA
A 
rs22819627 ACGTTGGATGTTCCCA
TCTGTGCCACAAAC 
ACGTTGGATGCGATGA
TTTCAGGAAAGGAG 
101 ACAAACGGCTGCAT
T 
rs23602938 ACGTTGGATGAGAGG
GTCCTGTTGATACAC 
ACGTTGGATGGCCAGT
AAGCTAGAAGTTCG 
101 CCCATACTCCTCAG
GC 
rs22349092 ACGTTGGATGGGCTTT
AGTAAGCAAGTCTG 
ACGTTGGATGTTGTAG
CTAAGTCCGCTCTG 
100 AAGGACAGTGCGTT
CA 
rs22349093 ACGTTGGATGTCCGAC
ACAAGAATGCAAAG 
ACGTTGGATGCAGGG
AAAATGACTCGAGAT 
113 ATAACCCGTTGCAT
CCC 
rs22959786 ACGTTGGATGGGATGC
AGACCGTCTGGATT 
ACGTTGGATGGTCAGC
AGACAACACTTAAC 
115 CCGTCTGGATTTCCT
TA 
rs22509070 ACGTTGGATGGCCACG
AGCAGTCAGGAGA 
ACGTTGGATGTGGCCT
GCTGTCCTTGATGT 
80 TGGACAGAGCCAGA
CAC 
rs9070190 ACGTTGGATGCGCAG
GATGTCCAGGTAGTT 
ACGTTGGATGAGAGA
CTTCTTCCCTTCCTG 
117 GTCCAGGTAGTTCT
GGTT 
rs22000474 ACGTTGGATGTCTGCT
TAACAGTCTCCTCC 
ACGTTGGATGAGGCAT
ATTAGATTGGCAGG 
105 TGGCCACACCCATT
CCTTC 
rs24613432 ACGTTGGATGTAGGTC
AAACCACTGATCCC 
ACGTTGGATGGCCATC
TGTCGTAACATTGC 
102 CCGTGCTTGCTTTTT
TTCC 
rs24267550 ACGTTGGATGTCAATT
TGAGCCCGGACTTG 
ACGTTGGATGTCAAGA
ATGGACCCTCTGAC 
103 CGGGTAGATTCTCA
TAGTC 
rs22871627 ACGTTGGATGAGTCAG
GTAGAGACTTACAG 
ACGTTGGATGCACTTG
CAGATGGAAGCAAC 
110 CTCACATCTGGAGA
GAGTT 
rs23026134 ACGTTGGATGAGATCC
TGGTTTGGAAGGAG 
ACGTTGGATGCTTGGT
GAGATCTCCTATGG 
87 GGAGCATTGAGTGA
GTCTAT 
rs9150577 ACGTTGGATGAGATCT
GTGAGCTCCTTGAG 
ACGTTGGATGATGACA
TCTATGTCTTCGGG 
114 CTCGCGGTCACCCA
CCGAGTT 
rs24408651 ACGTTGGATGTCCTCT
ACCAAATCTATGTG 
ACGTTGGATGGCCAAC
AGTATGCTGGTTAG 
98 CAAATCTATGTGAA
TAGCCCT 
S100A8_p3 ACGTTGGATGACCTCC
CTTAGCTTTCTCTC 
ACGTTGGATGTCAGTC
TGCTCCATGCTTTG 
106 TCCCTTAGCTTTCTC
TCCCCTCT 
rs22986082 ACGTTGGATGCCCAGA
ATAGTGAGAAACAG 
ACGTTGGATGCTGCCT
TGTGACTCTACTTG 
101 GAATAGTGAGAAAC
AGGATCAT 
rs22328353 ACGTTGGATGACCTGC
TACCAGCATTAAAG 
ACGTTGGATGTTGCTT
TCCTTCTCCCTTAG 
99 GCTACCAGCATTAA
AGCTTTAAC 
rs8877521 ACGTTGGATGAATTCC
AGCTCCCTCTTCAG 
ACGTTGGATGGTGAA
AACCCCTTACTGGAG 
102 CTCCCTCTTCAGAA
ACATCAGCCA 
rs8806978 ACGTTGGATGGATGTG
ACAAGCCTTTCTGC 
ACGTTGGATGAGTCCG
TGCTTTATCAAGCC 
100 AGAGGCACCACATG
TGCCCAGTTA 
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rs22931896 ACGTTGGATGTCCACT
TGGAGAATACTGGG 
ACGTTGGATGTGTAAT
AAAGATGCCCCCAC 
102 GGGAATTACTGCCA
TCTGGTATAT 
rs22605727 ACGTTGGATGTCCGTA
GGAGGTTCTCTGG 
ACGTTGGATGTGAGA
ATGGAATCCTGGCAC 
116 GGTTCTCTGGGCCC
ACTGCCACTTC 
rs22185491 ACGTTGGATGGGGAA
TACAGCGGTCTTGA 
ACGTTGGATGTTGTTC
TCCTTCATCCTGGG 
110 GGAATACAGCGGTC
TTGACGGGTTG 
rs23907319 ACGTTGGATGAGAGCT
CAGTTTCCCATTGC 
ACGTTGGATGTGAGA
GGCACTGGAGATAAC 
107 AAAGTAAGAAAGTT
CTACAGGTAGG 
rs8860216 ACGTTGGATGGTAAA
ATCATGCACTGTCCC 
ACGTTGGATGGTTCCT
TGATTGTATTTACC 
99 AAAATCATGCACTG
TCCCACACAGTAG 
rs23428471 ACGTTGGATGCCACAT
GCTGATTACAAGCC 
ACGTTGGATGGACCAC
TTTTGTCTAGTAAG 
117 CTATTGGAGTTGTAT
TTATCGACAAAC 
rs24657063 ACGTTGGATGACCACA
GGTTAACCAGTGAC 
ACGTTGGATGGCAGTG
CGACTTTGTTGAAG 
90 AACCAGTGACGAGA
CTGATAGCCAATG 
rs22511526 ACGTTGGATGTGGATT
CCGAGTCTCGGTG 
ACGTTGGATGATCAAG
GACAGCAGGCCAC 
80 ATTCCGAGTCTCGG
TGGGCAGAGTCAGG 
rs24328835 ACGTTGGATGCGATTG
TGCCCATGTCCAAG 
ACGTTGGATGGTAGAT
CTCATACTGCTCCG 
91 GCCCGCCAAGCCCT
C 
rs8555045 ACGTTGGATGTGTCCT
TGGCGTGACCCTG 
ACGTTGGATGATCCAG
CACTAGGGAAAGAC 
101 ACCCTGCGTGTCTTG 
rs22542262 ACGTTGGATGACCAG
ATCCATGTCCAGTTC 
ACGTTGGATGATGGA
GACTCAGATCTCAGC 
118 GACTGCTGATGGTG
G 
rs22976618 ACGTTGGATGATCACC
CCATCCCCTTCAC 
ACGTTGGATGCTAGAC
CCTTTGATGTGAAC 
99 CTTCACCTCCAGGA
AG 
rs24332727 ACGTTGGATGTGTGGA
GAGATGGATGGAAC 
ACGTTGGATGATCCTT
GAGCAACAGCCTTC 
111 GTGAGGCTGTGTGT
CC 
rs22000453 ACGTTGGATGTTCCTC
ACTGCTTAGGAGAC 
ACGTTGGATGAAAGC
GATTCCTAAATGCCC 
99 AGGTCAAGGATGGT
GG 
rs24630609 ACGTTGGATGTGGACG
ATGAGAGCCTCTTC 
ACGTTGGATGACGTGG
TCCCCTTGAATAAG 
90 TCTTCCGGGCCGCA
ATC 
rs24404800 ACGTTGGATGGTTCAT
TACAGCCACTGGAG 
ACGTTGGATGAGCTGT
GGTTTTGGAGCTGA 
96 AACTTGGAGATCTT
GGG 
rs22655278 ACGTTGGATGAAATCC
ATTTCCCCCTCTGC 
ACGTTGGATGTCGTTC
TTCCTCAGCTTCTC 
106 AGACCTCCTCCTTA
CTAC 
rs23472497 ACGTTGGATGGGCCA
GAGGATGGGAAATTC 
ACGTTGGATGATCTCT
GTCAGTGCACTAGG 
99 ACCTGTCAAGGTCA
TGTC 
rs22212359 ACGTTGGATGAATCCC
TCTTTTCCCCTCTG 
ACGTTGGATGGCACA
AGATGGAAGATGGAG 
119 CCCCTCTGAAATTC
CCTTT 
rs24639522 ACGTTGGATGCCTGGA
GGCAAAAGAAGATG 
ACGTTGGATGGTAAGC
ACTGATCCACTGAC 
111 TCTGGAATGGAACA
CGTCT 
rs22542234 ACGTTGGATGATGACC
AGATCCCTGTCTTC 
ACGTTGGATGGCACA
GAACCAATCATGGAC 
102 CTGTCTTCTCCCAAT
ACCAG 
rs22655274 ACGTTGGATGCTAGAC
AGCAGTTCAGTCTC 
ACGTTGGATGTGGAG
AAAGCCAGGCTTGCG 
94 TTCAGTCTCCAGTCA
GTGGG 
rs24194054 ACGTTGGATGCAAAC
AGATTGCTCCGTGTG 
ACGTTGGATGGGTACA
GAGACCAAGGAAAG 
100 GTTGATGGAGAACA
GCATGT 
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rs23066224 ACGTTGGATGGGGCTA
TTAGTGACCCAATG 
ACGTTGGATGTCTGCA
GTCAGATCAACTGT 
94 CAGAAGTAGGATCA
TCTGCTC 
rs22009467 ACGTTGGATGAGAGA
CCTCACCTCTGCTCC 
ACGTTGGATGTCTGAT
CGTGGCATTCTTCC 
92 TGCTCCCGTTCTCTC
CCGTGTC 
rs8649732 ACGTTGGATGGCTATT
CAACTTTGGTGGCG 
ACGTTGGATGTGGTTG
TTGTCACTAGTTGG 
101 CCTCACAAATCGGC
TTAACTCT 
rs22114085 ACGTTGGATGAAGCTC
CACGATGAACAGTC 
ACGTTGGATGGACTGT
ACACGACCTTTACC 
115 CAGCAGCACTTCCA
GAATGTACC 
rs22615134 ACGTTGGATGAACCTT
GGAACAAAGTCCCC 
ACGTTGGATGTCAAGC
TGGGTAGGTTAGTG 
113 TTCAGCCAGAGTGT
CCAGCCGTT 
rs22588226 ACGTTGGATGTGGATC
CCGAGTCTCGGTG 
ACGTTGGATGAGGGTC
ACGCCAAGGACAG 
88 CCGTATCGGTGGGC
AGAGTCAGG 
rs22212677 ACGTTGGATGTAACTT
CTGCTCAGAAATG 
ACGTTGGATGTGTGGT
TTTGTATTCAAGGG 
99 AATTGAGAATAATC
AGTGAAATAG 
rs22374487 ACGTTGGATGAACTCA
CACATCCCAGAGAG 
ACGTTGGATGTCCAGT
AATGACAGTGACAG 
115 CCAGAGAGATCATT
TTTATACTTTT 
rs9255897 ACGTTGGATGTCTCCA
TGCGTTTCATGTCC 
ACGTTGGATGTTTGTC
CGGATGCAGCTATG 
93 TTCATGTCCATCAGC
TTCTCCACGTT 
rs22599138 ACGTTGGATGGATCCG
GTAACAGCAAACAC 
ACGTTGGATGCTGAGT
CTCTGAGTCTAGTG 
103 CCGGGAATCCAGTG
TCAGTCAGGCCA 
rs23768387 ACGTTGGATGTCTCAC
TTCTCAGTCAGTGC 
ACGTTGGATGGAAGA
AAGAGATGAGGAGAG 
99 TCACTTCTCAGTCAG
TGCTGTCTCATA 
rs9019919 ACGTTGGATGCACTGA
GGACCAATTAGGTG 
ACGTTGGATGTCCCAC
TATGAGCGAAACTG 
101 CTGAGGACCAATTA
GGTGTTTGAAATT 
rs9095590 ACGTTGGATGTTCTTT
CCTCTTCCCTCCTC 
ACGTTGGATGGCAGA
GCTCTTACCTACAAC 
103 TTCCCTCCTCAGAAT
CATCTTCTCGAAC 
rs22871630 ACGTTGGATGGGCAAT
AGATTAAGCCCAAG 
ACGTTGGATGCTGCAA
AGTTATATGTCTGG 
119 ACTCCATACCTCTAT
GTAAAAACTGAAT 
rs8857124 ACGTTGGATGGTGAAC
AGGACGTCCTCTC 
ACGTTGGATGGGGGC
CTGCAGATCAGTAT 
87 CACAGCCACCGCCT
C 
rs24613434 ACGTTGGATGAGTCAC
TTGGGTATGTGTCG 
ACGTTGGATGGGCTTG
GATGCTGAGAAATG 
108 TTTCACTCTGGCCCG 
rs8555036 ACGTTGGATGAGTGG
ACGATTGCTGGTGG 
ACGTTGGATGTGACAG
CTCTAGGCACTCAG 
111 CTGGTGGCGAGATC
C 
rs22542263 ACGTTGGATGCTGTCC
TGTGACTGCTGATG 
ACGTTGGATGTGACTC
TGCCCATGGAGACT 
95 TGCCCTTGTCTGTCT
A 
rs23545080 ACGTTGGATGCTTCTA
ACCTGAGTGAAGGC 
ACGTTGGATGTGTGTT
TCTGGAGTCCTACC 
100 TGTGTTTGTGGGGTT
A 
rs24319791 ACGTTGGATGTGGCCT
CGCAGATCCAGAAG 
ACGTTGGATGAAGCA
GCTGTCACCCAAAGG 
116 ATCCAGAAGGCGCC
GGA 
rs22839343 ACGTTGGATGTATACT
TCTCCATCAGCACC 
ACGTTGGATGAACTTT
CGGCAGTACGTGAG 
103 TCCATCAGCACCAC
TCAC 
rs24872415 ACGTTGGATGTTGGCA
AGCCTGACAAATGG 
ACGTTGGATGTGTTGA
GGAGACTTCACCTG 
100 ACCCAAGTGCCCAA
ACAA 
rs24327271 ACGTTGGATGAGAACT
CACTCTCTGTGGAC 
ACGTTGGATGTGCCAA
GAACAAGCCCAAAC 
113 TCTGTGGACTAACT
GAAA 
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rs21902631 ACGTTGGATGGTCTGT
CTCTCTCCTTCTAC 
ACGTTGGATGTATCTT
ATGTTGAACATTTG 
106 ATCTCCCAGTGATA
ATTCC 
rs22818977 ACGTTGGATGGATGGC
AGGATGCATGGCAA 
ACGTTGGATGAAGCTC
CACTTTACCCATCC 
120 GGATGCATGGCAAT
AAATG 
rs22874976 ACGTTGGATGCCACAT
GCCTCTGACTTTTG 
ACGTTGGATGAGACA
ATCTGAGAACACAGC 
85 CTCTGACTTTTGAGG
AGTTC 
rs23360288 ACGTTGGATGCAGCGT
CAGACAGTTCTCCT 
ACGTTGGATGAACCCA
GCGGTGCTCACGTA 
104 TCAGACAGTTCTCCT
TCTCCA 
rs24482628 ACGTTGGATGCAGGAT
GCAGATTTTTCCAG 
ACGTTGGATGACTTGG
TGATTCTATGGAGG 
96 TTCCAGTTTTCCCAT
AGCCTG 
rs22871624 ACGTTGGATGGCACTG
GATTGAGACACTTC 
ACGTTGGATGCTGGAG
AGAGTTACTTAGAG 
104 GGAAGCAACTAGAA
TTTTAGC 
rs22511518 ACGTTGGATGCACTGG
ATTCCCGGTGTTTG 
ACGTTGGATGCATCAG
CAGTCACAGGACAG 
99 ATTCCCGGTGTTTGC
TGTTACC 
rs22511504 ACGTTGGATGAGTCAG
GATGCCCACGGGT 
ACGTTGGATGAGACA
GAGCCAGACACGCAG 
82 AACGTGTGGCCTGC
TGTCCTTG 
rs24872954 ACGTTGGATGAAAGC
CATCCATCCTCTCTG 
ACGTTGGATGTCTGAG
AGGGATCATGAGTG 
117 TCCATCCTCTCTGTG
CCACCTGT 
rs22184220 ACGTTGGATGAGACC
ATAGCCAGCTTGCAC 
ACGTTGGATGTGGCAC
AATCCCTTTGATGG 
101 GAGTTAAAGGTATC
TTCCATAGG 
rs23122280 ACGTTGGATGGATTTC
ACTCAGCCCCATAG 
ACGTTGGATGAAACA
GATGTCTCTAGTTGG 
98 AGCCCCATAGAGCT
TTCTTTAAAT 
rs24438947 ACGTTGGATGTTTTCC
TACTTCCCCACCTC 
ACGTTGGATGTCTGGT
TTCTCAACCAGGTG 
99 CACCTCCCATCAAA
ATTTTTCATTC 
rs22908459 ACGTTGGATGCTTGAG
GAATGTCCACCATC 
ACGTTGGATGAGGAT
GAAGCTTCTCGTAGG 
101 ATGTCCACCATCTCT
GGCTGCTGAC 
rs22986033 ACGTTGGATGATAGGT
AACACAAATTCTG 
ACGTTGGATGATATTG
ATCACGGAGCAGAC 
92 GGTAACACAAATTC
TGATTGCCTTG 
rs24435410 ACGTTGGATGGACCAT
TGGCCATTCTCTTG 
ACGTTGGATGACCTGT
AGCTTCCATTGTCC 
100 TCTTGGCATGCTGTT
CTCGCTGATCC 
rs22989468 ACGTTGGATGAGGGA
GTCACCTGCAAACTG 
ACGTTGGATGATGCTC
ACCTTGCGGAACTC 
100 GCAAATGCAGTTGT
GATGCAGTCGTG 
rs24150067 ACGTTGGATGTTCGGC
ACACAAAGTTCCTC 
ACGTTGGATGATGGA
ATGTATGCCCGCATC 
95 GCACACAAAGTTCC
TCACAAAGACATA 
rs23274229 ACGTTGGATGGACTCA
GGACCCACAATAAC 
ACGTTGGATGACCTCC
ATGGATCACTTCAG 
119 AGGACCCACAATAA
CAAAGGTCAAAAT 
rs22750909 ACGTTGGATGAAGGA
GAAGCAAATTCCCCC 
ACGTTGGATGTTAGAA
TTTGGTGCCCCCTC 
116 CAAATTCCCCCCAC
TCCAAAAAAAAAAA 
rs21902676 ACGTTGGATGTTGGGC
ATCTGTGTGGTTGG 
ACGTTGGATGTCAGAC
AGCTCCCATTTAGG 
111 AGAGAGTCTCTGGT
ACCCAGAGAACCCT 
rs22655272 ACGTTGGATGAATTGT
AGCCAACGTGCACC 
ACGTTGGATGCCCATC
TGGTTGTTCTAAGG 
119 TGCACCGAGCACTG
A 
rs8867188 ACGTTGGATGTTTATC
CTTGTCAGGTGCGG 
ACGTTGGATGTTTAAC
GTGGAGTGGGATGG 
82 CAGGTGCGGTGCTT
T 
rs22864357 ACGTTGGATGAGATCT
CGCACGTGTACTGG 
ACGTTGGATGACTGAG
CGACACCACTTCAC 
111 CGTCCTCCACTACC
AC 
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rs22523565 ACGTTGGATGAGACTG
GATCTCTTGCTGTG 
ACGTTGGATGGAAAA
GGAGCTGTGAGGATG 
100 CTTCACAAACTCTTG
CC 
rs24404799 ACGTTGGATGGTTCAT
TACAGCCACTGGAG 
ACGTTGGATGAGCTGT
GGTTTTGGAGCTGA 
96 ACTTGGAGATCTTG
GGC 
rs22859255 ACGTTGGATGGCATCT
CAAATATTTCTGGG 
ACGTTGGATGTCAGAG
AAAGCCAAAAGCCG 
90 TCTGGGTAAGAGGA
ACA 
rs21941198 ACGTTGGATGCCTGCC
CATTGCTCATATTC 
ACGTTGGATGGCTGCA
GCTTGAAGATCAAC 
97 GCTCGTCCACTCTAT
TAG 
rs22146864 ACGTTGGATGAATATG
GTTGCAGGGCCTTC 
ACGTTGGATGCTCTCC
CTACTGATTTCCTC 
101 GCCTTCCTCATACA
CTCAC 
rs23586992 ACGTTGGATGCACAGC
CGTTGCTGTCCTT 
ACGTTGGATGAGCACT
GAGTTCCCACAGGC 
120 CGTTGCTGTCCTTGG
AGAA 
rs22374481 ACGTTGGATGTTAGTC
CCTCCTTGAGGTAG 
ACGTTGGATGGGCAG
GGCTCAACAGAAAAG 
95 TGAGGTAGGAAAAC
TCACA 
rs24380950 ACGTTGGATGACTTTC
TGGTACCCGTTTTG 
ACGTTGGATGTATCTT
CAATGAATGATGC 
117 TCTTTTTTCCATCAG
CAACT 
rs22410121 ACGTTGGATGTTCTTC
TCTGTCCTGTGACC 
ACGTTGGATGTCTCAC
AGCTGCTGTGAGCC 
111 GCCGCTCCAGATCT
TTGAACT 
rs22509090 ACGTTGGATGTGCTGT
CCTTGGCGTGACC 
ACGTTGGATGAAGCC
GCCACGAGCAGTCA 
80 CCCGAGTGACCCTG
CGTGTCT 
rs8944179 ACGTTGGATGGAATG
ACCAAGTAACTCTGC 
ACGTTGGATGTATTCA
TCAAGGACGCCAGC 
94 AGTAACTCTGCTAA
AATATGG 
rs9013510 ACGTTGGATGGCGAG
AAACACAGATTCTCT 
ACGTTGGATGGAGAC
AGACAGGCTATTTCC 
117 TTTTTTTTCCTTTCC
AATCTCA 
rs22511502 ACGTTGGATGTGGCGG
CTTCCTTGTCTTTC 
ACGTTGGATGATCCTG
ACTCTGCCCACCGA 
81 CTTGTCTTTCCCTAG
TGCTGGAT 
rs9190946 ACGTTGGATGTCTTCT
GTCTCCATCAGCAC 
ACGTTGGATGGGAAA
GCCTTTCTGCAGCGT 
105 ATTGATGTAAAAAC
CATGATGAA 
S100A8_p2 ACGTTGGATGCCTGCA
TATCCTCTGTCAAC 
ACGTTGGATGCAAAG
CATGGAGCAGACTGA 
93 ATTTCGGGAAACCT
GGTAAGTAA 
rs22263793 ACGTTGGATGTAACTT
ACCTTAGTATCTG 
ACGTTGGATGCACCAG
CTTAAAATCTACTG 
100 ACTTACCTTAGTATC
TGATATTTC 
S100A8_P ACGTTGGATGCAGTGA
TTGCCCCATTCACC 
ACGTTGGATGCCTAGG
CCATGCAGAGATAG 
103 TTGATTGCCCCATTC
ACCTGGTTGA 
rs23567144 ACGTTGGATGGATGA
GCCCACACACAGAG 
ACGTTGGATGTATCCC
TGAAGCATCTGGGC 
120 CCCACACACAGAGG
CTGCTGGAATA 
rs22986026 ACGTTGGATGTCCGGG
TCACTCTTGGTAGA 
ACGTTGGATGTCGGCC
TAATGTTTAGGAGC 
95 AGGCGGGAGCTGCG
TGTCCACACAG 
rs22871646 ACGTTGGATGGACAG
GATACTGAAGGATGG 
ACGTTGGATGGTTGTT
CTGGGTCATGCTAC 
87 TGAAGGATGGAAAC
TAAATTGATGT 
rs8667691 ACGTTGGATGATCCAA
GCCCCTGGAGGTG 
ACGTTGGATGTGTTGG
AGATGCGCAGCG 
100 ATGCTTCTGCTGGA
GAAGAACCGCTC 
rs22565034 ACGTTGGATGTGCACT
ACTGCCACGTTGTC 
ACGTTGGATGCACTAG
ACTCAGAGACTCAG 
100 TTCTCCTCTGACTGG
ACCTGGACCGTT 
rs22529256 ACGTTGGATGAAGAG
TCTGGATCTGGAGAG 
ACGTTGGATGTGACCA
TCTGAGTTGGATTC 
120 CGATTCTGGCTCCA
ATAATTCTTCTAG 
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rs8988459 ACGTTGGATGGTCAGA
ATTACCAAGCTACG 
ACGTTGGATGTCACTA
GGTCTTACTTACCG 
93 CAGAATTACCAAGC
TACGGAAACAAGT 
rs22915894 ACGTTGGATGGCCACT
ATCGTGTTGTCTAC 
ACGTTGGATGCTGAGA
ATGGCTTCACAGAG 
93 TGTCTACAGAACCA
GATTTTGCAGAAGG 
rs22807086 ACGTTGGATGAATGAT
GTAGCAGACAGGAC 
ACGTTGGATGAGAGG
GAACTGAACCCATGC 
113 ATGATGGAATAAAT
CATTAGAACAAAAG 
rs22655276 ACGTTGGATGTCTTCC
TCCTAATCTCCTCC 
ACGTTGGATGTGATGA
CCACCCTAGGACAC 
99 CCACCCCCAAGCCA
G 
rs22542266 ACGTTGGATGACGGTG
CTGAGATCTGAGTC 
ACGTTGGATGACACAC
AGGGTCACAGCAAG 
101 CAGGCTGCCAACGG
G 
rs22910701 ACGTTGGATGGACAA
ATACTTCCATGCCCG 
ACGTTGGATGTGATCA
CTTTAGCAGCCCAG 
99 CCGGGGGAACTATG
A 
rs24630571 ACGTTGGATGAGGAG
GAAGAGGCCTCTGG 
ACGTTGGATGGTGAA
GCCACCAAGAGAGAC 
114 AAGGCGGCGGTGGC
GG 
MS4A2_E5 ACGTTGGATGTATGCT
GCTGACAGTGTTGG 
ACGTTGGATGCTATTG
AACGCACTGGCAGG 
116 TCTCCCAGGCTGCC
CCA 
rs22029672 ACGTTGGATGATGCAG
GGCTGGGTTTCTAC 
ACGTTGGATGAGCAA
GAGGAGCTATTCCTG 
113 GGGTTTCTACCACG
AAG 
rs23690306 ACGTTGGATGTACTTC
ACCTGCAAGCTTGG 
ACGTTGGATGGGTAGT
TGAGGTAGATGAGG 
103 AATAAGCCAATCCT
CCTG 
SPRR1B_E
3_1 
ACGTTGGATGAGGAA
GTTTGGTGTTCCCAG 
ACGTTGGATGACCTCA
GGAGCCATTTGTTC 
99 TTGCGGTAACTTGG
TGTC 
rs22509074 ACGTTGGATGCCAGG
ACAAGCAGACATCAG 
ACGTTGGATGACGGGT
CGTTAAGAATTCTC 
100 GGGAGGAATCCAGC
CTGA 
rs21902632 ACGTTGGATGGAATG
GTGGATGCCTTCAAC 
ACGTTGGATGTAGACA
CCACAAGATCCTGC 
95 ACGCCTTCAACACA
AAGAG 
rs9241373 ACGTTGGATGATGGGC
CGCTGTCCTGCGT 
ACGTTGGATGTCACGG
AATTCTCCAAGGAC 
115 CACTGCTCCGGCCC
CCACAG 
rs23593765 ACGTTGGATGCTGCAA
GTATCTAAGGCCAC 
ACGTTGGATGGGTATT
CCAGGACTCTCAAG 
99 CAAGGAGAGTTGGA
GAGAG 
rs24732893 ACGTTGGATGTTTCTT
TGATTCTCTGGCGG 
ACGTTGGATGTTGGTA
CCAGATCCAGCTAC 
117 GGCCGGCGAAGATC
CCCCAA 
rs22509072 ACGTTGGATGAGTCAG
GATGCCCACGGGT 
ACGTTGGATGAGACA
GAGCCAGACACGCAG 
82 GTGTGGCCTGCTGT
CCTTGA 
rs22872666 ACGTTGGATGCGACCT
TATGTGAAGGATGG 
ACGTTGGATGTTTCCA
TCAGAGCCAAGGAC 
91 GGATGGAAGACTTG
TATGCAC 
rs23478400 ACGTTGGATGTCTGCC
TAGAATCTTGTCAC 
ACGTTGGATGTTGCCC
CCAGACATTTTTTG 
118 GTACTTACATATGC
ATTTCCCA 
rs24318716 ACGTTGGATGGTTGAA
CAGGACACCTCATC 
ACGTTGGATGACTGTT
GGAGGAGGCAGGAG 
89 GAATCGGGCCCATT
TGTTTCTA 
rs22155657 ACGTTGGATGATGTTG
AAGATTGAATGAC 
ACGTTGGATGTATCTA
AACCACCAGTTTC 
113 TGTATATAAAGATT
TCTCCTCAA 
rs22935368 ACGTTGGATGTTTTCT
GCGTGGGTTTAGGG 
ACGTTGGATGTTATGG
CCCAGATCCTTCTC 
101 GAGTGAGGGCGGGC
ACCTTAATA 
rs22913552 ACGTTGGATGTGAAAC
AAGATCACAAAGCC 
ACGTTGGATGTGTCAG
CACTGTGTGTGTTC 
96 CCAAAGCCAAACTG
AACAATAATC 
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rs22821176 ACGTTGGATGTATACA
GACTGAATTGTTG 
ACGTTGGATGGGAGA
AAGAAGGAAAATAT 
105 AAATTTATTTACTGC
TAGTGTTAA 
rs9196801 ACGTTGGATGCCCGTA
CACAGTTGTCATTG 
ACGTTGGATGTTCCTT
GGTTCTGTAGGTGC 
105 AGCGCGGGGCATTT
AAATGGATTT 
rs22511501 ACGTTGGATGATCCTG
ACTCTGCCCACCGA 
ACGTTGGATGTGGCGG
CTTCCTTGTCTTTC 
81 ACTATGCCCACCGA
GACTCGGAATC 
rs24264853 ACGTTGGATGTACCCA
AACCCAAGAGGATG 
ACGTTGGATGCCTATG
CATATGACTAGCCC 
103 GTACCTACATGTGA
GTAATTGCTAA 
rs22931897 ACGTTGGATGTAAAG
ATGCCCCCACTTAGG 
ACGTTGGATGTCCACT
TGGAGAATACTGGG 
97 AACTATGCCCCCAC
TTAGGGCGATAT 
rs22020166 ACGTTGGATGGTCTTT
CCTTCTTAACCTGC 
ACGTTGGATGGGGAA
TCAAGAAAGGCTTTAC 
120 TATTAACCTGCATA
CAAAATTGTTGCT 
rs9081246 ACGTTGGATGGACCCA
AAGATATTCTGACC 
ACGTTGGATGCCGCCC
ATGTCTCATGAATA 
104 AAAGATATTCTGAC
CTAAAATACTATG 
rs9013509 ACGTTGGATGCAAATT
TAGTAGAAGATAGAG 
ACGTTGGATGTCTCCC
AGTGATAATTCCTC 
114 AGAAGATAGAGTTT
TAAAATATTTTTTT 
rs8555046 ACGTTGGATGTGGCGG
CTTCCTTGTCTTTC 
ACGTTGGATGAGCCTG
ACTCTGCCCACCGA 
81 TCCCTAGTGCTGGA
T 
rs22181912 ACGTTGGATGTTCTGC
AAGGATGGGCATTC 
ACGTTGGATGTCCAGT
TTTTCTATGTCCTG 
102 AGAACATGTCCTTG
TGG 
rs24202381 ACGTTGGATGACCGGC
TCAATGATGATGTC 
ACGTTGGATGAGCTTC
AGCTCCTCTCTTAG 
99 TGTCAAGCGCTATA
GCTG 
rs22588227 ACGTTGGATGAGTCAG
GATGCCCACGGGT 
ACGTTGGATGAGACA
GAGCCAGACACGCAG 
82 ACCCCGGGTGGCCT
GCTGT 
rs22217971 ACGTTGGATGATCCCG
AGCCCCTGCCGGT 
ACGTTGGATGGAAGTC
CAGGTGGTGGAATG 
115 GCCGGTGGTGCCTC
C 
rs22509067 ACGTTGGATGTGGATC
CCGAGTCTCGGTG 
ACGTTGGATGATCAAG
GACAGCAGGCCAC 
80 GTGGGCAGAGTCAG
G 
rs8555044 ACGTTGGATGTGCTGT
CCTTGGCGTGACC 
ACGTTGGATGAAGCC
GCCACGAGCAGTCA 
80 TTGACCCTGCGTGTC
T 
rs8877519 ACGTTGGATGCGGAG
AGGTACTTCTGAAAG 
ACGTTGGATGGAGAG
AATTTTTCTCAGGGC 
100 AGTTCAATTTCAGG
TGC 
rs22542260 ACGTTGGATGTGACTG
ACACTGGATTCCCG 
ACGTTGGATGCATCAG
CAGTCACAGGACAG 
106 TTCCCGGTGTTTGCT 
rs22588228 ACGTTGGATGAGACA
GAGCCAGACACGCAG 
ACGTTGGATGAGTCAG
GATGCCCACGGGT 
82 CGACACGCAGGGTC
AC 
rs22908463 ACGTTGGATGGTCTCC
TTTTCATGTGTCCC 
ACGTTGGATGAGGAC
CAGGGAGCACAATAG 
98 GGGATGAAGCTTCT
CGT 
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Appendix 13 Candidate gene study: Individual breed analysis (p<0.05) 
 
Breed Statistical 
Test 
Marker Chr Bp A1 F_A F_U A2 Chisq Orx P Correct P Value 
(X48) 
L95 U95 
Shiba Inu Allelic Rs22986026 21 53629181 C 0.5 0.1 T 18.4 7.4 0.0000 0.0009 2.8 19.9 
Usa Whwt Allelic Rs23274229 25 6184255 C 1 0.1 T 17.6 NA 0.0000 0.0010 NA NA 
Uk Labrador Allelic Rs23907319 36 10444284 C 0.4 0.1 T 19.4 6.4 0.0000 0.0005 2.6 15.4 
Shiba Inu Allelic Rs9070190 21 28910870 G 0.8 0.3 A 24 9.2 0.0000 0.0001 3.6 23.4 
Shiba Inu Allelic Rs9150577 21 28912392 A 0.2 0.7 G 21.3 0.1 0.0000 0.0002 0.1 0.3 
Uk golden retriever Trend Rs22542260 17 - - - - - 15.1 - 0.0001 0.0050 - - 
Uk golden retriever Allelic Rs22542260 17 64296760 A 0.3 0 G 14.5 19.8 0.0001 0.0067 2.6 153.7 
Uk Labrador Trend Rs22588227 17 - - - - - 16.1 - 0.0001 0.0030 - - 
Pit Bull Allelic Rs24613432 39 751050 A 0 0.4 G 15.1 0 0.0001 0.0048 0 0.3 
Shiba Inu Trend Rs9070190 21 - - - - - 15.5 - 0.0001 0.0040 - - 
Shiba Inu Trend Rs9150577 21 - - - - - 14.4 - 0.0001 0.0070 - - 
Uk golden retriever Trend Rs22542263 17 - - - - - 13.8 - 0.0002 0.0100 - - 
Uk Labrador Allelic Rs22588227 17 64297022 G 0.3 0.1 C 13.8 5.6 0.0002 0.0098 2.1 14.9 
Uk Labrador Add Rs22588227 17 64297022 - - - - - 8.7 0.0002 0.0099 2.8 27.1 
Uk Labrador Trend Rs23907319 36 - - - - - 13.7 - 0.0002 0.0110 - - 
Uk golden retriever Allelic Rs22542263 17 64296837 T 0.3 0 C 13.2 18.2 0.0003 0.0135 2.3 140.9 
Usa German Shepherd Dog Allelic Rs22807086 2 45212191 A 0.7 0.1 G 13.1 14 0.0003 0.0138 3 66.4 
Shiba Inu Allelic Rs24328835 6 10890690 T 0.7 0.3 C 13.4 4.6 0.0003 0.0123 2 10.6 
Uk golden retriever Allelic Rs24613434 39 750979 G 1 0.3 A 12.4 NA 0.0004 0.0201 NA NA 
Shiba Inu Add Rs9070190 21 28910870 - - - - - 4.7 0.0004 0.0181 2 11 
Usa Whwt Allelic Rs22009467 10 23005117 A 0.5 0 G 11.7 Na 0.0006 0.0310 Na Na 
Uk golden retriever Allelic Rs22871630 2 45133611 A 0.5 0.1 C 11.7 12.1 0.0006 0.0296 2.1 68.9 
Shiba Inu Add Rs9150577 21 28912392 - - - - - 0.2 0.0006 0.0264 0.1 0.5 
Shiba Inu Trend Rs22986026 21 - - - - - 11.4 - 0.0007 0.0360 - - 
Pit Bull Trend Rs24613432 39 - - - - - 11.4 - 0.0008 0.0360 - - 
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Pit Bull Allelic Rs24319791 6 10917564 A 0.3 0 G 11 NA 0.0009 0.0440 NA NA 
Uk golden retriever Trend Rs22871630 2 - - - - - 10.9 - 0.0010 0.0470 - - 
Uk Labrador Add Rs23907319 36 10444284 - - - - - 3.9 0.0010 0.0501 1.7 9 
Usa Labrador Allelic RS21902632 1 16476102 G 0.1 0.3 C 10.4 0.2 0.0013 0.0605 0.1 0.6 
Usa golden retriever Allelic RS22819627 2 45159024 T 0.6 0.3 A 9.9 4.3 0.0016 0.0775 1.7 11.0 
Uk Labrador Allelic RS24657063 39 755447 G 0.7 0.4 A 9.5 3.1 0.0021 0.1007 1.5 6.5 
Uk golden retriever Allelic RS8555046 17 64298495 T 0.3 0.0 C 9.5 11.7 0.0021 0.1011 1.7 79.7 
Uk Labrador Allelic RS22818977 2 45167469 C 0.3 0.1 T 9.2 3.7 0.0024 0.1149 1.5 8.9 
Uk Labrador Allelic RS22871630 2 45133611 A 0.3 0.1 C 8.9 4.0 0.0028 0.1340 1.5 10.6 
Uk golden retriever Allelic RS22819627 2 45159024 T 0.5 0.1 A 8.9 9.2 0.0028 0.1356 1.7 50.6 
Uk golden retriever Allelic RS22871627 2 45133465 T 0.5 0.1 C 8.9 9.2 0.0028 0.1356 1.7 50.6 
Uk golden retriever Allelic RS22871646 2 45133786 G 0.5 0.1 A 8.9 9.2 0.0028 0.1356 1.7 50.6 
Uk golden retriever Allelic RS22872666 2 45162084 T 0.5 0.1 G 8.9 9.2 0.0028 0.1356 1.7 50.6 
Uk golden retriever Allelic RS22874976 2 45176838 A 0.5 0.1 G 8.9 9.2 0.0028 0.1356 1.7 50.6 
Uk Labrador Allelic RS22374481 14 46159795 C 0.2 0.0 T 8.9 5.2 0.0029 0.1380 1.6 16.9 
Shiba Inu Allelic RS21902676 1 16469324 G 0.3 0.6 A 8.8 0.3 0.0029 0.1409 0.1 0.7 
Shiba Inu Allelic RS21941198 1 16475961 C 0.3 0.6 A 8.8 0.3 0.0029 0.1409 0.1 0.7 
Uk golden retriever Allelic RS24657063 39 755447 G 1.0 0.4 A 8.7 NA 0.0032 0.1547 NA NA 
Usa Labrador Allelic RS9013510 1 16476441 A 0.1 0.0 G 8.6 12.8 0.0034 0.1631 1.5 107.7 
Uk golden retriever Allelic RS22818977 2 45167469 C 0.5 0.1 T 8.5 8.8 0.0035 0.1687 1.6 48.7 
Usa golden retriever Allelic RS24613432 39 751050 A 0.0 0.2 G 8.4 0.0 0.0038 0.1801 0.0 NA 
Usa German Shepherd Dog Allelic MS4A2_E5 21 53634435 A 0.0 0.4 G 8.2 0.0 0.0042 0.2031 0.0 NA 
Uk golden retriever Allelic RS22807086 2 45212191 A 0.5 0.1 G 8.1 8.4 0.0044 0.2132 1.5 45.9 
Uk Labrador Allelic RS9013510 1 16476441 A 0.2 0.1 G 8.0 4.6 0.0047 0.2239 1.5 14.2 
Uk Labrador Allelic RS22542263 17 64296837 T 0.1 0.0 C 7.0 5.7 0.0083 0.3962 1.4 24.1 
Uk Labrador Allelic RS8555046 17 64298495 T 0.2 0.0 C 6.7 4.4 0.0095 0.4560 1.3 14.8 
Shiba Inu Allelic RS22529256 17 64273415 T 0.1 0.0 C 6.7 NA 0.0096 0.4632 NA NA 
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Usa German Shepherd Dog Allelic RS22655278 9 5853780 G 0.0 0.3 A 6.3 0.0 0.0121 0.5794 0.0 NA 
Uk Labrador Allelic RS22871646 2 45133786 G 0.3 0.1 A 6.2 3.1 0.0126 0.6029 1.2 7.6 
Japan golden retriever Allelic RS8877521 21 53631234 C 0.2 0.5 T 6.1 0.2 0.0138 0.6634 0.1 0.8 
Uk Labrador Allelic RS24328835 6 10890690 C 0.3 0.1 T 6.1 2.8 0.0139 0.6658 1.2 6.4 
Shiba Inu Allelic RS22872666 2 45162084 T 0.3 0.1 G 6.0 3.4 0.0144 0.6931 1.2 9.4 
Usa Labrador Allelic RS24630609 39 745403 G 0.2 0.0 A 6.0 4.8 0.0146 0.7003 1.2 18.8 
Uk German Shepherd Dog Allelic RS9019919 21 53636716 A 0.1 0.0 G 5.9 NA 0.0149 0.7128 NA NA 
Boxer Allelic RS8555046 17 64298495 T 0.0 0.3 C 5.9 0.0 0.0155 0.7459 0.0 NA 
Usa golden retriever Allelic RS22986082 21 53634938 G 0.2 0.5 A 5.8 0.3 0.0161 0.7747 0.1 0.8 
Uk golden retriever Allelic RS22588227 17 64297022 G 0.3 0.1 C 5.6 7.0 0.0184 0.8813 1.1 44.2 
Shiba Inu Allelic RS22986082 21 53634938 G 0.2 0.5 A 5.5 0.4 0.0191 0.9158 0.2 0.9 
Usa German Shepherd Dog Allelic RS23907319 36 10444284 C 0.4 0.1 T 5.4 5.6 0.0198 0.9504 1.2 25.8 
Uk German Shepherd Dog Allelic RS21902632 1 16476102 G 0.1 0.4 C 5.3 0.1 0.0207 0.9955 0.0 0.9 
Boxer Allelic RS23274229 25 6184255 T 0.2 0.0 C 5.3 NA 0.0216 1.0354 NA NA 
Uk Labrador Allelic SPRR_E3_1 17 64883377 T 0.1 0.3 C 5.2 0.3 0.0231 1.1088 0.1 0.9 
Usa golden retriever Allelic RS22871627 2 45133465 T 0.4 0.2 C 4.9 3.2 0.0261 1.2547 1.1 9.4 
Uk golden retriever Allelic RS22542262 17 64296821 T 0.3 0.1 C 4.9 6.3 0.0268 1.2854 1.0 39.1 
Usa golden retriever Allelic RS22986026 21 53629181 C 0.5 0.3 T 4.7 2.8 0.0299 1.4352 1.1 7.2 
Uk Labrador Allelic RS22819627 2 45159024 T 0.2 0.1 A 4.7 2.7 0.0306 1.4698 1.1 6.8 
Uk Labrador Allelic RS8877519 21 53631150 G 0.5 0.4 A 4.7 2.1 0.0308 1.4774 1.1 4.3 
Japan Shih Tzu Allelic RS24613432 39 751050 A 0.0 0.1 G 4.6 0.1 0.0318 1.5269 0.0 1.1 
Uk Labrador Allelic MS4A2_E5 21 53634435 A 0.2 0.4 G 4.6 0.4 0.0323 1.5504 0.2 0.9 
Pit Bull Allelic RS24613434 39 750979 G 0.4 0.6 A 4.6 0.4 0.0324 1.5542 0.1 0.9 
Shiba Inu Allelic RS22931896 20 9213048 A 0.3 0.1 G 4.5 3.1 0.0342 1.6392 1.1 9.2 
Japan Shih Tzu Allelic RS22146864 11 23976639 G 0.2 0.3 A 4.5 0.5 0.0345 1.6555 0.2 1.0 
Usa Labrador Allelic RS21941198 1 16475961 C 0.2 0.4 A 4.4 0.4 0.0365 1.7496 0.2 1.0 
Uk German Shepherd Dog Allelic RS22986082 21 53634938 G 0.6 0.3 A 4.3 3.7 0.0382 1.8341 1.0 13.5 
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Uk German Shepherd Dog Allelic RS21941198 1 16475961 C 0.1 0.5 A 4.3 0.2 0.0383 1.8379 0.0 1.0 
Boxer Allelic RS21941198 1 16475961 A 0.1 0.4 C 4.3 0.2 0.0383 1.8403 0.0 1.0 
Shih Tzu Allelic RS24613432 39 751050 A 0.0 0.1 G 4.3 0.1 0.0384 1.8446 0.0 1.2 
Japan golden retriever Allelic RS24264853 5 71503539 G 0.5 0.2 A 4.2 3.3 0.0407 1.9526 1.0 10.4 
Japan golden retriever Allelic RS8877519 21 53631150 A 0.2 0.5 G 4.2 0.3 0.0407 1.9526 0.1 1.0 
Shiba Inu Allelic RS22871627 2 45133465 T 0.3 0.1 C 4.2 2.9 0.0408 1.9574 1.0 8.2 
Boxer Allelic MS4A2_E5 21 53634435 A 0.4 0.1 G 4.2 4.5 0.0411 1.9728 1.0 20.3 
Boxer Allelic RS8877519 21 53631150 A 0.4 0.1 G 4.1 4.0 0.0425 2.0410 1.0 16.0 
Boxer Allelic RS8877521 21 53631234 C 0.4 0.1 T 4.1 4.0 0.0425 2.0410 1.0 16.0 
Uk German Shepherd Dog Allelic RS22871646 2 45133786 G 0.2 0.5 A 4.1 0.2 0.0436 2.0947 0.1 1.0 
Uk golden retriever Allelic RS9190946 3 15784064 T 0.8 0.4 C 4.1 7.0 0.0439 2.1082 0.8 62.2 
Uk German Shepherd Dog Allelic RS22871630 2 45133611 A 0.2 0.5 C 4.1 0.2 0.0441 2.1144 0.1 1.0 
Uk golden retriever Allelic MS4A2_E5 21 53634435 A 0.0 0.4 G 4.0 0.0 0.0453 2.1725 0.0 NA 
Japan Shih Tzu Allelic RS21902632 1 16476102 G 0.1 0.1 C 4.0 0.3 0.0458 2.2003 0.1 1.0 
Pit Bull Allelic RS9190946 3 15784064 T 0.2 0.1 C 4.0 4.7 0.0459 2.2018 0.9 23.4 
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Appendix 14 Candidate gene study: Individual Breed Meta-analysis (p<0.05) 
 
Breed SNP Chromosome Base Pairs Odds Ratio P Value Corrected P 
Value (X48) 
L95 U95 
Labradors RS21902632 1 16476102 0.4 0.006 0.26635 0.2 0.8 
Whwt RS23274229 25 6184255 5.4 0.008 0.36437 1.5 19.4 
German Shepherd Dog RS22655278 9 5853780 0.0 0.009 0.42302 NA NA 
golden retriever RS22986082 21 53634938 0.4 0.012 0.57072 0.2 0.8 
golden retriever SPRR1B_E3_1 17 64883377 0.3 0.013 0.62064 0.1 0.8 
German Shepherd Dog RS21902632 1 16476102 0.2 0.013 0.63024 0.1 0.7 
Labradors RS21941198 1 16475961 0.5 0.018 0.84720 0.2 0.9 
Labradors RS21902676 1 16469324 0.5 0.026 1.22688 0.3 0.9 
German Shepherd Dog RS22818977 2 45167469 0.4 0.043 2.04384 0.1 1.0 
German Shepherd Dog RS8877519 21 53631150 0.3 0.045 2.16096 0.1 1.0 
German Shepherd Dog RS22807086 2 45212191 2.5 0.048 2.32608 0.9 6.4 
German Shepherd Dog RS22374481 14 46159795 3.7 0.051 2.42640 0.9 14.5 
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